REPORT ON CANCER IN NEVADA

2000-2004



A Comprehensive Report on Cancer from:

Nevada Central Cancer Registry Nevada Death Registry Nevada Inpatient Hospital Discharge (UB92) Behavioral Risk Factor Surveillance Survey (BRFSS)

Joint Publication of Nevada Center for Health Statistics and Informatics University of Nevada, Reno

and

Center for Health Data and Research Bureau of Health Planning and Statistics Nevada State Health Division Department of Health and Human Services

Jim Gibbons, Governor Michael J. Willden, Director Department of Health and Human Services



June 2008

Written, compiled and edited by:

University of Nevada, Reno:

Wei Yang, M.D., Ph.D. Professor of Health Informatics, School of Public Health Director, Nevada Center for Health Statistics and Informatics

Tim Pollard, B.A. Senior Biostatistician, Nevada Center for Health Statistics and Informatics

Nevada State Health Division:

Alicia Chancellor Hansen, M.S. Chief Biostatistician, Bureau of Health Planning and Statistics

> Luana J. Ritch, Ph.D. Chief, Bureau of Health Planning and Statistics

Mona Lisa Brown, B.A. Health Resource Analyst, Bureau of Health Planning and Statistics

Readers of this publication are welcome to offer their suggestions and/or comments concerning this publication by filling out the attached form at the end of this report. Readers are also welcome to submit requests for additional information by submitting them to:

Alicia Hansen, M.S., Chief Biostatistician, Center for Health Data & Research, Bureau of Health Planning & Statistics 4150 Technology Way, Suite #104 Carson City, Nevada 89706 Phone: (775) 684-4161 Fax: (775) 684-4156 Email: ahansen@health.nv.gov

ACKNOWLEDGEMENTS

Report Prepared by:

(In alphabetical order)

Alicia Chancellor Hansen, M.S. Chief Biostatistician Center for Health Data and Research

Tim Pollard, B.A. Senior Biostatistician Center for Health Statistics and Informatics

Luana J. Ritch, Ph.D. Chief Bureau of Health Planning and Statistics

Wei Yang, Ph.D. Director Center for Health Statistics and Informatics

Nevada Central Cancer Registry Bureau of Health Planning and Statistics 1 Breakthrough Way Las Vegas, NV 89135 Phone: (702) 822-5240 Fax: (702) 944-2365 http://www.health.nv.gov

Joseph Greenway, Director Center for Health Information Analysis University of Nevada, Las Vegas 4505 Maryland Parkway, Box 455058 Las Vegas, Nevada 89154-5058 Phone (702) 895-4389 Fax (702) 895-4276 http://www.unlv.edu/Research_Centers/chia/

Office of Vital Statistics Bureau of Health Planning and Statistics 4150 Technology Way, Suite 104 Carson City, Nevada 89706 Phone: (775) 684-4162 Fax: (775) 684-4156 http://www.health.nv.gov

Data Provided By:

PREFACE

This report provides a comprehensive overview of the risks and burden of cancer in Nevada from 2000 to 2004. Cancer represents a group of diseases that will affect nearly half of the population at some time during their lifetime. Nationally, cancer-related costs total billions of dollars in treatment annually. Cancer has also consistently been the second leading cause of death for Nevada and the nation for the last 20 years. This report provides a variety of information on cancer from four different data sources and has been organized to focus on specific aspects of cancer, (e.g. screening, diagnosis, inpatient treatment, mortality, and survival rate) with each section adding to the overall picture of cancer in Nevada.

The first section provides a comparison of the 22 leading types of cancer that comprise 93.1% of all types of cancer in Nevada; including incidence, inpatient hospital discharges, mortality, and survival rate subsections for comparison.

The second section includes various statistics on all cancers, reported among Nevada residents, to provide a complete look at cancer in the state. There are subsections for diagnosis, treatment, mortality and survival rate statistics for the 2000 to 2004 period.

The top ten leading types of cancer diagnosed in Nevada from 2000 to 2004, which accounts for 77.0 percent of the total number of cancer cases, are then highlighted within their own section to provide a more detailed look at the types of cancer that are most prevalent in Nevada. The reader should note that these types of cancer are presented based on the number of cases reported. Therefore, those cancers whose ranking is within the top ten based on inpatient discharges or mortality are not necessarily highlighted within their own section.

Statistics on those cancers not highlighted in the top ten sections are available in the Overview section and in a general section for All Other Cancers at the end of this report, where the remaining twelve leading cancers are briefly profiled.

Each major section in this report includes regional, gender, racial/ethnic, and age statistics in order to draw attention to potential targets for prevention and treatment efforts. These efforts in prevention and treatment will help to achieve progress toward reducing the risks and burden of Cancer in Nevada.

This report is also available online at the websites of the Center for Health Statistics and Informatics and the Center for Health Data and Research: http://hhs.unr.edu/nchsi

http://www.health.nv.gov

TABLE OF CONTENTS

ACKNOWLEDGEMENTS	i
PREFACE	1
TABLE OF CONTENTS	2
LIST OF FIGURES AND TABLES	5
TECHNICAL NOTES	
OVERVIEW	
INCIDENCE	
INPATIENT HOSPITAL DISCHARGES	
MORTALITY	65
SURVIVAL RATE	74
ALL CANCERS	
INCIDENCE	
INPATIENT HOSPITAL DISCHARGES	
MORTALITY	
SURVIVAL RATE	
LUNG AND BRONCHUS CANCER	
INCIDENCE	
INPATIENT HOSPITAL DISCHARGES	
MORTALITY	
SURVIVAL RATE	
BREAST CANCER	
SCREENING (BRFSS)	
INCIDENCE	
INPATIENT HOSPITAL DISCHARGES	
MORTALITY	
SURVIVAL RATE	
PROSTATE CANCER	
SCREENING (BRFSS)	
INCIDENCE	

INPATIENT HOSPITAL DISCHARGES	
MORTALITY	
SURVIVAL RATE	
COLORECTAL CANCER	
SCREENING (BRFSS)	
INCIDENCE	
INPATIENT HOSPITAL DISCHARGES	
MORTALITY	
SURVIVAL RATE	
URINARY BLADDER CANCER	
INCIDENCE	
INPATIENT HOSPITAL DISCHARGES	
MORTALITY	
SURVIVAL RATE	
NON-HODGKIN'S LYMPHOMA	
INCIDENCE	
INPATIENT HOSPITAL DISCHARGES	
MORTALITY	
SURVIVAL RATE	
KIDNEY AND RENAL PELVIS CANCER	
INCIDENCE	
INPATIENT HOSPITAL DISCHARGES	
MORTALITY	
SURVIVAL RATE	
LIP, ORAL CAVITY AND PHARYNX CANCER	
INCIDENCE	
INPATIENT HOSPITAL DISCHARGES	
MORTALITY	
SURVIVAL RATE	
LEUKEMIA	
INCIDENCE	
INPATIENT HOSPITAL DISCHARGES	
MORTALITY	

SURVIVAL RATE	
PANCREATIC CANCER	
INCIDENCE	
INPATIENT HOSPITAL DISCHARGES	
MORTALITY	
SURVIVAL RATE	401
ALL OTHER CANCERS	404
SKIN CANCER	406
UTERINE CANCER	410
OVARIAN CANCER	414
THYROID GLAND CANCER	418
BRAIN AND OTHER CENTRAL NERVOUS SYSTEM CANCER	422
STOMACH CANCER	426
LIVER AND INTRAHEPATIC BILE DUCTS CANCER	430
CERVICAL CANCER	434
ESOPHAGEAL CANCER	439
LARYNX CANCER	
MULTIPLE MYELOMA	447
HODGKIN'S LYMPHOMA	451
ALL OTHER SITES	455
APPENDIX A – CODES USED FOR GROUPING	458
APPENDIX B – FORMULAS	463
REFERENCES	466
FEEDBACK AND SUGGESTIONS	467

LIST OF FIGURES AND TABLES

OVERVIEW

Figure 1. Top Ten Leading Types of Cancer by Percentage of Total Incidence, Discharges and Mortality, Nevada Residents, 2000-2004
Figure 2. Highest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer,
Nevada Residents, 2000-2004
Figure 3. Lowest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer, Nevada Residents, 2000-2004
Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer, Nevada, 2000-2004
Table 2. Leading Types of Cancer for Nevada Incidence, Inpatient Hospital Discharges and Mortality, Nevada Residents, 2000-2004
Table 3. Top Ten Types of Cancer by Gender, Incidence, Hospital Discharges, and Mortality,
Nevada Residents, 2000-2004
Table 4. Incidence to Mortality Age-Adjusted Rate Ratios for the Leading Types of Cancer, Nevada
Residents, 2000-2004
INCIDENCE
Figure 4. Top Ten Leading Cancers as a Percentage of Total Cases, Nevada (2000-2004) and SEER-17 (2000-2004)
Figure 5. Comparison of Age-Adjusted (2000) Incidence Rates of Blacks compared to Whites, Nevada Residents, 2000-2004
Figure 6. Comparison of Age-Adjusted (2000) Incidence Rates of Native Americans compared to
Whites, Nevada Residents, 2000-2004
Figure 7. Comparison of Age-Adjusted (2000) Incidence Rates of Asians compared to Whites,
Nevada Residents, 2000-2004
Figure 8. Comparison of Age-Adjusted (2000) Incidence Rates of Hispanics compared to Whites, Nevada Residents, 2000-2004
Table 5. Nevada Incidence by Type of Cancer, Nevada (2000-2004) and SEER-17 (2000-2004)48
Table 6. Nevada Incidence by Type of Cancer and Gender, Nevada, 2000-2004
Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer, Nevada, 2000-2004
Table 8. Top Ten Types of Cancer Incidence by County/Region of Residence,
Nevada Residents, 2000-2004
Table 9. Top Ten Types of Cancer Incidence by Age Group, Nevada Residents, 2000-2004
Table 10. Median Age at Time of Diagnosis by Leading Types of Cancer and Race/Ethnicity,
Nevada Residents, 2000-2004
INPATIENT HOSPITAL DISCHARGES
Figure 9. Top Ten Leading Cancers in Total Inpatient Discharge Charges (000s), Nevada Residents,
2000-2004
Figure 10. Top Ten Leading Cancers in Average Inpatient Discharge Charges, Nevada Residents,
2000-2004
Figure 11. Top Ten Leading Cancers in Median Inpatient Discharge Charges, Nevada Residents, 2000-2004
Figure 12. Top Ten Leading Cancers in Total Number of Days Stayed for Inpatient Hospital Discharges, Nevada Residents, 2000-2004
Figure 13. Top Ten Leading Cancers in Average Length of Stay (Days) for Inpatient Hospital

Discharges, Nevada Residents, 2000-2004	60
Figure 14. Top Ten Leading Cancers in Median Length of Stay (Days) for Inpatient Hosp	oital
Discharges, Nevada Residents, 2000-2004	60
Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender,	
Nevada, 2000-2004	
Table 12. Top Ten Types of Cancer Inpatient Hospital Discharges by County/Region of H	
Nevada Residents, 2000-2004	
Table 13. Top Ten Types of Cancer Hospital Discharges by Age Group, Nevada Residen	
2004	64
ORTALITY	
Figure 15. Top Ten Leading Cancers by Percentage of Total Cancer Mortality,	
Nevada Residents, 2000-2004	66
Figure 16. Comparison of Age-Adjusted (2000) Mortality Rates of Blacks compared to W	Vhites,
Nevada Residents, 2000-2004	
Figure 17. Comparison of Age-Adjusted (2000) Mortality Rates of Native Americans cor	
Whites, Nevada Residents, 2000-2004	
Figure 18. Comparison of Age-Adjusted (2000) Mortality Rates of Asians compared to W	
Nevada Residents, 2000-2004	
Figure 19. Comparison of Age-Adjusted (2000) Mortality Rates of Hispanics compared to	
Nevada Residents, 2000-2004 Table 14. Nevada Mortality by Type of Cancer and Gender, Nevada, 2000-2004	
Table 15. Top Ten Types of Cancer Mortality by County/Region of Residence,	09
Nevada Residents, 2000-2004	71
Table 16. Top Ten Types of Cancer Mortality by Age Group, Nevada Residents, 2000-20	
Table 17. Median Age at Time of Death by Leading Types of Cancer and Race/Ethnicity.	
Nevada Residents, 2000-2004	
URVIVAL RATE	
Figure 20. Ten Highest One-Year Survival Rates by Type of Cancer,	75
Nevada Residents, 2000-2004 Figure 21. Ten Lowest One-Year Survival Rates by Type of Cancer,	
Nevada Residents, 2000-2004	75
Figure 22. Ten Highest Five-Year Survival Rates by Type of Cancer,	
Nevada Residents, 2000-2004	76
Figure 23. Ten Lowest Five-Year Survival Rates by Type of Cancer,	
Nevada Residents, 2000-2004	76
Table 18. One-Year, Five-Year and Median Survival Rates by Type of Cancer,	
Nevada Residents, 2000-2004	77
Table 19. One-, Five-Year and Median Survival Rates by Type of Cancer,	
Nevada Residents (2000-2004) and SEER-17 (2000-2004)	
Table 20. One- and Five-Year Survival Rates by Type of Cancer and Gender,	
Nevada Residents, 2000-2004	79

ALL CANCERS

INCIDENCE	
Figure 24. Age-Adjusted (2000) Incidence Rates for All Cancers,	
Nevada Residents, 2000-2004	84

Figure 25. All Cancers Age-Adjusted Incidence Rates by County/Region of Residence,	
Nevada Residents, 2000-2004	85
Figure 26. All Cancers Age-Adjusted Incidence Rates by Race/Ethnicity,	
Nevada Residents, 2000-2004	85
Table 21. All Cancers Cases by Gender, Race/Ethnicity and County/Region of Residence at	
Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)	86
Table 22. All Cancers Cases by Age Group and County/Region of Residence at Diagnosis,	
Nevada Residents (2000-2004) and SEER-17 (2000-2004)	87
Table 23. All Cancers Cases by County of Residence at Diagnosis,	
Nevada Residents, 2000-2004	88
Table 24. All Cancers Cases by Race/Ethnicity and Gender, Nevada Residents, 2000-2004	88
Table 25. All Cancers Cases by Age Group and Gender, Nevada Residents, 2000-2004	89
Table 26. All Cancers Cases by Age Group and Stage, Nevada Residents, 2000-2004	90
Table 27. Cancer Incidence by Stage and Race/Ethnicity, Nevada Residents, 2000-2004	91
Table 28. Median Age at Diagnosis of All Cancers by Race/Ethnicity and Gender, Nevada	
Residents, 2000-2004	91
INPATIENT HOSPITAL DISCHARGES	
Figure 27. All Cancers Age-Adjusted (2000) Inpatient Discharge Rates,	
Nevada Residents, 2000-2004	92
Figure 28. All Cancers Age-Adjusted Inpatient Discharge Rates by County/Region of Residence	> <u>-</u>
Nevada Residents, 2000-2004	
Figure 29. Median Charges for All Cancer Inpatient Discharges by County/Region of Residence	
Nevada Residents, 2000-2004	
Figure 30. Average Length of Stay for All Cancer Inpatient Discharges by County/Region of	
Residence, Nevada Residents, 2000-2004	94
Table 29. All Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Reg	ion
of Residence, Nevada Residents, 2000-2004	95
Table 30. Cancer Inpatient Discharges by Age Group and County/Region of Residence,	
Nevada Residents, 2000-2004	96
Table 31. All Cancer Inpatient Discharges by Age Group and Gender,	
Nevada Residents, 2000-2004	97
Table 32. All Cancer Inpatient Discharges by County/Region of Residence,	
Nevada Residents, 2000-2004	98
Table 33. All Cancer Inpatient Discharges by Age Group, Charges and Length of Stay,	
Nevada Residents, 2000-2004	98
MORTALITY	
Figure 31. Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 2000-2004	99
Figure 32. Cancer Age-Adjusted Mortality Rates by County/Region of Residence,	
Nevada Residents, 2000-2004	100
Figure 33. Cancer Age-Adjusted Mortality Rates by Race/Ethnicity,	
Nevada Residents, 2000-2004	100
Table 34. All Cancers Mortality by Gender, Race/Ethnicity and County/Region of Residence,	
Nevada Residents, 2000-2004	101
Table 35. All Cancers Mortality by Age Group and County/Region of Residence,	
Nevada Residents, 2000-2004	
Table 36. Cancer Mortality by County of Residence, Nevada Residents, 2000-2004	103
Table 37. Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 2000-2004	103

Table 38. Cancer Mortality by Age Group and Gender, Nevada Residents, 2000-2004104Table 39. Median Age at Death from All Cancers by Race/Ethnicity and Gender, Nevada Residents, 2000-2004105
 SURVIVAL RATE Figure 34. Survival Rates for All Cancers by Race/Ethnicity, Nevada Residents, 2000-2004106 Figure 35. Survival Rates for All Cancers by Stage of Cancer at Diagnosis, Nevada Residents, 2000-2004
 Table 40. Cause-Specific Survival Rates for All Cancers by Race/Ethnicity and Gender, Nevada Residents, 2000-2004
LUNG AND BRONCHUS CANCER
GENERAL PROFILE ⁴ Figure 36. Anatomy of the Respiratory Tract ⁵ 110 INCIDENCE
Figure 37. Lung and Bronchus Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004
Residence, Nevada Residents, 2000-2004
 Table 42. Lung and Bronchus Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)115 Table 43. Lung and Bronchus Cancer Cases by Age Group and County/Region of Residence at
Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)
Table 45. Lung and Bronchus Cancer Cases by Race/Ethnicity and Gender,Nevada Residents, 2000-2004Table 46. Lung and Bronchus Cancer Cases by Age Group and Gender,
Nevada Residents, 2000-2004
Nevada Residents, 2000-2004
Table 49. Median Age at Diagnosis of Lung and Bronchus Cancer by Race/Ethnicity and Gender, Nevada Residents, 2000-2004 120
INPATIENT HOSPITAL DISCHARGES Figure 40. Lung and Bronchus Cancer Age-Adjusted (2000) Inpatient Hospital Discharge Rates, Nevada Residents, 2000-2004
 Figure 41. Lung and Bronchus Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 2000-2004
of Residence, Nevada Residents, 2000-2004

County/Region of Residence, Nevada Residents, 2000-2004
Table 50. Lung and Bronchus Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and
County/Region of Residence, Nevada Residents, 2000-2004124
Table 51. Lung and Bronchus Cancer Inpatient Discharges by Age Group and County/Region of
Residence, Nevada Residents, 2000-2004
Nevada Residents, 2000-2004
Table 53. Lung and Bronchus Cancer Inpatient Discharges by County/Region of Residence,
Nevada Residents, 2000-2004
Table 54. Lung and Bronchus Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 2000-2004
MORTALITY
Figure 44. Lung and Bronchus Cancer Age-Adjusted (2000) Mortality Rates,
Nevada Residents, 2000-2004
Figure 45. Lung and Bronchus Cancer Age-Adjusted Mortality Rates by County/Region of
Residence, Nevada Residents, 2000-2004129
Figure 46. Lung and Bronchus Cancer Age-Adjusted Mortality Rates by Race/Ethnicity,
Nevada Residents, 2000-2004
Table 55. Lung and Bronchus Cancer Mortality by Gender, Race/Ethnicity and County/Region of
Residence, Nevada Residents, 2000-2004
Table 56. Lung and Bronchus Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 2000-2004
Table 57. Lung and Bronchus Cancer Mortality by County of Residence,
Nevada Residents, 2000-2004
Table 58. Lung and Bronchus Cancer Mortality by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004
Table 59. Lung and Bronchus Cancer Mortality by Age Group and Gender,
Nevada Residents, 2000-2004133
Table 60. Median Age at Death from Lung and Bronchus Cancer by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004
SURVIVAL RATE
Figure 47. Survival Rates for Lung and Bronchus Cancer by Race/Ethnicity, Nevada Residents, 2000-2004
Figure 48. Survival Rates for Lung and Bronchus Cancer by Stage of Cancer at Diagnosis,
Nevada Residents, 2000-2004
Table 61. Cause-Specific Survival Rates for Lung and Bronchus Cancer by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004
Table 62. Cause-Specific Survival Rates for Lung and Bronchus Cancer by Stage of Cancer at
Diagnosis and Gender, Nevada Residents, 2000-2004137
BREAST CANCER
CENEDAL DROEH E ⁴

Education, Age Group,

Figure 50. Female Breast Cancer Age-Adjusted (2000) Incidence Rates,
Nevada Residents, 2000-2004
Figure 51. Female Breast Cancer Age-Adjusted Incidence Rates by County/Region of Residence,
Nevada Residents, 2000-2004144
Figure 52. Female Breast Cancer Age-Adjusted Incidence Rates by Race/Ethnicity,
Nevada Residents, 2000-2004144
Table 64. Breast Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at
Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)145
Table 65. Female Breast Cancer Cases by Age Group and County/Region of Residence at Diagnosis,
Nevada Residents (2000-2004) and SEER-17 (2000-2004)146
Table 66. Female Breast Cancer Cases by County of Residence at Diagnosis, Nevada Residents,
2000-2004
Table 67. Breast Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 2000-2004147
Table 68. Breast Cancer Cases by Age Group and Gender, Nevada Residents, 2000-2004148
Table 69. Breast Cancer Cases by Age Group and Stage, Nevada Residents, 2000-2004
Table 70. Breast Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 2000-2004150
Table 71. Median Age at Diagnosis of Breast Cancer by Race/Ethnicity and Gender, Nevada
Residents, 2000-2004
INPATIENT HOSPITAL DISCHARGES
Figure 53. Female Breast Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents,
2000-2004
Figure 54. Female Breast Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of
Residence, Nevada Residents, 2000-2004152
Figure 55. Median Charges for Breast Cancer Inpatient Discharges by County/Region of Residence,
Nevada Residents, 2000-2004152
Figure 56. Average Length of Stay for Breast Cancer Inpatient Discharges by County/Region of
Residence, Nevada Residents, 2000-2004
Table 72. Breast Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and
County/Region of Residence, Nevada Residents, 2000-2004
Table 73. Female Breast Cancer Inpatient Discharges by Age Group and County/Region of
Residence, Nevada Residents, 2000-2004
Table 74. Breast Cancer Inpatient Discharges by Age Group and Gender,
Nevada Residents, 2000-2004
Table 75. Female Breast Cancer Inpatient Discharges by County/Region of Residence, 157
Nevada Residents, 2000-2004
Table 76. Breast Cancer Inpatient Discharges by Age Group, Charges and Length of Stay,
Nevada Residents, 2000-2004
MORTALITY
Figure 57. Female Breast Cancer Age-Adjusted (2000) Mortality Rates,
Nevada Residents, 2000-2004158
Figure 58. Female Breast Cancer Age-Adjusted Mortality Rates by County/Region of Residence,
Nevada Residents, 2000-2004
Figure 59. Female Breast Cancer Age-Adjusted Mortality Rates by Race/Ethnicity,
Nevada Residents, 2000-2004
Table 77. Breast Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence,
Nevada Residents, 2000-2004

Table 78. Female Breast Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 2000-2004
Table 79. Female Breast Cancer Mortality by County of Residence,
Nevada Residents, 2000-2004
Table 80. Breast Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 2000-2004
 Table 81. Breast Cancer Mortality by Age Group and Gender, Nevada Residents, 2000-2004163 Table 82. Median Age at Death from Breast Cancer by Race/Ethnicity and Gender, Nevada Residents, 2000-2004
SURVIVAL RATE
Figure 60. Survival Rates for Breast Cancer by Race/Ethnicity, Nevada Residents, 2000-2004165 Figure 61. Survival Rates for Breast Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 2000-2004
Table 83. Cause-Specific Survival Rates for Breast Cancer by Race/Ethnicity and Gender, Nevada Residents, 2000-2004
Table 84. Cause-Specific Survival Rates for Breast Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 2000-2004
PROSTATE CANCER
GENERAL PROFILE ⁴
Figure 62. Anatomy of the Male Urogenital System ⁵ 169
SCREENING (BRFSS) Table 85. Prostate Cancer Screening by County/Region of Residence, Education, Age Group, and Income, Nevada Residents, 2001 and 2002 and 2004
INCIDENCE
Figure 63. Prostate Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004
Figure 64. Prostate Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 2000-2004
Figure 65. Prostate Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 2000-2004
Table 86. Prostate Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)
Table 87. Prostate Cancer Cases by Age Group and County/Region of Residence at Diagnosis,Nevada Residents (2000-2004) and SEER-17 (2000-2004)
Table 88. Prostate Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 2000-2004 178
Table 89. Prostate Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 2000-2004178Table 90. Prostate Cancer Cases by Age Group and Gender, Nevada Residents, 2000-2004
 Table 91. Prostate Cancer Cases by Age Group and Stage, Nevada Residents, 2000-2004180 Table 92. Prostate Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 2000-2004181 Table 93. Median Age at Diagnosis of Prostate Cancer by Race/Ethnicity and Gender, Nevada Residents, 2000-2004
INPATIENT HOSPITAL DISCHARGES
Figure 66. Prostate Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 2000-2004

Figure 67. Prostate Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence,
Nevada Residents, 2000-2004
Residence, Nevada Residents, 2000-2004
Figure 69. Average Length of Stay for Prostate Cancer Inpatient Discharges by County/Region of
Residence, Nevada Residents, 2000-2004
Table 94. Prostate Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and
County/Region of Residence, Nevada Residents, 2000-2004
Table 95. Prostate Cancer Inpatient Discharges by Age Group and County/Region of Residence,
Nevada Residents, 2000-2004
Table 96. Prostate Cancer Inpatient Discharges by Age Group and Gender,
Nevada Residents, 2000-2004
Table 97. Prostate Cancer Inpatient Discharges by County/Region of Residence,
Nevada Residents, 2000-2004
Table 98. Prostate Cancer Inpatient Discharges by Age Group, Charges and Length of Stay,
Nevada Residents, 2000-2004
MORTALITY
Figure 70. Prostate Cancer Age-Adjusted (2000) Mortality Rates,
Nevada Residents, 2000-2004
Figure 71. Prostate Cancer Age-Adjusted Mortality Rates by County/Region of Residence,
Nevada Residents, 2000-2004
Figure 72. Prostate Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents,
2000-2004
Table 99. Prostate Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence,
Nevada Residents, 2000-2004
Table 100. Prostate Cancer Mortality by Age Group and County/Region of Residence,
Nevada Residents, 2000-2004
Table 101. Prostate Cancer Mortality by County of Residence,
Nevada Residents, 2000-2004
Table 102. Prostate Cancer Mortality by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004
Table 103. Prostate Cancer Mortality by Age Group and Gender,
Nevada Residents, 2000-2004
Table 104. Median Age at Death from Prostate Cancer by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004
SURVIVAL RATE
Figure 73. Survival Rates for Prostate Cancer by Race/Ethnicity,
Nevada Residents, 2000-2004
Figure 74. Survival Rates for Prostate Cancer by Stage of Cancer at Diagnosis, Nevada Residents,
2000-2004
Table 105. Cause-Specific Survival Rates for Prostate Cancer by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004
Table 106. Cause-Specific Survival Rates for Prostate Cancer by Stage of Cancer at Diagnosis and
Gender, Nevada Residents, 2000-2004

COLORECTAL CANCER

GENERAL PROFILE⁴

Figure 75. Anatomy of the Digestive System ⁵	.200
SCREENING (BRFSS)	
Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, Ag Group, and Income, Nevada Residents, 2001 and 2002 and 2004	
INCIDENCE	
Figure 76. Colorectal Cancer Age-Adjusted (2000) Incidence Rates,	
Nevada Residents, 2000-2004	.205
Figure 77. Colorectal Cancer Age-Adjusted Incidence Rates by County/Region of Residence,	
Nevada Residents, 2000-2004	
Figure 78. Colorectal Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Resident	
2000-2004 Table 108. Colorectal Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence	
Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)	
Table 109. Colorectal Cancer Cases by Age Group and County/Region of Residence at Diagnosis	
Nevada Residents (2000-2004) and SEER-17 (2000-2004)	,
Table 110. Colorectal Cancer Cases by County of Residence at Diagnosis,	
Nevada Residents, 2000-2004	.209
Table 111. Colorectal Cancer Cases by Race/Ethnicity and Gender,	
Nevada Residents, 2000-2004	
Table 112. Colorectal Cancer Cases by Age Group and Gender, Nevada Residents, 2000-2004	
Table 113. Colorectal Cancer Cases by Age Group and Stage, Nevada Residents, 2000-2004 Table 114. Colorectal Cancer Cases by Stage and Race/Ethnicity,	.211
Nevada Residents, 2000-2004	212
Table 115. Median Age at Diagnosis of Colorectal Cancer by Race/Ethnicity and Gender, Nevad	a
Residents, 2000-2004	
INPATIENT HOSPITAL DISCHARGES	
Figure 79. Colorectal Cancer Age-Adjusted (2000) Inpatient Discharge Rates,	
Nevada Residents, 2000-2004	.213
Figure 80. Colorectal Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of	
Residence, Nevada Residents, 2000-2004	.214
Figure 81. Median Charges for Colorectal Cancer Inpatient Discharges by County/Region of	014
Residence, Nevada Residents, 2000-2004 Figure 82. Average Length of Stay for Colorectal Cancer Inpatient Discharges by County/Region	
Residence, Nevada Residents, 2000-2004	
Table 116. Colorectal Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and	.215
County/Region of Residence, Nevada Residents, 2000-2004	.216
Table 117. Colorectal Cancer Inpatient Discharges by Age Group and County/Region of Residen	ice,
Nevada Residents, 2000-2004	.217
Table 118. Colorectal Cancer Inpatient Discharges by Age Group and Gender,	• 1 0
Nevada Residents, 2000-2004	.218
Table 119. Colorectal Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 2000-2004	210
Table 120. Colorectal Cancer Inpatient Discharges by Age Group, Charges and Length of Stay,	.219
Nevada Residents, 2000-2004	.219
MORTALITY	

Figure 83. Colorectal Cancer Age-Adjusted (2000) Mortality Rates,

Nevada Residents, 2000-2004	220
Figure 84. Colorectal Cancer Age-Adjusted Mortality Rates by County/Region of Residence,	
Nevada Residents, 2000-2004	221
Figure 85. Colorectal Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Resider 2000-2004	
Table 121. Colorectal Cancer Mortality by Gender, Race/Ethnicity and County/Region of Resid	
Nevada Residents, 2000-2004	
Table 122. Colorectal Cancer Mortality by Age Group and County/Region of Residence,	
Nevada Residents, 2000-2004	223
Table 123. Colorectal Cancer Mortality by County of Residence,	223
Nevada Residents, 2000-2004	224
Table 124. Colorectal Cancer Mortality by Race/Ethnicity and Gender,	
Nevada Residents, 2000-2004	224
Table 125. Colorectal Cancer Mortality by Age Group and Gender,	
Nevada Residents, 2000-2004	225
Table 126. Median Age at Death from Colorectal Cancer by Race/Ethnicity and Gender,	223
Nevada Residents, 2000-2004	226
	220
SURVIVAL RATE	
Figure 86. Survival Rates for Colorectal Cancer by Race/Ethnicity,	
Nevada Residents, 2000-2004	
Figure 87. Survival Rates for Colorectal Cancer by Stage of Cancer at Diagnosis, Nevada Resid 2000-2004	
Table 127. Cause-Specific Survival Rates for Colorectal Cancer by Race/Ethnicity and Gender,	
Nevada Residents, 2000-2004	
Table 128. Cause-Specific Survival Rates for Colorectal Cancer by Stage of Cancer at Diagnosi	
Gender, Nevada Residents, 2000-2004	
URINARY BLADDER CANCER	
GENERAL PROFILE ⁴	
Figure 88. Anatomy of the Urinary System ⁵	231
INCIDENCE	
Figure 89. Urinary Bladder Cancer Age-Adjusted (2000) Incidence Rates,	224
Nevada Residents, 2000-2004	
Figure 90. Urinary Bladder Cancer Age-Adjusted Incidence Rates by County/Region of Resider	
Nevada Residents, 2000-2004	233
Figure 91. Urinary Bladder Cancer Age-Adjusted Incidence Rates by Race/Ethnicity,	225
Nevada Residents, 2000-2004	235
Table 129. Urinary Bladder Cancer Cases by Gender, Race/Ethnicity and County/Region of	226
Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)	236
Table 130. Urinary Bladder Cancer Cases by Age Group and County/Region of Residence at	207
Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)	237
Table 131. Urinary Bladder Cancer Cases by County of Residence at Diagnosis,	•••
Nevada Residents, 2000-2004	238
Table 132. Urinary Bladder Cancer Cases by Race/Ethnicity and Gender,	
Nevada Residents, 2000-2004	238
Table 133. Urinary Bladder Cancer Cases by Age Group and Gender,	
Nevada Residents, 2000-2004	239

Table 134. Urinary Bladder Cancer Cases by Age Group and Stage,
Nevada Residents, 2000-2004
Table 135. Urinary Bladder Cancer Cases by Stage and Race/Ethnicity,
Nevada Residents, 2000-2004
Table 136. Median Age at Diagnosis of Urinary Bladder Cancer by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004
INPATIENT HOSPITAL DISCHARGES
Figure 92. Urinary Bladder Cancer Age-Adjusted (2000) Inpatient Discharge Rates,
Nevada Residents, 2000-2004
Figure 93. Urinary Bladder Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of
Residence, Nevada Residents, 2000-2004
Figure 94. Median Charges for Urinary Bladder Cancer Inpatient Discharges by County/Region of
Residence, Nevada Residents, 2000-2004
Figure 95. Average Length of Stay for Urinary Bladder Cancer Inpatient Discharges by
County/Region of Residence, Nevada Residents, 2000-2004
Table 137. Urinary Bladder Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and
County/Region of Residence, Nevada Residents, 2000-2004
Table 138. Urinary Bladder Cancer Inpatient Discharges by Age Group and County/Region of
Residence, Nevada Residents, 2000-2004
Table 139. Urinary Bladder Cancer Inpatient Discharges by Age Group and Gender, Nevada
Residents, 2000-2004
Table 140. Urinary Bladder Cancer Inpatient Discharges by County/Region of Residence, Nevada
Residents, 2000-2004
Table 141. Urinary Bladder Cancer Inpatient Discharges by Age Group, Charges and Length of
Stay, Nevada Residents, 2000-2004
MORTALITY
Figure 96. Urinary Bladder Cancer Age-Adjusted (2000) Mortality Rates,
Nevada Residents, 2000-2004
Figure 97. Urinary Bladder Cancer Age-Adjusted Mortality Rates by County/Region of Residence,
Nevada Residents, 2000-2004
Figure 98. Urinary Bladder Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada
Residents, 2000-2004
Table 142. Urinary Bladder Cancer Mortality by Gender, Race/Ethnicity and County/Region of Desidence Desidence New de Desidence 2000 2001
Residence, Nevada Residents, 2000-2004
Table 143. Urinary Bladder Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 2000-2004
Table 144. Urinary Bladder Cancer Mortality by County of Residence,
Nevada Residents, 2000-2004
Table 145. Urinary Bladder Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents,
2000-2004
Table 146. Urinary Bladder Cancer Mortality by Age Group and Gender,
Nevada Residents, 2000-2004
Table 147. Median Age at Death from Urinary Bladder Cancer by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004
SURVIVAL RATE

Figure 99. Survival Rates for Urinary Bladder Cancer by Race/Ethnicity,

Nevada Residents, 2000-2004
Figure 100. Survival Rates for Urinary Bladder Cancer by Stage of Cancer at Diagnosis, Nevada
Residents, 2000-2004
Table 148. Cause-Specific Survival Rates for Urinary Bladder Cancer by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004
Table 149. Cause-Specific Survival Rates for Urinary Bladder Cancer by Stage of Cancer at
Diagnosis and Gender, Nevada Residents, 2000-2004
NON-HODGKIN'S LYMPHOMA
GENERAL PROFILE ⁴
GENERAL PROFILE Figure 101. Anatomy of the Lymphatic System
INCIDENCE
Figure 102. Non-Hodgkin's Lymphoma Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004
Figure 103. Non-Hodgkin's Lymphoma Age-Adjusted Incidence Rates by County/Region of
Residence, Nevada Residents, 2000-2004
Figure 104. Non-Hodgkin's Lymphoma Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 2000-2004
Table 150. Non-Hodgkin's Lymphoma Cases by Gender, Race/Ethnicity and County/Region of
Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)265
Table 151. Non-Hodgkin's Lymphoma Cases by Age Group and County/Region of Residence at
Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)
Table 152. Non-Hodgkin's Lymphoma Cases by County of Residence at Diagnosis, Nevada
Residents, 2000-2004
Table 153. Non-Hodgkin's Lymphoma Cases by Race/Ethnicity and Gender, Nevada Residents, 2000-2004
Table 154. Non-Hodgkin's Lymphoma Cases by Age Group and Gender,
Nevada Residents, 2000-2004
Table 155. Non-Hodgkin's Lymphoma Cases by Age Group and Stage,
Nevada Residents, 2000-2004
Table 156. Non-Hodgkin's Lymphoma Cases by Stage and Race/Ethnicity,
Nevada Residents, 2000-2004
Table 157. Median Age at Diagnosis of Non-Hodgkin's Lymphoma by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004
INPATIENT HOSPITAL DISCHARGES
Figure 105. Non-Hodgkin's Lymphoma Age-Adjusted (2000) Inpatient Discharge Rates, Nevada
Residents, 2000-2004
Figure 106. Non-Hodgkin's Lymphoma Age-Adjusted Inpatient Discharge Rates by County/Region
of Residence, Nevada Residents, 2000-2004
Figure 107. Median Charges for Non-Hodgkin's Lymphoma Discharges by County/Region of
Residence, Nevada Residents, 2000-2004
Figure 108. Average Length of Stay for Non-Hodgkin's Lymphoma Discharges by County/Region
of Residence, Nevada Residents, 2000-2004
County/Region of Residence, Nevada Residents, 2000-2004
Table 159. Non-Hodgkin's Lymphoma Discharges by Age Group and County/Region of Residence,
Nevada Residents, 2000-2004

Table 160. Non-Hodgkin's Lymphoma Discharges by Age Group and Gender,	
Nevada Residents, 2000-2004	276
Table 161. Non-Hodgkin's Lymphoma Discharges by County/Region of Residence, Nevada	~
	277
Table 162. Non-Hodgkin's Lymphoma Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 2000-2004	777
	211
MORTALITY	
Figure 109. Non-Hodgkin's Lymphoma Age-Adjusted (2000) Mortality Rates,	270
Nevada Residents, 2000-2004	278
Figure 110. Non-Hodgkin's Lymphoma Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 2000-2004	270
Figure 111. Non-Hodgkin's Lymphoma Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada	
Residents, 2000-2004	
Table 163. Non-Hodgkin's Lymphoma Mortality by Gender, Race/Ethnicity and County/Region of	
Residence, Nevada Residents, 2000-2004	
Table 164. Non-Hodgkin's Lymphoma Mortality by Age Group and County/Region of Residence	
Nevada Residents, 2000-2004	281
Table 165. Non-Hodgkin's Lymphoma Mortality by County of Residence,	
Nevada Residents, 2000-2004	282
Table 166. Non-Hodgkin's Lymphoma Mortality by Race/Ethnicity and Gender,	202
Nevada Residents, 2000-2004 Table 167. Non-Hodgkin's Lymphoma Mortality by Age Group and Gender,	282
Nevada Residents, 2000-2004	783
Table 168. Median Age at Death from Non-Hodgkin's Lymphoma by Race/Ethnicity and Gender,	
Nevada Residents, 2000-2004	
SURVIVAL RATE	
Figure 112. Survival Rates for Non-Hodgkin's Lymphoma by Race/Ethnicity,	
	285
Figure 113. Survival Rates for Non-Hodgkin's Lymphoma by Stage of Cancer at Diagnosis, Neva	
Residents, 2000-2004	
Table 169. Cause-Specific Survival Rates for Non-Hodgkin's Lymphoma by Race/Ethnicity and	
Gender, Nevada Residents, 2000-2004	286
Table 170. Cause-Specific Survival Rates for Non-Hodgkin's Lymphoma by Stage of Cancer at	• • •
Diagnosis and Gender, Nevada Residents, 2000-2004	287
KIDNEY AND RENAL PELVIS CANCER	
GENERAL PROFILE ⁴	
Figure 114. Anatomy of the Urinary System ⁵	289
INCIDENCE	
Figure 115. Kidney and Renal Pelvis Cancer Age-Adjusted (2000) Incidence Rates, Nevada	
	292
Figure 116. Kidney and Renal Pelvis Cancer Age-Adjusted Incidence Rates by County/Region of	
Residence, Nevada Residents, 2000-2004	
Figure 117. Kidney and Renal Pelvis Cancer Age-Adjusted Incidence Rates by Race/Ethnicity,	
Nevada Residents, 2000-2004	293
Table 171. Kidney and Renal Pelvis Cancer Cases by Gender, Race/Ethnicity and County/Region	of

Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)	294
Table 172. Kidney and Renal Pelvis Cancer Cases by Age Group and County/Region of Resider	
at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)	295
Table 173. Kidney and Renal Pelvis Cancer Cases by County of Residence at Diagnosis, Nevad	a
Residents, 2000-2004	296
Table 174. Kidney and Renal Pelvis Cancer Cases by Race/Ethnicity and Gender,	
Nevada Residents, 2000-2004	296
Table 175. Kidney and Renal Pelvis Cancer Cases by Age Group and Gender,	
Nevada Residents, 2000-2004	297
Table 176. Kidney and Renal Pelvis Cancer Cases by Age Group and Stage,	
Nevada Residents, 2000-2004	298
Table 177. Kidney and Renal Pelvis Cancer Cases by Stage and Race/Ethnicity,	
Nevada Residents, 2000-2004	299
Table 178. Median Age at Diagnosis of Kidney and Renal Pelvis Cancer by Race/Ethnicity and	
Gender, Nevada Residents, 2000-2004	299
INPATIENT HOSPITAL DISCHARGES	
Figure 118. Kidney and Renal Pelvis Cancer Age-Adjusted (2000) Inpatient Discharge Rates,	
	300
Figure 119. Kidney and Renal Pelvis Cancer Age-Adjusted Inpatient Discharge Rates by	
County/Region of Residence, Nevada Residents, 2000-2004	301
Figure 120. Median Charges for Kidney and Renal Pelvis Cancer Inpatient Discharges by	
County/Region of Residence, Nevada Residents, 2000-2004	301
Figure 121. Average Length of Stay for Kidney and Renal Pelvis Cancer Inpatient Discharges b	y
County/Region of Residence, Nevada Residents, 2000-2004	302
Table 179. Kidney and Renal Pelvis Cancer Inpatient Discharges by Gender, Charges, Length o	f
Stay, and County/Region of Residence, Nevada Residents, 2000-2004	303
Table 180. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group and County/Re	gion
of Residence, Nevada Residents, 2000-2004	304
Table 181. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group and Gender,	
Nevada Residents, 2000-2004	
Table 182. Kidney and Renal Pelvis Cancer Inpatient Discharges by County/Region of Residend	
Nevada Residents, 2000-2004	306
Table 183. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group, Charges and	
Length of Stay, Nevada Residents, 2000-2004	306
MORTALITY	
Figure 122. Kidney and Renal Pelvis Cancer Age-Adjusted (2000) Mortality Rates, Nevada	
Residents, 2000-2004	
Figure 123. Kidney and Renal Pelvis Cancer Age-Adjusted Mortality Rates by County/Region of	of
Residence, Nevada Residents, 2000-2004	308
Figure 124. Kidney and Renal Pelvis Cancer Age-Adjusted Mortality Rates by Race/Ethnicity,	
Nevada Residents, 2000-2004	308
Table 184. Kidney and Renal Pelvis Cancer Mortality by Gender, Race/Ethnicity and	
County/Region of Residence, Nevada Residents, 2000-2004	309
Table 185. Kidney and Renal Pelvis Cancer Mortality by Age Group and County/Region of	
Residence, Nevada Residents, 2000-2004	310
Table 186. Kidney and Renal Pelvis Cancer Mortality by County of Residence,	
Nevada Residents, 2000-2004	311

Table 187. Kidney and Renal Pelvis Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 2000-2004	311
Table 188. Kidney and Renal Pelvis Cancer Mortality by Age Group and Gender, Nevada Residents, 2000-2004	
Table 189. Median Age at Death from Kidney and Renal Pelvis Cancer by Race/Ethnicity and Gender, Nevada Residents, 2000-2004.	313
SURVIVAL RATE	
Figure 125. Survival Rates for Kidney and Renal Pelvis Cancer by Race/Ethnicity, Nevada Residents, 2000-2004	314
Figure 126. Survival Rates for Kidney and Renal Pelvis Cancer by Stage of Cancer at Diagnosis Nevada Residents, 2000-2004	,
Table 190. Cause-Specific Survival Rates for Kidney and Renal Pelvis Cancer by	314
Race/Ethnicity and Gender, Nevada Residents, 2000-2004	315
Table 191. Cause-Specific Survival Rates for Kidney and Renal Pelvis Cancer byStage of Cancer at Diagnosis and Gender, Nevada Residents, 2000-2004	316

LIP, ORAL CAVITY AND PHARYNX CANCER

GENERAL PROFILE ⁴	
Figure 127. Anatomy of the Oral Cavity ⁵	318
INCIDENCE	
Figure 128. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2000) Incidence Rates,	
Nevada Residents, 2000-2004	
Figure 129. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Incidence Rates by County/Region	
of Residence, Nevada Residents, 2000-2004	
Figure 130. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Incidence Rates by Race/Ethnicit	
Nevada Residents, 2000-2004	322
Table 192. Lip, Oral Cavity and Pharynx Cancer Cases by Gender, Race/Ethnicity and	
County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and	
	323
Table 193. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and County/Region of	224
Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)	324
Table 194. Lip, Oral Cavity and Pharynx Cancer Cases by County of Residence at Diagnosis,	325
Nevada Residents, 2000-2004 Table 195. Lip, Oral Cavity and Pharynx Cancer Cases by Race/Ethnicity and Gender,	525
Nevada Residents, 2000-2004	325
Table 196. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and Gender,	525
Nevada Residents, 2000-2004	326
Table 197. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and Stage,	520
Nevada Residents, 2000-2004	327
Table 198. Lip, Oral Cavity and Pharynx Cancer Cases by Stage and Race/Ethnicity,	
	328
Table 199. Median Age at Diagnosis of Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity a	nd
Gender, Nevada Residents, 2000-2004	
INPATIENT HOSPITAL DISCHARGES	
Figure 131. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2000) Inpatient Discharge Rates	5.
Nevada Residents, 2000-2004	

Figure 132. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 2000-2004
County/Region of Residence, Nevada Residents, 2000-2004
Figure 134. Average Length of Stay for Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges
by County/Region of Residence, Nevada Residents, 2000-2004
Table 200. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004
Table 201. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group and
County/Region of Residence, Nevada Residents, 2000-2004
Table 202. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 2000-2004
Table 203. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by County/Region of
Residence, Nevada Residents, 2000-2004
Table 204. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group, Charges and
Length of Stay, Nevada Residents, 2000-2004
MORTALITY
Figure 135. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2000) Mortality Rates,
Nevada Residents, 2000-2004
Figure 136. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 2000-2004
Figure 137. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Mortality Rates by Race/Ethnicity,
Nevada Residents, 2000-2004
Table 205. Lip, Oral Cavity and Pharynx Cancer Mortality by Gender, Race/Ethnicity and
County/Region of Residence, Nevada Residents, 2000-2004
Table 206. Lip, Oral Cavity and Pharynx Cancer Mortality by Age Group and County/Region of
Residence, Nevada Residents, 2000-2004
Table 207. Lip, Oral Cavity and Pharynx Cancer Mortality by County of Residence,
Nevada Residents, 2000-2004
Table 208. Lip, Oral Cavity and Pharynx Cancer Mortality by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004
Table 209. Lip, Oral Cavity and Pharynx Cancer Mortality by Age Group and Gender, Nevada Description
Residents, 2000-2004
Table 210. Median Age at Death from Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity and Gender, Nevada Residents, 2000-2004
SURVIVAL RATE
Figure 138. Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity,
Nevada Residents, 2000-2004
Diagnosis, Nevada Residents, 2000-2004
Table 211. Cause-Specific Survival Rates for Lip, Oral Cavity and Pharynx Cancer by
Race/Ethnicity and Gender, Nevada Residents, 2000-2004
Table 212. Cause-Specific Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Stage of
Cancer at Diagnosis and Gender, Nevada Residents, 2000-2004
Cancer at Diagnosis and Cender, i terada residents, 2000-200 fining and and and a

LEUKEMIA

GENERAL PROFILE⁴

Figure 140. Anatomy of Stem Cell Maturation	347
INCIDENCE	
Figure 141. Leukemia Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004	350
Figure 142. Leukemia Age-Adjusted Incidence Rates by County/Region of Residence, Nevada	
Residents, 2000-2004	351
Figure 143. Leukemia Age-Adjusted Incidence Rates by Race/Ethnicity,	
Nevada Residents, 2000-2004	351
Table 213. Leukemia Cases by Gender, Race/Ethnicity and County/Region of Residence at	
Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)	352
Table 214. Leukemia Cases by Age Group and County/Region of Residence at Diagnosis, Neva	
Residents (2000-2004) and SEER-17 (2000-2004)	353
Table 215. Leukemia Cases by County of Residence at Diagnosis,	
Nevada Residents, 2000-2004	354
Table 216. Leukemia Cases by Race/Ethnicity and Gender, Nevada Residents, 2000-2004	354
Table 217. Leukemia Cases by Age Group and Gender, Nevada Residents, 2000-2004	
Table 218. Leukemia Incidence by Age Group and Stage, Nevada Residents, 2000-2004	356
Table 219. Leukemia Cases by Stage and Race/Ethnicity, Nevada Residents, 2000-2004	357
Table 220. Median Age at Diagnosis of Leukemia by Race/Ethnicity and Gender,	
Nevada Residents, 2000-2004	357
INPATIENT HOSPITAL DISCHARGES	
Figure 144. Leukemia Age-Adjusted (2000) Inpatient Discharge Rates,	
Nevada Residents, 2000-2004	
Figure 145. Leukemia Age-Adjusted Inpatient Discharge Rates by County/Region of Residence	
Nevada Residents, 2000-2004	
Figure 146. Median Charges for Leukemia Inpatient Discharges by County/Region of Residence	
Figure 147. Average Length of Stay for Leukemia Inpatient Discharges by County/Region of	
Residence, Nevada Residents, 2000-2004	
Table 221. Leukemia Inpatient Discharges by Gender, Charges, Length of Stay, and County/Reg	
of Residence, Nevada Residents, 2000-2004.	
Table 222. Leukemia Inpatient Discharges by Age Group and County/Region of Residence,	
Nevada Residents, 2000-2004	362
Table 223. Leukemia Inpatient Discharges by Age Group and Gender,	
Nevada Residents, 2000-2004	363
Table 224. Leukemia Inpatient Discharges by County/Region of Residence, Nevada Residents,	
2000-2004	364
Table 225. Leukemia Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada	
Residents, 2000-2004	364
MORTALITY	
Figure 148. Leukemia Age-Adjusted (2000) Mortality Rates, Nevada Residents, 2000-2004	
Figure 149. Leukemia Age-Adjusted Mortality Rates by County/Region of Residence,	
Nevada Residents, 2000-2004	366
Figure 150. Leukemia Age-Adjusted Mortality Rates by Race/Ethnicity,	
Nevada Residents, 2000-2004	366
Table 226. Leukemia Mortality by Gender, Race/Ethnicity and County/Region of Residence,	
Nevada Residents, 2000-2004	

Table 227. Leukemia Mortality by Age Group and County/Region of Residence,
Nevada Residents, 2000-2004
Table 228. Leukemia Mortality by County of Residence, Nevada Residents, 2000-2004
Table 229. Leukemia Mortality by Race/Ethnicity and Gender, Nevada Residents, 2000-2004369
Table 230. Leukemia Mortality by Age Group and Gender, Nevada Residents, 2000-2004
Table 231. Median Age at Death from Leukemia by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004
SURVIVAL RATE
Figure 151. Survival Rates for Leukemia by Race/Ethnicity, Nevada Residents, 2000-2004
Figure 152. Survival Rates for Leukemia by Stage of Cancer at Diagnosis,
Nevada Residents, 2000-2004
Table 232. Cause-Specific Survival Rates for Leukemia by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004
Table 233. Cause-Specific Survival Rates for Leukemia by Stage of Cancer at Diagnosis and
Gender, Nevada Residents, 2000-2004
PANCREATIC CANCER
GENERAL PROFILE ⁴
Figure 153. Anatomy of the Endocrine System ⁵
INCIDENCE
Figure 154. Pancreatic Cancer Age-Adjusted (2000) Incidence Rates,
Nevada Residents, 2000-2004
Figure 155. Pancreatic Cancer Age-Adjusted Incidence Rates by County/Region of Residence,
Nevada Residents, 2000-2004
Figure 156. Pancreatic Cancer Age-Adjusted Incidence Rates by Race/Ethnicity,
Nevada Residents, 2000-2004
Table 234. Pancreatic Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at
Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)
Table 235. Pancreatic Cancer Cases by Age Group and County/Region of Residence at Diagnosis,
Nevada Residents (2000-2004) and SEER-17 (2000-2004)
Table 236. Pancreatic Cancer Cases by County of Residence at Diagnosis,
Nevada Residents, 2000-2004
Table 237. Pancreatic Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 2000-2004
Table 238. Pancreatic Cancer Cases by Age Group and Gender, Nevada Residents, 2000-2004
Table 239. Pancreatic Cancer Cases by Age Group and Stage, Nevada Residents, 2000-2004385
Table 240. Pancreatic Cancer Cases by Stage and Race/Ethnicity, Name da Davidante 2000/2004
Nevada Residents, 2000-2004
Table 241. Median Age at Diagnosis of Pancreatic Cancer by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004
INPATIENT HOSPITAL DISCHARGES
Figure 157. Pancreatic Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents,
2000-2004
Figure 158. Pancreatic Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of
Residence, Nevada Residents, 2000-2004
Figure 159. Median Charges for Pancreatic Cancer Inpatient Discharges by County/Region of

Residence, Nevada Residents, 2000-2004	388
Figure 160. Average Length of Stay for Pancreatic Cancer Inpatient Discharges by County/Reg	
of Residence, Nevada Residents, 2000-2004	
Table 242. Pancreatic Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and	
County/Region of Residence, Nevada Residents, 2000-2004	
Table 243. Pancreatic Cancer Inpatient Discharges by Age Group and County/Region of Reside	
Nevada Residents, 2000-2004	
Table 244. Pancreatic Cancer Inpatient Discharges by Age Group and Gender, Nevada Residen 2000-2004	ts,
Table 245. Pancreatic Cancer Inpatient Discharges by County/Region of Residence, Nevada	
Residents, 2000-2004	393
Table 246. Pancreatic Cancer Inpatient Discharges by Age Group, Charges and Length of Stay,	
Nevada Residents, 2000-2004	
MORTALITY	
Figure 161. Pancreatic Cancer Age-Adjusted (2000) Mortality Rates,	20.4
Nevada Residents, 2000-2004	394
Figure 162. Pancreatic Cancer Age-Adjusted Mortality Rates by County/Region of Residence,	205
Nevada Residents, 2000-2004	395
Figure 163. Pancreatic Cancer Age-Adjusted Mortality Rates by Race/Ethnicity,	205
Nevada Residents, 2000-2004	
Table 247. Pancreatic Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residents. 2000. 2004	
Nevada Residents, 2000-2004 Table 248. Pancreatic Cancer Mortality by Age Group and County/Region of Residence,	
Nevada Residents, 2000-2004	307
Table 249. Pancreatic Cancer Mortality by County of Residence,	
Nevada Residents, 2000-2004	308
Table 250. Pancreatic Cancer Mortality by Race/Ethnicity and Gender,	
Nevada Residents, 2000-2004	398
Table 251. Pancreatic Cancer Mortality by Age Group and Gender,	
Nevada Residents, 2000-2004	399
Table 252. Median Age at Death from Pancreatic Cancer by Race/Ethnicity and Gender, Nevad	
Residents, 2000-2004.	
SURVIVAL RATE Figure 164 Survival Botos for Dependencetic Concernby Boos (Ethnicity	
Figure 164. Survival Rates for Pancreatic Cancer by Race/Ethnicity,	401
Nevada Residents, 2000-2004 Figure 165. Survival Rates for Pancreatic Cancer by Stage of Cancer at Diagnosis, Nevada	401
Residents, 2000-2004	401
Table 253. Cause-Specific Survival Rates for Pancreatic Cancer by Race/Ethnicity and Gender,	
Nevada Residents, 2000-2004	
Table 254. Cause-Specific Survival Rates for Pancreatic Cancer by Stage of Cancer at Diagnos	
Gender, Nevada Residents, 2000-2004	
	105
ALL OTHER CANCERS	
Table 255. Cancer Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer,	

	Ý 1	1	U	5 5 51	,
Nevada Residents.	2000-2004.				

SKIN CANCER

Figure 166. Anatomy of the Skin ⁴
Table 256. Skin Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence atDiagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)
Table 257. Skin Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004 408
Table 258. Skin Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 2000-2004
UTERINE CANCER
Figure 167. Anatomical Drawing of Female Reproductive System ⁴ 410 Table 259. Uterine Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at
Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)
County/Region of Residence, Nevada Residents, 2000-2004
Table 261. Uterine Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 2000-2004
OVARIAN CANCER
 Figure 168. Anatomical Drawing of Female Reproductive System⁴
County/Region of Residence, Nevada Residents, 2000-2004
Table 264. Ovarian Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 2000-2004
THYROID GLAND CANCER
Figure 169. Anatomical Drawing of the Thyroid Gland ⁴
Table 265. Thyroid Gland Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)
Table 266. Thyroid Gland Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004 420
Table 267. Thyroid Gland Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 2000-2004
BRAIN AND OTHER CENTRAL NERVOUS SYSTEM CANCER Figure 170. Anatomical Drawing of the Brain and Nearby Structures ⁴
Table 268. Brain and Other Central Nervous System Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and
SEER-17 (2000-2004)
Table 269. Brain and Other Central Nervous System Cancer Inpatient Discharges by Gender,Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004424
Table 270. Brain and Other Central Nervous System Cancer Mortality by Age Group andCounty/Region of Residence, Nevada Residents, 2000-2004425
STOMACH CANCER Figure 171. Anatomical Drawing of the Esophagus and Stomach ⁵ 426
Table 271. Stomach Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)
= 1000000000000000000000000000000000000

 Table 272. Stomach Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004
LIVER AND INTRAHEPATIC BILE DUCTS CANCER Figure 172. Anatomical Drawing of the Digestive System ⁵
CERVICAL CANCER Figure 173. Anatomical Drawing of the Female Reproductive System ⁴
 ESOPHAGEAL CANCER Figure 174. Anatomical Drawing of the Esophagus and Stomach⁵
 LARYNX CANCER Figure 175. Anatomy of the Oral Cavity⁵
MULTIPLE MYELOMA Figure 176. Picture of Myeloma Cells ⁴

County/Region of Residence, Nevada Residents, 2000-2004	
Table 289. Multiple Myeloma Mortality by Age Group and County/Region of Residen	
Residents, 2000-2004	

HODGKIN'S LYMPHOMA

Figure 177. Anatomy of the Lymphatic System ⁴	451
Table 290. Hodgkin's Lymphoma Cases by Gender, Race/Ethnicity and County/Region of	
Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)	452
Table 291. Hodgkin's Lymphoma Inpatient Discharges by Gender, Charges, Length of Stay, and	ıd
County/Region of Residence, Nevada Residents, 2000-2004	453
Table 292. Hodgkin's Lymphoma Mortality by Age Group and County/Region of Residence,	
Nevada Residents, 2000-2004	454

ALL OTHER SITES

Table 293. Cancer Cases for All Other Sites by Gender, County/Region of Residence at Diagno	osis
and Race/Ethnicity, Nevada Residents (2000-2004) and SEER-17 (2000-2004)	455
Table 294. Inpatient Discharges for All Other Sites by Gender, Charges, Length of Stay, and	
County/Region of Residence, Nevada Residents, 2000-2004	456
Table 295. All Other Sites Cancer Mortality by Age Group and County/Region of Residence,	
Nevada Residents, 2000-2004	457

APPENDIX A – CODES USED FOR GROUPING

Table 296. ICD-O Codes Used		9
Table 297. ICD-9 and ICD-10 Codes	Used46	1

TECHNICAL NOTES

This report brings together information from four primary data sources. The Nevada Central Cancer Registry (NCCR) within the Bureau of Health Planning and Statistics provided cancer incidence data. The Center for Health Information Analysis at the University of Nevada, Las Vegas (UNLV) provided inpatient hospital discharge (UB92) data. The Office of Vital Records (OVR), also within the Bureau of Health Planning and Statistics, provided the mortality data for this report. The Behavioral Risk Factor Surveillance System (BRFSS) data used to determine the rates of cancer screening are collected by the Center for Applied Research at the University of Nevada, Reno (UNR) and are stored and maintained by the Bureau of Health Planning and Statistics, Center for Health Data and Research.

General considerations that were made for this report include:

Aggregation of Data

This is a statistical report. Every attempt has been made to present the data in a format that does not allow the identification of an individual to be possible. While demographic information such as sex, race/ethnicity and age has been included in aggregate form, no attempt should be made to identify any individual detailed in this report.

<u>Types of Cancer Classification Systems</u>

The classification of the types of cancer was based upon a different coding system for each data source. The NCCR uses the International Classification of Disease, Oncology coding structure (ICD-O) that includes Topography (Primary Site) as well as Morphology (Tumor Type). This is similar to the ICD-10 system used in the 2000 to 2004 mortality data, to classify types of cancers. The 1998 mortality data that has been used for previous reports were coded using the ICD-9 classification system, which was also used by the inpatient hospital discharge data. A more detailed description of the codes used for this report is listed under considerations for each data source below, as well as in Appendix B.

<u>Each data source is exclusive</u>

While this report presents cancer data from four different sources, it is important to remember that each dataset is external to the others shown. Individual records were not linked for this report, so caution should be used when comparing data from each data source.

<u>Selection of Residence</u>

Only those events where the person was recorded as a Nevada resident at the time of diagnosis, time of discharge or time of death were included in this report. Those individuals who were listed as an Out of State resident were excluded.

<u>County/Region of Residence</u>

This report details regional data as: Clark County, Washoe County and All Other Counties, as regions. This aggregation of the 15 remaining counties within Nevada was implemented to accommodate the significantly smaller population sizes in these counties. Aggregation of the smaller population minimizes any extraneous fluctuations in the disease rates presented in this report that may occur due to the large variance in the number of cancer events for each area due to the small size of the resident population for these remaining counties. The counties included in the All Other Counties region are: Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine.

Map Representation

The maps presented in this report are provided to facilitate visual comparisons of rates within the state. However, caution should be used when interpreting these rates due to the small cell size and large variance that are present with many of the smaller counties in Nevada.

<u>Gender Specific Cancer Rates</u>

For gender specific cancers, such as Prostate, Female Breast, Cervix Uteri, Corpus Uteri & Uterus Not Otherwise Specified (NOS), and Ovary Cancers the rates listed in this report are per 100,000 gender-specific population, unless otherwise noted.

<u>Calculation of Rates and Confidence Intervals</u>

Rates and their respective confidence intervals were not calculated for those categories where the number of events was less than ten.

<u>Racial/Ethnic Groups</u>

Race/ethnicity groups used in this report: White, Black, Native American, Asian, and Hispanic were calculated to be mutually exclusive, except for the national rates where a similar population base could not be calculated. So, national rates for racial/ethnic groups are calculated based on either the race or ethnicity listed on the record. These rates may not be directly comparable with others listed in this report.

<u>Other/Unknown Groups</u>

Due to the relatively small number of cases/admissions/deaths that occur with the classification of Other/Unknown, these have not been shown separately in most tables due to the limited number and any incremental information that would be provided is minimal. Therefore, while the numbers of unknown cases may not be shown in all tables, these values are included in the more general groups for reporting purposes.

While every effort was made to develop reliable comparisons between all the data sources, each source had their own unique factors to consider. Below, in detail, are the specific differences between each source and how this report uses each type of information.

CANCER INCIDENCE STATISTICS:

The cancer incidence statistics used for this report are from the NCCR, which compiles cancer cases that are reported by, or abstracted from, hospitals and pathology labs in Nevada. Both Chapter 457 of the Nevada Revised Statutes and those regulations adopted by the State Board of Health regulate the Nevada Central Cancer Registry. More information on the reporting of information on cancer can be found under Chapter 457 of the Nevada Administrative Code. The NCCR also receives information from other states on Nevada residents who were diagnosed, or are being treated, in other states.

The main considerations for this data source include:

<u>Cancer Registry Reporting</u>

The NCCR is a population-based registry. The validity of the numbers and rates used in this report depend on the completeness of cancer reporting, as well as the accuracy of the population estimates used. The North American Association of Central Cancer Registries (NAACCR) estimates the most current year of data presented in this report (2004) at 96.1% complete for case ascertainment and meets all other requirements for gold certification.

Updated Data

The NCCR is constantly being updated with new information, so the numbers published in this report may not match, or be directly comparable, with previously published data. The data that are presented in this report are from the NCCR as of the December 2006 NAACR submission.

<u>Type of Cancers Reported</u>

The number of cases included in this report are those reported as having an invasive disease, except for Breast and Urinary Bladder Cancer that also include those diagnosed with an in situ cancer. This distinction is not available in the other data sources.

<u>Type of Cancer Classification System</u>

The type of cancer was classified based on ICD-O2 Topography and Morphology codes. These codes provide levels of detail to the type of cancer that are not included in either the inpatient hospital discharge or mortality data. A detailed list of the actual groupings used for cancer incidence data, using both Topography and Morphology codes, can be found in Appendix B.

<u>Survival Rates & Calculation</u>

The survival rates listed in this report may not be directly comparable to national survival statistics. The reader should exercise caution in comparing statistics listed in this report to those nationally reported. Major factors that should be considered are:

- 1. Survival rate calculations are based upon the number of cases being followed up and being verified for the survival status with the cohort subjects. Due to certain cancers having large numbers of "lost to follow-up" and "withdrawn alive" cases the remaining cohorts of these cancers are very small, especially after several years of follow-up. Therefore, please use extreme caution in interpreting the data (especially the four to five year groupings) presented in this report.
- 2. The rates do not include those reported as an Autopsy Only or Death Certificate Only (DCO) case.
- 3. Only those individuals who died from cancer and those still alive at last update are included in these calculations. Those dying from other causes of death are not included. However, it should be noted that the cause of death is not necessarily specific to the type of cancer listed at time of diagnosis. This is to include those cases where the cancer may have metastasized to another site.
- 4. The NCCR actively matches registry records to the Nevada Death Registry on a continuous basis. National statistics are usually based on data submitted at a certain point in time without future updates and data improvements. While calculations account for this difference, caution should be used when comparing the two areas.
- 5. Those individuals who are recorded as having multiple primaries are included for the first primary only.
- 6. Calculations exclude records with invalid dates and unknown ages.
- 7. National statistics typically exclude those cases not actively followed. This report does not make this exclusion.

INPATIENT HOSPITAL DISCHARGE STATISTICS:

The Inpatient Hospital Discharge data used for this report were compiled by the Center for Health Information Analysis (CHIA) at the University of Nevada, Las Vegas (UNLV/CHIA) from the universal billing form [#]92, (UB92) for inpatient hospital discharges. These data represent patients discharged from January 1, 2000 through December 31, 2004, inclusive. This information was gathered and computerized by UNLV/CHIA as part of a contractual agreement between the Department of Health and Human Services and the University of Nevada under the authority granted in Section 439B of the Nevada Revised Statutes. The information was then given to the Center for Health Data and Research where it was analyzed for this report.

The main considerations for this data source include:

Primary Diagnosis Selection

The number of resident inpatient discharges detailed in this report is based on a primary diagnosis of cancer. However, the database contains up to fourteen additional diagnoses. The difference between the two classifications is that there were 64,038 inpatient discharges that had cancer as any of the fifteen diagnoses. The number drops to 34,449 for those with cancer as the primary diagnosis. So, approximately 53.8% of the inpatient discharges related to cancer are published in

this report. This was done to minimize any confusion that might occur from someone being treated for different types of cancer, as well as to focus on those discharges where cancer was the primary reason for being admitted.

Occurrence Based Data

These statistics are based on the occurrence of inpatient hospital discharges. An individual could be counted more than once had they been admitted to the hospital for cancer more than once during this period. So, caution should be used when comparing inpatient hospital discharge data to the other data sources in this report.

<u>Type of Cancer Classification System</u>

The inpatient hospital discharge statistics were coded with the ICD-9 system. This is the same structure that was used in previous reports for the mortality data prior to 1999. After 1999 the mortality data changed to the ICD-10 version. A detailed list of the codes used to produce the groupings provided in this report for inpatient hospital discharge statistics can be found in Appendix B.

<u>Racial/Ethnic Groups</u>

Race/ethnicity information is not available in this database.

MORTALITY STATISTICS:

The mortality statistics used in this report are from the Nevada Death Registry maintained by the Office of Vital Records (OVR). The OVR, within the Bureau of Health Planning and Statistics, is the official government entity that collects, processes and maintains the state of Nevada's vital records. Deaths are first recorded at the county level before being forwarded to the State Registrar. Funeral Directors, or persons acting as such, are legally charged with filing death certificates.

These certificates are checked for completeness and accuracy and then entered into a database on the state mainframe computer system. When a certificate is found to be inaccurate or incomplete, staff follow up with the providing entity in accordance with NRS 440.150 to make the necessary corrections and/or additions to make the record satisfactory and complete. It should be noted that the quality of mortality data presented in this report is directly related to the accuracy and completeness of the information contained on the death certificates.

The main considerations for this data source include:

<u>Underlying Cause of Death</u>

The mortality data presented in this report are classified by the underlying (primary) cause responsible for death. Only those deaths where the underlying cause of death was cancer are included in this report.

<u>Type of Cancer Classification System</u>

The 1998 data used for previous reports were originally coded using the ICD-9 coding structure, while data after 1999 were coded using the ICD-10 system. The ICD-9 system is a purely numeric coding system while the ICD-10 is an alphanumeric system. While there are many similarities between the ICD-9 and ICD-10 groupings, there are some differences between the types of cancer within the two versions. While there are comparability ratios available for the conversion between the two systems, the groups used in this report are based upon some customized groupings of which comparability ratios are unavailable. The mortality numbers in this report have not been adjusted for coding differences that may have occurred with the transition from the ICD-9 to ICD-10 system. A detailed list of the actual groupings used for cancer mortality data, with both the ICD-9 and ICD-10 codes, can be found in Appendix B.

CANCER SCREENING STATISTICS:

The cancer screening data shown in this report come from the Behavioral Risk Factor Surveillance System (BRFSS), which is funded by the Center for Disease Control and Prevention (CDC). The data were compiled by the Center for Applied Research at the University of Nevada, Reno (UNR/CAR), through the nation's largest telephone survey. The survey data presented in this report covers years from 2000 to 2004. This information was gathered and computerized by the Center for Applied Research and then given to the Center for Health Data and Research as part of a contractual agreement between the Department of Health and Human Services and the University of Nevada.

The main considerations for this data source include:

Age of Respondents

The survey covers only those people 18 years of age and older.

• <u>Frequency of questions</u>

The tables presented in this report are not for 2000 to 2004 inclusively. Some of the questions were asked on alternate years, while some have only been asked once. So, caution should be used when comparing these data.

Weighted percentages

The percentages listed in this report are weighted on the survey population characteristics and may not match percentages that are directly calculated from the numbers listed in the table.

NATIONAL STATISTICS:

The only national cancer statistics provided in this report are for cancer incidence. This information is from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program. This program is the most comprehensive source of population-based cancer incidence information available for the United States. SEER covers approximately 26.2 percent of the US population through 17 population-based cancer registries.

The information presented in this report is based upon the customized use of SEER's public-use data featured within the SEER*Stat program. The "Incidence – SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying)" and "Incidence – SEER 17 Regs Limited-Use, Nov 2006 Sub (2000-2004)" databases were those used in this report's calculations. These databases are based upon SEER's 17 population-based cancer registries, which are: San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey. These registries have been designed to represent the incidence of cancer within the aggregate population of the United States.

The main considerations for this data source include:

Aggregation of Data

National statistics published in this report follow the guidelines in the SEER Public-Use data agreement. Therefore, those categories where the number is less than five are not shown.

<u>Cancer Registry Reporting</u>

The national data in this report are based upon data collected from populationbased registries. The validity of the numbers and rates used in this report depend upon the completeness of the cancer reporting, as well as the accuracy of the population estimates used.

<u>Period of Reportable Data</u>

The most recent SEER data available are for the 2000 to 2004 period, so there is not a period difference between the Nevada and SEER data in this report.

<u>Type of Cancers Reported</u>

The number of cases listed in this report are those cases reported as having malignant behavior, except for Breast and Urinary Bladder Cancer that include those diagnosed with an in situ behavior, in order to be comparable with Nevada data.

Prostate Cancer Stage Revision

Prostate Cancer cases where the stage of cancer at time of diagnosis was originally coded as "Localized/regional (Prostate Cases 1995+)" are shown as localized within this report. Therefore, there will not be any regionally diagnosed cases of Prostate Cancer for the nation listed in this report.

Racial/Ethnic Groups

Race/ethnicity groupings, similar to Nevada, were not available for rates, since the population estimates provided in SEER*Stat were not organized in a similar format. Rates were available by either race or ethnicity, which means that the national rates presented in this report represent rates of Whites, Blacks, Native Americans and Asians (of any ethnicity) and Hispanics (of any race). Caution should be used when interpreting these rates, which may not be directly comparable with others listed in this report.


POPULATION ESTIMATES:


The Nevada population data used in this report are based on the database established by the Nevada State Demographer's Office and the Nevada Department of Taxations, as well as 1990 and 2000 Census data from the US Bureau of the Census.

OVERVIEW

OVERVIEW <u>HIGHLIGHTS</u>


- Lung And Bronchus was the leading type of cancer for incidence, inpatient hospital discharges and mortality in Nevada from 2000 to 2004. This type of cancer accounted for 15.7% of the total cancer incidence, 13.9% of all cancer inpatient hospital discharges, and 31.0% of cancer mortality during this period.
- Thyroid Gland Cancer by far had the highest comparison ratio of incidence to mortality age-adjusted rates of any type of cancer in Nevada, with a ratio of 34.99, from 2000 to 2004. This means that for every 100 deaths from Thyroid Gland Cancer there would be 3,499 cases. The second leading type was Hodgkin's Lymphoma with a ratio of 7.08.
- Pancreatic Cancer had the lowest comparison ratio of incidence to mortality age-adjusted rates of any type of cancer in Nevada, with a ratio of 1.04 during this period. This means that for every 100 deaths from Pancreatic Cancer there were 104 cases. The second leading type of cancer, Liver and Intrahepatic Bile Ducts, had a ratio of 1.08.







Note: "N/A" indicates that this type of Cancer was not in the Top Ten for the respective data source.

Figure 2. Highest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer, Nevada Residents, 2000-2004







	Incide	nce	Inpatient Di	Mort	
Type of Cancer	Number	Rate*	Number	Rate*	Number
Total	49,963	480.00	34,796	330.00	19,379
Lip, Oral Cavity and Pharynx	1,171	11.00	526	4.80	296
Lip	48	0.46	8		2
Base of Tongue	184	1.70	90	0.81	3
Other & Unspecified Parts of Tongue	182	1.70	95	0.86	77
Parotid Gland	96	0.96	46	0.44	15
Other & Unspecified Major Salivary glands	30	0.28	10	0.08	3
Floor of Mouth	89	0.83	46	0.40	3
Gum	33	0.31	31	0.29	4
Palate	47	0.45	12	0.11	6
Other & Unspecified Parts of Mouth	61	0.58	26	0.24	26
Nasopharynx	70	0.64	24	0.21	28
Tonsil	162	1.50	43	0.38	19
Oropharynx	48	0.43	24	0.21	20
Pyriform Sinus	45	0.44	16	0.15	1
Hypopharynx	41	0.37	25	0.22	3
Other & Unspecified Oral (Buccal) Cavity & Pharynx	35	0.33	30	0.30	86
Digestive System	8,452	84.00	7,018	69.00	4,527
Esophagus	545	5.20	302	2.90	459
Stomach	639	6.40	597	5.80	346
Small Intestine	140	1.30	161	1.60	34
Colon (excluding Rectum)	3,593	36.00	2,966	30.00	1,718
Cecum	827	8.50	643	6.70	10
Appendix	50	0.49	34	0.31	4
Ascending Colon	543	5.60	553	5.60	3
Hepatic Flexure	147	1.50	126	1.30	0
Transverse Colon	263	2.70	258	2.70	1
Splenic Flexure	97	0.91	111	1.10	0
Descending Colon	182	1.80	151	1.50	0
Sigmoid Colon	1,038	10.00	789	7.70	10
Large Intestine, NOS	446	4.70	301	3.00	1,690
Rectum	959	9.20	726	7.00	205
Rectosigmoid Junction	474	4.60	598	5.70	86
Anus, Anal Canal and Anorectum	147	1.40	143	1.40	21
Liver	503	4.80	336	3.20	419
Intrahepatic Bile Ducts	52	0.53	43	0.43	82
Gallbladder	68	0.68	29	0.28	39
Other & Unspecified Biliary Tract	160	1.60	151	1.50	51
Pancreas	1,075	11.00	848	8.30	1,017
Retroperitoneum	42	0.38	55	0.51	4
Peritoneum, Omentum and Mesentery	34	0.32	54	0.50	15
Other Digestive Organs	21	0.20	9		31
Respiratory System	8,401	81.00	5,155	49.00	6,138
Nasal Cavity and Middle Ear	40	0.38	10	-0.00	0,100
Accessory Sinuses	33	0.30	10	0.11	13
Larynx	391	3.70	166	1.60	108
Lung and Bronchus	7,839	76.00	4,842	46.00	6,005

Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality byType of Cancer, Nevada, 2000-2004

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and ageadjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality byType of Cancer, Nevada, 2000-2004 (Continued)

Trans (10)	Incide	Incidence		scharges	Mortality	
Type of Cancer	Number	Rate*	Number	Rate*	Number	Rate*
Total	49,963	480.00	34,796	330.00	19,379	197.00
Skin (Excluding Basal And Squamous)	2,023	19.00	206	2.00	378	3.70
Melanomas Of The Skin	2,023	19.00	93	0.86	298	2.80
Other Non-Epithelial Skin	0		113	1.10	80	0.83
Breast	7,824	73.00	2,276	22.00	1,357	14.00
Female Genital System*	2,474	45.00	2,488	45.00	801	15.00
Cervix Uteri*	514	9.40	609	11.00	149	2.80
Corpus Uteri*	986	18.00	915	17.00	59	1.10
Uterus, NOS*	47	0.88	31	0.58	96	1.90
Ovary*	734	13.00	721	13.00	456	8.50
Vagina*	33	0.62	37	0.70	10	0.19
Vulva*	132	2.50	129	2.40	18	0.35
Placenta*	4		3		0	
Other Female Genital Organs*	24	0.44	43	0.77	13	0.26
Male Genital System*	7,880	158.00	2,682	51.00	1,016	28.00
Prostate*	7,569	153.00	2,614	50.00	995	27.00
Testis*	268	4.70	51	0.87	15	0.30
Penis*	27	0.62	15	0.37	4	
Other Male Genital Organs*	16	0.32	2		2	
Urinary System	3,978	39.00	2,191	21.00	902	9.30
Urinary Bladder	2,567	26.00	1,033	11.00	474	5.10
Kidney	1,237	12.00	986	9.10	396	3.90
Renal Pelvis	73	0.70	84	0.82	4	
Ureter	56	0.54	71	0.70	11	0.10
Other Urinary Organs	45	0.47	17	0.16	17	0.17
Eye and Orbit	63	0.61	9		8	
Brain and Other Central Nervous System	663	6.30	946	8.80	415	4.00
Brain	611	5.80	874	8.10	409	3.90
Meninges	25	0.24	47	0.44	2	
Spinal Cord, Cranial Nerves, & Other Parts of CNS	27	0.25	25	0.23	4	
Endocrine System	1,178	11.00	1,617	15.00	53	0.53
Thyroid Gland	1,126	10.00	1,570	14.00	29	0.29
Adrenal Gland	19	0.19	19	0.18	14	0.14
Other Endocrine (Including Thymus)	33	0.32	28	0.28	10	0.10
Hodgkin's Lymphoma	279	2.50	118	1.10	37	0.35
Non-Hodgkin's Lymphoma	1,815	18.00	1,055	10.00	630	6.60
Multiple Myeloma	453	4.40	373	3.60	341	3.40
Leukemia	1,201	12.00	1,041	10.00	699	7.30
Lymphocytic	553	5.40	442	4.20	184	2.00
Acute Lymphocytic	137	1.30	302	2.80	44	0.44
Chronic Lymphocytic	381	3.80	136	1.40	128	1.40
Other Lymphocytic	35	0.33	4		12	0.13
Myeloid and Monocytic	565	5.60	552	5.30	295	3.00
Acute Myeloid	396	3.90	443	4.30	227	2.30
Acute Monocytic	22	0.24	10	0.11	2	
Chronic Myeloid	133	1.30	92	0.92	47	0.47
Other Myeloid/Monocytic	14	0.14	7		19	0.20
Other	83	0.91	47	0.47	220	2.30
Other Acute	39	0.40	33	0.33	84	0.84
Aleukemic, Subleukemic and NOS	44	0.51	14	0.14	136	1.50
Mesothelioma	0		1		73	0.72
Kaposi Sarcoma	0		0		0	
Other, III-Defined and Unspecified Sites	1,763	18.00	6,798	64.00	1,535	16.00

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 2. Leading Types of Cancer for Nevada Incidence, Inpatient HospitalDischarges and Mortality, Nevada Residents, 2000-2004

Type of Cancer	Incidence		Hosp Admis		Mortality		
	Number	Percent	Number	Percent	Number	Percent	
Lung and Bronchus	7,838	15.7%	4,842	13.9%	6,005	31.0%	
Breast	7,823	15.7%	2,276	6.5%	1,357	7.0%	
Prostate	7,569	15.2%	2,614	7.5%	995	5.1%	
Lip, Oral Cavity and Pharynx	1,171	2.3%	526	1.5%	296	1.5%	
Urinary Bladder	2,567	5.1%	1,033	3.0%	474	2.4%	
Non-Hodgkin's Lymphoma	1,815	3.6%	1,055	3.0%	630	3.3%	
Pancreas	1,074	2.1%	848	2.4%	1,017	5.2%	
Thyroid Gland	1,126	2.3%	1,570	4.5%	29	0.1%	
Ovary	734	1.5%	721	2.1%	457	2.4%	
Stomach	639	1.3%	597	1.7%	346	1.8%	
Esophagus	545	1.1%	302	0.9%	459	2.4%	
Cervix Uteri	514	1.0%	609	1.8%	149	0.8%	
Multiple Myeloma	453	0.9%	373	1.1%	341	1.8%	
Larynx	391	0.8%	166	0.5%	108	0.6%	
Hodgkin's Lymphoma	279	0.6%	117	0.3%	37	0.2%	
Colorectal	5,173	10.4%	4,433	12.7%	2,030	10.5%	
Kidney and Renal Pelvis	1,310	2.6%	1,070	3.1%	400	2.1%	
Leukemia	1,200	2.4%	1,040	3.0%	699	3.6%	
Skin	2,022	4.0%	93	0.3%	298	1.5%	
Corpus Uteri & Uterus NOS	1,033	2.1%	946	2.7%	156	0.8%	
Brain and Other Central Nervous System	663	1.3%	946	2.7%	415	2.1%	
Liver and Intrahepatic Bile Ducts	555	1.1%	379	1.1%	501	2.6%	
All Other Sites	3,463	6.9%	8,237	23.7%	2,180	11.2%	
Total	49,957	100.0%	34,793	100.0%	19,379	100.0%	

Note: Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

REPORT ON CANCER IN NEVADA 2000-2004

Table 3. Top Ten Types of Cancer by Gender, Incidence, Hospital Discharges, and Mortality,Nevada Residents, 2000-2004

Total

1 Lung And Bronchus 7,838 15.7% Lung And Bronchus 4,433 12.7% Colorectal 2 Breast 7,823 15.7% Colorectal 4,433 12.7% Colorectal 3 Prostate 7,569 Breast 2,276 6.5% Pancest 4 Colorectal 5.173 10.4% Breast 2,276 6.5% Pancest 5 Urinary Bladder 2,567 5.1% Thyroid Gland 1,570 4.5% Prostate 6 Skin 2,022 4.0% Kidney And Renal Pelvis 1,000 3.0% Lung And Bronchus 9 Leukernia 1,040 3.0% Lure And Intrahepatic Bile Duct: 3.0% Unrany Bladder 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus Total 49,963 100.0% Total 34,796 100.0% Total 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Li	Mortolity			
1 Lung And Bronchus 7,838 15,7% Lung And Bronchus 4,433 12,7% Colorectal 2 Breast 7,823 15,7% Colorectal 4,433 12,7% Colorectal 3 Prostate 7,569 Breast 2,276 6,5% Pancreas 4 Colorectal 5,1% Frootate 2,276 6,5% Pancreas 5 Urinary Bladder 2,567 5.1% Thyroid Gland 1,570 4,5% Prostate 6 Skin 2,022 4,0% Kidney And Renal Pelvis 1,040 3,0% Uriner And Intrahepatic Bile Ducts 9 Leukernia 1,040 3,0% Uriner Magkins Lymphoma 1,055 3,0% Uriner Magkins Lymphoma 10 Lip, Oral Cavity And Pharynx 1,171 2,3% Corpus Uteri & Uterus Nos 946 2,7% Esophagus 10 Lip, Oral Cavity And Pharynx 1,171 2,3% Total 34,796 100.0% Total 10 Prostate 7,569 </td <td></td> <td></td>				
2 Breast 7.823 15.7% Colorectal 4.433 12.7% Colorectal 3 Prostate 7.669 15.1% Prostate 2.614 7.5% Breast 4 Colorectal 5.13% Thyrind Gland 1.670 4.5% Prostate 5 Urinary Bladder 2.567 5.1% Thyrind Gland 1.670 3.0% Leukernia 7 Non-Hodgkins Lymphoma 1.815 3.6% Non-Hodgkins Lymphoma 1.055 3.0% Uner And Intrahepatic Bile Ducts 9 Leukernia 1.000 2.4% Urinary Bladder 1.033 3.0% Unrer And Intrahepatic Bile Ducts 9 Leukernia 1.010 38.488 77.0% Total of Top 10 20.879 60.0% Total of Top 10 7.58 England 10 Lip, Oral Castly And Pharynx 1.171 2.3% Corpost Total 3.4796 100.0% Total 100.0% Total 100.0% Total 100.0% Total 100.0% Total 100.0%<	Number	Percent		
3 Prostate 7.569 15.1% Prostate 2,276 6.5% Breast 4 Colorectal 5.173 10.4% Breast 2,227 6.5% Prostate 5 Urinary Bladder 2,267 5.1% Thyroid Gland 1,570 4.5% Prostate 6 Skin 2,222 4.0% Kidney And Renal Pelvis 1,010 3.1% Leukemia 1,040 3.0% Non-Hodgkins Lymphoma 8 Kidney And Renal Pelvis 1,310 2.6% Leukemia 1,040 3.0% Kinary Bladder 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus 11 Lor of Top 10 38,488 77.0% Total of Top 10 2.9,470 Total of Top 10 Top 10 12 Long And Bronchus 4,139 8.3% Long And Bronchus 7,1%	6,005	31.0%		
4 Colorectal 5, 173 10.4% Breast 2, 276 6.5% Pancreas 5 Winary Bladder 2, 577 5.1% Thynoid Gland 1, 570 3.1% Leukemia 6 Skin 2, 022 4.0% Kidney And Renal Pelvis 1, 010 3.1% Leukemia 7 Non-Hodgkins Lymphoma 1, 815 3.6% Non-Hodgkins Lymphoma 1, 055 3.0% Non-Hodgkins Lymphoma 9 Leukemia 1, 200 2.6% Leukemia 1, 040 3.0% Uriary Bladder 1, 033 3.0% Uniary Bladder 9 Leukemia 1, 200 2.4% Urinary Bladder 1, 033 3.0% Uniary Bladder 10 Lip, Oral Cavity And Pharynx 1, 171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus 10 Lotal of Top 10 38.4% 7.6% Total of Top 10 20.879 60.0% Total 11 Prostate 7.669 15.1% Prostate 2,643 7.1% Colorectal 12 Lung And Bronchus 4,139 8.3%	2,030	10.5%		
5Urinary Bladder2,6675,1%Thyroid Gland1,5704,5%Prostate6Skin2,0224.0%Kidney And Renal Pelvis1,0703,1%Leukemia7Non-Hodgkins Lymphoma1,8153.6%Non-Hodgkins Lymphoma1,0653,0%Non-Hodgkins Lymphoma8Kidney And Renal Pelvis1,3102.6%Urinary Bladder1,0333,0%Urinary Bladder10Leukemia1,2002.4%Urinary Bladder1,0333,0%Urinary Bladder10Total of Top 1038,48877.0%Total of Top 1020,87960.0%Total of Top 10-Total of Top 1038,48877.0%Total of Top 1020,87960.0%Total of Top 10-Total of Top 1038,48877.0%Total of Top 1020,87960.0%Total of Top 10-Total of Top 1038,48877.0%Total of Top 1020,87960.0%Total of Top 10-Total of Top 1038,48810.0%Total of Top 107.5%Long And Bronchus1,6751Iorge And Bronchus4,1398.3%Lung And Bronchus2,4637.1%Long And Bronchus1Long And Bronchus4,1398.3%Lung And Bronchus2,4637.1%Long And Bronchus3Colorectal2,8105.6%Colorectal2,3006.6%Prostate4Urinary Bladder1,9814.0%Urinary Bladder8.3%1.7%Non-Hodgkins Lym	1,357	7.0%		
6 Skin 2.022 4.0% Kidney And Renal Pelvis 1.070 3.1% Leukemia 7 Non-Hodgkins Lymphoma 1.815 3.6% Non-Hodgkins Lymphoma 1.055 3.0% Non-Hodgkins Lymphoma 8 Kidney And Renal Pelvis 1.310 2.6% Leukemia 1.040 3.0% Liver And Intrahepatic Bile Ducts 9 Leukemia 1.200 2.4% Urnary Bladder 1.033 3.0% Liver And Intrahepatic Bile Ducts 10 Lip, Oral Cavity And Pharynx 1.171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus - Total of Top 10 38,488 77.0% Total of Top 10 20,879 60.0% Total of Top 10 - Total 49,963 100.0% Total 34.796 100.0% Total of Top 10 1 Prostate 7.1% Lung And Bronchus 2.463 7.1% Colorectal 2 Lung And Bronchus 4.139 8.3% Lung And Bronchus 2.464 7.1% Colorectal	1,017	5.2%		
7 Non-Hodgkins Lymphoma 1,815 3.6% Non-Hodgkins Lymphoma 1,055 3.0% Non-Hodgkins Ligmphoma 8 Kidney And Renal Pelvis 1,200 2.4% Leukemia 1,003 3.0% Liver And Intrahepatic Bile Ducts 9 Leukemia 1,200 2.4% Urinary Bladder 1,033 3.0% Urinary Bladder 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus 7 Total of Top 10 38,488 77.0% Total of Top 10 20,879 60.0% Total of Top 10 7 Total 49,963 100.0% Total 34,796 100.0% Total 7 Total 49,963 100.0% Total 7.5% Lung And Bronchus 2,843 1 Prostate 7.569 15.1% Prostate 2,643 7.5% Lung And Bronchus 2 Colorectal 2,840 5.6% Colorectal 2,300 6.6% Prostate 6.6% Prostate	995	5.1%		
8 Kidney And Renal Pelvis 1,310 2.6% Leukemia 1,040 3.0% Liver And Intrahepatic Bile Ducts 9 Leukemia 1,200 2.4% Urinary Bladder 1,033 3.0% Urinary Bladder 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uleria & Ulerus Nos 94 2.7% Esophagus 7010 10 38.488 77.0% Total of Top 10 20.879 60.0% Total of Top 10 - Total 49.963 100.0% Total 34,796 100.0% Total 7 Total 10.1dence Hospital Admissions Mortality Mortality 7 Upg And Bronchus 4,139 8.3% Lung And Bronchus 2,430 6.6% Prostate 2.3% Pancreas 3 Colorectal 2,810 5.6% Colorectal 2.3% Pancreas 1.7% Sophagus 4 Urinary Bladder 1,981 4.0% Urinary Bladder 8.3% 1.7% Sophagus 1.7%<	699	3.6%		
9 Leukomia 1.200 2.4% Urinary Bladder 1,033 3.0% Urinary Bladder 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus Total of Top 10 38,488 77.0% Total of Top 10 20,879 60.0% Total of Top 10 Total of Top 10 20,879 60.0% Total 34,796 100.0% Total Male Mortality Type Number Percent Type Number Percent Type 1 Prostate 7,569 15.1% Prostate 2,614 7.5% Lung And Bronchus 2,463 7.1% Colorectal 2,300 6.6% Prostate 2 Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 2,300 6.6% Prostate 3 Colorectal 2,310 5.6% Kicholy And Renal Pelvis 664 2.0% Leukemia	630	3.3%		
10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos. 946 2.7% Esophagus Total of Top 10 38,488 77.0% Total of Top 10 20,879 60.0% Total of Top 10 - Total 49,963 100.0% Total 34,796 100.0% Total Male Male Mortality Type Number Percent Type Number Percent Type 1 Prostate 7,569 15.1% Prostate 2,463 7.1% Colorectal 2 Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 3 Colorectal 2,810 5.6% Colorectal 2.300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia <t< td=""><td>501</td><td>2.6%</td></t<>	501	2.6%		
10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos. 946 2.7% Esophagus Total of Top 10 38,488 77.0% Total of Top 10 20,879 60.0% Total of Top 10 - Total 49,963 100.0% Total 34,796 100.0% Total Male Male Mortality Type Number Percent Type Number Percent Type 1 Prostate 7,569 15.1% Prostate 2,463 7.1% Colorectal 2 Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 3 Colorectal 2,810 5.6% Colorectal 2.300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia <t< td=""><td>474</td><td>2.4%</td></t<>	474	2.4%		
- Total 49,963 100.0% Total 34,796 100.0% Total Male Incidence Hospital Admissions Mortality Type Number Percent Type Number Percent Type 1 Prostate 7,569 15.1% Prostate 2,614 7.5% Lung And Bronchus 2,483 7.1% Colorectal 2 Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 3 Colorectal 2,810 5.6% Colorectal 2,300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 597 1.7% Non-Hodgkins Lymphoma 1035 2.1% Lukemia 583 1.7% Non-Hodgkins Lymphoma 1035 2.1% Lukemia 1.5% Liver And Intrahepatic Bile Ducts	459	2.4%		
Male Hospital Admissions Mortality Type Number Percent Hospital Admissions Mortality 1 Prostate 7,569 15.1% Prostate 2,614 7.5% Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal Colorectal 2,300 6.6% Prostate Colorectal Prostate 1.014nary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 597 1.7% Isophagus Leukemia 597 1.7% Non-Hodgkins Lymphoma 1,035 2.1% Leukemia 597 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 1.035 2.1% Leukemia 597 1.7% Non-Hodgkins Lymphoma 1.035 2.1% Non-Hodgkins Lymphoma 1.0% Non-Hodgkins Lymphoma Liver And Intrahepatic Bile Ducts 1.0%	14,167	73.1%		
Ranking Incidence Hospital Admissions Mortality Type Number Percent Type Number Percent Type 1 Prostate 7,669 15.1% Prostate 2,614 7.5% Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 2,300 6.6% Prostate 3 Colorectal 2,810 5.6% Colorectal 2,300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 7 Lip, Oral Cavity And Pharynx 846 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 8 Kidney And Renal Pelvis 843 1.7% Brain And Other Central Nervou: 524 1.5% Liver And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Pancreas	19,379	100.0%		
Ranking Incidence Hospital Admissions Mortality Type Number Percent Type Number Percent Type 1 Prostate 7,669 15.1% Prostate 2,614 7.5% Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 2,300 6.6% Prostate 3 Colorectal 2,810 5.6% Colorectal 2,300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 7 Lip, Oral Cavity And Pharynx 846 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 8 Kidney And Renal Pelvis 843 1.7% Brain And Other Central Nervou: 524 1.5% Liver And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Pancreas				
TypeNumberPercentTypeNumberPercentType1Prostate7,56915.1%Prostate2,6147.5%Lung And Bronchus2Lung And Bronchus4,1398.3%Lung And Bronchus2,4637.1%Colorectal3Colorectal2,8105.6%Colorectal2,3006.6%Prostate4Urinary Bladder1,9814.0%Urinary Bladder8032.3%Pancreas5Skin1,2272.5%Kidney And Renal Pelvis6942.0%Leukemia6Non-Hodgkins Lymphoma1,0352.1%Leukemia5971.7%Resolvagus7Lip, Oral Cavity And Pharynx8461.7%Non-Hodgkins Lymphoma5831.7%Non-Hodgkins Lymphoma8Kidney And Renal Pelvis8431.7%Brain And Other Central Nervous5241.5%Liver And Intrahepatic Bile Ducts9Leukemia7001.4%Pancreas4181.2%Kidney And Renal Pelvis10Pancreas5521.1%Stomach4091.2%Kidney And Renal Pelvis10Evelkemia26,366100.0%Total16,799100.0%Total1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%				
1 Prostate 7,569 15.1% Prostate 2,614 7.5% Lung And Bronchus 2 Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 3 Colorectal 2,810 5.6% Colorectal 2,300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 6 Non-Hodgkins Lymphoma 1,035 2.1% Leukemia 597 1.7% Esophagus 7 Lip, Oral Cavity And Pharynx 846 1.7% Brain And Other Central Nervous 524 1.5% Live And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Pancreas 418 1.2% Urinary Bladder 10 Pancreas 552 1.1% Stomach 409 1.2% Kidney And Renal Pelvis Total of Top 10	Number	Percent		
2 Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 3 Colorectal 2,810 5.6% Colorectal 2,300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 6 Non-Hodgkins Lymphoma 1,035 2.1% Leukemia 597 1.7% Esophagus 7 Lip, Oral Cavity And Pharynx 846 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 8 Kidney And Renal Pelvis 843 1.7% Brain And Other Central Nervour 524 1.5% Lure And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Pancreas 418 1.2% Kidney And Renal Pelvis 10 Pancreas 552 1.1% Stomach 409 1.2% Kidney And Renal Pelvis		16.7%		
3 Colorectal 2,810 5.6% Colorectal 2,300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 6 Non-Hodgkins Lymphoma 1,035 2.1% Leukemia 597 1.7% Esophagus 7 Lip, Oral Cavity And Pharynx 846 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 8 Kidney And Renal Pelvis 843 1.7% Brain And Other Central Nervou: 524 1.5% Liver And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Brain And Other Central Nervou: 524 1.5% Liver And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Brain And Other Central Nervou: 524 1.5% Liver And Renal Pelvis 10 Pancreas 552 1.1% Stomach 409 1.2% Kid	3,244			
4Urinary Bladder1,9814.0%Urinary Bladder8032.3%Pancreas5Skin1,2272.5%Kidney And Renal Pelvis6942.0%Leukemia6Non-Hodgkins Lymphoma1,0352.1%Leukemia5971.7%Esophagus7Lip, Oral Cavity And Pharynx8461.7%Non-Hodgkins Lymphoma5831.7%Non-Hodgkins Lymphoma8Kidney And Renal Pelvis8431.7%Brain And Other Central Nervous5241.5%Liver And Intrahepatic Bile Ducts9Leukemia7001.4%Pancreas4181.2%Urinary Bladder10Pancreas5521.1%Stomach4091.2%Kidney And Renal Pelvis7Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-IncidenceHospital AdmissionsMortalityMortalityMortality2	1,120	5.8%		
5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 6 Non-Hodgkins Lymphoma 1,035 2.1% Leukemia 597 1.7% Esophagus 7 Lip, Oral Cavity And Pharynx 846 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 8 Kidney And Renal Pelvis 843 1.7% Brain And Other Central Nervous 524 1.5% Liver And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Pancreas 418 1.2% Urinary Bladder 10 Pancreas 552 1.1% Stomach 409 1.2% Kidney And Renal Pelvis 6 100 21,702 82.3% Total of Top 10 11,405 67.9% Total of Top 10 - Total of Top 10 21,702 82.3% Total of Top 10 11,405 67.9% Total of Top 10 - Total of Top 10 21,702 82.3% Total of Top 10 11,405 67.9% Total of Top 10 - Total 26,366 100.0% Total 16,	995	5.1%		
6Non-Hodgkins Lymphoma1,0352.1%Leukemia5971.7%Esophagus7Lip, Oral Cavity And Pharynx8461.7%Non-Hodgkins Lymphoma5831.7%Non-Hodgkins Lymphoma8Kidney And Renal Pelvis8431.7%Brain And Other Central Nervous5241.5%Liver And Intrahepatic Bile Ducts9Leukemia7001.4%Pancreas4181.2%Urinary Bladder10Pancreas5521.1%Stomach4091.2%Kidney And Renal Pelvis10rotal of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total26,366100.0%Total16,799100.0%Total-Total7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Corpus Uteri & Uterus Nos1,2383.6%Pancreas4Corpus Uteris & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas	529	2.7%		
7Lip, Oral Cavity And Pharynx8461.7%Non-Hodgkins Lymphoma5831.7%Non-Hodgkins Lymphoma8Kidney And Renal Pelvis8431.7%Brain And Other Central Nervous5241.5%Liver And Intrahepatic Bile Ducts9Leukemia7001.4%Pancreas4181.2%Urinary Bladder10Pancreas5521.1%Stomach4091.2%Kidney And Renal Pelvis10Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total26,366100.0%Total16,799100.0%Total-Total26,366100.0%Total16,799100.0%Total-Total26,366100.0%Total16,799100.0%Total-Total26,366100.0%Total16,799100.0%Total-Total26,366100.0%Total16,799100.0%Total-Total26,366100.0%Total16,799100.0%Total-IncidenceHospital AdmissionsMortality-TypeNumberPercentTypeMortality-1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%BreastColorectal3Colorectal2,3634.7%Corpus Uter	421	2.2%		
8 Kidney And Renal Pelvis 843 1.7% Brain And Other Central Nervous 524 1.5% Liver And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Pancreas 418 1.2% Urinary Bladder 10 Pancreas 552 1.1% Stomach 409 1.2% Kidney And Renal Pelvis 10 Pancreas 552 1.1% Stomach 409 1.2% Kidney And Renal Pelvis 10 Pancreas 552 1.1% Total of Top 10 11,405 67.9% Total of Top 10 - Total of Top 10 21,702 82.3% Total of Top 10 11,405 67.9% Total of Top 10 - Total of Top 10 21,702 82.3% Total of Top 10 11,405 67.9% Total of Top 10 - Total of Top 10 21,702 82.3% Total of Top 10 10.0% Total - Total of Top 10 21,702 82.3% Total of Top 10 Total of Top 10 - Total 26,366 100.0% Total 16,799 100.0% Total	368	1.9%		
9Leukemia7001.4%Pancreas4181.2%Urinary Bladder10Pancreas5521.1%Stomach4091.2%Kidney And Renal PelvisTotal of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total26,366100.0%Total16,799100.0%TotalFemaleRankingIncidenceFemaleRankingIncidenceType1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary	357	1.8%		
10Pancreas5521.1%Stomach4091.2%Kidney And Renal PelvisTotal of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total26,366100.0%Total16,799100.0%TotalFemaleRankingIncidenceMortality1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary	348	1.8%		
Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total26,366100.0%Total16,799100.0%TotalFemaleRankingIncidenceMumberPercentMortalityIncidencePercentMortality1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary	339	1.7%		
Female Mortality Ranking Incidence Hospital Admissions Mortality 1 Breast 7,742 15.5% Lung And Bronchus 2,379 6.8% Lung And Bronchus 2 Lung And Bronchus 3,699 7.4% Breast 2,253 6.5% Breast 3 Colorectal 2,363 4.7% Colorectal 2,133 6.1% Colorectal 4 Corpus Uteri & Uterus Nos 1,033 2.1% Thyroid Gland 1,238 3.6% Pancreas 5 Thyroid Gland 881 1.8% Corpus Uteri & Uterus Nos 946 2.7% Ovary	265	1.4%		
Female Mortality Mortality Type Number Percent Mortality 1 Breast 7,742 15.5% Lung And Bronchus 2,379 6.8% Lung And Bronchus 2 Lung And Bronchus 3,699 7.4% Breast 2,253 6.5% Breast 3 Colorectal 2,363 4.7% Colorectal 2,133 6.1% Colorectal 4 Corpus Uteri & Uterus Nos 1,033 2.1% Thyroid Gland 1,238 3.6% Pancreas 5 Thyroid Gland 881 1.8% Corpus Uteri & Uterus Nos 946 2.7% Ovary	7,986	76.8%		
RankingIncidenceMortalityTypeNumberPercentTypeNumberPercentType1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary	10,396	100.0%		
RankingIncidenceHospital AdmissionsMortalityTypeNumberPercentTypeNumberPercentType1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary				
TypeNumberPercentTypeNumberPercentType1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary				
2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary	Number	Percent		
3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary	2,761	14.2%		
4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary	1,342	6.9%		
5 Thyroid Gland 881 1.8% Corpus Uteri & Uterus Nos 946 2.7% Ovary	910	4.7%		
	488	2.5%		
	456	2.4%		
6 Skin 795 1.6% Ovary 721 2.1% Leukemia	278	1.4%		
7 Non-Hodgkins Lymphoma 780 1.6% Cervix Uteri 609 1.8% Non-Hodgkins Lymphoma	273	1.4%		
8 Ovary 734 1.5% Non-Hodgkins Lymphoma 472 1.4% Brain And Other Central Nervous	175	0.9%		
9 Urinary Bladder 586 1.2% Leukemia 443 1.3% Corpus Uteri & Uterus Nos	155	0.8%		
10 Pancreas 522 1.0% Pancreas 430 1.2% Liver And Intrahepatic Bile Ducts	153	0.8%		
Total of Top 10 19,135 81.1% Total of Top 10 11,624 64.6% Total of Top 10	6,991	77.8%		
- Total 23,591 100.0% Total 17,994 100.0% Total	8,983	100.0%		
Note: Those of other/unknown gender are not listed separately, but are included in the total.				


Table 4. Incidence to Mortality Age-Adjusted Rate Ratios for the LeadingTypes of Cancer, Nevada Residents, 2000-2004


T		Incidence	e		1	Ratio	
Type of Cancer	Number	Rate*	95% C.I.	Number	Rate*	95% C.I.	Ratio
Lung and Bronchus	7,839	75.77	(74.1-77.5)	6,005	59.26	(57.7-60.8)	1.28
Breast*	7,742	140.8	(137.7-144.0)	1,342	25.2	(23.9-26.6)	5.59
Prostate*	7,569	152.8	(149.3-156.5)	995	27.4	(25.6-29.4)	5.57
Colorectal	5,173	51.4	(50.0-52.9)	2,030	21.4	(20.4-22.4)	2.41
Urinary Bladder	2,567	25.7	(24.7-26.7)	474	5.1	(4.7-5.6)	5.01
Non-Hodgkin's Lymphoma	1,815	17.7	(16.9-18.6)	630	6.6	(6.0-7.1)	2.69
Kidney and Renal Pelvis	1,310	12.3	(11.6-13.0)	400	3.9	(3.6-4.4)	3.12
Leukemia	1,201	12.0	(11.3-12.7)	699	7.3	(6.8-7.9)	1.64
Lip, Oral Cavity and Pharynx	1,171	10.8	(10.2-11.5)	296	2.9	(2.6-3.3)	3.75
Pancreas	1,075	10.6	(10.0-11.3)	1,017	10.2	(9.6-10.9)	1.04
Skin	2,023	19.2	(18.4-20.1)	298	2.8	(2.5-3.2)	6.75
Corpus Uteri & Uterus NOS*	1,033	18.8	(17.6-20.0)	155	3.0	(2.5-3.5)	6.29
Ovary*	734	13.4	(12.5-14.5)	456	8.5	(7.7-9.3)	1.59
Thyroid Gland	1,126	10.1	(9.5-10.7)	29	0.3	(0.2-0.4)	35.01
Brain and Other Central Nervous System	663	6.3	(5.8-6.8)	415	4.0	(3.6-4.4)	1.58
Stomach	639	6.4	(5.9-6.9)	346	3.6	(3.2-4.0)	1.77
Liver and Intrahepatic Bile Ducts	555	5.4	(4.9-5.8)	501	4.9	(4.5-5.4)	1.08
Cervix Uteri*	514	9.4	(8.6-10.3)	149	2.8	(2.3-3.3)	3.41
Esophagus	545	5.2	(4.8-5.7)	459	4.4	(4.0-4.9)	1.18
Larynx	391	3.7	(3.3-4.1)	108	1.1	(0.9-1.3)	3.50
Multiple Myeloma	453	4.4	(4.0-4.9)	341	3.4	(3.1-3.8)	1.29
Hodgkin's Lymphoma	279	2.5	(2.2-2.8)	37	0.4	(0.2-0.5)	7.08
All Other Sites	3,464	33.9	(32.7-35.1)	2,180	22.4	(21.4-23.4)	1.51
Total	49,963	479.9	(475.6-484.2)	19,379	196.5	(193.7-199.4)	2.44

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

INCIDENCE HIGHLIGHTS

- Lung And Bronchus Cancer was the leading type of cancer in Nevada from 2000 to 2004. This type of cancer accounted for 15.69% of all resident cancer cases during this period. The second leading type, Breast Cancer, accounted for 15.66% of all cancer incidence.
- When compared to national (2000-2004) incidence, Nevada had a much higher percentage of Lung & Bronchus Cancer, 15.7% vs 13.5% during the 2000-2004 period.
- Blacks had the highest ratio of the remaining racial/ethnic groups when compared to the age-adjusted cancer incidence rates for Whites, with a ratio of 0.91. This means that for every 100 White cancer cases Blacks would be expected to have 91 cases. Asians, Hispanics and Native Americans had comparison ratios of 0.57, 0.50 and 0.25, respectively, for Nevada from 2000 to 2004.
- Stomach cancer had the highest age-adjusted incidence comparison ratio for Blacks when compared to Whites in Nevada from 2000 to 2004 with a comparison ratio of 1.98. This means that for every 100 White Stomach cancer cases Blacks would be expected to have 198 cases. Liver and Intrahepatic Bile Ducts cancer had the highest age-adjusted comparison ratio for Asians when compared to Whites in Nevada from 2000 to 2004 at a 2.70 ratio.
- Skin cancer had the lowest age-adjusted incidence comparison ratio for Blacks and Hispanics at 0.13 and 0.12, respectively. Meaning for every 100 White Skin cancer cases Blacks and Hispanics would be expected to have 13 and 12 cases respectively.
- Hodgkin's Lymphoma had the lowest median age at time of diagnosis for Nevada residents from 2000 to 2004 at 40 years. The median age for females diagnosed with Hodgkin's Lymphoma was 38 years, while for males it was 42 years.
- Urinary Bladder cancer had the lowest median age at time of diagnosis for Nevada residents from 2000 to 2004 at 71 years. The median age for males and females diagnosed with Urinary Bladder was 71 years.





Note: "N/A" indicates that this type of Cancer was not in the Top Ten for the SEER region.

Figure 5. Comparison of Age-Adjusted (2000) Incidence Rates of Blacks compared to Whites, Nevada Residents, 2000-2004







Figure 6. Comparison of Age-Adjusted (2000) Incidence Rates of Native Americans compared to Whites, Nevada Residents, 2000-2004



Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 7. Comparison of Age-Adjusted (2000) Incidence Rates of Asians compared to Whites, Nevada Residents, 2000-2004










Table 5. Nevada Incidence by Type of Cancer, Nevada (2000-2004) andSEER-17 (2000-2004)

T (A	Incidence (2000-2004)			SEER-17 (2000-2004)		
Type of Cancer	Number	Rate*	95% C.I.	Number	Rate*	95% C.I.
Total	49,963	480.00	(475.6-484.2)	1,671,265	469.97	(469.3-470.7)
Lip, Oral Cavity and Pharynx	1,171	11.00	(10.2-11.5)	37,724	10.47	(10.4-10.6
Lip	48	0.46	(0.3-0.6)	3,069	0.86	(0.8-0.9
Base of Tongue	184	1.70	(1.4-1.9)	4,664	1.29	(1.3-1.3)
Other & Unspecified Parts of Tongue	182	1.70	(1.4-1.9)	5,264	1.46	(1.4-1.5
Parotid Gland	96	0.96	(0.8-1.2)	3,478	0.97	(0.9-1.0
Other & Unspecified Major Salivary glands	30	0.28	(0.2-0.4)	798	0.22	(0.2-0.2
Floor of Mouth	89	0.83	(0.7-1.0)	2,490	0.69	(0.7-0.7
Gum	33	0.31	(0.2-0.4)	1,355	0.38	(0.4-0.4
Palate	47	0.45	(0.3-0.6)	1,965	0.55	(0.5-0.6
Other & Unspecified Parts of Mouth	61	0.58	(0.4-0.8)	2,244	0.63	(0.6-0.7
Nasopharynx	70	0.64	(0.5-0.8)	2,408	0.66	(0.6-0.7
Tonsil	162	1.50	(1.2-1.7)	5,356	1.46	(1.4-1.5
Oropharynx	48	0.43	(0.3-0.6)	1,151	0.32	(0.3-0.3
Pyriform Sinus	45	0.44	(0.3-0.6)	1,528	0.43	(0.4-0.5
Hypopharynx	41	0.37	(0.3-0.5)	1,094	0.31	(0.3-0.3
Other & Unspecified Oral (Buccal) Cavity & Pharynx	35	0.33	(0.2-0.5)	0		
Digestive System	8,452	84.00	(81.8-85.4)	315,879	89.48	(89.2-89.8
Esophagus	545	5.20	(4.8-5.7)	16,224	4.60	(4.5-4.7
Stomach	639	6.40	(5.9-6.9)	28,577	8.10	(8.0-8.2
Small Intestine	140	1.30	(1.1-1.6)	6,354	1.79	(1.7-1.8
Colon (excluding Rectum)	3,593	36.00	(35.1-37.5)	131,311	37.35	(37.2-37.6
Cecum	827	8.50	(7.9-9.1)	29,637	8.46	(8.4-8.6
Appendix	50	0.49	(0.4-0.7)	1,929	0.53	(0.5-0.6
Ascending Colon	543	5.60	(5.1-6.1)	22,814	6.52	(6.4-6.6
Hepatic Flexure	147	1.50	(1.3-1.8)	7,111	2.03	(2.0-2.1
Transverse Colon	263	2.70	(2.3-3.0)	11,668	3.33	(3.3-3.4
Splenic Flexure	97	0.91	(0.7-1.1)	4,797	1.36	(1.3-1.4
Descending Colon	182	1.80	(1.5-2.1)	7,866	2.23	(2.2-2.3
Sigmoid Colon	1,038	10.00	(9.5-10.8)	37,928	10.74	(10.6-10.9
Large Intestine, NOS	446	4.70	(4.3-5.2)	7,561	2.15	(2.1-2.2
Rectum	959	9.20	(8.6-9.8)	36,060	10.13	(10.0-10.2
Rectosigmoid Junction	474	4.60	(4.2-5.0)	14,666	4.14	(4.1-4.2
Anus, Anal Canal and Anorectum	147	1.40	(1.2-1.6)	5,330	1.48	(1.4-1.5
Liver	503	4.80	(4.4-5.3)	19,944	5.57	(5.5-5.7
Intrahepatic Bile Ducts	52	0.53	(0.4-0.7)	2,133	0.61	(0.6-0.6
Gallbladder	68	0.68	(0.5-0.9)	4,124	1.18	(1.1-1.2
Other & Unspecified Biliary Tract	160	1.60	(1.4-1.9)	5,924	1.69	(1.6-1.7
Pancreas	1,075	11.00	(10.0-11.3)	39,880	11.35	(11.2-11.5
Retroperitoneum	42	0.38	(0.3-0.5)	1,458	0.40	(0.4-0.4
Peritoneum, Omentum and Mesentery	34	0.32	(0.2-0.5)	2,185	0.62	(0.6-0.7
Other Digestive Organs	21	0.20	(0.1-0.3)	1,704	0.48	(0.5-0.5
Respiratory System	8,401	81.00	(79.3-82.9)	241,947	69.09	(68.8-69.4
Nasal Cavity and Middle Ear	40	0.38	(0.3-0.5)	1,377	0.38	(0.4-0.4
Accessory Sinuses	33	0.31	(0.2-0.4)	1,572	0.44	(0.4-0.5
Larynx	391	3.70	(3.3-4.1)	13,225	3.72	(3.7-3.8
Lung and Bronchus	7,839	76.00	(74.1-77.5)	225,459	64.47	(64.2-64.7
Pleura	81	0.79	(0.6-1.0)	136	0.04	(0.0-0.1
Trachea	6			250	0.07	(0.1-0.1
Mediastinum and Other Respiratory Organs	11	0.10	(0.0-0.2)	650	0.17	(0.2-0.2
Bones, Joints and Articular Cartilage	80	0.76	(0.6-1.0)	4,741	1.29	(1.3-1.3
Bones, Joints & Articular Cartilage of Limbs	40	0.38	(0.3-0.5)	2,126	0.57	(0.6-0.6
Bones, Joints & Articular Cartilage of Other & Unspec Site	40	0.39	(0.3-0.6)	2,615	0.72	(0.7-0.7
Soft Tissue (Including Heart)	265	2.60	(2.3-2.9)	11,229	3.08	(3.0-3.1
Heart	3			155	0.04	(0.0-0.1
Peripheral Nerves & Autonomic Nervous System	4			549	0.15	(0.1-0.2
Connective, Subcutaneous & Other Soft Tissues	258	2.50	(2.2-2.8)	11,675	3.21	(3.2-3.3

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten.






* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten.

REPORT ON CANCER IN NEVADA 2000-2004

Table 6. Nevada Incidence by Type of Cancer and Gender,Nevada, 2000-2004



* Those of unknown gender are not shown separately, but are included in the total.

** Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 genderspecific population and age-adjusted to the 2000 US Standard population.

Note: The "----" is used for rates calculated on numbers less than ten.

Table 6. Nevada Incidence by Type of Cancer and Gender,Nevada, 2000-2004 (Continued)

Turne of Conner	Tota	Total*		е	Female	
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	49,963	480.00	26,366	538.00	23,591	436.00
Skin (Excluding Basal And Squamous)	2,023	19.00	1,227	24.00	795	15.00
Melanomas Of The Skin	2,023	19.00	1,227	24.00	795	15.00
Other Non-Epithelial Skin	0		0		0	
Breast	7,824	73.00	81	1.70	7,742	141.00
Female Genital System	2,474	23.00	0		2,474	45.00
Cervix Uteri	514	4.70	0		514	9.40
Corpus Uteri	986	9.20	0		986	18.00
Uterus, NOS	47	0.46	0		47	0.88
Ovary	734	7.00	0		734	13.00
Vagina	33	0.33	0		33	0.62
Vulva	132	1.30	0		132	2.50
Placenta	4		0		4	
Other Female Genital Organs	24	0.23	0		24	0.44
Male Genital System	7,880	75.00	7,880	158.00	0	
Prostate	7,569	72.00	7,569	153.00	0	
Testis	268	2.40	268	4.70	0	
Penis	27	0.27	27	0.62	0	
Other Male Genital Organs	16	0.15	16	0.32	0	
Urinary System	3,978	39.00	2,892	61.00	1,086	20.00
Urinary Bladder	2,567	26.00	1,981	43.00	586	11.00
Kidney	1,237	12.00	801	16.00	436	8.00
Renal Pelvis	73	0.70	42	0.86	31	0.56
Ureter	56	0.54	39	0.79	17	0.32
Other Urinary Organs	45	0.47	29	0.63	16	0.31
Eye and Orbit	63	0.61	39	0.78	24	0.44
Brain and Other Central Nervous System	663	6.30	385	7.50	278	5.20
Brain	611	5.80	358	6.90	253	4.70
Meninges	25	0.24	12	0.22	13	0.24
Spinal Cord, Cranial Nerves, & Other Parts of CNS	27	0.25	15	0.30	12	0.22
Endocrine System	1,178	11.00	276	5.10	902	16.00
Thyroid Gland	1,126	10.00	245	4.40	881	16.00
Adrenal Gland	19	0.19	14	0.32	5	
Other Endocrine (Including Thymus)	33	0.32	17	0.36	16	0.30
Hodgkin's Lymphoma	279	2.50	151	2.70	128	2.30
Non-Hodgkin's Lymphoma	1,815	18.00	1,035	21.00	780	15.00
Multiple Myeloma	453	4.40	264	5.50	189	3.50
Leukemia	1,201	12.00	700	15.00	500	9.60
Lymphocytic	553	5.40 1.30	333	7.00	220	4.20
Acute Lymphocytic	137		69 225	1.30	68 146	1.30
Chronic Lymphocytic	381	3.80	235	5.10	146	2.80
Other Lymphocytic	35	0.33	29	0.57	6	
Myeloid and Monocytic Acute Myeloid	565 396	5.60 3.90	319 230	6.70 4.90	245 165	4.70 3.10
Acute Monocytic	22	0.24	10	0.20	12	0.28
Chronic Myeloid Other Myeloid/Monocytic	133 14	1.30 0.14	74 5	1.60	59 9	1.10
Other	83	0.14 0.91	5 48	1.20	9 35	0.69
Other Acute	39	0.40	26	0.59	13	0.25
Aleukemic, Subleukemic and NOS	44	0.51	22	0.59	22	0.44
Mesothelioma	0 0		0 0		0 0	
Kaposi Sarcoma						

* Those of unknown gender are not shown separately, but are included in the total.

** Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer,
Nevada, 2000-2004

Type of Cancer	Total	In situ	Localized	Regional	Distant	Unstaged
Total	49,963	2,237	18,170	7,901	8,259	13,396
Lip, Oral Cavity and Pharynx	1,171		331	400	92	348
Lip	48		35	4	0	9
Base of Tongue	184		28	88	16	52
Other & Unspecified Parts of Tongue	182		83	41	4	54
Parotid Gland	96		35	22	5	34
Other & Unspecified Major Salivary glands	30		8	8	1	13
Floor of Mouth	89		31	31	10	17
Gum	33		5	13	6	9
Palate	47		19	13	1	14
Other & Unspecified Parts of Mouth	61		18	13	9	21
Nasopharynx	70		8	22	12	28
Tonsil	162		33	79	5	45
Oropharynx	48		7	16	10	15
Pyriform Sinus	45		8	26	4	7
Hypopharynx	41		12	15	3	11
Other & Unspecified Oral (Buccal) Cavity & Pharynx	35		1	9	6	19
Digestive System	8,452 545		2,027 91	2,298 88	1,640 130	2,487 236
Esophagus Stomach	639		117	00 163	130	230
Stomach Small Intestine	140		32	45	29	34
Colon (excluding Rectum)	3,593		1,005	1,230	610	748
Cecum	3,333 827		214	332	162	119
Appendix	50		18	17	9	6
Ascending Colon	543		152	215	64	112
Hepatic Flexure	147		45	53	23	26
Transverse Colon	263		75	104	39	45
Splenic Flexure	97		27	44	13	13
Descending Colon	182		59	71	23	29
Sigmoid Colon	1,038		358	336	177	167
Large Intestine, NOS	446		57	58	100	231
Rectum	959		320	256	107	276
Rectosigmoid Junction	474		136	168	86	84
Anus, Anal Canal and Anorectum	147		64	24	12	47
Liver	503		129	34	81	259
Intrahepatic Bile Ducts	52		8	10	4	30
Gallbladder	68		14	19	20	15
Other & Unspecified Biliary Tract	160		27	38	20	75
Pancreas	1,075		71	210	376	418
Retroperitoneum	42		10	7	9	16
Peritoneum, Omentum and Mesentery	34		3	4	14	13
Other Digestive Organs	21		0	2	7	12
Respiratory System	8,401		1,329	1,497	2,624	2,951
Nasal Cavity and Middle Ear	40		20	3	1	16
Accessory Sinuses	33		7	11	4	11
Larynx	391		152	65	25	149
Lung and Bronchus	7,839		1,132	1,397	2,573	2,737
Pleura	81		15	18	19	29
Trachea	6		1	2	0	3
Mediastinum and Other Respiratory Organs	11		2	1	2	6
Bones, Joints and Articular Cartilage	80		28	16	12	24
Bones, Joints & Articular Cartilage of Limbs	40		18	5	5	12
Bones, Joints & Articular Cartilage of Other & Unspec Sites	40		10	11	7	12
Soft Tissue (Including Heart)	265		100	23	34	108
Heart	3		1	1	0	1
Peripheral Nerves & Autonomic Nervous System	4		1	1	1	1
Connective, Subcutaneous & Other Soft Tissues	258		98	21	33	106

Type of Cancer	Total	In situ	Localized	Regional	Distant	Unstaged
Total	49,963	2,237	18,170	7,901	8,259	13,396
Skin (Excluding Basal And Squamous)	2,023		1,304	146	77	496
Melanomas Of The Skin	2,023		1,304	146	77	496
Other Non-Epithelial Skin	0		0	0	0	0
Breast	7,824	1,243	3,254	1,676	336	1,315
Female Genital System	2,474		1,074	442	412	546
Cervix Uteri	514		248	128	40	98
Corpus Uteri	986		616	135	44	191
Uterus, NOS	47		5	7	15	20
Ovary	734		113	135	302	184
Vagina	33		11	9	3	10
Vulva	132		76	23	3	30
Placenta	4		1	1	0	2
Other Female Genital Organs	24		4	4	5	11
Male Genital System	7,880		5,599	630	264	1,387
Prostate	7,569		5,423	587	232	1,327
Testis	268		159	38	31	40
Penis	27		10	5	1	11
Other Male Genital Organs	16		7	0	0	9
Urinary System	3,978	994	1,520	384	283	797
Urinary Bladder	2,567	994	855	194	85	439
Kidney	1,237		590	160	190	297
Renal Pelvis	73		34	18	4	17
Ureter	56		28	8	4	16
Other Urinary Organs	45		13	4	0	28
Eye and Orbit	63		27	2	2	32
Brain and Other Central Nervous System	663		392	16	6	249
Brain	611		374	14	6	217
Meninges	25		9	2	0	14
Spinal Cord, Cranial Nerves, & Other Parts of CNS	27		9	0	0	18
Endocrine System	1,178		713	186	40	239
Thyroid Gland	1,126		693	180	34	219
Adrenal Gland	19		4	3	6	6
Other Endocrine (Including Thymus)	33		16	3	0	14
Hodgkin's Lymphoma	279		85	38	52	104
Non-Hodgkin's Lymphoma	1,815		387	147	554	727
Multiple Myeloma	453		0	0	409	44
Leukemia	1,201		0	0	1,123	78
Lymphocytic	553		0	0	525	28
Acute Lymphocytic	137		0	0	132	5
Chronic Lymphocytic	381		0	0	359	22
Other Lymphocytic	35		0	0	34	1
Myeloid and Monocytic	565		0	0	529	36
Acute Myeloid	396		0	0	376	20
Acute Monocytic	22		0	0	20	2
Chronic Myeloid	133		0	0	122	11
Other Myeloid/Monocytic	14		0	0	11	3
Other	83		0	0	69	14
Other Acute	39		0	0	36	3
Aleukemic, Subleukemic and NOS	44		0	0	33	11
Mesothelioma	0		0	0	0	0
Kaposi Sarcoma	0		0	0	0	0
Other, III-Defined and Unspecified Sites	1,763		0	0	299	1,464

Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer,
Nevada, 2000-2004 (Continued)

Table 8. Top Ten Types of Cancer Incidence by County/Region of Residence,
Nevada Residents, 2000-2004

Rank Type of Cancer Nevada Total Clark Washoe All Other Counties 1 Lung And Bronchus Incidence 7.839 5.515 1,402 1,180 1 Lung And Bronchus Incidence 7.839 5.515 1,402 1,180 95% C.1 (74.1-77.5) (76.0-80.3) (77.8-86.6) (67.0-75.3) 2 Breast Incidence 7.824 5,397 1,243 1,153 3 Prostate Incidence 7.824 5,397 (71.5-80.1) (65.3-7.5.) 3 Prostate Incidence 7,569 5,145 1,166 1,018 4 Colorectal Incidence 7,569 5,145 1,166 1,018 5 Urinary Bladder Incidence 5,173 3,628 832 710 5 Urinary Bladder Incidence 2,567 1,727 394 445 6 Skin Incidence 2,567 1,727 394 445 5<					County/Region	n of Residence	
Rate* 75.77 78.14 82.13 71.05 95% C.I. (74.1-77.5) (76.0-80.3) (77.8-86.6) (67.0-75.3) 2 Breast Incidence 7,824 5,397 1,243 1,153 3 Prostate Incidence 7,824 5,397 (71.7-80.1) (65.3-73.5) 3 Prostate Incidence 7,569 5,145 1,166 1,018 4 Colorectal Incidence 7,573 (69.0-73.0) (67.9-76.4) (58.4-66.2) 4 Colorectal Incidence 5,173 3,628 832 7110 5 Urinary Bladder Incidence 2,567 1,727 394 445 5 Urinary Bladder Incidence 2,567 1,727 394 445 6 Skin Incidence 2,023 1,505 301 247 6 Skin Incidence 2,027 1,727 394 445 7 Non-Hodgkin's Lymphoma 1nc	Rank	Type of Cancer	,		Clark	Washoe	
95% C.I. (74.1-77.5) (76.0-80.3) (77.8-86.6) (67.0-75.3) 2 Breast Incidence 7,824 5,397 1,243 1,153 2 Breast Incidence 7,824 5,397 1,243 1,153 3 Prostate Incidence 7,829 5,145 1,166 1,018 3 Prostate Incidence 7,569 5,145 1,166 1,018 4 Colorectal Incidence 5,173 70.97 72.02 62.17 95% C.I. (70.1-73.4) (69.0-73.0) (67.9-76.4) (58.4-66.2) 4 Colorectal Incidence 5,173 3,628 832 7110 8ate* 51.43 52.76 44.33 95% C.I. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 66 Skin Incidence 2,023 1,505 301 2247	1	Lung And Bronchus	Incidence	7,839	5,515	1,402	1,180
2 Breast Incidence 7,824 5,397 1,243 1,153 Rate* 73.33 73.64 75.72 69.33 95% C.I. (71.7-75.0) (71.7-75.7) (71.5-80.1) (65.3-73.5) 3 Prostate Incidence 7,569 5,145 1,166 1,018 Rate* 71.75 70.97 72.02 62.17 95% C.I. (70.1-73.4) (69.0-73.0) (67.9-76.4) (58.4-66.2) 4 Colorectal Incidence 5,173 3,628 832 710 Rate* 51.43 52.76 52.68 44.33 95% C.I. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 Rate* 25.68 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 </td <td></td> <td></td> <td>Rate*</td> <td>75.77</td> <td>78.14</td> <td>82.13</td> <td>71.05</td>			Rate*	75.77	78.14	82.13	71.05
Rate* 73.33 73.64 75.72 69.33 95% C.I. (71.7-75.0) (71.7-75.7) (71.5-80.1) (65.3-73.5) 3 Prostate Incidence 7,569 5,145 1,166 1,018 3 Prostate Incidence 7,569 5,145 1,166 1,018 4 Colorectal Incidence 5,173 3,628 832 710 4 Colorectal Incidence 5,173 3,628 832 710 5 Urinary Bladder Incidence 5,173 3,628 832 710 5 Urinary Bladder Incidence 2,567 1,727 394 445 5 Urinary Bladder Incidence 2,567 1,727 394 445 6 Skin Incidence 2,023 1,505 301 247 6 Skin Incidence 2,023 1,505 301 247 7 Non-Hodgkin's Lymphoma Incidence 1,815<			95% C.I.	(74.1-77.5)	(76.0-80.3)	(77.8-86.6)	(67.0-75.3)
95% C.I. (71.7-75.0) (71.7-75.7) (71.5-80.1) (66.3-73.5) 3 Prostate Incidence 7,569 5,145 1,166 1,018 3 Prostate Rate* 71.75 70.97 72.02 62.17 95% C.I. (70.1-73.4) (69.0-73.0) (67.9-76.4) (58.4-66.2) 4 Colorectal Incidence 5,173 3,628 8322 710 4 Colorectal Incidence 5,173 3,628 832 710 5 Urinary Bladder Incidence 2,567 1,727 394 445 5 Urinary Bladder Incidence 2,567 1,727 394 28.18 6 Skin Incidence 2,023 1,505 301 247 7 Non-Hodgkin's Lymphoma Incidence 2,023 1,505 301 247 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215	2	Breast	Incidence	7,824	5,397	1,243	1,153
3 Prostate Incidence 7,569 5,145 1,166 1,018 Rate* 71.75 70.97 72.02 62.17 95% C.I. (70.1-73.4) (69.0-73.0) (67.9-76.4) (58.4-66.2) 4 Colorectal Incidence 5,173 3,628 832 710 Rate* 51.43 52.76 52.68 44.33 95% C.I. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 Rate* 25.68 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.6-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 </td <td></td> <td></td> <td>Rate*</td> <td>73.33</td> <td>73.64</td> <td>75.72</td> <td>69.33</td>			Rate*	73.33	73.64	75.72	69.33
Rate* 71.75 70.97 72.02 62.17 95% C.I. (70.1-73.4) (69.0-73.0) (67.9-76.4) (58.4-66.2) 4 Colorectal Incidence 5,173 3,628 832 710 Rate* 51.43 52.76 52.68 44.33 95% C.I. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 6 Skin Incidence 2,023 1,505 301 247 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 5% (13.6-17.6) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 84t* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6)			95% C.I.	(71.7-75.0)	(71.7-75.7)	(71.5-80.1)	(65.3-73.5)
95% C.I. (70.1-73.4) (69.0-73.0) (67.9-76.4) (58.4-66.2) 4 Colorectal Incidence 5,173 3,628 832 710 Rate* 51.43 52.76 52.68 44.33 95% C.I. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 6 Skin Incidence 2,568 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 8 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 <t< td=""><td>3</td><td>Prostate</td><td>Incidence</td><td>7,569</td><td>5,145</td><td>1,166</td><td>1,018</td></t<>	3	Prostate	Incidence	7,569	5,145	1,166	1,018
4 Colorectal Incidence 5,173 3,628 832 710 Rate* 51.43 52.76 52.68 44.33 95% C.I. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 Rate* 25.68 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176			Rate*	71.75	70.97	72.02	62.17
Rate* 51.43 52.76 52.68 44.33 95% C.1. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 6 Rate* 25.68 25.12 25.23 28.18 95% C.1. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 7 Non-Hodgkin's Lymphoma Incidence 19.20 20.77 17.48 15.52 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176			95% C.I.	(70.1-73.4)	(69.0-73.0)	(67.9-76.4)	(58.4-66.2)
95% C.I. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 Rate* 25.68 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176	4	Colorectal	Incidence	5,173	3,628	832	710
5 Urinary Bladder Incidence 2,567 1,727 394 445 Rate* 25.68 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176			Rate*	51.43	52.76	52.68	44.33
Rate* 25.68 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176			95% C.I.	(50.0-52.9)	(51.0-54.6)	(49.1-56.5)	(41.1-47.8)
95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 6 Skin Incidence 2,023 1,505 301 247 7 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176	5	Urinary Bladder	Incidence	2,567	1,727	394	445
6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176			Rate*	25.68	25.12	25.23	28.18
Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176			95% C.I.	(24.7-26.7)	(23.9-26.4)	(22.8-28.0)	(25.6-31.0)
95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176	6	Skin	Incidence	2,023	1,505	301	247
7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176			Rate*	19.20	20.77	17.48	15.52
Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176			95% C.I.	(18.4-20.1)	(19.7-21.9)	(15.5-19.7)	(13.6-17.6)
95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176	7	Non-Hodgkin's Lymphoma	Incidence	1,815	1,274	293	215
8 Kidney And Renal Pelvis Incidence 1,310 910 225 176			Rate*	17.69	18.20	17.58	13.82
			95% C.I.	(16.9-18.6)	(17.2-19.3)	(15.6-19.8)	(12.0-15.9)
	8	Kidney And Renal Pelvis	Incidence	1,310	910	225	176
Rate* 12.30 13.34 13.39 10.79			Rate*	12.30	13.34	13.39	10.79
95% C.I. (11.6-13.0) (12.5-14.3) (11.7-15.3) (9.2-12.6)			95% C.I.	(11.6-13.0)	(12.5-14.3)	(11.7-15.3)	(9.2-12.6)
9 Leukemia Incidence 1,201 909 196 168	9	Leukemia	Incidence	1,201	909	196	168
Rate* 11.98 12.40 10.65 10.03			Rate*	11.98	12.40	10.65	10.03
95% C.I. (11.3-12.7) (11.6-13.3) (9.2-12.3) (8.6-11.7)			95% C.I.	(11.3-12.7)	(11.6-13.3)	(9.2-12.3)	(8.6-11.7)
10 Lip, Oral Cavity And Pharynx Incidence 1,171 820 182 157	10	Lip, Oral Cavity And Pharynx	Incidence	1,171	820	182	157
Rate* 10.85 11.05 10.59 9.57			Rate*	10.85	11.05	10.59	9.57
95% C.I. (10.2-11.5) (10.3-11.9) (9.1-12.3) (8.1-11.2)			95% C.I.	(10.2-11.5)	(10.3-11.9)	(9.1-12.3)	(8.1-11.2)
Total Incidence 49,963 34,851 8,080 7,004		Total	Incidence	49,963	34,851	8,080	7,004
Rate* 479.88 487.85 489.61 432.94			Rate*	479.88	487.85	489.61	432.94
95% C.I. (475.6-484.2) (482.6-493.1) (478.8-500.6) (422.7-443.8)			95% C.I.	(475.6-484.2)	(482.6-493.1)	(478.8-500.6)	(422.7-443.8)

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

Table 9. Top Ten Types of Cancer Incidence by Age Group, Nevada Residents, 2000-2004

Ranking					Age Group				
Nanking	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75+	Total
1	Leukemia	Thyroid Gland	Thyroid Gland	Breast	Breast	Prostate	Prostate	Lung & Bronchus	Lung & Bronchus
	98	56	175	762	1,629	2,072	3,097	2,376	7,839
	30.1%	14.7%	17.0%	28.2%	25.6%	17.7%	21.0%	18.7%	15.7%
2	Brain and OCNS	Skin	Skin	Skin	Lung & Bronchus	Breast	Lung & Bronchus	Prostate	Breast
	57	43	136	271	624	2,046	2,822	1,834	7,824
	17.5%	11.3%	13.2%	10.0%	9.8%	17.5%	19.2%	14.4%	15.7%
3	NHL	HL	Breast	Thyroid Gland	Colorectal	Lung & Bronchus	Breast	Colorectal	Prostate
	20	37	114	256	563	1,898	1,880	1,775	7,568
	6.1%	9.7%	11.1%	9.5%	8.8%	16.2%	12.8%	13.9%	15.1%
4	KRP	Leukemia	Cervix Uteri	Colorectal	Prostate	Colorectal	Colorectal	Breast	Colorectal
	18	29	73	168	540	1,080	1,539	1,385	5,173
	5.5%	7.6%	7.1%	6.2%	8.5%	9.2%	10.5%	10.9%	10.4%
5	HL	Brain and OCNS	NHL	NHL	Skin	Urinary Bladder	Urinary Bladder	Urinary Bladder	Urinary Bladder
	17	28	61	131	359	492	870	957	2,567
	5.2%	7.4%	5.9%	4.9%	5.6%	4.2%	5.9%	7.5%	5.1%
6	Liver and IBD	NHL	HL	Cervix Uteri	Thyroid Gland	NHL	NHL	NHL	Skin
	11	23	54	127	269	384	463	511	2,023
	3.4%	6.1%	5.2%	4.7%	4.2%	3.3%	3.1%	4.0%	4.0%
7	Skin	Ovary	Colorectal	Lung & Bronchus	LOCP	Skin	Skin	Skin	NHL
	10	9	42	105	222	382	434	388	1,815
	3.1%	2.4%	4.1%	3.9%	3.5%	3.3%	2.9%	3.0%	3.6%
8	LOCP	LOCP	Brain and OCNS	CU & Uterus NOS	NHL	KRP	KRP	Leukemia	KRP
	4	7	42	85	222	362	366	372	1,310
	1.2%	1.8%	4.1%	3.2%	3.5%	3.1%	2.5%	2.9%	2.6%
9	Ovary	Breast	Leukemia	KRP	CU & Uterus NOS	LOCP	Pancreas	Pancreas	Leukemia
	2	7	37	81	200	355	310	366	1,200
	0.6%	1.8%	3.6%	3.0%	3.1%	3.0%	2.1%	2.9%	2.4%
10	Urinary Bladder	Colorectal	Ovary	LOCP	KRP	CU & Uterus NOS	LOCP	KRP	LOCP
	2	5	29	68	200	281	304	271	1,171
	0.6%	1.3%	2.8%	2.5%	3.1%	2.4%	2.1%	2.1%	2.3%
Sum	239	244	763	2,054	4,828	9,352	12,085	10,235	38,490
Percent	73.3%	64.2%	74.1%	76.1%	75.8%	80.0%	82.1%	80.4%	77.0%
Total	326	380	1,029	2,698	6,373	11,689	14,727	12,736	49,958
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma. Note: Those cases with unknown ages are not shown separately, but are included in the total.

Table 10. Median Age at Time of Diagnosis by Leading Types of Cancer and
Race/Ethnicity, Nevada Residents, 2000-2004


	Race/Ethnicity										
Type of Cancer	White	Black	Native American	Asian	Hispanic	Total					
Lung and Bronchus	69.0	66.0	63.5	67.0	67.0	69.0					
Breast	62.0	58.0	59.5	54.0	52.0	61.0					
Prostate	68.0	65.0	69.5	68.0	67.0	68.0					
Colorectal	70.0	65.0	58.5	66.0	64.5	69.0					
Urinary Bladder	72.0	68.0	60.0	68.5	65.0	71.0					
Non-Hodgkin's Lymphoma	67.0	58.0	68.5	57.0	55.0	66.0					
Kidney and Renal Pelvis	65.0	61.0	70.0	58.0	60.0	64.0					
Leukemia	69.0	53.0		58.0	28.0	67.0					
Lip, Oral Cavity and Pharynx	63.0	62.0		56.0	51.5	62.0					
Pancreas	70.0	66.5		65.0	62.0	69.0					
Skin	60.0	72.0		43.5	46.0	60.0					
Corpus Uteri & Uterus NOS	63.0	64.5	48.0	52.0	56.5	61.5					
Ovary	65.0	70.5	55.0	55.0	52.0	63.0					
Thyroid Gland	48.0	44.0		49.0	42.0	47.0					
Stomach Brain and Other Central	71.0	68.0		64.0	65.0	70.0					
Nervous System	59.0	48.0	0.0	47.5	35.0	57.0					
Cervix Uteri	50.0	48.0		49.0	45.5	48.0					
Liver and Intrahepatic Bile Ducts	65.5	56.5		65.0	65.0	65.0					
Esophagus	68.0	68.0	0.0	65.0	68.0	68.0					
Larynx	66.0	64.0	0.0		65.0	66.0					
Multiple Myeloma	69.0	67.0		71.0	67.0	68.0					
Hodgkin's Lymphoma	42.0	44.0		27.0	20.0	40.0					
All Other Sites	67.0	59.0	53.0	61.5	49.0	65.0					
Total	67.0	63.0	62.0	61.0	59.0	66.0					

Note: Those of other/unknown race/ethnicity are not shown separately, but are included in the total. Those deaths of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

HIGHLIGHTS

- Lung And Bronchus Cancer was the leading type of cancer in Nevada from 2000 to 2004. This type of cancer accounted for 13.9% of all resident cancer inpatient hospital discharges during this period. The second leading type, Colorectal Cancer, accounted for 12.7% of all cancer inpatient discharges.
- The two leading types of cancer for inpatient hospital discharges, Colorectal and Lung And Bronchus cancer accounted for 434.2 million dollars in total billed amounts in Nevada from 2000 to 2004. This accounted for 29.7% of the total 1.46 billion dollars in billed amounts for cancer inpatient hospital discharges during this period.
- The five types of cancer that had the highest average total billed amount for Nevada from 2000 to 2004 were: Leukemia (\$88,266), Stomach (\$67,784), Ovary (\$62,375), Larynx (\$60,478), and Non-Hodgkin's Lymphoma (\$56,600) Cancers.
- The five types of cancer that had the highest average length of stay (days) for cancer inpatient hospital discharges in Nevada from 2000 to 2004 were: Leukemia (13.8), Stomach (11.2), Larynx (10.3), Multiple Myeloma (9.8), and Pancreatic (9.5) Cancers.
- The five types of cancer that had the highest average daily billed amount for Nevada from 2000 to 2004 were: Breast (\$7,736), Thyroid Gland (\$7,540), Corpus Uteri & Uterus NOS (\$7,497), Prostate (\$7,370), and Ovary (\$7,234) Cancers.







Figure 10. Top Ten Leading Cancers in Average Inpatient Discharge Charges, Nevada Residents, 2000-2004










Figure 12. Top Ten Leading Cancers in Total Number of Days Stayed for Inpatient Hospital Discharges, Nevada Residents, 2000-2004









Figure 14. Top Ten Leading Cancers in Median Length of Stay (Days) for Inpatient Hospital Discharges, Nevada Residents, 2000-2004



Type of Cancer	Total*		Male		Female	
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	34,796	330.00	16,799	335.00	17,994	331.00
Lip, Oral Cavity and Pharynx	526	4.80	362	6.70	164	3.00
Lip	8		7		1	
Base of Tongue	90	0.81	68	1.20	22	0.40
Other & Unspecified Parts of Tongue	95	0.86	62	1.10	33	0.61
Parotid Gland	46	0.44	31	0.64	15	0.28
Other & Unspecified Major Salivary glands	10	0.08	5		5	
Floor of Mouth	46	0.40	35	0.61	11	0.19
Gum	31	0.29	18	0.33	13	0.24
Palate	12	0.11	4		8	
Other & Unspecified Parts of Mouth	26	0.24	17	0.31	9	
Nasopharynx	24	0.21	17	0.30	7	
Tonsil	43	0.38	34	0.59	9	
Oropharynx	24	0.21	19	0.34	5	
Pyriform Sinus	16	0.15	8		8	
Hypopharynx	25	0.22	16	0.28	9	
Other & Unspecified Oral (Buccal) Cavity & Pharynx	30	0.30	21	0.48	9	
Digestive System	7,018	69.00	3,831	79.00	3,187	60.00
Esophagus	302	2.90	227	4.50	75	1.40
Stomach	597	5.80	409	8.20	188	3.60
Small Intestine	161	1.60	92	1.90	69	1.30
Colon (excluding Rectum)	2,966	30.00	1,455	31.00	1,511	29.00
Cecum	643	6.70	309	6.70	334	6.50
Appendix	34	0.31	14	0.27	20	0.35
Ascending Colon	553	5.60	250	5.40	303	5.80
Hepatic Flexure	126	1.30	59	1.30	67	1.30
Transverse Colon	258	2.70	107	2.20	151	2.90
Splenic Flexure	111	1.10	57	1.20	54	0.99
Descending Colon	151	1.50	88	1.80	63	1.20
Sigmoid Colon	789	7.70	426	8.80	363	6.80
Large Intestine, NOS	301	3.00	145	3.20	156	3.00
Rectum	726	7.00	433	8.70	293	5.50
Rectosigmoid Junction	598	5.70	337	6.80	261	4.80
Anus, Anal Canal and Anorectum	143	1.40	75	1.50	68	1.30
Liver	336	3.20	239	4.50	97	1.90
Intrahepatic Bile Ducts	43	0.43	18	0.36	25	0.48
Gallbladder	29	0.48	5		24	0.45
Other & Unspecified Biliary Tract	151	1.50	85	1.90	66	1.20
Pancreas	848	8.30	418	8.70	430	8.00
Retroperitoneum	55	0.50	29	0.70	26	0.00
Peritoneum, Omentum and Mesentery	54	0.50	29 5		49	0.89
Other Digestive Organs	9		4		-15	
Respiratory System	5,155	49.00	2,673	54.00	2,482	45.00
Nasal Cavity and Middle Ear	10	0.11	2,010		2,402	-0.00
Accessory Sinuses	10	0.11	11	0.20	8	
Larynx	166	1.60	125	2.50	41	0.77
Lung and Bronchus	4,842	46.00	2,463	49.00	2,379	43.00
Pleura	-,0-2	0.55	2,403	0.78	2,373	0.35
Trachea	12	0.55	30 7	0.78	19	0.35
	49				5 25	0.44
Mediastinum and Other Respiratory Organs Bones, Joints and Articular Cartilage	49 121	0.46 1.10	24 66	0.50 1.30	25 55	
			66 10			1.00
Bones, Joints & Articular Cartilage of Limbs	53	0.48	19	0.33	34	0.64
Bones, Joints & Articular Cartilage of Other & Unspec Sites	68	0.66	47	0.94	21	0.39
Soft Tissue (Including Heart)	175	1.70	86	1.70	89	1.70
Heart	4		1		3	
Peripheral Nerves & Autonomic Nervous System	0		0		0	
Connective, Subcutaneous & Other Soft Tissues	171	1.60	85	1.70	86	1.60

Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender, Nevada, 2000-2004

* Those of unknown gender are not shown separately, but are included in the total.
 ** Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.
 Note: The "---" is used for rates calculated on numbers less than ten.

7	Tota	Total*		Male		Female	
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**	
Total	34,796	330.00	16,799	335.00	17,994	331.00	
Skin (Excluding Basal And Squamous)	206	2.00	143	2.90	63	1.20	
Melanomas Of The Skin	93	0.86	63	1.20	30	0.56	
Other Non-Epithelial Skin	113	1.10	80	1.80	33	0.63	
Breast	2,276	22.00	23	0.52	2,253	41.00	
Female Genital System	2,488	23.00	0		2,488	45.00	
Cervix Uteri	609	5.50	0		609	11.00	
Corpus Uteri	915	8.50	0		915	17.00	
Uterus, NOS	31	0.30	0		31	0.58	
Ovary	721	6.70	0		721	13.00	
Vagina	37	0.37	0		37	0.70	
Vulva	129	1.30	0		129	2.40	
Placenta	3		0		3		
Other Female Genital Organs	43	0.39	0		43	0.77	
Male Genital System	2,682	24.00	2,682	51.00	0		
Prostate	2,614	24.00	2,614	50.00	0		
Testis	51	0.45	51	0.87	0		
Penis	15	0.16	15	0.37	0		
Other Male Genital Organs	2		2		0		
Urinary System	2,191	21.00	1,550	32.00	641	12.00	
Urinary Bladder	1,033	11.00	803	18.00	230	4.40	
Kidney	986	9.10	638	12.00	348	6.30	
Renal Pelvis	84	0.82	56	1.20	28	0.51	
Ureter	71	0.70	45	0.94	26	0.49	
Other Urinary Organs	17	0.16	8		9		
Eye and Orbit	9		3		6		
Brain and Other Central Nervous System	946	8.80	524	9.80	422	7.80	
Brain	874	8.10	494	9.30	380	7.00	
Meninges	47	0.44	19	0.37	28	0.52	
Spinal Cord, Cranial Nerves, & Other Parts of CNS	25	0.23	11	0.20	14	0.26	
Endocrine System	1,617	15.00	353	6.50	1,264	23.00	
Thyroid Gland	1,570	14.00	332	6.00	1,238	23.00	
Adrenal Gland	19	0.18	9		10	0.18	
Other Endocrine (Including Thymus)	28	0.28	12	0.29	16	0.29	
Hodgkin's Lymphoma	118	1.10	63	1.10	54	0.97	
Non-Hodgkin's Lymphoma	1,055	10.00	583	12.00	472	8.90	
Multiple Myeloma	373	3.60	213	4.30	160	2.90	
Leukemia	1,041	10.00	597	12.00	443	8.40	
Lymphocytic	442	4.20	257	5.00	184	3.50	
Acute Lymphocytic	302	2.80	177	3.20	124	2.30	
Chronic Lymphocytic	136	1.40	77	1.70	59	1.10	
Other Lymphocytic	4		3		1		
Myeloid and Monocytic	552	5.30	314	6.30	238	4.50	
Acute Myeloid	443	4.30	252	5.10	191	3.60	
Acute Monocytic	10	0.11	2		8		
Chronic Myeloid	92	0.92	57	1.20	35	0.69	
Other Myeloid/Monocytic	7		3		4		
Other	47	0.47	26	0.55	21	0.41	
Other Acute	33	0.33	18	0.40	15	0.28	
Aleukemic, Subleukemic and NOS	14	0.14	8		6		
Mesothelioma	1		1		0		
Kaposi Sarcoma	0		0		0		
Other, III-Defined and Unspecified Sites	6,798	64.00	3,046	61.00	3,751	68.00	

Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender,
Nevada, 2000-2004 (Continued)

* Those of unknown gender are not shown separately, but are included in the total.

** Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 genderspecific population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 12. Top Ten Types of Cancer Inpatient Hospital Discharges by
County/Region of Residence, Nevada Residents, 2000-2004

		County/Region of Residence						
Rank	Type of Cance	Nevada Total	Clark	Washoe	All Other Counties			
1	Lung And Bronchus	Admissions	4,842	3,449	738	653		
		Rate*	45.98	47.80	45.18	39.02		
		95% C.I.	(44.7-47.3)	(46.2-49.5)	(41.9-48.6)	(36.1-42.2)		
2	Colorectal	Admissions	4,433	3,098	717	617		
		Rate*	44.10	44.96	45.55	38.54		
		95% C.I.	(42.8-45.5)	(43.3-46.6)	(42.2-49.1)	(35.5-41.8)		
3	Prostate	Admissions	2,614	1,696 49		425		
		Rate*	23.80	22.61	28.32	24.53		
		95% C.I.	(22.9-24.7)	(21.5-23.7)	(25.8-31.0)	(22.2-27.0)		
4	Breast	Admissions	2,276	1,654	362	260		
		Rate*	21.51	22.72	21.43	16.06		
		95% C.I.	(20.6-22.4)	(21.6-23.9)	(19.2-23.8)	(14.1-18.2)		
5	Thyroid Gland	Admissions	1,570	1,312	196	145		
		Rate*	14.10	16.90	11.79	8.75		
		95% C.I.	(13.4-14.8)	(16.0-17.9)	(10.2-13.6)	(7.4-10.3)		
6	Kidney And Renal Pelvis	Admissions	1,070	780	176	141		
		Rate*	9.92	10.77	10.25	8.83		
		95% C.I.	(9.3-10.5)	(10.0-11.6)	(8.8-11.9)	(7.4-10.5)		
7	Non-Hodgkins Lymphoma	Admissions	1,055	749	161	140		
		Rate*	10.20	10.14	9.51	8.75		
		95% C.I.	(9.6-10.9)	(9.4-10.9)	(8.1-11.1)	(7.3-10.4)		
8	Leukemia	Admissions	1,041	746	161	133		
		Rate*	10.02	11.16	8.75	8.09		
		95% C.I.	(9.4-10.7)	(10.4-12.0)	(7.4-10.2)	(6.8-9.6)		
9	Urinary Bladder	Admissions	1,033	736	158	131		
		Rate*	10.52	10.30	9.75	8.49		
		95% C.I.	(9.9-11.2)	(9.6-11.1)	(8.3-11.5)	(7.1-10.1)		
10	Corpus Uteri & Uterus Nos	Admissions	946	676	145	122		
		Rate*	8.84	9.07	8.50	7.86		
		95% C.I.	(8.3-9.4)	(8.4-9.8)	(7.2-10.1)	(6.5-9.4)		
	Total	Admissions	34,796	24,777	5,576	4,431		
		Rate*	330.42	341.87	335.05	272.11		
		95% C.I.	(326.9-334.0)	(337.5-346.2)	(326.2-344.1)	(264.0-280.8)		
			,	,	,	. ,		

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

Table 13. Top Ten Types of Cancer Hospital Discharges by Age Group, Nevada Residents, 2000-2004

Ranking		Age Group										
Kalikilig	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75+	Total			
1	Leukemia	Thyroid Gland	Thyroid Gland	Thyroid Gland	Colorectal	Lung & Bronchus	Lung & Bronchus	Colorectal	Lung & Bronchus			
	205	77	259	394	493	1,268	1,695	1,514	4,842			
	44.3%	20.4%	28.7%	18.4%	9.8%	14.9%	17.8%	19.3%	13.9%			
2	Brain and OCNS	Leukemia	Leukemia	Breast	Breast	Prostate	Colorectal	Lung & Bronchus	Colorectal			
	68	55	66	232	487	1,019	1,310	1,313	4,433			
	14.7%	14.6%	7.3%	10.8%	9.7%	12.0%	13.8%	16.7%	12.7%			
3	NHL	Brain and OCNS	Cervix Uteri	Cervix Uteri	Lung & Bronchus	Colorectal	Prostate	Urinary Bladder	Prostate			
	26	37	62	164	457	929	905	464	2,614			
	5.6%	9.8%	6.9%	7.7%	9.1%	10.9%	9.5%	5.9%	7.5%			
4	Liver and IBD	NHL	Brain and OCNS	Colorectal	Thyroid Gland	Breast	Breast	Breast	Breast			
	24	31	62	145	373	543	535	433	2,276			
	5.2%	8.2%	6.9%	6.8%	7.4%	6.4%	5.6%	5.5%	6.5%			
5	KRP	HL	NHL	Brain and OCNS	Prostate	KRP	Urinary Bladder	Prostate	Thyroid Gland			
	20	18	44	106	321	305	307	354	1,570			
	4.3%	4.8%	4.9%	5.0%	6.4%	3.6%	3.2%	4.5%	4.5%			
6	HL	Ovary	Breast	Lung & Bronchus	Brain and OCNS	Thyroid Gland	KRP	NHL	KRP			
	15	12	41	95	179	273	303	268	1,070			
	3.2%	3.2%	4.6%	4.4%	3.6%	3.2%	3.2%	3.4%	3.1%			
7	Thyroid Gland	Stomach	Ovary	CU & Uterus NOS	KRP	CU & Uterus NOS	NHL	Pancreas	NHL			
	5	8	37	79	173	263	257	246	1,055			
	1.1%	2.1%	4.1%	3.7%	3.5%	3.1%	2.7%	3.1%	3.0%			
8	LOCP	Colorectal	Colorectal	NHL	CU & Uterus NOS	Pancreas	Pancreas	Leukemia	Leukemia			
	3	8	33	77	172	211	255	218	1,041			
	0.6%	2.1%	3.7%	3.6%	3.4%	2.5%	2.7%	2.8%	3.0%			
9	Ovary	Lung & Bronchus	HL	KRP	Cervix Uteri	NHL	CU & Uterus NOS	KRP	Urinary Bladder			
	3	6	22	66	159	199	237	193	1,033			
	0.6%	1.6%	2.4%	3.1%	3.2%	2.3%	2.5%	2.5%	3.0%			
10	Breast	Liver and IBD	CU & Uterus NOS	Leukemia	NHL	Brain and OCNS	Leukemia	CU & Uterus NOS	CU & Uterus NOS			
	2	4	16	59	153	194	192	179	946			
	0.4%	1.1%	1.8%	2.8%	3.1%	2.3%	2.0%	2.3%	2.7%			
Sum	371	256	642	1,417	2,967	5,204	5,996	5,182	20,880			
Percent	80.1%	67.7%	71.3%	66.2%	59.2%	61.0%	63.0%	65.9%	60.0%			
Total	463	378	901	2,141	5,014	8,525	9,513	7,861	34,796			
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%			

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma. Note: Those cases with unknown ages are not shown separately, but are included in the total.

MORTALITY <u>HIGHLIGHTS</u>

- Lung And Bronchus Cancer was the leading type of cancer for cancer mortality in Nevada from 2000 to 2004. This type of cancer accounted for 31.0% of all resident cancer deaths during this period. The second leading type of cancer for cancer mortality, Colorectal Cancer, accounted for 10.5% of all Cancer deaths.
- Blacks had the highest ratio of the remaining racial/ethnic groups when compared to the age-adjusted cancer mortality rates for Whites, with a ratio of 1.06. This means that for every 100 White cancer deaths Blacks would be expected to have 106 deaths. Asians, Hispanics and Native Americans had comparison ratios of 0.57, 0.55 and 0.48, respectively, for Nevada from 2000 to 2004.
- Stomach cancer had the highest age-adjusted mortality comparison ratio for Blacks when compared to Whites in Nevada from 2000 to 2004 with a comparison ratio of 2.27. This means that for every 100 White Stomach cancer deaths Blacks would be expected to have 227. Liver and Intrahepatic Bile Ducts cancer had the highest age-adjusted comparison ratio for Asians when compared to Whites in Nevada from 2000 to 2004 at 2.07.
- Cervix Uteri had the lowest median age at time of death for Nevada residents from 2000 to 2004 at 58 years. Prostate Cancer had the highest median age at time of death for Nevada residents during this same period at 78 years.
- Hodgkin's Lymphoma had the lowest median age at time of death for male Nevada residents from 2000 to 2004 at 56.5 years, while the highest median age was Prostate Cancer at 78 years.
- Cervix Uteri had the lowest median age at time of death for male Nevada residents from 2000 to 2004 at 58 years, while the highest median age was Urinary Bladder Cancer at 76 years.






Figure 16. Comparison of Age-Adjusted (2000) Mortality Rates of Blacks compared to Whites, Nevada Residents, 2000-2004






Figure 17. Comparison of Age-Adjusted (2000) Mortality Rates of Native Americans compared to Whites, Nevada Residents, 2000-2004




Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 18. Comparison of Age-Adjusted (2000) Mortality Rates of Asians compared to Whites, Nevada Residents, 2000-2004



Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 19. Comparison of Age-Adjusted (2000) Mortality Rates of Hispanics compared to Whites, Nevada Residents, 2000-2004



Note: "N/A" indicates that a comparison ratio could not be calculated.

Turns of Osmann	Total*		Male		Female	
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	19,379	197.00	10,396	231.00	8,983	170.00
Lip, Oral Cavity and Pharynx	296	2.90	209	4.30	87	1.70
Lip	2		1		1	
Base of Tongue	3		3		0	
Other & Unspecified Parts of Tongue	77	0.71	58	1.10	19	0.35
Parotid Gland	15	0.15	10	0.22	5	
Other & Unspecified Major Salivary glands	3		3		0	
Floor of Mouth	3		3		0	
Gum	4		2		2	
Palate	6		2		4	
Other & Unspecified Parts of Mouth	26	0.26	15	0.34	11	0.21
Nasopharynx	28	0.25	21	0.38	7	
Tonsil	19	0.18	12	0.24	7	
Oropharynx	20	0.19	15	0.29	5	
Pyriform Sinus	1		1		0	
Hypopharynx	3		3		0	
Other & Unspecified Oral (Buccal) Cavity & Pharynx	86	0.86	60	1.30	26	0.49
Digestive System	4,527	46.00	2,666	58.00	1,861	36.00
Esophagus	459	4.40	368	7.40	91	1.70
Stomach	346	3.60	221	4.90	125	2.50
Small Intestine	34	0.35	16	0.37	18	0.34
Colon (excluding Rectum)	1,718	18.00	934	22.00	784	15.00
Cecum	10	0.13	5		5	
Appendix	4		3		- 1	
Ascending Colon	3		3		0	
Hepatic Flexure	0		0		0	
Transverse Colon	1		0		1	
Splenic Flexure	0		0		0	
Descending Colon	0		0		0	
Sigmoid Colon	10	0.10	5		5	
Large Intestine, NOS	1,690	18.00	918	21.00	772	15.00
Rectum	205	2.10	126	2.90	79	1.50
Rectosigmoid Junction	86	0.87	50	1.00	36	0.70
Anus, Anal Canal and Anorectum	21	0.20	10	0.20	11	0.19
Liver	419	4.10	294	5.90	125	2.40
Intrahepatic Bile Ducts	82	0.81	54	1.10	28	0.52
Gallbladder	39	0.41	17	0.46	20	0.41
Other & Unspecified Biliary Tract	51	0.53	25	0.58	26	0.50
Pancreas	1,017	10.00	529	11.00	488	9.30
Retroperitoneum	4		3		-00	
Peritoneum, Omentum and Mesentery	15	0.16	4		11	0.21
Other Digestive Organs	31	0.10	15	0.29	16	0.30
Respiratory System	6,138	61.00	3,338	71.00	2,800	52.00
Nasal Cavity and Middle Ear	0,100		0,000		2,000	02.00
Accessory Sinuses	13	0.13	7		6	
Larynx	108	1.10	78	1.60	30	0.57
Lung and Bronchus	6,005	59.00	3,244	69.00	2,761	52.00
Pleura	3		2		2,701	
Trachea	2		2		0	
Mediastinum and Other Respiratory Organs	2 7		2 5		2	
Bones, Joints and Articular Cartilage	49	0.50	29	0.62	20	0.39
-				0.62		
Bones, Joints & Articular Cartilage of Limbs	1		0		1	
Bones, Joints & Articular Cartilage of Other & Unspec Sites		0.49	29	0.62	19	0.37
Soft Tissue (Including Heart)	122	1.20	61	1.20	61	1.10
Heart Derinherel Nersen & Autonomia Nerseus System	3		2		1	
Peripheral Nerves & Autonomic Nervous System	2		1		1	
Connective, Subcutaneous & Other Soft Tissues	117	1.10	58	1.20	59	1.10

Table 14. Nevada Mortality by Type of Cancer and Gender,
Nevada, 2000-2004

* Those of unknown gender are not shown separately, but are included in the total.

**Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

	Total	*	Male		Female		
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**	
Total	19,379	197.00	10,396	231.00	8,983	170.00	
Skin (Excluding Basal And Squamous)	378	3.70	263	5.40	115	2.20	
Melanomas Of The Skin	298	2.80	201	4.00	97	1.80	
Other Non-Epithelial Skin	80	0.83	62	1.40	18	0.36	
Breast	1,357	14.00	15	0.30	1,342	25.00	
Female Genital System	803	8.00	2		801	15.00	
Cervix Uteri	149	1.40	0		149	2.80	
Corpus Uteri	60	0.62	1		59	1.10	
Uterus, NOS	96	1.00	0		96	1.90	
Ovary	457	4.50	1		456	8.50	
Vagina	10	0.10	0		10	0.19	
Vulva	18	0.19	0		18	0.35	
Placenta	0		0		0		
Other Female Genital Organs	13	0.15	0		13	0.26	
Male Genital System	1,016	12.00	1,016	28.00	0		
Prostate	995	11.00	995	27.00	0		
Testis	15	0.14	15	0.30	0		
Penis	4		4		0		
Other Male Genital Organs	2		2		0		
Urinary System	902	9.30	623	14.00	279	5.40	
Urinary Bladder	474	5.10	339	8.50	135	2.70	
Kidney	396	3.90	263	5.60	133	2.50	
Renal Pelvis	4		2		2		
Ureter	11	0.10	6		5		
Other Urinary Organs	17	0.17	13	0.31	4		
Eye and Orbit	8		7		1		
Brain and Other Central Nervous System	415	4.00	240	4.70	175	3.30	
Brain	409	3.90	236	4.60	173	3.20	
Meninges	2		2		0		
Spinal Cord, Cranial Nerves, & Other Parts of CNS	4		2		2		
Endocrine System	53	0.53	30	0.66	23	0.43	
Thyroid Gland	29	0.29	18	0.39	11	0.20	
Adrenal Gland	14	0.14	7		7		
Other Endocrine (Including Thymus) Hodgkin's Lymphoma	10 37	0.10	5		5		
Non-Hodgkin's Lymphoma	630	0.35 6.60	20 357	0.36 8.20	17 273	0.33 5.30	
Multiple Myeloma	341	3.40	201	4.40	140	2.70	
Leukemia	699	7.30	421	9.50	278	5.40	
Lymphocytic	184	2.00	115	2.70	69	1.40	
Acute Lymphocytic	44	0.44	29	0.62	15	0.28	
Chronic Lymphocytic	128	1.40	78	1.90	50	1.00	
Other Lymphocytic	12	0.13	8		4		
Myeloid and Monocytic	295	3.00	176	3.80	119	2.30	
Acute Myeloid	200	2.30	131	2.80	96	1.80	
Acute Monocytic	2		1		1		
Chronic Myeloid	47	0.47	28	0.57	19	0.37	
Other Myeloid/Monocytic	19	0.20	16	0.37	3	0.57	
Other	220	2.30	130	3.00	90	1.80	
Other Acute	84	0.84	53	1.20	30	0.58	
Aleukemic, Subleukemic and NOS	136	1.50	55 77	1.80	59	1.20	
Mesothelioma	73	0.72	56	1.20	17	0.31	
Kaposi Sarcoma	0		0		0		
Other, III-Defined and Unspecified Sites	1,535	16.00	842	19.00	693	13.00	

Table 14. Nevada Mortality by Type of Cancer and Gender,
Nevada, 2000-2004 (Continued)

* Those of unknown gender are not shown separately, but are included in the total.

**Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 15. Top Ten Types of Cancer Mortality by County/Region of Residence,
Nevada Residents, 2000-2004

	- (A		County/Region of Residence					
Rank	Type of Cano	er	Nevada Total	Clark	Washoe	All Other Counties		
1 l	Lung And Bronchus	Mortality	6,005	4,066	943	996		
		Rate*	59.26	59.03	59.34	60.69		
		95% C.I.	(57.7-60.8)	(57.2-60.9)	(55.6-63.3)	(56.9-64.7)		
2 (Colorectal	Mortality	2,030	1,422	322	286		
		Rate*	21.37	21.96	21.28	18.88		
		95% C.I.	(20.4-22.4)	(20.8-23.2)	(19.0-23.8)	(16.7-21.3)		
3 E	Breast	Mortality	1,357	943	238	185		
		Rate*	13.60	13.90	14.83	12.89		
		95% C.I.	(12.9-14.4)	(13.0-14.9)	(13.0-16.9)	(11.1-15.0)		
4 F	Pancreas	Mortality	1,017	693	173	176		
		Rate*	10.23	10.07	12.38	11.00		
		95% C.I.	(9.6-10.9)	(9.3-10.9)	(10.6-14.4)	(9.4-12.8)		
5 F	Prostate	Mortality	995	637	160	164		
		Rate*	11.37	10.72	10.37	10.51		
		95% C.I.	(10.7-12.1)	(9.9-11.6)	(8.8-12.2)	(8.9-12.3)		
6 l	Leukemia	Mortality	699	471	112	116		
		Rate*	7.31	7.20	7.43	8.11		
		95% C.I.	(6.8-7.9)	(6.5-7.9)	(6.1-9.0)	(6.4-10.6)		
7 1	Non-Hodgkin's Lymphoma	Mortality	630	415	109	106		
		Rate*	6.57	6.32	7.07	7.08		
		95% C.I.	(6.0-7.1)	(5.7-7.0)	(5.8-8.6)	(5.8-8.6)		
8 l	Liver And Intrahepatic Bile Du	ct: Mortality	501	352	80	78		
		Rate*	4.95	5.06	4.96	4.75		
		95% C.I.	(4.5-5.4)	(4.5-5.6)	(3.9-6.2)	(3.7-6.0)		
9 l	Urinary Bladder	Mortality	474	327	77	78		
		Rate*	5.13	4.60	4.95	5.18		
		95% C.I.	(4.7-5.6)	(4.1-5.1)	(3.9-6.2)	(4.1-6.5)		
10 E	Esophagus	Mortality	459	322	75	75		
		Rate*	4.43	4.61	5.05	4.75		
		95% C.I.	(4.0-4.9)	(4.1-5.2)	(4.0-6.4)	(3.7-6.0)		
	Total	Mortality	19,379	13,190	3,105	3,084		
		Rate*	196.53	195.98	199.37	196.35		
		95% C.I.	(193.7-199.4)	(192.5-199.5)	(192.3-206.7)	(189.3-204.0)		

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

Table 16. Top Ten Types of Cancer Mortality by Age Group, Nevada Residents, 2000-2004

Ranking					Age Group				
Kaliking	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75+	Total
1	Leukemia	Brain and OCNS	Leukemia	Breast	Lung & Bronchus				
	19	11	19	89	418	1,271	2,135	2,103	6,003
	43.2%	20.0%	14.3%	18.0%	24.9%	33.6%	37.0%	28.3%	31.0%
2	Brain and OCNS	Leukemia	Brain and OCNS	Lung & Bronchus	Breast	Colorectal	Colorectal	Colorectal	Colorectal
	12	10	13	69	213	330	576	917	2,030
	27.3%	18.2%	9.8%	13.9%	12.7%	8.7%	10.0%	12.4%	10.5%
3	Liver and IBD	NHL	Breast	Colorectal	Colorectal	Breast	Breast	Prostate	Breast
	4	5	9	46	154	307	317	627	1,356
	9.1%	9.1%	6.8%	9.3%	9.2%	8.1%	5.5%	8.5%	7.0%
4	KRP	Liver and IBD	Cervix Uteri	Skin	Pancreas	Pancreas	Pancreas	Breast	Pancreas
	1	3	9	31	86	210	307	421	1,017
	2.3%	5.5%	6.8%	6.3%	5.1%	5.5%	5.3%	5.7%	5.2%
5	NHL	Skin	Colorectal	Brain and OCNS	Liver and IBD	Esophagus	Prostate	Pancreas	Prostate
	1	3	7	29	84	130	271	394	995
	2.3%	5.5%	5.3%	5.9%	5.0%	3.4%	4.7%	5.3%	5.1%
6	LOCP	Stomach	Skin	Cervix Uteri	Skin	KRP	NHL	Leukemia	Leukemia
	0	2	7	24	58	113	177	304	699
	0.0%	3.6%	5.3%	4.8%	3.5%	3.0%	3.1%	4.1%	3.6%
7	Esophagus	LOCP	Lung & Bronchus	NHL	Brain and OCNS	NHL	Leukemia	NHL	NHL
	0	1	6	24	58	107	175	273	630
	0.0%	1.8%	4.5%	4.8%	3.5%	2.8%	3.0%	3.7%	3.3%
8	Stomach	Pancreas	Stomach	Leukemia	Ovary	Ovary	Liver and IBD	Urinary Bladder	Liver and IBD
	0	1	5	23	52	106	152	253	501
	0.0%	1.8%	3.8%	4.6%	3.1%	2.8%	2.6%	3.4%	2.6%
9	Colorectal	Lung & Bronchus	NHL	Ovary	Leukemia	Leukemia	Esophagus	Liver and IBD	Urinary Bladder
	0	1	5	17	48	101	135	156	474
	0.0%	1.8%	3.8%	3.4%	2.9%	2.7%	2.3%	2.1%	2.4%
10	Pancreas	HL	Liver and IBD	Liver and IBD	Esophagus	Brain and OCNS	Ovary	Ovary	Esophagus
	0	1	3	16	45	90	128	152	459
	0.0%	1.8%	2.3%	3.2%	2.7%	2.4%	2.2%	2.0%	2.4%
Sum	37	38	83	368	1,216	2,765	4,373	5,600	14,164
Percent	84.1%	69.1%	62.4%	74.3%	72.4%	73.0%	75.9%	75.5%	73.1%
Total	44	55	133	495	1,680	3,786	5,764	7,419	19,376
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma. Note: Those cases with unknown ages are not shown separately, but are included in the total.


Table 17. Median Age at Time of Death by Leading Types of Cancer and
Race/Ethnicity, Nevada Residents, 2000-2004

			Race/E	thnicity		
Type of Cancer	White	Black	Native American	Asian	Hispanic	Total
Lung and Bronchus	71.0	67.0	69.0	67.0	70.0	70.0
Breast	68.0	62.0	60.0	57.0	57.0	67.0
Prostate	78.0	74.5		77.0	78.5	78.0
Colorectal	73.0	69.0	58.0	67.0	72.0	73.0
Urinary Bladder	76.0	73.0		67.0	80.5	76.0
Non-Hodgkin's Lymphoma	73.0	67.0		71.0	70.0	73.0
Kidney and Renal Pelvis	69.0	64.0	69.5	71.0	60.5	68.0
Leukemia	73.0	62.5		66.5	60.0	72.0
Lip, Oral Cavity and Pharynx	70.0	64.0		53.5	63.0	69.0
Pancreas	72.0	68.0		68.0	66.0	71.0
Skin	63.0					63.0
Corpus Uteri & Uterus NOS	72.0	65.5		56.5	64.0	71.0
Ovary	70.0	65.0		62.0	60.0	68.0
Thyroid Gland	73.0					72.0
Stomach Brain and Other Central	73.0	70.5		68.0	63.0	72.0
Nervous System	65.0	66.0		53.0	49.0	64.0
Cervix Uteri Liver and Intrahepatic Bile	59.0	50.0		55.0	52.0	58.0
Ducts	71.0	54.0	73.0	63.0	65.5	69.0
Esophagus	68.0	65.0		62.0	68.0	67.0
Larynx	68.0	69.0				68.0
Multiple Myeloma	72.0	68.0		65.0	69.0	71.0
Hodgkin's Lymphoma	65.0					65.0
All Other Sites	72.0	64.0	69.0	68.5	62.0	71.0
Total	71.0	67.0	69.5	66.0	66.0	71.0

Note: Those of other/unknown race/ethnicity are not shown separately, but are included in the total. Those deaths of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE <u>HIGHLIGHTS</u>

- Thyroid Gland Cancer had the highest one-year survival rate of all types of cancer in Nevada from 2000 to 2004 with a rate of 98.6%. This was followed by Prostate, Breast, Hodgkin's Lymphoma, and Skin Cancers, which had one-year survival rates of 96.6%, 96.4%, 96.4%, and 96.2%, respectively.
- Pancreatic Cancer had the lowest one-year survival rate of all types of cancer in Nevada from 2000 to 2004 with a rate of 34.6%. This was followed by Liver and Intrahepatic Bile Ducts, Esophageal, Lung and Bronchus, and Stomach Cancers, which had one-year survival rates of 42.0%, 51.6%, 52.9%, and 59.9%, respectively.
- The five types of cancer with the highest five-year survival rates in Nevada from 2000 to 2004 were Thyroid Gland (97.7%), Hodgkin's Lymphoma (92.6%), Prostate (92.0%), Skin (90.1%), and Breast (88.9%) Cancers.
- The five types of cancer with the lowest five-year survival rates in Nevada from 2000 to 2004 were Pancreatic (23.4%), Liver and Intrahepatic Bile Ducts (30.1%), Esophageal (33.8%), Lung and Bronchus (37.1%), and Stomach (46.9%) Cancers.








Figure 21. Ten Lowest One-Year Survival Rates by Type of Cancer, Nevada Residents, 2000-2004








Figure 23. Ten Lowest Five-Year Survival Rates by Type of Cancer, Nevada Residents, 2000-2004




Table 18. One-Year, Five-Year and Median Survival Rates by Type of
Cancer, Nevada Residents, 2000-2004

Type of Cancer	1-Year	5-Year	Median Survival (Years)
Lung and Bronchus	52.9%	37.1%	1.31
Colorectal	84.7%	67.5%	> 5 YEARS
Breast	96.4%	88.9%	> 5 YEARS
Prostate	96.6%	92.0%	> 5 YEARS
Pancreas	34.6%	23.4%	0.76
Non-Hodgkin's Lymphoma	85.6%	73.3%	> 5 YEARS
Leukemia	87.1%	77.3%	> 5 YEARS
Liver and Intrahepatic Bile Ducts	42.0%	30.1%	0.86
Urinary Bladder	92.2%	81.3%	> 5 YEARS
Esophagus	51.6%	33.8%	1.15
Ovary	76.4%	54.5%	> 5 YEARS
Stomach	59.9%	46.9%	3.19
Kidney and Renal Pelvis	82.3%	71.1%	> 5 YEARS
Brain and Other Central Nervous System	63.4%	49.4%	3.60
Skin	96.2%	90.1%	> 5 YEARS
Multiple Myeloma	87.0%	67.5%	> 5 YEARS
Lip, Oral Cavity and Pharynx	84.6%	70.3%	> 5 YEARS
Larynx	85.5%	76.0%	> 5 YEARS
Cervix Uteri	89.8%	79.8%	> 5 YEARS
Corpus Uteri & Uterus NOS	94.8%	88.3%	> 5 YEARS
Hodgkin's Lymphoma	96.4%	92.6%	> 5 YEARS
Thyroid Gland	98.6%	97.7%	> 5 YEARS
All Other Sites	71.4%	61.5%	> 5 YEARS
Total	82.3%	71.9%	> 5 YEARS

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 19. One-, Five-Year and Median Survival Rates by Type of Cancer,
Nevada Residents (2000-2004) and SEER-17 (2000-2004)

Type of Capacr	1-1	<i>l</i> ear	5-Ye	ear	Median	Survival
Type of Cancer	Nevada	SEER	Nevada	SEER	Nevada	SEER
Lung and Bronchus	52.9%	43.1%	37.1%	16.0%	1.31	88.0%
Colorectal	84.7%	83.4%	67.5%	0.62	> 5 YEARS	> 5 YEARS
Breast	96.4%	96.8%	88.9%	0.86	> 5 YEARS	> 5 YEARS
Prostate	96.6%	98.1%	92.0%	0.91	> 5 YEARS	> 5 YEARS
Pancreas	34.6%	25.4%	23.4%	0.05	0.76	0.67
Non-Hodgkin's Lymphoma	85.6%	81.3%	73.3%	0.66	> 5 YEARS	> 5 YEARS
Leukemia	87.1%	70.1%	77.3%	0.51	> 5 YEARS	> 5 YEARS
Liver and Intrahepatic Bile Ducts	42.0%	38.3%	30.1%	0.16	0.86	0.81
Urinary Bladder	92.2%	90.4%	81.3%	0.77	> 5 YEARS	> 5 YEARS
Esophagus	51.6%	47.0%	33.8%	0.17	1.15	0.94
Ovary	76.4%	74.7%	54.5%	0.42	> 5 YEARS	3.50
Stomach	59.9%	51.5%	46.9%	0.25	3.19	1.10
Kidney and Renal Pelvis	82.3%	81.5%	71.1%	0.66	> 5 YEARS	> 5 YEARS
Brain and Other Central Nervous System	63.4%	61.1%	49.4%	0.38	3.60	1.75
Skin	96.2%	96.5%	90.1%	0.87	> 5 YEARS	> 5 YEARS
Multiple Myeloma	87.0%	75.9%	67.5%	0.39	> 5 YEARS	3.36
Lip, Oral Cavity and Pharynx	84.6%	84.1%	70.3%	0.62	> 5 YEARS	> 5 YEARS
Larynx	85.5%	87.1%	76.0%	0.64	> 5 YEARS	> 5 YEARS
Cervix Uteri	89.8%	88.6%	79.8%	0.72	> 5 YEARS	> 5 YEARS
Corpus Uteri & Uterus NOS	94.8%	92.2%	88.3%	0.80	> 5 YEARS	> 5 YEARS
Hodgkin's Lymphoma	96.4%	93.9%	92.6%	0.86	> 5 YEARS	> 5 YEARS
Thyroid Gland	98.6%	97.6%	97.7%	0.95	> 5 YEARS	> 5 YEARS
All Other Sites	71.4%	64.6%	61.5%	0.48	> 5 YEARS	3.82
Total	82.3%	79.0%	71.9%	0.63	> 5 YEARS	> 5 YEARS

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 20. One- and Five-Year Survival Rates by Type of Cancer and Gender,Nevada Residents, 2000-2004

			Gei	nder					
Type of Cancer	Tot	al	Ма	le	Fem	ale			
	1-Year	5-Year	1-Year	5-Year	1-Year	5-Year			
Lung and Bronchus	52.9%	37.1%	51.0%	34.9%	55.0%	39.4%			
Colorectal	84.7%	67.5%	85.3%	66.4%	84.1%	68.7%			
Breast	96.4%	88.9%	95.0%	91.5%	96.5%	88.9%			
Prostate	96.6%	92.0%	96.6%	92.0%					
Pancreas	34.6%	23.4%	34.7%	24.1%	34.5%	22.5%			
Non-Hodgkin's Lymphoma	85.6%	73.3%	84.9%	71.1%	86.5%	75.9%			
Leukemia	87.1%	77.3%	86.0%	76.3%	88.6%	79.6%			
Liver and Intrahepatic Bile Ducts	42.0%	30.1%	36.9%	22.8%	53.0%	43.8%			
Urinary Bladder	92.2%	81.3%	93.0%	82.0%	89.7%	79.1%			
Esophagus	51.6%	33.8%	50.8%	32.0%	54.1%	39.0%			
Ovary	76.4%	54.5%			76.4%	54.5%			
Stomach	59.9%	46.9%	59.3%	44.6%	60.8%	51.7%			
Kidney and Renal Pelvis	82.3%	71.1%	81.5%	70.9%	83.6%	71.2%			
Brain and Other Central Nervous System	63.4%	49.4%	61.9%	47.9%	65.4%	51.4%			
Skin	96.2%	90.1%	95.3%	89.2%	97.7%	91.7%			
Multiple Myeloma	87.0%	67.5%	90.0%	65.2%	83.3%	75.6%			
Lip, Oral Cavity and Pharynx	84.6%	70.3%	84.0%	70.3%	86.2%	70.6%			
Larynx	85.5%	76.0%	85.3%	77.0%	86.1%	71.3%			
Cervix Uteri	89.8%	79.8%			89.8%	79.8%			
Corpus Uteri & Uterus NOS	94.8%	88.3%			94.8%	88.3%			
Hodgkin's Lymphoma	96.4%	92.6%	94.1%	94.1%	99.0%	91.4%			
Thyroid Gland	98.6%	97.7%	97.0%	93.9%	99.0%	98.8%			
All Other Sites	71.4%	61.5%	73.0%	63.0%	69.1%	59.3%			
Total	82.3%	71.9%	81.4%	71.0%	83.4%	73.0%			

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

ALL CANCERS

ALL CANCERS

HIGHLIGHTS

- The ratio of the cancer age-adjusted incidence rate, 479.9, to the age-adjusted mortality rate, 196.5 (per 100,000 2000 US Standard population), was 2.44 during the 2000 to 2004 period, which means that for every 244 cancer cases there were 100 deaths due to Cancer in Nevada during this period.
- Nevadan females had a higher ratio than males when the cancer incidence and cancer mortality age-adjusted rates were compared. For every 256 female cancer cases there were 100 female deaths while there were 233 male cases for every 100 male cancer deaths in Nevada from 2000 to 2004.
- The median age at diagnosis of cancer was 66 years of age for Nevada residents from 2000 to 2004. The median age at time of death due to cancer was 71 years. The median age at diagnosis for females was lower than the age for males, 65 and 67 years, respectively, while the median age at time of death was 71 years for females and 71 years for males.

INCIDENCE

- Nevada's lower cancer incidence rate for Males (538.0) was statistically significant when compared to the 2000-2004 national rate of 555.8 (per 100,000 – 2000 US Standard population) from 2000 to 2004, while Nevada's female population had an age-adjusted incidence rate (436.0) that was statistically significant above the rate for their national counterparts (411.2) during this period.
- There were 49,963 Resident Cancer cases reported in Nevada from 2000 to 2004. Statistical significance tests show that Washoe County had the highest age-adjusted incidence rate of cancer once regional comparisons were made, with a rate of 489.6. Clark County and All Other Counties, as a region, followed with rates of 487.8 and 432.9 (per 100,000 – 2000 US Standard population), respectively. BothWashoe and Clark County's rates also showed statistical significance over the 2000-2004 national rate of 470.0, while All Other Counties as a region had a statistically significant lower rate.
- Whites, as a racial/ethnic group, accounted for 84.7% of all reported cancer cases in Nevada during the 2000 to 2004 period. Their age-adjusted incidence rate of 508.8, followed by Blacks (461.0) showed statistical significance over the rates for Asians, Hispanics and Native Americans, who had rates of 287.6, 256.7 and 128.2, respectively, during this period.
- Males had a statistically significant higher age-adjusted cancer incidence rate, 538.0 (531.2-544.9) over the female rate of 435.7 (430.1-441.3) during the 2000 to 2004 period.

INPATIENT HOSPITAL DISCHARGES

- There were 34,796 hospital inpatient discharges for a primary diagnosis of cancer to Nevada Residents from 2000 to 2004. Clark County had the highest cancer age-adjusted inpatient discharge rate, 341.9 (337.5-346.2), once regional comparisons were made. This region showed statistical significance over the rates for Washoe County, Nevada Overall, and All Other Counties who had rates of 335.1 (326.2-344.1), 330.4 (326.9-334.0) and 272.1 (264.0-280.8) (per 100,000 – 2000 US Standard population), respectively, during this period.
- Total billed charges for hospital inpatient discharges due to a primary diagnosis for Cancer in Nevada totaled over 1.46 billion dollars from 2000 to 2004. Nevadans in the <1 year age group had the highest median total billed amount at \$45,493 during this period. The overall average billed charge per day for a hospital inpatient discharge due to cancer was approximately \$6,009 in Nevada from 2000 to 2004.

MORTALITY

- There were 19,379 resident deaths due to cancer in Nevada from 2000 to 2004, which followed Diseases of the Heart as the second leading cause of death during this period. Males had a 35.6% higher statistically significant age-adjusted mortality rate, 231.2 (226.4-236.0) than the female rate of 170.5 (166.9-174.1), per 100,000 2000 US Standard population, in Nevada during this period.
- Racial/ethnic comparisons showed that Blacks and Whites, as racial/ethnic groups, had the highest statistically significant cancer age-adjusted mortality rates of 219.8 (206.1-234.4) and 207.2 (204.1-210.5), respectively, of all racial/ethnic groups. They were followed by Asians, Hispanics and Native Americans who had age-adjusted mortality rates of 118.6 (106.7-132.1), 114.3 (104.9-124.6) and 100.4 (80.6-124.3), respectively from 2000 to 2004.

SURVIVAL RATE


- The one-year survival rate for cancer in Nevada was 75.9% during the 2000 to 2004 period, while the five-year survival rate was 61.2% during this same time. The median survival rate in Nevada was greater than five years during this period.
- Females in Nevada had a higher one-year survival rate (77.5%) than males (74.4%) for all cancers during the 2000 to 2004 period. This trend was similar for the five-year survival rate with females at 62.8% and males at 59.7%.
- Native Americans, as a racial/ethnic group, had the highest One-Year Survival Rate for all cancers (95.3%) in the state, and were followed by Hispanics, Asians, and Whites, with rates of 78.3%, 75.9%, and 75.4%, respectively, during the 2000 to 2004 period.
- The five-year survival rate for those diagnosed at the in situ stage was 94.3% for Nevada from 2000 to 2004. The rate for those at the localized stage was 85.3%, while those

recorded at the regional, distant and unstaged stages had rates of 60.5%, 23.0% and 39.0%, respectively.


While the Median Survival time for those diagnosed at the in situ, localized and regional stages was over five years for all types of cancer, those diagnosed at the distant and unstaged levels had median survival times of 0.88 and 1.96 respectively, for Nevada during the 2000 to 2004 period.

INCIDENCE

Figure 24. Age-Adjusted (2000) Incidence Rates for All Cancers, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 26. All Cancers Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 21. All Cancers Cases by Gender, Race/Ethnicity and County/Region ofResidence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

			County/Region	gion of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)				
Total										
Cases	49,963	34,851	8,080	7,004	28	1,671,265				
Rate*	479.9	487.8	489.6	432.9		470.0				
95% C.I.	(475.6-484.2)	(482.6-493.1)	(478.8-500.6)	(422.7-443.8)		(469.3-470.7)				
Gender										
Male	26,366	18,307	4,128	3,919	12	862,486				
Rate*	538.0	545.7	542.9	500.7		555.8				
95% C.I.	(531.2-544.9)	(537.3-554.2)	(525.7-560.7)	(484.6-518.0)		(554.6-557.0)				
Female	23,591	16,542	3,951	3,082	16	808,779				
Rate*	435.7	444.9	453.3	373.7		411.2				
95% C.I.	(430.1-441.3)	(438.1-451.8)	(439.2-467.9)	(360.5-388.3)		(410.3-412.1)				
Other/Unknown	6	2	1	3	0	0				
Race/Ethnicity										
White	42,342	28,392	7,350	6,581	19	1,398,768				
Rate*	508.8	520.9	521.4	449.4		477.4				
95% C.I.	(503.9-513.7)	(514.8-527.1)	(509.4-533.7)	(438.4-461.1)		(476.6-478.2)				
Black	2,541	2,367	136	36	2	154,210				
Rate*	461.0	460.5	508.7	381.6		504.0				
95% C.I.	(442.3-480.5)	(441.1-480.8)	(423.1-608.6)	(266.1-533.2)		(501.5-506.6)				
Native American	148	37	37	73	1	6,787				
Rate*	128.2	80.5	143.4	170.2		216.5				
95% C.I.	(107.3-152.8)	(54.5-117.6)	(98.7-207.5)	(132.5-216.9)		(211.0-211.0)				
Asian	1,460	1,197	218	43	2	90,608				
Rate*	287.6	288.5	318.2	199.6		314.9				
95% C.I.	(270.4-306.2)	(268.9-310.0)	(269.9-377.4)	(142.7-276.2)		(312.8-317.0)				
Hispanic	2,283	1,858	257	166	2	137,483				
Rate*	256.7	268.3	222.0	213.0		356.3				
95% C.I.	(244.0-270.1)	(253.5-284.1)	(190.4-259.7)	(176.1-260.1)		(354.3-358.4)				
Other/Unknown	1,189	1,000	82	105	2	20,892				

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing rates for racial/ethnic

groups to the national (SEER) rates. See Technical Notes for more information.

Table 22. All Cancers Cases by Age Group and County/Region of Residence at
Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)			
Total									
Cases	49,963	34,851	8,080	7,004	28	1,671,265			
Rate*	479.9	487.8	489.6	432.9		470.0			
95% C.I.	(475.6-484.2)	(482.6-493.1)	(478.8-500.6)	(422.7-443.8)		(469.3-470.7)			
Age Group									
<1	41	29	9	3	0	1,263			
Rate*	64.4	57.9				23.2			
95% C.I.	(44.71-84.16)	(36.82-78.96)				(22.0-24.5)			
1-4	102	72	12	18	0	4,374			
Rate*	16.2	15.6	11.9	25.5		20.7			
95% C.I.	(13.02-19.28)	(12.03-19.26)	(5.17-18.66)	(13.71-37.26)		(20.1-21.3)			
5-14	183	127	33	23	0	6,644			
Rate*	11.8	11.6	13.1	11.1		11.9			
95% C.I.	(10.08-13.49)	(9.58-13.61)	(8.66-17.63)	(6.57-15.66)		(11.6-12.2)			
15-24	380	259	73	48	0	14,390			
Rate*	24.3	23.6	27.5	24.1		26.9			
95% C.I.	(21.89-26.78)	(20.74-26.50)	(21.19-33.80)	(17.26-30.88)		(26.4-27.3)			
25-34	1,029	762		89	1	36,432			
Rate*	63.6	63.5	68.3	55.6		67.3			
95% C.I.	(59.68-67.45)	(59.02-68.05)	(58.19-78.30)	(44.02-67.11)		(66.6-68.0)			
35-44	2,698	1,954	449	294	1	99,352			
Rate*	158.2	162.6	157.4	134.6		166.3			
95% C.I.	(152.26-164.20)	(155.43-169.85)	(142.82-171.94)	(119.24-150.02)		(165.2-167.3)			
45-54	6,373	4,468	1,144	753	8	227,318			
Rate*	426.8	443.4		337.0		438.8			
95% C.I.	(416.29-437.25)	(430.36-456.36)	(411.11-461.69)	(312.96-361.11)		(437.0-440.6)			
55-64	11,689	8,175		1,647	4	350,063			
Rate*	1,070.7	1,087.7		989.6		1,060.4			
95% C.I.			(1,023.87-1,121.29)	(941.81-1,037.40)		(1,056.9-1,063.9)			
65-74	14,727	10,354		2,150	4	431,145			
Rate*	2,054.5	2,092.9		1,860.4		1,975.7			
95% C.I.	,	,	(1,996.13-2,169.45)			(1,969.8-1,981.6)			
75-84	10,320	7,089		1,590	8	377,006			
Rate*	2,511.0	2,533.5		2,343.1		2,456.7			
95% C.I.			(2,453.80-2,703.96)			(2,448.9-2,464.6)			
85+	2,416	1,557		389	2	123,278			
Rate*	2,542.8	2,557.6		2,332.6		2,231.0			
95% C.I.		,	(2,437.86-2,923.61)			(2,218.5-2,243.5)			
Unknown	5	(2,100.02 2,001.00)	, ,	0	0	(2,210.0 2,210.0)			

*Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

County of		2000-2004 Incidence							
Residence	<u></u>	Rat	e*	Age-Adjusted Rate**					
at Diagnosis	Cases —	Rate	95% C.I.	Rate	95% C.I.				
Carson City	1,594	623.5	(592.9-654.1)	534.6	(506.4-571.5)				
Churchill	637	510.1	(470.5-549.7)	521.1	(481.1-563.8)				
Clark	34,851	452.8	(448.0-457.5)	487.8	(482.6-493.1)				
Douglas	1,116	503.7	(474.1-533.3)	394.5	(371.0-419.4)				
Elko	497	217.6	(198.5-236.8)	333.6	(300.3-375.9)				
Esmeralda	26	472.1	(290.7-653.6)	363.4	(234.0-549.3)				
Eureka	47	637.9	(455.5-820.3)	619.7	(445.0-862.7)				
Humboldt	241	297.8	(260.2-335.4)	343.5	(300.0-392.4)				
Lander	100	364.2	(292.8-435.6)	452.5	(361.5-562.4)				
Lincoln	95	539.2	(430.8-647.6)	420.6	(338.9-521.0)				
Lyon	1,045	533.3	(501.0-565.7)	454.6	(427.1-483.6)				
Mineral	184	775.8	(663.7-888.0)	519.4	(445.4-605.4)				
Nye	1,125	638.5	(601.2-675.9)	436.8	(410.3-465.2)				
Pershing	93	342.4	(272.8-412.0)	346.2	(278.8-426.2)				
Storey	63	343.9	(259.0 - 428.9)	275.8	(208.6-364.5)				
Washoe	8,080	450.1	(440.2-459.9)	489.6	(478.8-500.6)				
White Pine	141	369.9	(308.8-430.9)	310.0	(234.7-454.8)				
Unknown	28	0.0		0.0					
Total	49,963	456.6	(452.6-460.6)	479.9	(475.6-484.2)				

Table 23. All Cancers Cases by County of Residence at Diagnosis, NevadaResidents, 2000-2004

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 24. All Cancers Cases by Race/Ethnicity and Gender, Nevada Residents,2000-2004

			Gender							
Race/Ethnicity		Male	Female	Other/ Unknown	Total					
White	Incidence	22,366	19,970	6	42,342					
	Rate*	559.0	470.8		508.8					
	95% C.I.	(551.4-566.7)	(464.2-477.4)		(503.9-513.7)					
Black	Incidence	1,372	1,169	0	2,541					
	Rate*	540.2	398.4		461.0					
	95% C.I.	(509.2-573.7)	(375.1-422.9)		(442.3-480.5)					
Native	Incidence	72	76	0	148					
American	Rate*	141.0	116.8		128.2					
	95% C.I.	(108.5-181.6)	(91.0-148.6)		(107.3-152.8)					
Asian	Incidence	600	860	0	1,460					
	Rate*	298.9	280.2		287.6					
	95% C.I.	(271.2-330.3)	(258.6-304.3)		(270.4-306.2)					
Hispanic	Incidence	1,212	1,071	0	2,283					
	Rate*	323.6	210.7		256.7					
	95% C.I.	(300.3-349.3)	(196.3-226.2)		(244.0-270.1)					
Other/Unkr	IOWN	744	445	0	1,189					
Total	Incidence	26,366	23,591	6	49,963					
	Rate*	538.0	435.7		479.9					
	95% C.I.	(531.2-544.9)	(430.1-441.3)		(475.6-484.2)					

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and ageadjusted to the 2000 US Standard population.

Table 25. All Cancers Cases by Age Group and Gender, Nevada Residents,2000-2004

Age		Gen	der	
Group	Male	Female	Unknown	Total
<1	26	15	0	41
Rate*	79.60	48.44		64.43
95% C.I.	(49.00-110.19)	(23.93-72.95)		(44.71-84.16)
1-4	59	43	0	102
Rate*	18.25	13.94		16.15
95% C.I.	(13.60-22.91)	(9.78-18.11)		(13.02-19.28)
5-14	104	79	0	183
Rate*	13.03	10.46		11.78
95% C.I.	(10.53-15.54)	(8.15-12.77)		(10.08-13.49)
15-24	198	182	0	380
Rate*	24.43	24.23		24.34
95% C.I.	(21.03-27.83)	(20.71-27.76)		(21.89-26.78)
25-34	386	643	0	1,029
Rate*	45.76	82.94		63.56
95% C.I.	(41.19-50.32)	(76.53-89.35)		(59.68-67.45)
35-44	910	1,788	0	2,698
Rate*	102.80	218.08		158.23
95% C.I.	(96.12-109.48)	(207.97-228.19)		(152.26-164.20)
45-54	2,698	3,675	0	6,373
Rate*	356.45	499.05		426.77
95% C.I.	(343.00-369.90)	(482.91-515.18)		(416.29-437.25)
55-64	6,370	5,315	4	11,689
Rate*	1,183.55	960.30		1,070.73
95% C.I.	(1,154.49-1,212.62)	(934.48-986.12)		(1,051.32-1,090.14)
65-74	8,805	5,920	2	14,727
Rate*	2,492.07	1,628.55		2,054.45
95% C.I.	(2,440.02-2,544.12)	(1,587.07-1,670.04)		(2,021.27-2,087.63)
75-84	5,696	4,624	0	10,320
Rate*	3,067.89	2,052.09		2,510.97
95% C.I.	(2,988.22-3,147.56)	(1,992.95-2,111.24)		(2,462.53-2,559.42)
85+	1,111	1,305	0	2,416
Rate*	3,497.33	2,063.38		2,542.81
95% C.I.	(3,291.68-3,702.99)	(1,951.43-2,175.33)		(2,441.42-2,644.21)
Unknown	<u>ک</u>	22 E01	0	0
Total Rate*	26,366 474.31	23,591 438.28	0	49,963 456.64
95% C.I.	474.31 (468.6-480.0)	438.28 (432.7-443.9)		456.64 (452.6-460.6)
JJ /0 U.I.	(-00.0-+00.0)	(+02.1-++0.9)		(+02.0-400.0)

Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 26. All Cancers Cases by Age Group and Stage, Nevada Residents,2000-2004

Age Group		Stage							
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total		
<1	Number	0	19	0	9	13	41		
	Percent		46.3%		22.0%	31.7%	100.0%		
1-4	Number	0	19	5	64	14	102		
	Percent		18.6%	4.9%	62.7%	13.7%	100.0%		
5-14	Number	0	48	16	77	42	183		
	Percent		26.2%	8.7%	42.1%	23.0%	100.0%		
15-24	Number	3	154	60	75	88	380		
	Percent	0.8%	40.5%	15.8%	19.7%	23.2%	100.0%		
25-34	Number	16	472	168	118	255	1,029		
	Percent	1.6%	45.9%	16.3%	11.5%	24.8%	100.0%		
35-44	Number	131	1,135	505	342	585	2,698		
	Percent	4.9%	42.1%	18.7%	12.7%	21.7%	100.0%		
45-54	Number	416	2,401	1,155	982	1,419	6,373		
	Percent	6.5%	37.7%	18.1%	15.4%	22.3%	100.0%		
55-64	Number	539	4,306	2,028	1,972	2,844	11,689		
	Percent	4.6%	36.8%	17.3%	16.9%	24.3%	100.0%		
65-74	Number	636	5,572	2,231	2,399	3,889	14,727		
	Percent	4.3%	37.8%	15.1%	16.3%	26.4%	100.0%		
75-84	Number	424	3,400	1,421	1,823	3,252	10,320		
	Percent	4.1%	32.9%	13.8%	17.7%	31.5%	100.0%		
85+	Number	72	642	312	397	993	2,416		
	Percent	3.0%	26.6%	12.9%	16.4%	41.1%	100.0%		
Unknown	Number	0	2	0	1	2	5		
	Percent		40.0%		20.0%	40.0%	100.0%		
Total	Number	2,237	18,170	7,901	8,259	13,396	49,963		
	Percent	4.5%	36.4%	15.8%	16.5%	26.8%	100.0%		

Table 27. Cancer Incidence by Stage and Race/Ethnicity, Nevada Residents,2000-2004


		Race/Ethnicity							
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total	
In situ	Number	1,935	75	4	75	90	58	2,237	
	Percent	4.6%	3.0%	2.7%	5.1%	3.9%	4.9%	4.5%	
Localized	Number	15,560	927	47	436	805	395	18,170	
	Percent	36.7%	36.5%	31.8%	29.9%	35.3%	33.2%	36.4%	
Regional	Number	6,788	395	24	274	341	79	7,901	
	Percent	16.0%	15.5%	16.2%	18.8%	14.9%	6.6%	15.8%	
Distant	Number	6,883	502	31	297	439	107	8,259	
	Percent	16.3%	19.8%	20.9%	20.3%	19.2%	9.0%	16.5%	
Unstaged	Number	11,176	642	42	378	608	550	13,396	
	Percent	26.4%	25.3%	28.4%	25.9%	26.6%	46.3%	26.8%	
Total	Number	42,342	2,541	148	1,460	2,283	1,189	49,963	
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	


Table 28. Median Age at Diagnosis of All Cancers by Race/Ethnicity and Gender,Nevada Residents, 2000-2004

	Gender								
Race/Ethnicity	Male		Fem	ale	Total				
	Cases	Median Age	Cases	Median Age	Cases	Median Age			
White	22,364	68.0	19,970	66.0	42,334	67.0			
Black	1,372	64.0	1,169	62.0	2,541	63.0			
Native American	72	66.0	76	59.5	148	62.0			
Asian	600	65.0	860	57.0	1,460	61.0			
Hispanic	1,212	62.0	1,071	54.0	2,283	59.0			
Other/Unknown	743	68.0	443	62.0	1,186	66.0			
Total	26,363	67.0	23,589	65.0	49,952	66.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES





Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical Notes for more information.








Figure 29. Median Charges for All Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 2000-2004








Table 29. All Cancer Inpatient Discharges by Gender, Charges, Length of Stay,
and County/Region of Residence, Nevada Residents, 2000-2004

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	34,796	24,777	5,576	4,431	12
Rate*	330.4	341.9	335.1	272.1	
95% C.I.	(326.9-334.0)	(337.5-346.2)	(326.2-344.1)	(264.0-280.8)	
Gender					
Male	16,799	11,883	2,590	2,318	8
Rate*	335.3	346.2	332.3	290.5	
95% C.I.	(330.0-340.7)	(339.7-352.9)	(319.0-346.1)	(278.4-303.7)	
Female	17,994	12,891	2,986	2,113	4
Rate*	330.9	344.1	342.6	256.1	
95% C.I.	(326.1-335.9)	(338.1-350.1)	(330.3-355.1)	(245.2-267.4)	
Other/Unknown	3	3	0	0	0
Inpatient Discharge Cl	harges (\$)				
Total Charges	\$1,460,878,238	\$1,082,521,488	\$228,502,938	\$148,923,191	\$930,621
Average Charges	\$41,984	\$43,691	\$40,980	\$33,609	\$77,552
Median Charges	\$26,605	\$26,878	\$29,191	\$21,712	\$46,875
Discharge Length of S	itay (LOS) (Days)				
Total LOS	243,128	176,329	39,515	27,118	166
Average LOS	7.0	7.1	7.1	6.1	13.8
Median LOS	5.0	5.0	5.0	4.0	11.5

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 30. Cancer Inpatient Discharges by Age Group and County/Region ofResidence, Nevada Residents, 2000-2004

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Discharges	34,796	24,777	5,576	4,431			
Rate*	318.0	321.9	310.6	305.8			
95% C.I.	(314.7-321.4)	(317.9-325.9)	(302.4-318.7)	(296.8-314.9)			
Age Group							
<1	24	23	0	1			
Rate*	37.7	45.9					
95% C.I.	(22.63-52.81)	(27.15-64.68)					
1-4	155	131	8	16			
Rate*	24.5	28.5		22.7			
95% C.I.	(20.68-28.41)	(23.59-33.34)		(11.55-33.76)			
5-14	284	254	19	10			
Rate*	18.3	23.2	7.6	4.8			
95% C.I.	(16.16-20.41)	(20.34-26.05)	(4.17-10.97)	(1.84-7.83)			
15-24	378	291	54	33			
Rate*	24.2	26.5	20.3	16.6			
95% C.I.	(21.77-26.65)	(23.49-29.59)	(14.91-25.76)	(10.90-22.19)			
25-34	901	740	113	48			
Rate*	55.7	61.7	43.6	30.0			
95% C.I.	(52.02-59.29)	(57.25-66.15)	(35.54-51.60)	(21.49-38.45)			
35-44	2,141	1,591	327	223			
Rate*	125.6	132.4	114.6	102.1			
95% C.I.	(120.25-130.89)	(125.92-138.94)	(102.19-127.04)	(88.72-115.52)			
45-54	5,014	3,636	856	522			
Rate*	335.8	360.8	326.5	233.6			
95% C.I.	(326.47-345.06)	(349.08-372.53)	(304.66-348.41)	(213.60-253.68)			
55-64	8,525	6,070	1,342	1,111			
Rate*	780.9	807.7	772.6	667.6			
95% C.I.	(764.33-797.48)	(787.33-827.97)	(731.29-813.96)	(628.29-706.80)			
65-74	9,513	6,681	1,488	1,339			
Rate*	1,327.1	1,350.5	1,396.7	1,158.6			
95% C.I.	(1,300.42-1,353.75)	(1,318.06-1,382.83)	(1,325.69-1,467.62)	(1,096.56-1,220.68)			
75-84	6,429	4,459	1,062	906			
Rate*	1,564.3	1,593.6	1,677.1	1,335.1			
95% C.I.	(1,526.01-1,602.49)	(1,546.79-1,640.34)	(1,576.27-1,778.01)	(1,248.16-1,422.04)			
85+	1,432	901	307	222			
Rate*	1,507.2	1,480.0	1,758.5	1,331.2			
95% C.I.	(1,429.10-1,585.23)	(1,383.36-1,576.64)	(1,561.80-1,955.23)	(1,156.08-1,506.31)			
Unknown	0	0	0	0			

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Age		Gender	
Group	Male	Female	Total
<1	10	14	24
Rate*	30.61	45.21	37.72
95% C.I.	(11.64-49.59)	(21.53-68.89)	(22.63-52.81)
1-4	87	68	155
Rate*	26.92	22.05	24.54
95% C.I.	(21.26-32.57)	(16.81-27.29)	(20.68-28.41)
5-14	150	132	284
Rate*	18.80	17.48	18.29
95% C.I.	(15.79-21.81)	(14.50-20.46)	(16.16-20.41)
15-24	190	188	378
Rate*	23.44	25.03	24.21
95% C.I.	(20.11-26.78)	(21.45-28.61)	(21.77-26.65)
25-34	278	623	901
Rate*	32.95	80.36	55.66
95% C.I.	(29.08-36.83)	(74.05-86.67)	(52.02-59.29)
35-44	723	1,418	2,141
Rate*	81.68	172.95	125.57
95% C.I.	(75.72-87.63)	(163.95-181.95)	(120.25-130.89)
45-54	2,156	2,858	5,014
Rate*	284.84	388.10	335.76
95% C.I.	(272.82-296.87)	(373.87-402.33)	(326.47-345.06)
55-64	4,450	4,075	8,525
Rate*	826.81	736.26	780.90
95% C.I.	(802.52-851.11)	(713.65-758.86)	(764.33-797.48)
65-74	5,017	4,495	9,513
Rate*	1,419.96	1,236.55	1,327.09
95% C.I.	(1,380.66-1,459.25)	(1,200.40-1,272.69)	(1,300.42-1,353.75)
75-84	3,127	3,302	6,429
Rate*	1,684.22	1,465.40	1,564.25
95% C.I.	(1,625.18-1,743.25)	(1,415.42-1,515.38)	(1,526.01-1,602.49)
85+	611	821	1,432
Rate*	1,923.38	1,298.11	1,507.16
95% C.I.	(1,770.87-2,075.89)	(1,209.31-1,386.91)	(1,429.10-1,585.23)
Unknown	0	0	0
Total	16,799	17,994	34,796
Rate*	302.20	334.30	318.02
95% C.I.	(297.6-306.8)	(329.4-339.2)	(314.7-321.4)

Table 31. All Cancer Inpatient Discharges by Age Group and Gender, NevadaResidents, 2000-2004

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 32. All Cancer Inpatient Discharges by County/Region of Residence, NevadaResidents, 2000-2004

Country of	2000-2004 Inpatient Hospital Discharges						
County of Residence	0	Rat	Age-Adjust	Age-Adjusted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	694	271.5	(251.3-291.7)	229.7	(212.9-247.7)		
Churchill	398	318.7	(287.4-350.0)	323.2	(292.0-357.2)		
Clark	24,777	321.9	(317.9-325.9)	341.9	(337.5-346.2)		
Douglas	612	276.2	(254.3-298.1)	212.9	(195.9-231.3)		
Elko	272	119.1	(105.0-133.3)	197.1	(171.6-225.9)		
Esmeralda	16	290.5	(148.2-432.9)	212.5	(120.7-350.6)		
Eureka	31	420.7	(272.6-568.9)	448.1	(297.1-670.7)		
Humboldt	196	242.2	(208.3-276.1)	274.7	(236.2-318.4)		
Lander	71	258.6	(198.4-318.8)	311.4	(237.7-404.0)		
Lincoln	61	346.2	(259.3-433.1)	280.4	(213.2-366.9)		
Lyon	967	493.5	(462.4-524.6)	424.3	(397.6-452.5)		
Mineral	123	518.6	(427.0-610.3)	366.6	(302.5-443.3)		
Nye	794	450.7	(419.3-482.0)	315.0	(292.2-339.6)		
Pershing	70	257.7	(197.4-318.1)	261.5	(203.3-332.4)		
Storey	26	141.9	(87.4-196.5)	131.8	(75.5-242.5)		
Washoe	5,576	310.6	(302.4-318.7)	335.1	(326.2-344.1)		
White Pine	100	262.3	(210.9-313.7)	235.8	(165.0-379.5)		
Unknown	12	0.0		0.0			
Total	34,796	318.0	(314.7-321.4)	330.4	(326.9-334.0)		


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 33. All Cancer Inpatient Discharges by Age Group, Charges and Length ofStay, Nevada Residents, 2000-2004


Age	Discharges	Charges (\$)			Length of Stay (Days)		iys)
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	24	2,352,308	98,013	45,493	327	13.6	6.0
1-4	155	10,982,654	70,856	37,451	1,955	12.6	7.0
5-14	284	18,000,653	63,383	31,226	2,450	8.6	5.0
15-24	378	21,955,784	58,084	27,593	3,217	8.5	4.0
25-34	901	38,469,186	42,696	21,539	5,786	6.4	3.0
35-44	2,141	78,086,038	36,472	22,430	12,713	5.9	4.0
45-54	5,014	200,132,602	39,915	25,303	32,961	6.6	4.0
55-64	8,525	357,513,989	41,937	26,908	59,494	7.0	5.0
65-74	9,513	406,509,105	42,732	27,893	66,131	7.0	5.0
75-84	6,429	270,129,450	42,017	27,244	47,507	7.4	6.0
85+	1,432	56,746,469	39,627	23,919	10,587	7.4	6.0
Unknown	0						
Total	34,796	1,460,878,238	41,984	26,605	243,128	7.0	5.0

MORTALITY

Figure 31. Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 33. Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 34. All Cancers Mortality by Gender, Race/Ethnicity and County/Region of
Residence, Nevada Residents, 2000-2004

		County/Region	of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	19,379	13,190	3,105	3,084
Rate*	196.5	196.0	199.4	196.4
95% C.I.	(193.7-199.4)	(192.5-199.5)	(192.3-206.7)	(189.3-204.0)
Gender				
Male	10,396	7,038	1,621	1,737
Rate*	231.2	230.0	232.6	236.4
95% C.I.	(226.4-236.0)	(224.2-236.0)	(220.8-245.1)	(224.7-249.2)
Female	8,983	6,152	1,484	1,347
Rate*	170.5	171.0	175.4	163.0
95% C.I.	(166.9-174.1)	(166.7-175.4)	(166.5-184.6)	(154.3-172.0)
Other/Unknown	0	0	0	0
Race/Ethnicity				
White	16,847	11,087	2,826	2,934
Rate*	207.2	208.2	207.7	203.6
95% C.I.	(204.1-210.5)	(204.3-212.3)	(200.0-215.6)	(196.2-211.8)
Black	1,095	1,013	61	21
Rate*	219.8	219.7	242.9	229.0
95% C.I.	(206.1-234.4)	(205.3-235.0)	(182.3-319.0)	(140.6-354.9)
Native American	98	26	24	48
Rate*	100.4	70.7	128.0	118.8
95% C.I.	(80.6-124.3)	(44.7-108.6)	(79.8-198.2)	(86.7-160.3)
Asian	530	443	78	9
Rate*	118.6	119.2	147.1	
95% C.I.	(106.7-132.1)	(105.8-134.7)	(110.2-196.6)	
Hispanic	780	599	113	68
Rate*	114.3	115.6	112.2	113.0
95% C.I.	(104.9-124.6)	(104.6-127.8)	(89.7-141.2)	(84.5-152.8)
Other/Unknown	29	22	3	4

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 35. All Cancers Mortality by Age Group and County/Region of Residence,Nevada Residents, 2000-2004

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Deaths	19,379	13,190	3,105	3,084			
Rate*	196.5	196.0	199.4	196.4			
95% C.I.	(193.7-199.4)	(192.5-199.5)	(192.3-206.7)	(189.3-204.0)			
Age Group							
<1	5	3	0	2			
Rate*							
95% C.I.							
1-4	13	8	2	3			
Rate*	2.1						
95% C.I.	(0.94-3.18)						
5-14	26	20	5	1			
Rate*	1.7	1.8					
95% C.I.	(1.03-2.32)	(1.03-2.63)					
15-24	55	39	10	6			
Rate*	3.5	3.6	3.8				
95% C.I.	(2.59-4.45)	(2.44-4.67)	(1.43-6.10)				
25-34	133	112	14	7			
Rate*	8.2	9.3	5.4				
95% C.I.	(6.82-9.61)	(7.61-11.07)	(2.57-8.23)				
35-44	495	361	72	62			
Rate*	29.0	30.1	25.2	28.4			
95% C.I.	(26.47-31.59)	(26.95-33.15)	(19.41-31.07)	(21.32-35.46)			
45-54	1,680	1,187	284	209			
Rate*	112.5	117.8	108.3	93.6			
95% C.I.	(107.12-117.88)	(111.09-124.49)	(95.74-120.94)	(80.86-106.23)			
55-64	3,786	2,591	579	616			
Rate*	346.8	344.8	333.4	370.1			
95% C.I.	(335.76-357.85)	(331.47-358.02)	(306.19-360.50)	(340.90-399.35)			
65-74	5,764	3,952	902	910			
Rate*	804.1	798.8	846.6	787.4			
95% C.I.	(783.33-824.85)	(773.92-823.73)	(791.38-901.88)	(736.25-838.57)			
75-84	5,521	3,707	876	938			
Rate*	1,343.3	1,324.8	1,383.4	1,382.3			
95% C.I.	(1,307.89-1,378.76)	(1,282.16-1,367.46)	(1,291.79-1,475.01)	(1,293.80-1,470.71)			
85+	1,898	1,208	360	330			
Rate*	1,997.6	1,984.3	2,062.1	1,978.8			
95% C.I.	(1,907.75-2,087.50)	(1,872.39-2,096.19)	(1,849.09-2,275.12)	(1,765.31-2,192.31)			
Unknown	3	2	1	0			

Note: The "---" is used for rates calculated on numbers less than ten. * Rates are per 100,000 age-specific population.

Table 36. Cancer Mortality by County of Residence, Nevada Residents,2000-2004

County of	2000-2004 Mortality						
Residence	0	Ra	Age-Adjus	Age-Adjusted Rate**			
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	698	273.0	(252.8-293.3)	228.2	(211.5-246.1)		
Churchill	236	189.0	(164.9-213.1)	198.5	(173.7-226.1)		
Clark	13,190	171.4	(168.4-174.3)	196.0	(192.5-199.5)		
Douglas	411	185.5	(167.6-203.4)	151.2	(136.4-167.4)		
Elko	245	107.3	(93.8-120.7)	208.5	(179.4-247.2)		
Esmeralda	9						
Eureka	15	203.6	(100.6-306.6)	181.5	(100.2-308.0)		
Humboldt	120	148.3	(121.8-174.8)	181.8	(149.6-219.6)		
Lander	51	185.8	(134.8-236.7)	270.9	(196.7-366.0)		
Lincoln	41	232.7	(161.5-303.9)	181.3	(129.2-253.0)		
Lyon	490	250.1	(227.9-272.2)	221.8	(201.8-246.2)		
Mineral	93	392.1	(312.4-471.8)	265.3	(212.8-330.2)		
Nye	521	295.7	(270.3-321.1)	205.1	(186.9-225.2)		
Pershing	45	165.7	(117.3-214.1)	180.2	(131.0-242.8)		
Storey	27	147.4	(91.8-203.0)	130.5	(74.9-240.6)		
Washoe	3,105	172.9	(166.9-179.0)	199.4	(192.3-206.7)		
White Pine	82	215.1	(168.5-261.7)	152.9	(121.3-192.1)		
Unknown	0						
Total	19,379	177.1	(174.6-179.6)	196.5	(193.7-199.4)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 37. Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents,2000-2004

Race/Ethnicity			Gender					
		Male	Female	Other/ Unknown	Total			
White	Incidence	9,073	7,774	0	16,847			
	Rate*	241.9	180.9		207.2			
	95% C.I.	(236.7-247.3)	(176.8-185.0)		(204.1-210.5)			
Black	Incidence	579	516	0	1,095			
	Rate*	257.8	192.0		219.8			
	95% C.I.	(234.1-284.2)	(175.1-210.2)		(206.1-234.4)			
Native	Incidence	50	48	0	98			
American	Rate*	116.3	88.8		100.4			
_	95% C.I.	(83.8-161.0)	(64.6-119.6)		(80.6-124.3)			
Asian	Incidence	240	290	0	530			
	Rate*	132.7	108.3		118.6			
	95% C.I.	(113.1-156.4)	(93.7-125.4)		(106.7-132.1)			
Hispanic	Incidence	441	339	0	780			
•	Rate*	149.6	89.7		114.3			
	95% C.I.	(131.8-169.9)	(79.1-101.6)		(104.9-124.6)			
Other/Unknown		13	16	0	29			
Total	Incidence	10,396	8,983	0	19,379			
	Rate*	231.2	170.5		196.5			
	95% C.I.	(226.4-236.0)	(166.9-174.1)		(193.7-199.4)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Age	Gender					
Group	Male	Female	Total			
<1	4	1	5			
Rate*						
95% C.I.						
1-4	9	4	13			
Rate*			2.06			
95% C.I.			(0.94-3.18)			
5-14	10	16	26			
Rate*	1.25	2.12	1.67			
95% C.I.	(0.48-2.03)	(1.08-3.16)	(1.03-2.32)			
15-24	36	19	55			
Rate*	4.44	2.53	3.52			
95% C.I.	(2.99-5.89)	(1.39-3.67)	(2.59-4.45)			
25-34	69	64	133			
Rate*	8.18	8.26	8.22			
95% C.I.	(6.25-10.11)	(6.23-10.28)	(6.82-9.61)			
35-44	212	283	495			
Rate*	23.95	34.52	29.03			
95% C.I.	(20.73-27.17)	(30.50-38.54)	(26.47-31.59)			
45-54	860	820	1,680			
Rate*	113.62	111.35	112.50			
95% C.I.	(106.03-121.21)	(103.73-118.97)	(107.12-117.88)			
55-64	2,066	1,720	3,786			
Rate*	383.87	310.76	346.80			
95% C.I.	(367.31-400.42)	(296.08-325.45)	(335.76-357.85)			
65-74	3,274	2,490	5,764			
Rate*	926.64	684.98	804.09			
95% C.I.	(894.90-958.38)	(658.08-711.89)	(783.33-824.85)			
75-84	2,963	2,558	5,521			
Rate*	1,595.88	1,135.22	1,343.32			
95% C.I.	(1,538.42-1,653.35)	(1,091.23-1,179.21)	(1,307.89-1,378.76)			
85+	891	1,007	1,898			
Rate*	2,804.79	1,592.20	1,997.62			
95% C.I.	(2,620.62-2,988.96)	(1,493.86-1,690.54)	(1,907.75-2,087.50)			
Unknown	2	1	3			
Total	10,396	8,983	19,379			
Rate*	187.02	166.89	177.12			
95% C.I.	(183.4-190.6)	(163.4-170.3)	(174.6-179.6)			

Table 38. Cancer Mortality by Age Group and Gender, Nevada Residents,2000-2004


Note: The "---" is used for rates calculated on numbers less than ten. * Rates are per 100,000 age-specific population.

Table 39. Median Age at Death from All Cancers by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004

	Gender							
Race/Ethnicity	Male		Female		Total			
	Cases	Median Age	Cases	Median Age	Cases	Median Age		
White	9,072	71.0	7,774	72.0	16,846	71.0		
Black	578	67.0	516	67.0	1,094	67.0		
Native American	50	70.0	48	68.5	98	69.5		
Asian	240	67.0	289	65.0	529	66.0		
Hispanic	441	66.0	339	67.0	780	66.0		
Other/Unknown	13	67.0	16	62.5	29	65.0		
Total	10,394	71.0	8,982	71.0	19,376	71.0		

Note: Those deaths of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE






Figure 35. Survival Rates for All Cancers by Stage of Cancer at Diagnosis, Nevada Residents, 2000-2004




Table 40. Cause-Specific Survival Rates for All Cancers by Race/Ethnicityand Gender, Nevada Residents, 2000-2004

Race/			Cause S	pecific Surviva	al Rate		Median
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	41,555	75.9%	69.3%	65.8%	63.2%	61.2%	> 5 YEARS
Male	21,781	74.4%	67.5%	64.2%	61.7%	59.7%	> 5 YEARS
Female	19,770	77.5%	71.2%	67.6%	64.8%	62.8%	> 5 YEARS
Race/Ethnicity							
White	34,930	75.4%	68.8%	65.4%	62.9%	60.9%	> 5 YEARS
Male	18,310	74.0%	67.1%	63.7%	61.4%	59.5%	> 5 YEARS
Female	16,616	77.1%	70.8%	67.3%	64.7%	62.6%	> 5 YEARS
Black	2,158	72.4%	64.2%	59.2%	54.7%	52.4%	> 5 YEARS
Male	1,167	72.4%	65.1%	60.3%	57.3%	54.0%	> 5 YEARS
Female	991	72.4%	63.2%	57.9%	51.4%	50.4%	> 5 YEARS
Native American	73	95.3%	95.3%	95.3%	95.3%	95.3%	> 5 YEARS
Male	27						
Female	46	97.5%	97.5%	97.5%	97.5%	97.5%	> 5 YEARS
Asian	1,287	75.9%	69.1%	65.3%	61.0%	61.0%	> 5 YEARS
Male	519	68.5%	61.8%	59.7%	54.8%	54.8%	> 5 YEARS
Female	768	80.9%	74.0%	69.1%	65.2%	65.2%	> 5 YEARS
Hispanic	2,018	78.3%	72.6%	69.4%	66.7%	64.0%	> 5 YEARS
Male	1,071	74.9%	68.1%	65.2%	62.0%	60.1%	> 5 YEARS
Female	947	82.3%	77.8%	74.3%	72.1%	68.6%	> 5 YEARS

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Surviv	al Rate of Stage		Gender	
	t Diagnosis	Total	Male	Female
Total	Cases	41,555	21,781	19,770
	One Year	75.9%	74.4%	77.5%
	5 Years	61.2%	59.7%	62.8%
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS
Stage at Di	iagnosis			
In situ	Cases	1,893	601	1,292
	One Year	99.7%	99.5%	99.8%
	5 Years	94.3%	92.3%	95.2%
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS
Localized	Cases	15,510	8,779	6,731
	One Year	94.6%	94.2%	95.0%
	5 Years	85.3%	84.7%	86.0%
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS
Regional	Cases	6,617	2,986	3,630
	One Year	81.4%	77.7%	84.4%
	5 Years	60.5%	54.9%	65.0%
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS
Distant	Cases	6,792	3,722	3,069
	One Year	43.3%	41.6%	45.3%
	5 Years	23.0%	22.4%	23.8%
	Median Survival	0.88	0.86	0.91
Unstaged	Cases	10,743	5,693	5,048
	One Year	59.7%	58.8%	60.8%
	5 Years	39.0%	39.9%	37.7%
	Median Survival	1.96	1.93	2.01

Table 41. Cause-Specific Survival Rates for All Cancers by Stage of Cancer atDiagnosis and Gender, Nevada Residents, 2000-2004


Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

LUNG AND BRONCHUS CANCER

LUNG AND BRONCHUS CANCER

GENERAL PROFILE⁴

Figure 36. Anatomy of the Respiratory Tract⁵



General Anatomy: The lungs, a pair of sponge-like, cone-shaped organs, are part of the respiratory system. The right lung has three sections, called lobes; it is a little larger than the left lung, which has two lobes. When we breathe in, the lungs take in oxygen, which our cells need to live and carry out their normal functions. When we breathe out, the lungs get rid of carbon dioxide, which is a waste product of the body's cells.

Risk Factors: Smoking is the most prevalent risk factor in determining risk for Lung and Bronchus Cancer. Exposure to radon, asbestos, pollution, certain lung diseases, such as tuberculosis, and personal family history are all also important risk factors.

Signs and Symptoms: Common signs and symptoms include: a cough that doesn't go away and gets worse over time, constant chest pain, coughing up blood, shortness of breath, wheezing or hoarseness, repeated problems with pneumonia or bronchitis, swelling of the neck and face, loss of appetite or weight loss, and fatigue.

Diagnosing the Cancer: The most common ways of diagnosing Lung and Bronchus Cancer are: brochoscopy, needle aspiration, thoracentesis, thoracotomy.

Treatment: Treatment options include: surgery, chemotherapy, radiation therapy, and photodynamic therapy.

HIGHLIGHTS

- Nevadan females had a higher ratio than males when the incidence and mortality ageadjusted rates for Lung and Bronchus Cancer were compared. Females had a ratio of 1.32 while the ratio for males was 1.24. This means that for every 100 deaths due to Lung and Bronchus Cancer there would be 132 female cases while only 124 cases for every male death.
- The median age at diagnosis of Lung and Bronchus cancer was 69 years of age for Nevada residents from 2000 to 2004. The median age at time of death due to Lung and Bronchus cancer was 70 years for males and Nevada overall. The median age at time of death for females was 71 years of age.

INCIDENCE

- There were 7,839 cases of Lung and Bronchus Cancer reported in Nevada from 2000 to 2004, which was the highest of any type of cancer during this period. Clark County had a statistically significant higher incidence rate of Lung and Bronchus Cancer (78.1) during this period, with both Washoe County and All Other Counties, as a region having slightly lower rates of 72.0 and 69.3, respectively. Furthermore, Nevada, as a whole, as well as its three regions had statistically significant higher rates than the national rate of 64.52 (per 100,000 2000 US Standard population).
- Whites, as a racial/ethnic group, accounted for 88.7% of all reported cancer cases in Nevada during the 2000 to 2004 period. Their age-adjusted incidence rate of 81.7, followed by Blacks (71.6) showed statistical significance over the rates for Asians and Hispanics, who had rates of 40.2 and 31.6, respectively, during this period.
- The higher age-adjusted incidence rate [85.0,C.I. (82.5-88.0)] for males with Lung and Bronchus cancer was statistically significant at the 95% CL over the rate for females, [68.0, C.I. (65.8-70.3)], during the 2000 to 2004 period. However, both had statistically significant higher rates when compared to their national counterparts. The percentage point difference was considerably more for females who were 30.0% greater than the national rate, 52.3 (52.0-52.6), while the percentage point difference for males was still 4.7% over the national rate, 81.2 (80.7-81.7), during this period.

INPATIENT HOSPITAL DISCHARGES

- Billed charges from Lung and Bronchus Cancer inpatient discharges accounted for approximately 215.1 million dollars from 2000 to 2004. Nevadans in the 55-64 and 65-74 age groups accounted for 64.7% of the total charges during this period. The overall daily billed amount for these discharges was approximately \$5,598 in Nevada during this period.
- There were 4,842 Inpatient Discharges for Lung and Bronchus Cancer to Nevada residents in Nevada from 2000 to 2004. Clark County (47.8) had the highest age-adjusted

inpatient discharge rate for Lung and Bronchus Cancer in Nevada, followed by Nevada overall, Washoe County, and All Other Counties who had rates of 46.0, 45.2 and 39.0 (per 100,000 – 2000 US Standard population), respectively.

The median total billed charges in Nevada for inpatient discharges due to Lung and Bronchus Cancer from 2000 to 2004 was \$32,755. Clark County had the highest median total billed charge, \$35,058, when compared to the amounts for Washoe County and All Other Counties of \$28,173 and \$25,318.

MORTALITY


- There were 6,005 resident deaths due to Lung and Bronchus Cancer from 2000 to 2004. All Other Counties, as a region, had a higher age-adjusted mortality rate (60.7) than Washoe County (59.3) and Clark County, (59.0) during the 2000 to 2004 period.
- Nevadan males had a 33.1% higher statistically significant age-adjusted mortality rate 68.7 for Lung and Bronchus Cancer when compared to the female rate of 51.6 (per 100,000 2000 US Standard population) for the 2000 to 2004 period.
- Whites and Blacks, as racial/ethnic groups, accounted for 94.9% of all reported Lung and Bronchus cancer cases in Nevada during the 2000 to 2004 period. Their higher ageadjusted incidence rates of 64.4 and 55.7, respectively, showed statistical signifance over the rates for Asians, Hispanics and Native Americans, who had rates of 27.0, 24.2 and 25.2, respectively, during this period.

SURVIVAL RATE


- Females had a higher one-year survival rate (44.9%) than males (39.6%) for Lung and Bronchus Cancer in Nevada from 2000 to 2004. This trend was similar for the median survival time with females and males at 0.91 and 0.83 years, respectively. This difference maintained out to the five-year survival rate where females only had a higher rate at 22.4% with males at 18.0% during this period.
- Asians, as a racial/ethnic group, had the highest One-Year Survival Rate for Lung and Bronchus cancer (49.8%) in the state, and were followed by Hispanics, Whites, and Blacks, with rates of 44.6%, 41.6%, and 41.0%, respectively, during the 2000 to 2004 period.
- The Lung and Bronchus Cancer Survival Rate varies greatly by the stage of the cancer at time of diagnosis. Those diagnosed at the localized stage had the highest one- and five-year survival rates with 79.0% and 52.6%, respectively. This was followed by those with Regional and then Distant diagnoses with rates of 55.3% and 23.3% for the one year period and 24.5% and 8.1% for the five year period.

INCIDENCE

Figure 37. Lung and Bronchus Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 39. Lung and Bronchus Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 42. Lung and Bronchus Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)				
Total										
Cases	7,839	5,515	1,166	1,153	5	225,630				
Rate*	75.8	78.1	72.0	69.3		64.5				
95% C.I.	(74.1-77.5)	(76.0-80.3)	(67.9-76.4)	(65.3-73.5)		(64.3-64.8)				
Gender										
Male	4,139	2,908	601	626	4	122,993				
Rate*	85.2	87.7	81.1	78.4		81.3				
95% C.I.	(82.5-88.0)	(84.4-91.2)	(74.5-88.3)	(72.2-85.1)		(80.8-81.8)				
Female	3,699	2,607	565	526	1	102,637				
Rate*	68.0	70.2	65.6	61.5		52.3				
95% C.I.	(65.8-70.3)	(67.5-73.0)	(60.3-71.3)	(56.3-67.0)		(52.0-52.7)				
Other/Unknown	1	0	0	1	0	0				
Race/Ethnicity										
White	6,956	4,748	1,089	1,114	5	190,974				
Rate*	81.7	85.2	77.2	73.0		65.7				
95% C.I.	(79.7-83.6)	(82.7-87.7)	(72.6-81.9)	(68.7-77.5)		(65.4-66.0)				
Black	382	353	24	5	0	22,492				
Rate*	71.6	70.8	90.7			76.7				
95% C.I.	(64.3-79.7)	(63.3-79.2)	(57.0-139.7)			(75.7-77.7)				
Native American	22	11	4	7	0	908				
Rate*	19.2	21.6				33.1				
95% C.I.	(11.6-30.4)	(9.8-43.8)				(30.9-30.9)				
Asian	198	161	31	6	0	10,709				
Rate*	40.2	39.9	47.5			39.4				
95% C.I.	(34.1-47.8)	(33.1-48.7)	(30.1-77.8)			(38.7-40.2)				
Hispanic	210	180	16	14	0	10,856				
Rate*	31.6	35.7	18.3	19.1		33.6				
95% C.I.	(26.8-37.2)	(29.8-42.8)	(9.4-35.1)	(9.9-34.6)		(32.9-34.3)				
Other/Unknown	71	62	2	7	0	547				

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing rates for racial/ethnic groups to the national (SEER) rates. See Technical Notes for more information.

Table 43. Lung and Bronchus Cancer Cases by Age Group and County/Region ofResidence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)				
Total										
Cases	7,839	5,515	1,166	1,153	5	225,630				
Rate*	75.8	78.1	72.0	69.3		64.5				
95% C.I.	(74.1-77.5)	(76.0-80.3)	(67.9-76.4)	(65.3-73.5)		(64.3-64.8)				
Age Group										
<1	0	0	0	0	0	2				
Rate*						0.0				
95% C.I.						(0.0-0.1)				
1-4	0	0	0	0	0	10				
Rate*						0.1				
95% C.I.						(0.0-0.1)				
5-14	1	1	0	0	0	17				
Rate*						0.0				
95% C.I.						(0.0-0.1)				
15-24	4	3	1	0	0	109				
Rate*						0.2				
95% C.I.						(0.2-0.2)				
25-34	9	8	1	0	0	484				
Rate*						0.9				
95% C.I.						(0.8-1.0)				
35-44	105	79	14	12	0	4,609				
Rate*	6.2	6.6	4.9	5.5		7.7				
95% C.I.	(4.98-7.34)	(5.13-8.03)	(2.34-7.48)	(2.39-8.60)		(7.5-7.9)				
45-54	624	444	116	64	0	19,853				
Rate*	41.8	44.1	44.3	28.7		38.3				
95% C.I.	(38.51-45.06)	(39.96-48.16)	(36.20-52.30)	(21.63-35.66)		(37.8-38.9)				
55-64	1,898	1,337	266	295	0	47,466				
Rate*	173.9	177.9	153.1	177.3		144.2				
95% C.I.	(166.04-181.68)	(168.36-187.43)	(134.74-171.55)	(157.02-197.48)		(142.9-145.5)				
65-74	2,822	1,992	404	425	1	73,025				
Rate*	393.7	402.7	379.2	367.8		334.9				
95% C.I.	(379.15-408.20)	(384.97-420.33)	(342.22-416.18)	(332.78-402.71)		(332.4-337.3)				
75-84	2,020	1,395	310	311	4	64,165				
Rate*	491.5	498.6	489.6	458.3		419.0				
95% C.I.	(470.06-512.92)	(472.38-524.71)	(435.06-544.06)	(407.36-509.23)		(415.7-422.2)				
85+	356	256	54	46	0	15,890				
Rate*	374.7	420.5	309.3	275.8		287.6				
95% C.I.	(335.76-413.61)	(369.00-472.02)	(226.81-391.82)	(196.12-355.55)		(283.1-292.1)				
Unknown	0	0	()	0	0	0				

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 44. Lung and Bronchus Cancer Cases by County of Residence at Diagnosis,Nevada Residents, 2000-2004

County of	2000-2004 Incidence						
Residence	Casaa	Rat	Age-Adjus	ted Rate**			
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	231	90.4	(78.7-102.0)	73.9	(64.6-84.2)		
Churchill	101	80.9	(65.1-96.7)	83.3	(67.8-101.8)		
Clark	5,515	71.6	(69.8-73.5)	78.1	(76.0-80.3)		
Douglas	179	80.8	(69.0-92.6)	61.7	(52.8-72.0)		
Elko	61	26.7	(20.0-33.4)	43.5	(32.5-58.0)		
Esmeralda	1						
Eureka	8						
Humboldt	44	54.4	(38.3-70.4)	65.4	(46.9-89.5)		
Lander	17	61.9	(32.5-91.4)	80.5	(44.4-137.8)		
Lincoln	20	113.5	(63.8-163.3)	84.5	(51.3-134.2)		
Lyon	187	95.4	(81.8-109.1)	77.9	(67.1-90.3)		
Mineral	33	139.1	(91.7-186.6)	91.4	(62.3-133.6)		
Nye	232	131.7	(114.7-148.6)	84.2	(73.3-96.8)		
Pershing	14	51.5	(24.5-78.5)	52.5	(28.6-89.4)		
Storey	7						
Washoe	1,166	64.9	(61.2-68.7)	72.0	(67.9-76.4)		
White Pine	18	47.2	(25.4-69.0)	33.7	(19.9-53.4)		
Unknown	5						
Total	7,839	71.6	(70.1-73.2)	75.8	(74.1-77.5)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 45. Lung and Bronchus Cancer Cases by Race/Ethnicity and Gender,Nevada Residents, 2000-2004

			Ger	nder	
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total
White	Incidence	3,640	3,315	1	6,956
	Rate*	90.0	74.9		81.7
	95% C.I.	(87.0-93.2)	(72.4-77.5)		(79.7-83.6)
Black	Incidence	214	168	0	382
	Rate*	83.2	60.5		71.6
	95% C.I.	(71.9-97.0)	(51.4-70.9)		(64.3-79.7)
Native	Incidence	14	8	0	22
American	Rate*	28.1			19.2
	95% C.I.	(14.5-50.6)			(11.6-30.4)
Asian	Incidence	109	89	0	198
	Rate*	55.8	29.1		40.2
	95% C.I.	(44.4-71.3)	(22.8-38.0)		(34.1-47.8)
Hispanic	Incidence	123	87	0	210
	Rate*	38.3	25.6		31.6
	95% C.I.	(30.5-48.7)	(19.9-32.7)		(26.8-37.2)
Other/Unkr	nown	39	32	0	71
Total	Incidence	4,139	3,699	1	7,839
	Rate*	85.2	68.0		75.8
	95% C.I.	(82.5-88.0)	(65.8-70.3)		(74.1-77.5)

Note: The "---" is used for rates calculated on numbers less than ten.

*Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 46. Lung and Bronchus Cancer Cases by Age Group and Gender, NevadaResidents, 2000-2004

Age	Gender							
Group	Male	Female	Unknown	Total				
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	1	0	1				
Rate*								
95% C.I.								
15-24	2	2	0	4				
Rate*								
95% C.I.	<u> </u>							
25-34	5	4	0	9				
Rate*								
95% C.I.	<u> </u>							
35-44	60	45	0	105				
Rate*	6.78	5.49		6.16				
95% C.I.	(5.06-8.49)	(3.88-7.09)		(4.98-7.34)				
45-54	322	302	0	624				
Rate*	42.54	41.01		41.79				
95% C.I.	(37.89-47.19)	(36.38-45.64)		(38.51-45.06)				
55-64	974	923	1	1,898				
Rate*	180.97	166.76		173.86				
95% C.I.	(169.60-192.34)	(156.01-177.52)		(166.04-181.68)				
65-74	1,582	1,240	0	2,822				
Rate*	447.75	341.12		393.68				
95% C.I.	(425.69-469.82)	(322.13-360.10)		(379.15-408.20)				
75-84	1,030	990	0	2,020				
Rate*	554.76	439.35		491.49				
95% C.I.	(520.88-588.64)	(411.99-466.72)		(470.06-512.92)				
85+	164	192	0	356				
Rate* 95% C.I.	516.26 (437.24-595.27)	303.58 (260.64-346.52)		374.69 (335.76-413.61)				
Unknown	(437.24-595.27)	(200.04-340.32)	0	(335.76-413.61)				
Total	4,139	3,699	1	7,839				
Rate*	74.46	68.72		7,839				
95% C.I.	(72.2-76.7)	(66.5-70.9)		(70.1-73.2)				
	(- =-= - ••••)	(1111 1010)		(

Note: The "---" is used for rates calculated on numbers less than ten.

* Rates are per 100,000 age-specific population.

Table 47. Lung and Bronchus Cancer Cases by Age Group and Stage, NevadaResidents, 2000-2004

A == 0	Crown	Stage						
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total	
<1	Number		0	0	0	0	0	
	Percent							
1-4	Number		0	0	0	0	0	
	Percent							
5-14	Number		0	1	0	0	1	
	Percent			100.0%			100.0%	
15-24	Number		1	2	1	0	4	
	Percent		25.0%	50.0%	25.0%		100.0%	
25-34	Number		1	0	3	5	9	
	Percent		11.1%		33.3%	55.6%	100.0%	
35-44	Number		16	17	48	24	105	
	Percent		15.2%	16.2%	45.7%	22.9%	100.0%	
45-54	Number		69	131	271	153	624	
	Percent		11.1%	21.0%	43.4%	24.5%	100.0%	
55-64	Number		233	340	729	596	1,898	
	Percent		12.3%	17.9%	38.4%	31.4%	100.0%	
65-74	Number		466	523	867	966	2,822	
	Percent		16.5%	18.5%	30.7%	34.2%	100.0%	
75-84	Number		315	339	563	803	2,020	
	Percent		15.6%	16.8%	27.9%	39.8%	100.0%	
85+	Number		31	44	91	190	356	
	Percent		8.7%	12.4%	25.6%	53.4%	100.0%	
Unknown	Number		0	0	0	0	0	
	Percent							
Total	Number Percent		1,132 14.4%	1,397 17.8%	2,573 32.8%	2,737 34.9%	7,839 100.0%	

Table 48. Lung and Bronchus Cancer Cases by Stage and Race/Ethnicity, NevadaResidents, 2000-2004

			Race/Ethnicity						
S	itage	White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total	
In situ	Number								
	Percent								
Localized	Number	1,016	56	1	22	25	12	1,132	
	Percent	14.6%	14.7%	4.5%	11.1%	11.9%	16.9%	14.4%	
Regional	Number	1,269	58	6	23	33	8	1,397	
	Percent	18.2%	15.2%	27.3%	11.6%	15.7%	11.3%	17.8%	
Distant	Number	2,249	136	14	85	79	10	2,573	
	Percent	32.3%	35.6%	63.6%	42.9%	37.6%	14.1%	32.8%	
Unstaged	Number	2,422	132	1	68	73	41	2,737	
	Percent	34.8%	34.6%	4.5%	34.3%	34.8%	57.7%	34.9%	
Total	Number	6,956	382	22	198	210	71	7,839	
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	


Table 49. Median Age at Diagnosis of Lung and Bronchus Cancer by
Race/Ethnicity and Gender, Nevada Residents, 2000-2004

	Gender								
Race/Ethnicity	Male		Fem	nale	То	Total			
	Cases	Median Age	Cases	Median Age	Cases	Median Age			
White	3,640	69.0	3,315	70.0	6,955	69.0			
Black	214	65.0	168	67.0	382	66.0			
Native American	14	62.5	8	63.5	22	63.5			
Asian	109	68.0	89	65.0	198	67.0			
Hispanic	123	65.0	87	68.0	210	67.0			
Other/Unknown	39	69.0	32	69.0	71	69.0			
Total	4,139	69.0	3,699	69.0	7,838	69.0			


Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 40. Lung and Bronchus Cancer Age-Adjusted (2000) Inpatient Hospital Discharge Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical Notes for more information.







Figure 42. Median Charges for Lung and Bronchus Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 2000-2004






Figure 43. Average Length of Stay for Lung and Bronchus Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 2000-2004

Table 50. Lung and Bronchus Cancer Inpatient Discharges by Gender, Charges,Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	4,842	3,449	738	653	2
Rate*	46.0	47.8	45.2	39.0	
95% C.I.	(44.7-47.3)	(46.2-49.5)	(41.9-48.6)	(36.1-42.2)	
Gender					
Male	2,463	1,798	331	333	1
Rate*	49.3	52.5	43.6	41.4	
95% C.I.	(47.3-51.4)	(50.0-55.2)	(38.9-48.9)	(37.0-46.4)	
Female	2,379	1,651	407	320	1
Rate*	43.3	43.8	47.2	37.4	
95% C.I.	(41.6-45.1)	(41.7-46.0)	(42.7-52.0)	(33.4-41.8)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$215,074,862	\$163,330,103	\$29,067,516	\$22,553,901	\$123,342
Average Charges	\$44,419	\$47,356	\$39,387	\$34,539	\$61,671
Median Charges	\$32,755	\$35,058	\$28,173	\$25,318	\$61,671
Discharge Length of S	itay (LOS) (Days)				
Total LOS	38,422	28,461	5,548	4,386	27
Average LOS	7.9	8.3	7.5	6.7	13.5
Median LOS	6.0	7.0	6.0	5.0	13.5

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 51. Lung and Bronchus Cancer Inpatient Discharges by Age Group and
County/Region of Residence, Nevada Residents, 2000-2004

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Discharges	4,842	3,449	738	653
Rate*	44.3	44.8	41.1	45.1
95% C.I.	(43.0-45.5)	(43.3-46.3)	(38.1-44.1)	(41.6-48.5)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	6	4	1	1
Rate*				
95% C.I.				
25-34	8	6	1	1
Rate*				
95% C.I.				
35-44	95	73	10	12
Rate*	5.6	6.1	3.5	5.5
95% C.I.	(4.45-6.69)	(4.68-7.47)	(1.33-5.68)	(2.39-8.60)
45-54	457	348	69	40
Rate*	30.6	34.5	26.3	17.9
95% C.I.	(27.80-33.41)	(30.90-38.16)	(20.11-32.53)	(12.36-23.45)
55-64	1,268	912	184	172
Rate*	116.2	121.4	105.9	103.4
95% C.I.	(109.76-122.54)	(113.47-129.22)	(90.63-121.24)	(87.90-118.79)
65-74	1,695	1,200	255	238
Rate*	236.5	242.6	239.4	205.9
95% C.I.	(225.20-247.71)	(228.83-256.28)	(209.97-268.72)	(179.77-232.10)
75-84	1,173	809	192	172
Rate*	285.4	289.1	303.2	253.5
95% C.I.	(269.07-301.74)	(269.20-309.04)	(260.32-346.10)	(215.58-291.34)
85+	140	97	26	17
Rate*	147.4	159.3	148.9	101.9
95% C.I.	(122.94-171.76)	(127.63-191.04)	(91.68-206.18)	(53.48-150.40)
Unknown	0	0	0	0

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 52. Lung and Bronchus Cancer Inpatient Discharges by Age Group and
Gender, Nevada Residents, 2000-2004

Age		Gender	
Group	Male	Female	Total
<1	0	0	0
Rate*			
95% C.I.			
1-4	0	0	0
Rate*			
95% C.I.			
5-14	0	0	0
Rate*			
95% C.I.			
15-24	4	2	6
Rate*			
95% C.I.			
25-34	4	4	8
Rate*			
95% C.I.			
35-44	50	45	95
Rate*	5.65	5.49	5.57
95% C.I.	(4.08-7.21)	(3.88-7.09)	(4.45-6.69)
45-54	229	228	457
Rate*	30.25	30.96	30.60
95% C.I.	(26.34-34.17)	(26.94-34.98)	(27.80-33.41)
55-64	621	647	1,268
Rate* 95% C.I.	115.38 (106.31-124.46)	116.90 (107.89-125.91)	116.15 (109.76-122.54)
		· · · · · · · · · · · · · · · · · · ·	<u>`</u>
65-74 Rate*	907 256.71	788 216.77	1,695 236.46
95% C.I.	(240.00-273.41)	(201.64-231.91)	(225.20-247.71)
75-84	586	587	1,173
Rate*	315.62	260.51	285.40
95% C.I.	(290.07-341.18)	(239.43-281.58)	(269.07-301.74)
85+	62	78	140
Rate*	195.17	123.33	147.35
95% C.I.	(146.59-243.75)	(95.96-150.70)	(122.94-171.76)
Unknown	0	0	
Total	2,463	2,379	4,842
Rate*	44.31	44.20	44.25
95% C.I.	(42.6-46.1)	(42.4-46.0)	(43.0-45.5)

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 53. Lung and Bronchus Cancer Inpatient Discharges by County/Region ofResidence, Nevada Residents, 2000-2004

Occurrent of	2000-2004 Inpatient Hospital Discharges						
County of Residence	0	Rate*			Age-Adjusted Rate**		
	Cases –	Rate	95% C.I.	Rate	95% C.I.		
Carson City	84	32.9	(25.8-39.9)	26.6	(21.2-32.9)		
Churchill	58	46.4	(34.5-58.4)	47.8	(36.2-62.3)		
Clark	3,449	44.8	(43.3-46.3)	47.8	(46.2-49.5)		
Douglas	86	38.8	(30.6-47.0)	29.5	(23.5-37.0)		
Elko	30	13.1	(8.4-17.8)	23.8	(15.3-35.9)		
Esmeralda	2						
Eureka	7						
Humboldt	28	34.6	(21.8-47.4)	39.1	(25.6-58.3)		
Lander	16	58.3	(29.7-86.8)	81.6	(44.3-140.6)		
Lincoln	10	56.8	(21.6-91.9)	44.8	(21.1-86.4)		
Lyon	137	69.9	(58.2-81.6)	57.3	(48.0-68.0)		
Mineral	17	71.7	(37.6-105.8)	52.1	(29.4-89.2)		
Nye	144	81.7	(68.4-95.1)	52.4	(43.9-62.5)		
Pershing	11	40.5	(16.6-64.4)	40.5	(20.1-74.1)		
Storey	2						
Washoe	738	41.1	(38.1-44.1)	45.2	(41.9-48.6)		
White Pine	21	55.1	(31.5-78.6)	39.0	(24.1-60.4)		
Unknown	2						
Total	4,842	44.3	(43.0-45.5)	46.0	(44.7-47.3)		


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 54. Lung and Bronchus Cancer Inpatient Discharges by Age Group,Charges and Length of Stay, Nevada Residents, 2000-2004


Age	Discharges	C	Charges (\$)		Length of Stay (Days)		ays)
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	0						
15-24	6						
25-34	8						
35-44	95	3,517,080	37,022	33,497	652	6.9	6.0
45-54	457	19,667,064	43,035	31,511	3,721	8.1	6.0
55-64	1,268	59,528,600	46,947	34,168	10,545	8.3	6.0
65-74	1,695	79,539,882	46,926	33,468	13,566	8.0	6.0
75-84	1,173	47,474,844	40,473	30,958	8,763	7.5	6.0
85+	140	4,495,469	32,110	22,198	1,013	7.2	6.0
Unknown	0						
Total	4,842	215,074,862	44,419	32,755	38,422	7.9	6.0

MORTALITY

Figure 44. Lung and Bronchus Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 46. Lung and Bronchus Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 55. Lung and Bronchus Cancer Mortality by Gender, Race/Ethnicity and
County/Region of Residence, Nevada Residents, 2000-2004

		County/Regio	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	6,005	4,066	943	996
Rate*	59.3	59.0	59.3	60.7
95% C.I.	(57.7-60.8)	(57.2-60.9)	(55.6-63.3)	(56.9-64.7)
Gender				
Male	3,244	2,193	497	554
Rate*	68.7	68.4	68.8	70.5
95% C.I.	(66.2-71.2)	(65.4-71.6)	(62.6-75.6)	(64.6-76.9)
Female	2,761	1,873	446	442
Rate*	51.6	51.4	52.4	52.1
95% C.I.	(49.6-53.5)	(49.1-53.8)	(47.6-57.5)	(47.3-57.2)
Other/Unknown	0	0	0	0
Race/Ethnicity				
White	5,408	3,561	880	967
Rate*	64.4	65.0	63.3	64.1
95% C.I.	(62.7-66.2)	(62.8-67.2)	(59.2-67.7)	(60.1-68.3)
Black	287	263	18	6
Rate*	55.7	55.0	67.2	
95% C.I.	(49.1-63.2)	(48.2-62.7)	(38.3-111.9)	
Native American	25	8	8	9
Rate*	25.2			
95% C.I.	(16.0-38.2)			
Asian	127	105	22	0
Rate*	27.0	27.9	31.7	
95% C.I.	(21.8-33.8)	(21.8-36.3)	(19.3-50.3)	
Hispanic	151	125	14	12
Rate*	24.2	27.2	12.3	17.9
95% C.I.	(19.9-29.3)	(21.9-33.7)	(6.5-22.6)	(8.5-35.5)
Other/Unknown	7	4	1	2

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 56. Lung and Bronchus Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 2000-2004

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Deaths	6,005	4,066	943	996				
Rate*	59.3	59.0	59.3	60.7				
95% C.I.	(57.7-60.8)	(57.2-60.9)	(55.6-63.3)	(56.9-64.7)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	1	1	0	0				
Rate*								
95% C.I.								
25-34	6	6	0	0				
Rate*								
95% C.I.								
35-44	69	52	9	8				
Rate*	4.1	4.3						
95% C.I.	(3.09-5.00)	(3.15-5.50)						
45-54	418	301	68	49				
Rate*	28.0	29.9	25.9	21.9				
95% C.I.	(25.31-30.67)	(26.49-33.24)	(19.77-32.11)	(15.79-28.07)				
55-64	1,271	843	196	232				
Rate*	116.4	112.2	112.8	139.4				
95% C.I.	(110.02-122.83)	(104.59-119.74)	(97.04-128.64)	(121.46-157.34)				
65-74	2,135	1,457	332	346				
Rate*	297.8	294.5	311.6	299.4				
95% C.I.	(285.20-310.47)	(279.38-309.63)	(278.10-345.14)	(267.84-330.94)				
75-84	1,734	1,144	279	311				
Rate*	421.9	408.8	440.6	458.3				
95% C.I.	(402.04-441.76)	(385.15-432.54)	(388.90-492.31)	(407.36-509.23)				
85+	369	261	58	50				
Rate*	388.4	428.7	332.2	299.8				
95% C.I.	(348.74-427.99)	(376.71-480.74)	(246.73-417.73)	(216.71-382.93)				
Unknown	2	1	1	0				

Note: The "---" is used for rates calculated on numbers less than ten.

* Rates are per 100,000 age-specific population.

Table 57. Lung and Bronchus Cancer Mortality by County of Residence, NevadaResidents, 2000-2004

County of	2000-2004 Mortality						
Residence	0	Rate*			Age-Adjusted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	220	86.1	(74.7-97.4)	70.1	(61.1-80.1)		
Churchill	76	60.9	(47.2-74.5)	64.2	(50.5-80.9)		
Clark	4,066	52.8	(51.2-54.4)	59.0	(57.2-60.9)		
Douglas	4,000	58.2	(48.2-68.3)	44.2	(36.8-53.1)		
Elko	69	30.2	(40.2-00.3)	51.5	(39.0-67.5)		
Esmeralda	2	50.2	(23.1-37.3)	51.5	(39.0-07.3)		
Eureka	4						
	-				(42 7 05 0)		
Humboldt	42	51.9	(36.2-67.6)	61.5	(43.7-85.0)		
Lander	17	61.9	(32.5-91.4)	95.0	(53.2-158.8)		
Lincoln	12	68.1	(29.6-106.6)	50.0	(25.7-88.6)		
Lyon	157	80.1	(67.6-92.7)	65.7	(55.8-77.2)		
Mineral	27	113.8	(70.9-156.8)	72.2	(47.4-107.1)		
Nye	196	111.2	(95.7-126.8)	70.5	(60.6-82.0)		
Pershing	15	55.2	(27.3-83.2)	57.7	(32.1-96.3)		
Storey	8						
Washoe	943	52.5	(49.2-55.9)	59.3	(55.6-63.3)		
White Pine	22	57.7	(33.6-81.8)	41.7	(26.1-63.9)		
Unknown	0		· · · ·				
Total	6,005	54.9	(53.5-56.3)	59.3	(57.7-60.8)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 58. Lung and Bronchus Cancer Mortality by Race/Ethnicity and Gender,Nevada Residents, 2000-2004

		Gender				
Race/Ethnicity		Male	Female	Other/ Unknown	Total	
White	Incidence	2,897	2,511	0	5,408	
	Rate*	73.3	57.2		64.4	
	95% C.I.	(70.6-76.2)	(55.0-59.5)		(62.7-66.2)	
Black	Incidence	171	116	0	287	
	Rate*	69.8	43.3		55.7	
	95% C.I.	(58.9-83.4)	(35.6-52.5)		(49.1-63.2)	
Native	Incidence	15	10	0	25	
American	Rate*	32.6	18.9		25.2	
	95% C.I.	(17.7-56.5)	(8.8-36.1)		(16.0-38.2)	
Asian	Incidence	62	65	0	127	
	Rate*	32.1	23.3		27.0	
	95% C.I.	(23.4-45.1)	(17.2-32.3)		(21.8-33.8)	
Hispanic	Incidence	96	55	0	151	
-	Rate*	32.5	17.2		24.2	
	95% C.I.	(25.1-42.6)	(12.5-23.4)		(19.9-29.3)	
Other/Unkr	nown	3	4	0	7	
Total	Incidence	3,244	2,761	0	6,005	
	Rate*	68.7	51.6		59.3	
	95% C.I.	(66.2-71.2)	(49.6-53.5)		(57.7-60.8)	

Note: The "---" is used for rates calculated on numbers less than ten.

*Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 59. Lung and Bronchus Cancer Mortality by Age Group and Gender,Nevada Residents, 2000-2004

Age	Gender					
Group	Male	Female	Total			
<1	0	0	0			
Rate*						
95% C.I.						
1-4	0	0	0			
Rate*						
95% C.I.						
5-14	0	0	0			
Rate*						
95% C.I.						
15-24	0	1	1			
Rate*						
95% C.I.						
25-34	2	4	6			
Rate*						
95% C.I.						
35-44	36	33	69			
Rate*	4.07	4.02	4.05			
95% C.I.	(2.74-5.40)	(2.65-5.40)	(3.09-5.00)			
45-54	223	195	418			
Rate*	29.46	26.48	27.99			
95% C.I.	(25.59-33.33)	(22.76-30.20)	(25.31-30.67)			
55-64	691	580	1,271			
Rate*	128.39	104.79	116.43			
95% C.I.	(118.82-137.96)	(96.26-113.32)	(110.02-122.83)			
65-74	1,226	909	2,135			
Rate*	346.99	250.06	297.84			
95% C.I.	(327.57-366.42)	(233.80-266.32)	(285.20-310.47)			
75-84	894	840	1,734			
Rate*	481.51	372.79	421.90			
95% C.I.	(449.95-513.08)	(347.58-398.00)	(402.04-441.76)			
85+	170	199	369			
Rate*	535.15	314.65	388.37			
95% C.I.	(454.70-615.59)	(270.93-358.36)	(348.74-427.99)			
Unknown	2	0	2			
Total	3,244	2,761	6,005			
Rate*	58.36 (56.3.60.4)	51.29 (40.4.53.2)	54.88 (53 5 56 3)			
95% C.I.	(56.3-60.4)	(49.4-53.2)	(53.5-56.3)			

Note: The "---" is used for rates calculated on numbers less than ten.

* Rates are per 100,000 age-specific population.


Table 60. Median Age at Death from Lung and Bronchus Cancer by
Race/Ethnicity and Gender, Nevada Residents, 2000-2004

	Gender								
Race/Ethnicity	Ма	le	Fem	nale	То	Total			
	Cases	Median Age	Cases	Median Age	Cases	Median Age			
White	2,896	70.0	2,511	71.0	5,407	71.0			
Black	170	66.0	116	68.5	286	67.0			
Native American	15	70.0	10	68.5	25	69.0			
Asian	62	68.5	65	66.0	127	67.0			
Hispanic	96	69.0	55	71.0	151	70.0			
Other/Unknown	3		4		7	67.0			
Total	3,242	70.0	2,761	71.0	6,003	70.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 47. Survival Rates for Lung and Bronchus Cancer by Race/Ethnicity, Nevada Residents, 2000-2004



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 48. Survival Rates for Lung and Bronchus Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 2000-2004




Table 61. Cause-Specific Survival Rates for Lung and Bronchus Cancer byRace/Ethnicity and Gender, Nevada Residents, 2000-2004

Race/		Cause Specific Survival Rate				Median	
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	6,194	42.1%	28.4%	24.0%	21.5%	20.1%	0.86
Male	3,260	39.6%	25.8%	21.8%	19.3%	18.0%	0.83
Female	2,934	44.9%	31.4%	26.5%	24.1%	22.4%	0.91
Race/Ethnicity							
White	5,470	41.6%	28.0%	23.7%	21.4%	20.1%	0.86
Male	2,844	39.4%	25.4%	21.6%	19.2%	18.2%	0.82
Female	2,626	44.1%	30.8%	26.1%	23.8%	22.3%	0.89
Black	310	41.0%	25.5%	18.8%	15.9%	13.5%	0.85
Male	174	37.4%	23.2%	17.8%	14.3%	9.5%	0.80
Female	136	45.7%	28.4%	20.1%	18.0%	18.0%	0.92
Native American	3						
Male	2						
Female	1						
Asian	174	49.8%	38.4%	32.4%	27.3%	27.3%	1.00
Male	100	44.6%	35.2%	31.0%	25.4%	25.4%	0.90
Female	74	57.0%	42.8%	34.2%	29.9%	29.9%	1.49
Hispanic	176	44.6%	29.4%	27.3%	23.7%	18.4%	0.90
Male	106	38.7%	23.2%	21.5%	18.4%	18.4%	0.82
Female	70	53.3%	38.1%	35.5%	31.1%	20.7%	1.22

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Survival Rate of Stage at Diagnosis			Gender				
		Total	Male	Female			
Total	Cases	6,194	3,260	2,934			
	One Year	42.1%	39.6%	44.9%			
	5 Years	20.1%	18.0%	22.4%			
	Median Survival	0.86	0.83	0.91			
Stage at D	iagnosis						
In situ	Cases						
	One Year						
	5 Years						
	Median Survival						
Localized	Cases	858	421	437			
	One Year	79.0%	75.9%	81.9%			
	5 Years	52.6%	48.9%	56.2%			
	Median Survival	> 5 YEARS	3.76	> 5 YEARS			
Regional	Cases	1,096	593	503			
	One Year	55.3%	53.3%	57.6%			
	5 Years	24.5%	22.2%	27.3%			
	Median Survival	1.27	1.16	1.42			
Distant	Cases	2,134	1,179	955			
	One Year	23.3%	21.4%	25.6%			
	5 Years	8.1%	7.2%	9.3%			
	Median Survival	0.65	0.64	0.67			
Unstaged	Cases	2,106	1,067	1,039			
	One Year	39.4%	38.2%	40.7%			
	5 Years	15.1%	14.1%	16.0%			
	Median Survival	0.83	0.81	0.84			

Table 62. Cause-Specific Survival Rates for Lung and Bronchus Cancer byStage of Cancer at Diagnosis and Gender, Nevada Residents, 2000-2004


Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

BREAST CANCER

BREAST CANCER

GENERAL PROFILE⁴

Figure 49. Anatomy of the Breast⁵



General Anatomy: Each breast has 15 to 20 sections called lobes. Within each lobe are many smaller lobules, which end in dozens of tiny bulbs that can produce milk. The lobes, lobules, and bulbs are all linked by thin tubes called ducts. These ducts lead to the nipple in the center of a dark area of skin called the areola. Fat surrounds the lobules and ducts. Each breast also contains blood vessels and lymph vessels. The lymph vessels carry colorless fluid called lymph, and lead to small bean-shaped organs called lymph nodes. Clusters of lymph nodes are found near the breast in the axilla (under the arm), above the collarbone, and in the chest. Lymph nodes are also found in many other parts of the body.

Risk Factors: Personal, and/or family, history of Breast Cancer, atypical hyperplasia, lobular carcinoma in situ, prolonged levels of estrogen, later childbearing, breast density, radiation therapy, and alcohol use are all important risk factors.

Signs and Symptoms: Common signs and symptoms include: A lump or thickening in or near the breast or in the underarm area, change in the size or shape of the breast, nipple discharge or tenderness, nipple inverted into breast, ridges or pitting of the breast, and a change in the way the skin of the breast, areola, or nipple looks or feels (for example, warm, swollen, red, or scaly).

Diagnosing the Cancer: The most common ways of diagnosing Breast Cancer are: clinical breast exam, mammography, ultrasonography, fine-needle aspiration, and needle or surgical biopsy.

Treatment: Treatment options include: surgery (Lumpectomy, Segmental Mastectomy, Simple Mastectomy, and Radical Mastectomy), radiation therapy, chemotherapy, hormonal therapy, and biological therapy.

HIGHLIGHTS

- The ratio of the age-adjusted incidence rate, 140.8, to the age-adjusted mortality rate, 51.6 (per 100,000 – 2000 US Standard female population), for Female Breast Cancer was 2.7 during the 2000 to 2004 period, which means that for every 273 Female Breast Cancer cases there was 100 female deaths due to Breast Cancer in Nevada during this period.
- The median age at diagnosis of Breast Cancer for Nevada females was 61 years of age from 2000 to 2004. The median age at time of death due to Breast Cancer for females was 67 years.

CANCER SCREENING

- ➢ From 2000 to 2004, 92.6% of the 3,903 Nevadan females who responded had ever had a mammogram and/or a clinical breast exam to try and detect early signs of Breast Cancer.
- The percentage of women who stated their education level at less than high school (85.4%) or high school (90.0%) had lower rates of ever having had a mammogram and/or clinical breast exam than those who stated their education level at some post high school (94.6%) or college graduate (96.8%) during the 2000 to 2004 period.
- Those women whose age was 18 to 24 years, 73.9% (67.1-80.7), had the lowest statistically significant percentage of ever having a mammogram and/or a clinical breast exam of any age group surveyed from 2000 to 2004. However, those women 25 to 34 years of age also had a statistically significant lower percentage, 87.8% (83.7-91.8), than all other age groups surveyed.

INCIDENCE

- There were 7,742 cases of Female Breast Cancer reported in Nevada from 2000 to 2004. Regional comparisons showed that Washoe County's age-adjusted incidence rate, 156.3 (148.2-164.8), was statistically higher than the rate for Nevada as a whole 140.8 (137.7-144.0), Clark County 141.6 (137.9-145.5) and the All Other Counties region 119.6 (112.3-127.4) during this period.
- Hispanic females were considerably lower than the statewide median age at time of diagnosis for Breast Cancer (61 years) with a median age of 52 years, the lowest of any racial/ethnic group. The racial/ethnic group with the highest median age at diagnosis were White females with a median age of 62 years for the 2000 to 2004 period.
- White females accounted for 84.1% of all reported Female Breast Cancer cases in Nevada from 2000 to 2004. They had a statistically significant higher rate 152.3 (148.6-156.1) than Black females 128.1 (115.4-142.1), Asian females 82.8 (71.8-96.2), Hispanic females 64.9 (57.6-73.3) and Native American females 36.9 (23.3-56.8) (per 100,000 – 2000 US Standard female population), during this period.

INPATIENT HOSPITAL DISCHARGES

- There were 2,253 Inpatient Discharges for Breast Cancer to Nevada female residents in Nevada from 2000 to 2004. Clark County (43.6) had the highest age-adjusted inpatient discharge rate for Breast Cancer in Nevada, followed by Nevada overall, Washoe County, and All Other Counties who had rates of 41.2, 40.2 and 31.3 (per 100,000 – 2000 US Standard female population), respectively.
- Total billed charges for hospital inpatient discharges from Breast Cancer in Nevada totaled 41.1 million dollars from 2000 to 2004. Washoe County had the highest median total charge (\$17,341), however, Clark County had the highest average length of stay (2.4) during this time; once regional comparisons were made.
- The overall average billed charge per day for a Breast Cancer inpatient hospital discharge in Nevada was \$7,736 from 2000 to 2004.

MORTALITY

- There were 1,342 female resident deaths due to Breast Cancer from 2000 to 2004. Washoe County had a higher age-adjusted mortality rate (27.2) than Clark County (25.7) and All Other Counties, as a region, (20.9) during the 2000 to 2004 period.
- Racial/ethnic comparisons showed that Black and White females had higher ageadjusted mortality rates for Female Breast Cancer 31.0 and 26.8, respectively, when compared to Hispanics and Asians who had rates of 14.6 and 12.6 (per 100,000 – 2000 US Standard female population), respectively, from 2000 to 2004.

SURVIVAL RATE

- Asian females, as a racial/ethnic group, had the highest One-Year Survival Rate for Breast cancer (96.5%) in the state, and were followed by Whites, Hispanics, and Blacks, with rates of 95.6%, 94.5%, and 89.4%, respectively, during the 2000 to 2004 period.
- The five-year survival rate for females diagnosed with Breast Cancer at the in situ stage was 95.5% for Nevada from 2000 to 2004. The rate for those at the localized stage was 92.3%, while those recorded at the regional, distant and unstaged stages had rates of 84.1%, 28.4% and 58.1%, respectively.

SCREENING (BRFSS)

Table 63. Female Breast Cancer Screening by County/Region of Residence,Education, Age Group, and Income, Nevada Residents, 2000-2004

				Answers			
Responses		Yes			No		
	Number	Percent*	95% C.I.	Number	Percent*	95% C.I.	Total
Total							
Responses	3,903	92.6%	(91.2-93.9)	230	7.4%	(6.1-8.8)	4,133
County/Region of Resid	dence						
Clark County	1,264	93.0%	(91.3-94.7)	79	7.0%	(5.3-8.7)	1,343
Washoe County	1,287	94.7%	(93.1-96.3)	61	5.3%	(3.7-6.9)	1,348
All Other Counties	1,352	88.6%	(85.1-92.0)	90	11.4%	(8.0-14.9)	1,442
Education							
Less than High School	362	85.4%	(80.0-90.7)	48	14.6%	(9.3-20.0)	410
High School	1,191	90.0%	(87.4-92.5)	98	10.0%	(7.5-12.6)	1,289
Some Post High School	1,330	94.6%	(92.7-96.6)	58	5.4%	(3.4-7.3)	1,388
College Graduate	1,010	96.8%	(94.9-98.7)	26	3.2%	(1.3-5.1)	1,036
Age Group							
18-24 years old	269	73.9%	(67.1-80.7)	75	26.1%	(19.3-32.9)	344
25-34 years old	603	87.8%	(83.7-91.8)	59	12.2%	(8.2-16.3)	662
35-44 years old	806	95.0%	(92.9-97.1)	34	5.0%	(2.9-7.1)	840
45-54 years old	801	98.6%	(97.5-99.6)	14	1.4%	(0.4-2.5)	815
55-64 years old	601	98.6%	(97.0-100.0)	6	1.4%	(0.0-3.0)	607
65+ years old	818	96.0%	(94.2-97.8)	42	4.0%	(2.2-5.8)	860
Income							
Less than \$15,000	368	85.7%	(79.9-91.5)	45	14.3%	(8.5-20.1)	413
\$15,000-\$24,999	618	89.1%	(85.1-93.1)	55	10.9%	(6.9-14.9)	673
\$25,000-\$34,999	526	91.5%	(87.6-95.5)	30	8.5%	(4.5-12.4)	556
\$35,000-\$49,999	680	94.9%	(92.5-97.3)	28	5.1%	(2.7-7.5)	708
\$50,000 or More	1,193	96.9%	(95.2-98.5)	24	3.1%	(1.5-4.8)	1,217

*Denominator includes persons age 18-65 excluding those who responded "do not know/not sure" or who refused to respond. 95% of the time, the "true point estimate" will fall between the lower and upper bounds of the 95% Confidence Interval.


"N"= response numbers and "%"= Weighted prevalence rates

Note: This table includes those respondents who answered "Yes" or "No" to either of the following questions:

- 1) A mammogram is an x-ray of each breast to look for breast cancer. Have you ever had a mammogram?
- 2) A clinical breast exam is when a doctor, nurse, or other health professional feels the breast for lumps. Have you ever had a clinical breast exam?

INCIDENCE

Figure 50. Female Breast Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 female population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 52. Female Breast Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 64. Breast Cancer Cases by Gender, Race/Ethnicity and County/Region ofResidence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

			County/Region	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)
Total						
Cases	7,824	5,397	1,402	1,018	7	251,040
Rate*	73.3	73.6	82.1	62.2		69.6
95% C.I.	(71.7-75.0)	(71.7-75.7)	(77.8-86.6)	(58.4-66.2)		(69.3-69.8)
Gender						
Male	81	46	17	18	0	1,771
Rate*	1.7	1.4	2.6	2.3		1.2
95% C.I.	(1.3-2.2)	(1.0-1.9)	(1.4-4.4)	(1.4-3.7)		(1.1-1.2)
Female	7,742	5,351	1,385	999	7	249,269
Rate*	140.8	141.6	156.3	119.6		127.9
95% C.I.	(137.7-144.0)	(137.9-145.5)	(148.2-164.8)	(112.3-127.4)		(127.4-128.4)
Other/Unknown	1	0	0	1	0	0
Race/Ethnicity						
White	6,508	4,301	1,267	935	5	209,535
Rate*	152.3	154.9	169.7	125.0		132.5
95% C.I.	(148.6-156.1)	(150.3-159.7)	(160.5-179.4)	(117.0-133.4)		(132.0-133.1)
Black	391	368	18	5	0	21,966
Rate*	128.1	128.2	135.4			118.3
95% C.I.	(115.4-142.1)	(115.0-142.7)	(79.4-219.5)			(116.8-119.9)
Native American	24	7	8	9	0	966
Rate*	36.9					51.0
95% C.I.	(23.3-56.8)					(47.7-54.5)
Asian	271	222	38	10	1	15,182
Rate*	82.8	81.5	83.1	69.4		89.0
95% C.I.	(71.8-96.2)	(69.5-96.7)	(57.2-119.3)	(32.6-136.2)		(87.6-90.4)
Hispanic	362	296	38	27	1	20,516
Rate*	64.9	67.1	59.0	55.2		89.4
95% C.I.	(57.6-73.3)	(58.8-76.9)	(39.4-91.1)	(35.1-86.3)		(88.1-90.6)
Other/Unknown	186	157	16	13	0	1,620

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Rates for race/ethnicity groups are per 100,000 female population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the national (SEER) rates. See Technical Notes for more information.

Table 65. Female Breast Cancer Cases by Age Group and County/Region ofResidence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)			
Total									
Cases	7,742	5,351	1,385	999	7	251,040			
Rate*	140.8	141.6	156.3	119.6		127.9			
95% C.I.	(137.7-144.0)	(137.9-145.5)	(148.2-164.8)	(112.3-127.4)		(127.4-128.4)			
Age Group									
<1	0	0	0	0	0	0			
Rate*						0.0			
95% C.I.						(0.0-0.1)			
1-4	0	0	0	0	0	0			
Rate*						0.0			
95% C.I.						(0.0-0.0)			
5-14	1	1	0	0	0	3			
Rate*						0.0			
95% C.I.						(0.0-0.0)			
15-24	7	4	2	1	0	195			
Rate*						0.7			
95% C.I.						(0.6-0.9)			
25-34	113	87	17	9	0	4,531			
Rate*	14.6	15.2	13.6			17.1			
95% C.I.	(11.89-17.26)	(11.99-18.36)	(7.12-20.03)			(16.6-17.6)			
35-44	757	553	122	81	1	26,471			
Rate*	92.3	96.8	87.5	74.4		88.7			
95% C.I.	(85.75-98.91)	(88.69-104.82)	(71.93-102.97)	(58.21-90.63)		(87.6-89.7)			
45-54	1,623	1,125	317	180	1	55,417			
Rate*	220.4	226.6	246.1	162.2		210.2			
95% C.I.	(209.67-231.12)	(213.31-239.79)	(218.97-273.15)	(138.48-185.87)		(208.5-212.0)			
55-64	2,031	1,410	347	272	2	57,169			
Rate*	367.0	365.7	405.2	330.8		332.8			
95% C.I.	(351.00-382.91)	(346.58-384.76)	(362.54-447.80)	(291.44-370.05)		(330.0-335.5)			
65-74	1,853	1,280	326	247	0	50,354			
Rate*	509.8	509.0	598.8	428.8		421.2			
95% C.I.	(486.54-532.96)	(481.14-536.92)	(533.76-663.75)	(375.29-482.24)		(417.5-424.9)			
75-84	1,075	714	191	168	2	41,615			
Rate*	477.1	467.1	529.6	461.4		453.1			
95% C.I.	(448.56-505.60)	(432.86-501.39)	(454.45-604.65)	(391.62-531.16)		(448.7-457.4)			
85+	282	177	63	41	1	13,514			
Rate*	445.9	433.0	531.3	390.3		355.3			
95% C.I.	(393.84-497.92)	(369.18-496.75)	(400.07-662.44)	(270.80-509.71)		(349.3-361.3)			
Unknown	0	0	0	0	0	0			

*Rates are per 100,000 age-specific female population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 66. Female Breast Cancer Cases by County of Residence at Diagnosis,Nevada Residents, 2000-2004

County of	2000-2004 Incidence					
Residence	Cases	Rat	e*	Age-Adjust	ed Rate**	
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.	
Carson City	263	202.0	(177.6-226.5)	161.7	(142.4-183.1)	
Churchill	76	122.0	(94.6-149.4)	118.3	(93.1-148.5)	
Clark	5,351	141.5	(137.7-145.2)	141.6	(137.9-145.5)	
Douglas	165	149.9	(127.0-172.8)	111.0	(94.5-130.3)	
Elko	69	63.1	(48.2-78.0)	80.1	(61.1-104.2)	
Esmeralda	7					
Eureka	4					
Humboldt	35	91.4	(61.1-121.7)	91.5	(63.1-130.4)	
Lander	12	89.8	(39.0-140.6)	107.1	(53.3-197.5)	
Lincoln	4					
Lyon	169	174.3	(148.0-200.6)	143.8	(122.8-167.8)	
Mineral	16	136.0	(69.3-202.6)	95.1	(53.3-164.8)	
Nye	142	164.2	(137.2-191.2)	112.5	(94.1-134.3)	
Pershing	13	98.2	(44.8-151.5)	90.3	(47.8-156.3)	
Storey	9					
Washoe	1,385	156.6	(148.3-164.8)	156.3	(148.2-164.8)	
White Pine	15	77.0	(38.0-115.9)	55.5	(30.2-98.9)	
Unknown	7					
Total	7,742	143.8	(140.6-147.0)	140.8	(137.7-144.0)	

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 female population. **Rates are per 100,000 female population and are age-adjusted to the 2000 US Standard population.

Table 67. Breast Cancer Cases by Race/Ethnicity and Gender, Nevada Residents,2000-2004

			Ger	nder	
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total
White	Incidence	70	6,508	1	6,579
	Rate*	1.8	152.3		78.4
	95% C.I.	(1.4-2.4)	(148.6-156.1)		(76.5-80.4)
Black	Incidence	7	391	0	398
	Rate*		128.1		68.7
	95% C.I.		(115.4-142.1)		(61.8-76.5)
Native	Incidence	0	24	0	24
American	Rate*		36.9		19.8
	95% C.I.		(23.3-56.8)		(12.4-31.2)
Asian	Incidence	2	271	0	273
	Rate*		82.8		48.2
	95% C.I.		(71.8-96.2)		(41.8-56.1)
Hispanic	Incidence	1	362	0	363
	Rate*		64.9		33.1
	95% C.I.		(57.6-73.3)		(29.2-37.8)
Other/Unkr	IOWN	1	186	0	187
Total	Incidence	81	7,742	1	7,824
	Rate*	1.7	140.8		73.3
	95% C.I.	(1.3-2.2)	(137.7-144.0)		(71.7-75.0)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 female population and are age-adjusted to the 2000 US Standard population.

Table 68. Breast Cancer Cases by Age Group and Gender, Nevada Residents,2000-2004

Age		Gen	der	
Group	Male	Female	Unknown	Total
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	1	0	1
Rate*				
95% C.I.				
15-24	0	7	0	7
Rate*				
95% C.I.				
25-34	1	113	0	113
Rate*		14.58		14.58
95% C.I.		(11.89-17.26)		(11.89-17.26)
35-44	5	757	0	757
Rate*		92.33		92.33
95% C.I.		(85.75-98.91)		(85.75-98.91)
45-54	6	1,623	0	1,623
Rate*		220.40		220.40
95% C.I.		(209.67-231.12)		(209.67-231.12)
55-64 Rate*	14 2.60	2,031	1	2,031
95% C.I.	(1.24-3.96)	366.95 (351.00-382.91)		366.95 (351.00-382.91)
65-74	27	,	0	
Rate*	7.64	1,853 509.75	0	1,853 509.75
95% C.I.	(4.76-10.52)	(486.54-532.96)		(486.54-532.96)
75-84	24	1,075	0	1,075
Rate*	12.93	477.08		477.08
95% C.I.	(7.75-18.10)	(448.56-505.60)		(448.56-505.60)
85+	4	282	0	282
Rate*		445.88		445.88
95% C.I.		(393.84-497.92)		(393.84-497.92)
Unknown	0	0	0	
Total	81	7,742	1	7,824
Rate*	1.46	143.83		71.51
95% C.I.	(1.1-1.8)	(140.6-147.0)		(69.9-73.1)

Note: The "---" is used for rates calculated on numbers less than ten.

* Rates are per 100,000 age-specific population.

Table 69. Breast Cancer Cases by Age Group and Stage, Nevada Residents,2000-2004

				S	tage		
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	0	0	0	0	0
	Percent						
1-4	Number	0	0	0	0	0	0
	Percent						
5-14	Number	0	0	0	1	0	1
	Percent				100.0%		100.0%
15-24	Number	1	3	2	1	0	7
	Percent	14.3%	42.9%	28.6%	14.3%		100.0%
25-34	Number	9	35	34	6	29	113
	Percent	8.0%	31.0%	30.1%	5.3%	25.7%	100.0%
35-44	Number	106	271	217	33	130	757
	Percent	14.0%	35.8%	28.7%	4.4%	17.2%	100.0%
45-54	Number	321	626	374	70	232	1,623
	Percent	19.8%	38.6%	23.0%	4.3%	14.3%	100.0%
55-64	Number	331	870	448	66	316	2,031
	Percent	16.3%	42.8%	22.1%	3.2%	15.6%	100.0%
65-74	Number	270	846	352	84	301	1,853
	Percent	14.6%	45.7%	19.0%	4.5%	16.2%	100.0%
75-84	Number	109	492	193	59	222	1,075
	Percent	10.1%	45.8%	18.0%	5.5%	20.7%	100.0%
85+	Number	14	111	56	16	85	282
	Percent	5.0%	39.4%	19.9%	5.7%	30.1%	100.0%
Unknown	Number	0	0	0	0	0	0
	Percent						
Total	Number	1,243	3,254	1,676	336	1,315	7,824
	Percent	15.9%	41.6%	21.4%	4.3%	16.8%	100.0%

Table 70. Breast Cancer Cases by Stage and Race/Ethnicity, Nevada Residents,2000-2004

		Race/Ethnicity				ty		
Si	tage	White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total
In situ	Number	1,035	54	2	60	58	34	1,243
	Percent	15.7%	13.6%	8.3%	22.0%	16.0%	18.2%	15.9%
Localized	Number	2,802	155	10	98	134	55	3,254
	Percent	42.6%	38.9%	41.7%	35.9%	36.9%	29.4%	41.6%
Regional	Number	1,411	88	6	64	82	25	1,676
	Percent	21.4%	22.1%	25.0%	23.4%	22.6%	13.4%	21.4%
Distant	Number	265	34	2	15	18	2	336
	Percent	4.0%	8.5%	8.3%	5.5%	5.0%	1.1%	4.3%
Unstaged	Number	1,066	67	4	36	71	71	1,315
	Percent	16.2%	16.8%	16.7%	13.2%	19.6%	38.0%	16.8%
Total	Number	6,579	398	24	273	363	187	7,824
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%


Table 71. Median Age at Diagnosis of Breast Cancer by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004

		Gender							
Race/Ethnicity	Male		Fen	ale	То	Total			
	Cases	Median Age	Cases	Median Age	Cases	Median Age			
White	70	70.5	6,508	62.0	6,578	62.0			
Black	7	63.0	391	58.0	398	58.0			
Native American			24	59.5	24	59.5			
Asian	2		271	54.0	273	54.0			
Hispanic	1		362	52.0	363	52.0			
Other/Unknown	1		186	59.5	187	60.0			
Total	81	69.0	7,742	61.0	7,823	61.0			


Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 53. Female Breast Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 female population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical Notes for more information.








Figure 55. Median Charges for Breast Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 2000-2004








Table 72. Breast Cancer Inpatient Discharges by Gender, Charges, Length of Stay,
and County/Region of Residence, Nevada Residents, 2000-2004

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	2,276	1,654	362	260	0
Rate*	21.5	22.7	21.4	16.1	
95% C.I.	(20.6-22.4)	(21.6-23.9)	(19.2-23.8)	(14.1-18.2)	
Gender					
Male	23	15	7	1	0
Rate*	0.5	0.4			
95% C.I.	(0.3-0.8)	(0.2-0.7)			
Female	2,253	1,639	355	259	0
Rate*	41.2	43.6	40.2	31.3	
95% C.I.	(39.5-43.0)	(41.5-45.8)	(36.1-44.7)	(27.6-35.5)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$41,141,441	\$30,023,246	\$7,379,109	\$3,739,086	\$0
Average Charges	\$18,076	\$18,152	\$20,384	\$14,381	\$0
Median Charges	\$14,318	\$14,010	\$17,341	\$12,531	\$0
Discharge Length of S	tay (LOS) (Days)				
Total LOS	5,318	3,999	809	510	0
Average LOS	2.3	2.4	2.2	2.0	0.0
Median LOS	1.0	1.0	2.0	1.0	0.0

* Rates are per 100,000 female population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 73. Female Breast Cancer Inpatient Discharges by Age Group and
County/Region of Residence, Nevada Residents, 2000-2004

		County/Region	of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Discharges	2,253	1,639	355	259
Rate*	41.9	43.3	40.1	36.2
95% C.I.	(40.1-43.6)	(41.2-45.4)	(36.0-44.3)	(31.8-40.6)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	2	2	0	0
Rate*				
95% C.I.				
15-24	3	2	1	0
Rate*				
95% C.I.				
25-34	40	31	4	5
Rate*	5.2	5.4		
95% C.I.	(3.56-6.76)	(3.50-7.31)		
35-44	230	174	36	20
Rate*	28.1	30.4	25.8	18.4
95% C.I.	(24.43-31.68)	(25.92-34.97)	(17.38-34.23)	(10.32-26.43)
45-54	483	339	92	52
Rate*	65.6	68.3	71.4	46.9
95% C.I.	(59.74-71.44)	(61.00-75.53)	(56.82-86.00)	(34.12-59.58)
55-64	541	409	74	58
Rate*	97.8	106.1	86.4	70.5
95% C.I.	(89.51-105.98)	(95.79-116.35)	(66.72-106.09)	(52.38-88.68)
65-74	530	393	74	63
Rate*	145.8	156.3	135.9	109.4
95% C.I.	(133.39-158.21)	(140.84-171.74)	(104.95-166.88)	(82.36-136.37)
75-84	330	226	53	51
Rate*	146.5	147.9	146.9	140.1
95% C.I.	(130.65-162.25)	(128.58-167.13)	(107.38-186.50)	(101.62-178.51)
85+	94	63	21	10
Rate*	148.6	154.1	177.1	95.2
95% C.I.	(118.58-178.67)	(116.05-192.16)	(101.34-252.82)	(36.19-154.18)
Unknown	0	0	0	0

* Rates are per 100,000 female age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 74. Breast Cancer Inpatient Discharges by Age Group and Gender, NevadaResidents, 2000-2004

Age		Gender	
Group	Male	Female	Total
<1	0	0	0
Rate*			
95% C.I.			
1-4	0	0	0
Rate*			
95% C.I.			
5-14	0	2	2
Rate*			
95% C.I.			
15-24	0	3	3
Rate*			
95% C.I.			
25-34	1	40	41
Rate*		5.16	2.53
95% C.I.		(3.56-6.76)	(1.76-3.31)
35-44	2	230	232
Rate*		28.05	13.61
95% C.I.		(24.43-31.68)	(11.86-15.36)
45-54	4	483	487
Rate*		65.59	32.61
95% C.I.		(59.74-71.44)	(29.72-35.51)
55-64	2	541	543
Rate*		97.75	49.74
95% C.I.		(89.51-105.98)	(45.56-53.92)
65-74	5	530	535
Rate*		145.80	74.63
95% C.I.		(133.39-158.21)	(68.31-80.96)
75-84	7	330	337
Rate*		146.45	82.00
95% C.I.		(130.65-162.25)	(73.24-90.75)
85+ Datat	2	94	96
Rate*		148.63 (118.58-178.67)	101.04
95% C.I.	0	(110.30-170.07)	(80.83-121.25)
<u>Unknown</u> Total	23		2 276
Rate*	0.41	2,253 41.86	2,276 20.80
95% C.I.	(0.2-0.6)	(40.1-43.6)	(19.9-21.7)
0070 0.1.	(0.2 0.0)	(+0.1 +0.0)	(10.0 21.7)

* Rates are per 100,000 female age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 75. Female Breast Cancer Inpatient Discharges by County/Region ofResidence, Nevada Residents, 2000-2004

O	2000-2004 Inpatient Hospital Discharges						
County of Residence	0	Rate*			Age-Adjusted Rate**		
	Cases -	Rate 95% C.I.		Rate	95% C.I.		
Carson City	27	20.7	(12.9-28.6)	16.4	(10.7-24.4)		
Churchill	40	64.2	(44.3-84.1)	61.8	(44.1-84.6)		
Clark	1,639	43.3	(41.2-45.4)	43.6	(41.5-45.8)		
Douglas	18	16.4	(8.8-23.9)	12.2	(7.2-19.7)		
Elko	26	23.8	(14.6-32.9)	33.7	(21.2-51.9)		
Esmeralda	2						
Eureka	2						
Humboldt	10	26.1	(9.9-42.3)	27.7	(13.0-53.4)		
Lander	4						
Lincoln	2						
Lyon	57	58.8	(43.5-74.0)	49.8	(37.6-65.1)		
Mineral	8						
Nye	50	57.8	(41.8-73.8)	38.9	(28.6-52.6)		
Pershing	6						
Storey	2						
Washoe	355	40.1	(36.0-44.3)	40.2	(36.1-44.7)		
White Pine	5						
Unknown	0						
Total	2,253	41.9	(40.1-43.6)	41.2	(39.5-43.0)		


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 female population. **Rates are per 100,000 female population and are age-adjusted to the 2000 US Standard population.

Table 76. Breast Cancer Inpatient Discharges by Age Group, Charges and Lengthof Stay, Nevada Residents, 2000-2004

Age	Discharges	(Charges (\$)		Leng	gth of Stay (Da	ays)
Group	Group Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	2						
15-24	3						
25-34	41	850,209	20,737	17,216	106	2.6	2.0
35-44	232	5,054,492	21,787	16,857	691	3.0	2.0
45-54	487	9,705,749	19,930	15,840	1,231	2.5	2.0
55-64	543	9,075,586	16,714	14,080	1,144	2.1	1.0
65-74	535	9,223,797	17,241	13,461	1,098	2.1	1.0
75-84	337	5,316,375	15,776	13,240	707	2.1	1.0
85+	96	1,844,611	19,215	12,697	333	3.5	1.0
Unknown	0						
Total	2,276	41,141,441	18,076	14,318	5,318	2.3	1.0

MORTALITY

Figure 57. Female Breast Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 female population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 59. Female Breast Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 77. Breast Cancer Mortality by Gender, Race/Ethnicity and County/Region
of Residence, Nevada Residents, 2000-2004

		County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Mortality	1,357	943	238	176			
Rate*	13.6	13.9	14.8	11.0			
95% C.I.	(12.9-14.4)	(13.0-14.9)	(13.0-16.9)	(9.4-12.8)			
Gender							
Male	15	11	2	2			
Rate*							
95% C.I.							
Female	1,342	932	236	174			
Rate*	25.2	25.7	27.2	20.9			
95% C.I.	(23.9-26.6)	(24.0-27.4)	(23.9-31.0)	(17.9-24.3)			
Other/Unknown	0	0	0	0			
Race/Ethnicity							
White	1,140	757	221	162			
Rate*	26.8	27.3	29.6	21.5			
95% C.I.	(25.2-28.4)	(25.4-29.4)	(25.9-33.9)	(18.3-25.1)			
Black	89	84	3	2			
Rate*	31.0	31.6					
95% C.I.	(24.7-38.8)	(24.9-39.9)					
Native American	9	4	0	5			
Rate*							
95% C.I.							
Asian	38	33	4	1			
Rate*	12.6	13.2					
95% C.I.	(9.0-17.5)	(9.2-18.6)					
Hispanic	65	53	8	4			
Rate*	14.6	14.7					
95% C.I.	(10.7-19.8)	(10.4-20.8)					
Other/Unknown	1	1	0	0			

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Rates for race/ethnicity groups are per 100,000 female population and age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 78. Female Breast Cancer Mortality by Age Group and County/Region ofResidence, Nevada Residents, 2000-2004

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Deaths	1,342	932	236	174				
Rate*	25.2	25.7	27.2	20.9				
95% C.I.	(23.9-26.6)	(24.0-27.4)	(23.9-31.0)	(17.9-24.3)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	0	0	0	0				
Rate*								
95% C.I.								
25-34	9	8	1	0				
Rate*								
95% C.I.								
35-44	88	68	12	8				
Rate*	10.7	11.9	8.6					
95% C.I.	(8.49-12.98)	(9.07-14.73)	(3.73-13.47)					
45-54	211	138	45	28				
Rate*	28.7	27.8	34.9	25.2				
95% C.I.	(24.79-32.52)	(23.15-32.43)	(24.72-45.14)	(15.88-34.57)				
55-64	303	210	51	42				
Rate*	54.8	54.5	59.6	51.1				
95% C.I.	(48.58-60.91)	(47.10-61.83)	(43.21-75.89)	(35.63-66.52)				
65-74	311	216	53	42				
Rate*	85.6	85.9	97.3	72.9				
95% C.I.	(76.05-95.06)	(74.44-97.35)	(71.14-123.55)	(50.86-94.96)				
75-84	275	195	42	38				
Rate*	122.0	127.6	116.5	104.4				
95% C.I.	(107.62-136.47)	(109.67-145.48)	(81.23-151.66)	(71.18-137.54)				
85+	144	96	32	16				
Rate*	227.7	234.8	269.8	152.3				
95% C.I.	(190.49-264.87)	(187.85-281.80)	(176.35-363.34)	(77.67-226.92)				
Unknown	1	11	0	0				

* Rates are per 100,000 female age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 79. Female Breast Cancer Mortality by County of Residence, NevadaResidents, 2000-2004

County of	2000-2004 Mortality						
Residence	Cases	Rate*			Age-Adjusted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	45	34.6	(24.5-44.7)	27.3	(19.9-37.1)		
Churchill	15	24.1	(11.9-36.3)	23.0	(12.9-38.5)		
Clark	932	24.6	(23.1-26.2)	25.7	(24.0-27.4)		
Douglas	21	19.1	(10.9-27.2)	13.6	(8.4-20.9)		
Elko	11	10.1	(4.1-16.0)	14.7	(7.0-28.4)		
Esmeralda	0						
Eureka	1						
Humboldt	9						
Lander	4						
Lincoln	1						
Lyon	27	27.8	(17.3-38.3)	23.6	(15.5-34.7)		
Mineral	5						
Nye	27	31.2	(19.4-43.0)	25.1	(16.1-38.0)		
Pershing	2						
Storey	1						
Washoe	236	26.7	(23.3-30.1)	27.2	(23.9-31.0)		
White Pine	5						
Unknown	0						
Total	1,342	24.9	(23.6-26.3)	25.2	(23.9-26.6)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 female population. **Rates are per 100,000 female population and are age-adjusted to the 2000 US Standard population.

Table 80. Breast Cancer Mortality by Race/Ethnicity and Gender, NevadaResidents, 2000-2004

		Gender					
Race/Ethnicity		Male	Female	Other/ Unknown	Total		
White	Incidence	10	1,140	0	1,150		
	Rate*	0.2	26.8		14.3		
	95% C.I.	(0.1-0.4)	(25.2-28.4)		(13.4-15.1)		
Black	Incidence	5	89	0	94		
	Rate*		31.0		18.0		
	95% C.I.		(24.7-38.8)		(14.2-22.7)		
Native	Incidence	0	9	0	9		
American	Rate*						
	95% C.I.						
Asian	Incidence	0	38	0	38		
	Rate*		12.6		7.3		
	95% C.I.		(9.0-17.5)		(5.2-10.2)		
Hispanic	Incidence	0	65	0	65		
	Rate*		14.6		7.9		
	95% C.I.		(10.7-19.8)		(5.7-11.1)		
Other/Unkr	IOWN	0	1	0	1		
Total	Incidence	15	1,342	0	1,357		
	Rate*	0.3	25.2		13.6		
	95% C.I.	(0.2-0.6)	(23.9-26.6)		(12.9-14.4)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 81. Breast Cancer Mortality by Age Group and Gender, Nevada Residents,2000-2004

Age	Gender						
Group	Male	Female	Total				
<1	0	0	0				
Rate*							
95% C.I.							
1-4	0	0	0				
Rate*							
95% C.I.							
5-14	0	0	0				
Rate*							
95% C.I.							
15-24	0	0	0				
Rate*							
95% C.I.							
25-34	0	9	9				
Rate*							
95% C.I.							
35-44	1	88	89				
Rate*		10.73	5.22				
95% C.I.		(8.49-12.98)	(4.14-6.30)				
45-54	2	211	213				
Rate*		28.65	14.26				
95% C.I.		(24.79-32.52)	(12.35-16.18)				
55-64 Datat	4	303	307				
Rate*		54.75	28.12				
95% C.I.		(48.58-60.91)	(24.98-31.27)				
65-74 Rate*	6	311 85.55	317 44.22				
95% C.I.		(76.05-95.06)	(39.35-49.09)				
75-84	1	275	276				
Rate*		122.04	67.15				
95% C.I.		(107.62-136.47)	(59.23-75.08)				
85+	1	144	145				
Rate*		227.68	152.61				
95% C.I.		(190.49-264.87)	(127.77-177.45)				
Unknown	0	1	1				
Total	15	1,342	1,357				
Rate*	0.27	24.93	12.40				
95% C.I.	(0.1-0.4)	(23.6-26.3)	(11.7-13.1)				

Note: The "---" is used for rates calculated on numbers less than ten.


* Rates are per 100,000 age-specific population.


Table 82. Median Age at Death from Breast Cancer by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004

	Gender								
Race/Ethnicity	Male		Fem	ale	Total				
	Cases	Median Age	Cases	Median Age	Cases	Median Age			
White	10	64.0	1,140	68.0	1,150	68.0			
Black	5	68.0	89	61.0	94	62.0			
Native American	0		9	60.0	9	60.0			
Asian	0		37	57.0	37	57.0			
Hispanic	0		65	57.0	65	57.0			
Other/Unknown	0		1		1				
Total	15	67.0	1,341	67.0	1,356	67.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE





Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 61. Survival Rates for Breast Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 2000-2004




Table 83. Cause-Specific Survival Rates for Breast Cancer by Race/Ethnicityand Gender, Nevada Residents, 2000-2004

Race/			Cause Specific Survival Rate					
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Median Survival Time (years)	
Total	6,760	95.3%	92.5%	89.8%	86.8%	85.0%	> 5 YEARS	
Male	62	90.8%	90.8%	82.6%	82.6%	82.6%	> 5 YEARS	
Female	6,697	95.4%	92.5%	89.8%	86.8%	85.0%	> 5 YEARS	
Race/Ethnicity								
White	5,646	95.6%	92.8%	90.2%	87.4%	85.7%	> 5 YEARS	
Male	51	90.9%	90.9%	90.9%	90.9%	90.9%	> 5 YEARS	
Female	5,594	95.6%	92.9%	90.2%	87.4%	85.7%	> 5 YEARS	
Black	347	89.4%	85.1%	80.7%	72.6%	69.6%	> 5 YEARS	
Male	7							
Female	340	89.5%	85.1%	81.9%	73.4%	70.3%	> 5 YEARS	
Native American	15							
Male	0							
Female	15							
Asian	250	96.5%	93.7%	89.6%	86.5%	86.5%	> 5 YEARS	
Male	2							
Female	248	96.4%	93.6%	89.6%	86.4%	86.4%	> 5 YEARS	
Hispanic	324	94.5%	91.4%	89.0%	87.8%	83.2%	> 5 YEARS	
Male	1							
Female	323	94.5%	91.4%	88.9%	87.7%	83.1%	> 5 YEARS	

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 84. Cause-Specific Survival Rates for Breast Cancer by Stage of Cancer
at Diagnosis and Gender, Nevada Residents, 2000-2004


Survival Rate of Stage at Diagnosis			Gender	
		Total	Male	Female
Total	Cases	6,760	62	6,697
	One Year	95.3%	90.8%	95.4%
	5 Years	85.0%	82.6%	85.0%
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS
Stage at Di	iagnosis			
In situ	Cases	1,105	6	1,099
	One Year	100.0%		100.0%
	5 Years	95.5%		95.5%
	Median Survival	> 5 YEARS		> 5 YEARS
Localized	Cases	2,794	24	2,770
	One Year	99.0%		99.0%
	5 Years	92.3%		92.3%
	Median Survival	> 5 YEARS		> 5 YEARS
Regional	Cases	1,474	17	1,457
	One Year	97.7%		97.8%
	5 Years	84.1%		84.0%
	Median Survival	> 5 YEARS		> 5 YEARS
Distant	Cases	292	4	288
	One Year	57.5%		57.2%
	5 Years	28.4%		28.5%
	Median Survival	1.56		1.53
Unstaged	Cases	1,095	11	1,083
	One Year	85.4%		85.3%
	5 Years	58.1%		58.0%
	Median Survival	> 5 YEARS	<u> </u>	> 5 YEARS

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

PROSTATE CANCER

PROSTATE CANCER GENERAL PROFILE⁴

Figure 62. Anatomy of the Male Urogenital System⁵



General Anatomy: The prostate is a gland in a man's reproductive system. It makes and stores seminal fluid, a milky fluid that nourishes sperm. This fluid is released to form part of semen. The prostate is about the size of a walnut. It is located below the bladder and in front of the rectum. It surrounds the upper part of the urethra, the tube that empties urine from the bladder. If the prostate grows too large, the flow of urine can be slowed or stopped. To work properly, the prostate needs male hormones (androgens), which are responsible for male sex characteristics. The main male hormone is testosterone, which is made mainly by the testicles. Some male hormones are produced in small amounts by the adrenal glands.

Risk Factors: Age, family history of Prostate Cancer, race, and diet and dietary factors are all important risk factors in being diagnosed with Prostate Cancer.

Signs and Symptoms: A need to urinate frequently, especially at night, difficulty starting urination or holding back urine, inability to urinate, weak or interrupted flow of urine, painful or burning urination, difficulty in having an erection, painful ejaculation, blood in urine or semen, or frequent pain or stiffness in the lower back, hips, or upper thighs.

Diagnosing the Cancer: Digital rectal exam, blood test for prostate-specific antigen (PSA test), transrectal ultrasonography, intravenous pyelogram, and cystoscopy.

Treatment: Treatment options include: watchful waiting, surgery (Prostatectomy, Orchiectomy), radiation therapy, and hormonal therapy.

HIGHLIGHTS

- The ratio of the age-adjusted incidence rate, 152.8, to the age-adjusted mortality rate, 27.4 (per 100,000 2000 US Standard male population), for Prostate Cancer was 5.6 during the 2000 to 2004 period, which means that for every 557 Prostate Cancer cases there was 100 male deaths due to Prostate Cancer in Nevada during this period.
- The median age at diagnosis of Prostate Cancer was 68 years of age for Nevada residents from 2000 to 2004 and the median age at time of death due to Prostate Cancer was 78 years. Hispanics males had the largest difference (11.5 years) between the median age at diagnosis and median age at time of death (78.5 years) during this period.

CANCER SCREENING

- Of the 2,351 men in Nevada who were surveyed in 2001, 2002 and 2004, 80.7% responded yes to ever having a Prostate-Specific Antigen (PSA) test and/or a digital rectal exam to try and detect early signs of Prostate Cancer.
- The percentage of men who stated their education level at less than high school (63.0%) or high school (75.6%) had the lowest percentages of those ever having a PSA test and/or a digital rectal exam, while those who stated their education level as a college graduate college graduate had the highest percentage (87.8%) when the questions were asked in 2001, 2002 and 2004.
- Those men whose income was \$50,000 or more a year had the highest percentage of respondents who states that they had ever received a PSA test or a digital rectal exam with a percentage of 84.2% in 2001, 2002 and 2004.

INCIDENCE

- Nevada's Prostate Cancer age-adjusted incidence rate, 152.8 (149.3-156.5), showed statistically significance in being lower than the 2000-2004 national rate of 167.99 (167.33-168.64) (per 100,000 2000 US Standard male population) during this period.
- There were 7,569 cases of Prostate Cancer reported in Nevada from 2000 to 2004. Regional comparisons showed that Washoe County's age-adjusted incidence rate, 163.4 (154.0-173.3), was higher than the rate for Nevada as a whole 152.8 (149.3-156.5), Clark County 151.4 (147.1-155.9) and the All Other Counties region 148.5 (139.9-157.7) during this period.
- Racial/ethnic comparisons showed that Blacks and Whites, as racial/ethnic groups, had the highest statistically significant cancer age-adjusted mortality rates of 201.1 (182.3-222.4) and 151.2 (147.3-155.2), respectively, of all racial/ethnic groups. They were followed by Hispanics, Asians and Native Americans who had age-adjusted mortality rates of 101.3 (88.3-116.7), 58.7 (47.9-73.5) and 31.9 (17.6-55.0), respectively from 2000 to 2004.

INPATIENT HOSPITAL DISCHARGES

- There were 2,614 Inpatient Discharges for Prostate Cancer to Nevada male residents in Nevada from 2000 to 2004. Washoe County (59.1) had the highest age-adjusted inpatient discharge rate for Prostate Cancer in Nevada, followed by All Other Counties, Nevada overall, and Clark County who had rates of 50.1, 49.9 and 47.7 (per 100,000 – 2000 US Standard male population), respectively.
- Billed charges from Prostate Cancer inpatient discharges accounted for approximately 63.5 million dollars from 2000 to 2004. Nevadans in the 55-64 and 65-74 age groups accounted for 73.5% of the total charges during this period. The overall daily billed amount for these discharges was approximately \$7,370 in Nevada during this period.
- Washoe County had a considerably higher median total billed charge for Prostate Cancer inpatient discharges (\$31,336) than Clark County (\$20,114) and All Other Counties (\$17,727) from 2000 to 2004.
- The overall average billed charge per day for an inpatient hospital discharge due to Prostate cancer in Nevada was \$7,370 from 2000 to 2004.

MORTALITY

- There were 995 resident deaths due to Prostate Cancer in Nevada from 2000 to 2004. While Washoe County had the highest age-adjusted mortality rate from Prostate Cancer, 31.0, statistical analysis does not show statistical significance over the rates for Nevada overall, Clark County or All Other Counties, who had rates of 27.4, 25.9 and 29.6, respectively.
- Racial/ethnic comparisons showed that Black males had higher age-adjusted mortality rates for Prostate Cancer 52.9, when compared to Whites, Hispanics and Asians who had rates of 27.3, 22.2 and 12.6 (per 100,000 – 2000 US Standard male population), respectively, from 2000 to 2004.

SURVIVAL RATE

- The one-year survival rate for Prostate cancer in Nevada was 95.7% during the 2000 to 2004 period, while the five-year survival rate was 89.6% during this same time. The median survival rate in Nevada was greater than five years during this period.
- The one-year survival rate for those diagnosed with Prostate Cancer at the localized stage was 99.1%, while those diagnosed at the regional, distant and unstages stages had rates of 99.2%, 64.3% and 81.2%, respectively during the 2000 to 2004 period.
- The five-year survival rate for those diagnosed with Prostate Cancer at the localized stage was 94.7%, while those diagnosed at the regional, distant and unstages stages had rates of 93.2%, 30.6% and 68.4%, respectively during the 2000 to 2004 period.

The five-year survival rate for those diagnosed with Prostate Cancer at the distant stage was 1.73 years, while those diagnosed at the localized, regional and unstaged stages had median survival rates of greater than five years during the 2000 to 2004 period.

SCREENING (BRFSS)

Table 85. Prostate Cancer Screening by County/Region of Residence, Education,Age Group, and Income, Nevada Residents, 2001 and 2002 and 2004

	Answers							
Responses	Yes							
	Number	Percent*	95% C.I.	Number	Percent*	95% C.I.	Total	
Total								
Responses	2,351	80.7%	(78.5-82.9)	463	19.3%	(17.1-21.5)	2,814	
County/Region of Resid	dence							
Clark County	720	79.4%	(76.3-82.6)	173	20.6%	(17.4-23.7)	893	
Washoe County	770	83.8%	(81.0-86.7)	130	16.2%	(13.3-19.0)	900	
All Other Counties	861	82.4%	(78.9-86.0)	160	17.6%	(14.0-21.1)	1,021	
Education								
Less than High School	153	63.0%	(53.3-72.7)	70	37.0%	(27.3-46.7)	223	
High School	588	75.6%	(71.1-80.2)	160	24.4%	(19.8-28.9)	748	
Some Post High School	700	81.6%	(77.7-85.4)	131	18.4%	(14.6-22.3)	831	
College Graduate	905	87.8%	(84.8-90.8)	101	12.2%	(9.2-15.2)	1,006	
Age Group								
18-24 years old								
25-34 years old								
35-44 years old	286	54.4%	(48.2-60.7)	183	45.6%	(39.3-51.8)	469	
45-54 years old	675	76.3%	(72.0-80.6)	183	23.7%	(19.4-28.0)	858	
55-64 years old	658	91.5%	(88.5-94.4)	60	8.5%	(5.6-11.5)	718	
65+ years old	732	95.8%	(93.7-97.8)	37	4.2%	(2.2-6.3)	769	
Income								
Less than \$15,000	114	67.6%	(55.8-79.5)	50	32.4%	(20.5-44.2)	164	
\$15,000-\$24,999	245	74.7%	(67.4-81.9)	68	25.3%	(18.1-32.6)	313	
\$25,000-\$34,999	250	73.1%	(65.5-80.6)	66	26.9%	(19.4-34.5)	316	
\$35,000-\$49,999	380	77.6%	(72.0-83.3)	86	22.4%	(16.7-28.0)	466	
\$50,000 or More	1,096	84.2%	(81.3-87.2)	155	15.8%	(12.8-18.7)	1,251	

* Denominator includes persons age 35-65+ excluding those who responded "do not know/not sure" or who refused to respond. 95% of the time, the "true point estimate" will fall between the lower and upper bounds of the 95% Confidence Interval.

"N"= response numbers and "%"= Weighted prevalence rates


Note: This table includes those respondents who answered "Yes" or "No" to either of the following questions:

1) A Prostate-Specific Antigen test, also called a PSA test, is a blood test used to check men for prostate cancer. Have you ever had a PSA test?

2) A digital rectal exam is an exam in which a doctor, nurse, or other health professional places a gloved finger into the rectum to feel the size, and hardness of the prostate gland. Have you ever had a digital rectal exam?

INCIDENCE

Figure 63. Prostate Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 male population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 65. Prostate Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 86. Prostate Cancer Cases by Gender, Race/Ethnicity and County/Region ofResidence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)		
Total								
Cases	7,569	5,145	1,243	1,180	1	258,706		
Rate*	71.7	71.0	75.7	71.0		73.9		
95% C.I.	(70.1-73.4)	(69.0-73.0)	(71.5-80.1)	(67.0-75.3)		(73.6-74.2)		
Gender								
Male	7,569	5,145	1,243	1,180	1	258,706		
Rate*	152.8	151.4	163.4	148.5		168.0		
95% C.I.	(149.3-156.5)	(147.1-155.9)	(154.0-173.3)	(139.9-157.7)		(167.3-168.6)		
Female								
Rate*								
95% C.I.								
Other/Unknown	0	0	0	0	0	0		
Race/Ethnicity								
White	6,241	4,037	1,113	1,090	1	207,527		
Rate*	151.2	147.9	166.7	149.4		161.4		
95% C.I.	(147.3-155.2)	(143.2-152.7)	(156.8-177.4)	(140.3-158.9)		(160.7-162.1)		
Black	503	470	25	8	0	31,294		
Rate*	201.1	204.4	187.9			255.5		
95% C.I.	(182.3-222.4)	(184.4-227.4)	(117.3-293.3)			(252.6-258.5)		
Native American	16	1	5	10	0	657		
Rate*	31.9			53.2		52.5		
95% C.I.	(17.6-55.0)			(25.0-102.9)		(48.3-57.1)		
Asian	119	91	25	3	0	11,261		
Rate*	58.7	55.4	80.7			96.5		
95% C.I.	(47.9-73.5)	(43.5-73.2)	(51.5-122.5)			(94.7-98.3)		
Hispanic	318	248	43	27	0	20,118		
Rate*	101.3	103.6	101.4	81.7		140.7		
95% C.I.	(88.3-116.7)	(88.3-122.6)	(68.9-149.7)	(51.4-128.0)		(138.6-142.7)		
Other/Unknown	372	298	32	42	0	0		

*Rates are per 100,000 male population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the national (SEER) rates. See Technical Notes for more information.

Table 87. Prostate Cancer Cases by Age Group and County/Region of Residence at
Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

Category	County/Region of Residence							
	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)		
Total								
Cases	7,569	5,145	1,243	1,180	1	258,706		
Rate*	152.8	151.4	163.4	148.5		168.0		
95% C.I.	(149.3-156.5)	(147.1-155.9)	(154.0-173.3)	(139.9-157.7)		(167.3-168.6)		
Age Group								
<1	0	0	0	0	0	3		
Rate*						0.1		
95% C.I.						(0.0-0.3)		
1-4	0	0	0	0	0	5		
Rate*						0.1		
95% C.I.						(0.0-0.1)		
5-14	0	0	0	0	0	3		
Rate*						0.0		
95% C.I.						(0.0-0.0)		
15-24	1	1	0	0	0	7		
Rate*						0.0		
95% C.I.						(0.0-0.1)		
25-34	1	1	0	0	0	21		
Rate*						0.1		
95% C.I.						(0.1-0.1)		
35-44	23	15	3	5	0	1,348		
Rate*	2.6	2.4				4.5		
95% C.I.	(1.54-3.66)	(1.18-3.59)				(4.3-4.8)		
45-54	540	375	85	80	0	21,612		
Rate*	71.3	73.4	63.8	71.2		85.1		
95% C.I.	(65.33-77.36)	(65.94-80.79)	(50.20-77.31)	(55.56-86.75)		(84.0-86.2)		
55-64	2,072	1,411	350	311	0	70,555		
Rate*	385.0	385.6	397.5	369.4		445.8		
95% C.I.	(368.40-401.56)	(365.44-405.67)	(355.85-439.14)	(328.34-410.45)		(442.6-449.2)		
65-74	3,097	2,156	494	446	1	94,958		
Rate*	876.5	886.3	948.3	769.5		961.1		
95% C.I.	(845.67-907.41)	(848.86-923.68)	(864.67-1,031.92)	(698.06-840.89)		(955.0-967.3)		
75-84	1,550	1,018	258	274	0	58,010		
Rate*	834.8	801.8	946.7	871.3		946.0		
95% C.I.	(793.27-876.40)	(752.55-851.06)	(831.15-1,062.18)	(768.11-974.44)		(938.3-953.7)		
85+	284	167	53	64	0	12,184		
Rate*	894.0	835.1	946.6	1,037.2		707.6		
95% C.I.	(790.03-997.99)	(708.45-961.78)	(691.73-1,201.42)	(783.06-1,291.27)		(695.1-720.2)		
Unknown	1	1	0	0	0	0		

* Rates are per 100,000 age-specific male population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 88. Prostate Cancer Cases by County of Residence at Diagnosis, NevadaResidents, 2000-2004

County of	2000-2004 Incidence							
Residence	Cases	Rat	te*	Age-Adjus	Age-Adjusted Rate**			
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	287	228.7	(202.3-255.2)	211.7	(187.7-238.3)			
Churchill	115	183.8	(150.2-217.4)	197.4	(162.1-239.9)			
Clark	5,145	131.4	(127.8-135.0)	151.4	(147.1-155.9)			
Douglas	222	199.1	(172.9-225.3)	158.9	(137.7-183.3)			
Elko	58	48.7	(36.2-61.3)	93.9	(65.9-134.5)			
Esmeralda	7							
Eureka	5							
Humboldt	35	82.1	(54.9-109.3)	96.0	(65.9-136.3)			
Lander	12	85.2	(37.0-133.3)	103.5	(50.0-207.1)			
Lincoln	15	172.9	(85.4-260.4)	132.2	(73.1-229.9)			
Lyon	173	174.8	(148.7-200.8)	146.2	(124.9-171.0)			
Mineral	34	284.5	(188.9-380.2)	184.9	(127.1-263.8)			
Nye	160	178.4	(150.7-206.0)	114.2	(96.5-135.5)			
Pershing	12	86.2	(37.4-135.0)	106.0	(52.6-199.9)			
Storey	13	136.6	(62.3-210.9)	101.4	(51.9-183.4)			
Washoe	1,243	136.5	(128.9-144.1)	163.4	(154.0-173.3)			
White Pine	32	171.7	(112.2-231.2)	136.1	(92.7-195.5)			
Unknown	1							
Total	7,569	136.2	(133.1-139.2)	152.8	(149.3-156.5)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 male population. **Rates are per 100,000 male population and are age-adjusted to the 2000 US Standard population.

Table 89. Prostate Cancer Cases by Race/Ethnicity and Gender, Nevada Residents,2000-2004

			Gender					
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total			
White	Incidence	6,241	0	0	6,241			
	Rate*	151.2			71.9			
	95% C.I.	(147.3-155.2)			(70.2-73.8)			
Black	Incidence	503	0	0	503			
	Rate*	201.1			92.2			
	95% C.I.	(182.3-222.4)			(84.0-101.2)			
Native	Incidence	16	0	0	16			
American	Rate*	31.9			14.7			
	95% C.I.	(17.6-55.0)			(8.2-25.1)			
Asian	Incidence	119	0	0	119			
	Rate*	58.7			24.5			
	95% C.I.	(47.9-73.5)			(20.0-30.6)			
Hispanic	Incidence	318	0	0	318			
	Rate*	101.3			45.3			
	95% C.I.	(88.3-116.7)			(39.9-51.5)			
Other/Unkr	nown	372	0	0	372			
Total	Incidence	7,569	0	0	7,569			
	Rate*	152.8			71.7			
	95% C.I.	(149.3-156.5)			(70.1-73.4)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 male population and are age-adjusted to the 2000 US Standard population.

Table 90. Prostate Cancer Cases by Age Group and Gender, Nevada Residents,2000-2004

Age	Gender							
Group	Male	Female	Unknown	Total				
<1	0	0	0 =	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	1	0	0	1				
Rate* 95% C.I.								
25-34 Rate*	I	0	0	1				
95% C.I.								
35-44	23	0	0	23				
Rate*	2.60			2.60				
95% C.I.	(1.54-3.66)			(1.54-3.66)				
45-54	540	0	0	540				
Rate*	71.34			71.34				
95% C.I.	(65.33-77.36)			(65.33-77.36)				
55-64	2,072	0	0	2,072				
Rate*	384.98			384.98				
95% C.I.	(368.40-401.56)			(368.40-401.56)				
65-74	3,097	0	0	3,097				
Rate*	876.54			876.54				
95% C.I.	(845.67-907.41)			(845.67-907.41)				
75-84	1,550	0	0	1,550				
Rate*	834.84			834.84				
95% C.I.	(793.27-876.40)			(793.27-876.40)				
85+	284	0	0	284				
Rate* 95% C.I.	894.01 (790.03-997.99)			894.01 (790.03-997.99)				
Unknown	(790.03-997.99)	=	=	(790.03-997.99)				
Total	7,569	0	0	7,569				
Rate*	136.16			69.18				
95% C.I.	(133.1-139.2)			(67.6-70.7)				
	/			````/				

Note: The "---" is used for rates calculated on numbers less than ten.

* Rates are per 100,000 age-specific population.

Table 91. Prostate Cancer Cases by Age Group and Stage, Nevada Residents,2000-2004

• • • • •	0	Stage							
Age	Age Group		Localized	Regional	Distant	Unstaged	Total		
<1	Number		0	0	0	0	0		
	Percent								
1-4	Number		0	0	0	0	0		
	Percent								
5-14	Number		0	0	0	0	0		
	Percent								
15-24	Number		1	0	0	0	1		
	Percent		100.0%				100.0%		
25-34	Number		0	0	0	1	1		
	Percent					100.0%	100.0%		
35-44	Number		12	3	1	7	23		
	Percent		52.2%	13.0%	4.3%	30.4%	100.0%		
45-54	Number		389	52	17	82	540		
	Percent		72.0%	9.6%	3.1%	15.2%	100.0%		
55-64	Number		1,475	258	46	293	2,072		
	Percent		71.2%	12.5%	2.2%	14.1%	100.0%		
65-74	Number		2,306	206	85	500	3,097		
	Percent		74.5%	6.7%	2.7%	16.1%	100.0%		
75-84	Number		1,089	56	65	340	1,550		
	Percent		70.3%	3.6%	4.2%	21.9%	100.0%		
85+	Number		150	12	18	104	284		
	Percent		52.8%	4.2%	6.3%	36.6%	100.0%		
Unknown	Number		1	0	0	0	1		
	Percent		100.0%				100.0%		
Total	Number		5,423	587	232	1,327	7,569		
	Percent		71.6%	7.8%	3.1%	17.5%	100.0%		

Table 92. Prostate Cancer Cases by Stage and Race/Ethnicity, Nevada Residents,2000-2004

			Race/Ethnicity							
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total		
In situ	Number									
	Percent									
Localized	Number	4,522	373	10	73	233	212	5,423		
	Percent	72.5%	74.2%	62.5%	61.3%	73.3%	57.0%	71.6%		
Regional	Number	512	35	3	5	21	11	587		
	Percent	8.2%	7.0%	18.8%	4.2%	6.6%	3.0%	7.8%		
Distant	Number	194	15	0	10	10	3	232		
	Percent	3.1%	3.0%	<u> </u>	8.4%	3.1%	0.8%	3.1%		
Unstaged	Number	1,013	80	3	31	54	146	1,327		
	Percent	16.2%	15.9%	18.8%	26.1%	17.0%	39.2%	17.5%		
Total	Number	6,241	503	16	119	318	372	7,569		
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		


Table 93. Median Age at Diagnosis of Prostate Cancer by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004

	Gender								
Race/Ethnicity	Male		Fem	ale	Total				
	Cases	Median Age	Cases	Cases Median Age		Median Age			
White	6,240	68.0			6,240	68.0			
Black	503	65.0			503	65.0			
Native American	16	69.5			16	69.5			
Asian	119	68.0			119	68.0			
Hispanic	318	67.0			318	67.0			
Other/Unknown	372	69.0			372	69.0			
Total	7,568	68.0			7,568	68.0			


Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 66. Prostate Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 male population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical Notes for more information.








Figure 68. Median Charges for Prostate Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 2000-2004








Table 94. Prostate Cancer Inpatient Discharges by Gender, Charges, Length of
Stay, and County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	2,614	1,696	493	425	0			
Rate*	23.8	22.6	28.3	24.5				
95% C.I.	(22.9-24.7)	(21.5-23.7)	(25.8-31.0)	(22.2-27.0)				
Gender								
Male	2,614	1,696	493	425	0			
Rate*	49.9	47.7	59.1	50.1				
95% C.I.	(47.9-51.9)	(45.3-50.2)	(53.8-64.9)	(45.3-55.4)				
Female								
Rate*								
95% C.I.								
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Cl	narges (\$)							
Total Charges	\$63,464,400	\$40,128,751	\$14,780,126	\$8,555,523	\$0			
Average Charges	\$24,279	\$23,661	\$29,980	\$20,131	\$0			
Median Charges	\$20,772	\$20,114	\$31,336	\$17,727	\$0			
Discharge Length of S	itay (LOS) (Days)							
Total LOS	8,611	5,772	1,582	1,257	0			
Average LOS	3.3	3.4	3.2	3.0	0.0			
Median LOS	3.0	3.0	3.0	3.0	0.0			

* Rates are per 100,000 male population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 95. Prostate Cancer Inpatient Discharges by Age Group and County/Regionof Residence, Nevada Residents, 2000-2004

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Discharges	2,614	1,696	493	425				
Rate*	47.0	22.0	27.5	29.3				
95% C.I.	(45.2-48.8)	(21.0-23.1)	(25.0-29.9)	(26.5-32.1)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	0	0	0	0				
Rate*								
95% C.I.								
25-34	0	0	0	0				
Rate*								
95% C.I.								
35-44	15	10	1	4				
Rate*	1.7	1.6						
95% C.I.	(0.84-2.55)	(0.60-2.57)						
45-54	321	207	72	42				
Rate*	42.4	40.5	54.0	37.4				
95% C.I.	(37.77-47.05)	(34.98-46.01)	(41.53-66.48)	(26.06-48.66)				
55-64	1,019	654	189	176				
Rate*	189.3	178.7	214.7	209.1				
95% C.I.	(177.71-200.96)	(165.01-192.40)	(184.05-245.25)	(178.16-239.93)				
65-74	905	579	175	151				
Rate*	256.1	238.0	335.9	260.5				
95% C.I.	(239.45-272.83)	(218.62-257.40)	(286.16-385.71)	(218.97-302.07)				
75-84	278	199	42	37				
Rate*	149.7	156.7	154.1	117.7				
95% C.I.	(132.13-167.33)	(134.96-178.52)	(107.50-200.72)	(79.74-155.56)				
85+	76	47	14	15				
Rate*	239.2	235.0	250.0	243.1				
95% C.I.	(185.45-293.03)	(167.84-302.23)	(119.06-381.02)	(120.07-366.10)				
Unknown	0	0	0	0				

* Rates are per 100,000 age-specific male population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 96. Prostate Cancer Inpatient Discharges by Age Group and Gender,
Nevada Residents, 2000-2004

Age		Gender	
Group	Male	Female	Total
<1	0		0
Rate*			
95% C.I.			
1-4	0		0
Rate*			
95% C.I.			
5-14	0		0
Rate*			
95% C.I.			
15-24	0		0
Rate*			
95% C.I.			
25-34	0		0
Rate*			
95% C.I.			
35-44	15		15
Rate*	1.69		1.69
95% C.I.	(0.84-2.55)		(0.84-2.55)
45-54	321		321
Rate*	42.41		42.41
95% C.I.	(37.77-47.05)		(37.77-47.05)
55-64	1,019		1,019
Rate*	189.33		189.33
95% C.I.	(177.71-200.96)		(177.71-200.96)
65-74	905		905
Rate*	256.14		256.14
95% C.I.	(239.45-272.83)		(239.45-272.83)
75-84	278		278
Rate*	149.73		149.73
95% C.I.	(132.13-167.33)		(132.13-167.33)
85+	76		76
Rate*	239.24		239.24
95% C.I.	(185.45-293.03)		(185.45-293.03)
Unknown	0		0
Total	2,614		2,614
Rate*	47.02		23.89
95% C.I.	(45.2-48.8)		(23.0-24.8)

* Rates are per 100,000 male age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 97. Prostate Cancer Inpatient Discharges by County/Region of Residence,Nevada Residents, 2000-2004

Country of	2000-2004 Inpatient Hospital Discharges							
County of Residence	Casaa	Rat	te*	Age-Adjus	ted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	86	68.5	(54.0-83.0)	62.0	(49.6-77.1)			
Churchill	43	68.7	(48.2-89.3)	69.1	(49.7-95.9)			
Clark	1,696	43.3	(41.3-45.4)	47.7	(45.3-50.2)			
Douglas	91	81.6	(64.8-98.4)	59.5	(47.6-74.7)			
Elko	25	21.0	(12.8-29.2)	43.9	(22.9-79.9)			
Esmeralda	2							
Eureka	2							
Humboldt	14	32.8	(15.6-50.0)	29.7	(16.1-51.4)			
Lander	6							
Lincoln	2							
Lyon	85	85.9	(67.6-104.1)	69.3	(55.1-86.9)			
Mineral	13	108.8	(49.7-167.9)	73.1	(38.3-130.5)			
Nye	41	45.7	(31.7-59.7)	29.8	(21.0-42.7)			
Pershing	6							
Storey	2							
Washoe	493	54.1	(49.4-58.9)	59.1	(53.8-64.9)			
White Pine	7							
Unknown	0							
Total	2,614	47.0	(45.2-48.8)	49.9	(47.9-51.9)			


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 male population. **Rates are per 100,000 male population and are age-adjusted to the 2000 US Standard population.

Table 98. Prostate Cancer Inpatient Discharges by Age Group, Charges andLength of Stay, Nevada Residents, 2000-2004


Age	Discharges	Charges (\$)			Len	gth of Stay (Da	ays)
Group	bup	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	0						
15-24	0						
25-34	0						
35-44	15	397,424	26,495	21,858	47	3.1	3.0
45-54	321	8,529,109	26,570	22,274	1,030	3.2	3.0
55-64	1,019	25,321,412	24,849	21,854	3,287	3.2	3.0
65-74	905	21,341,726	23,582	20,714	2,904	3.2	3.0
75-84	278	6,392,280	22,994	13,988	1,022	3.7	2.0
85+	76	1,482,449	19,506	13,266	321	4.2	2.0
Unknown	0						
Total	2,614	63,464,400	24,279	20,772	8,611	3.3	3.0

MORTALITY

Figure 70. Prostate Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 male population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 72. Prostate Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 99. Prostate Cancer Mortality by Gender, Race/Ethnicity and	
County/Region of Residence, Nevada Residents, 2000-2004	

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	995	637	173	185
Rate*	11.4	10.7	12.4	12.9
95% C.I.	(10.7-12.1)	(9.9-11.6)	(10.6-14.4)	(11.1-15.0)
Gender				
Male	995	637	173	185
Rate*	27.4	25.9	31.0	29.6
95% C.I.	(25.6-29.4)	(23.8-28.3)	(26.3-36.4)	(25.3-34.6)
Female				
Rate*				
95% C.I.				
Other/Unknown	0	0	0	0
Race/Ethnicity				
White	856	517	162	177
Rate*	27.3	24.9	32.8	30.6
95% C.I.	(25.4-29.4)	(22.6-27.4)	(27.7-38.7)	(26.0-35.9)
Black	86	81	4	1
Rate*	52.9	55.7		
95% C.I.	(40.6-68.6)	(42.1-73.2)		
Native American	3	0	0	3
Rate*				
95% C.I.				
Asian	16	11	4	1
Rate*	12.6	12.8		
95% C.I.	(6.4-24.2)	(5.2-28.6)		
Hispanic	34	28	3	3
Rate*	22.2	27.6		
95% C.I.	(14.4-33.3)	(16.7-44.0)		
Other/Unknown	0	0	0	0

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Rates for race/ethnicity groups are per 100,000 male population and age-adjusted to the 2000 US Standard population.

Table 100. Prostate Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 2000-2004

		County/Region	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties					
Total									
Deaths	995	637	173	185					
Rate*	27.4	25.9	31.0	29.6					
95% C.I.	(25.6-29.4)	(23.8-28.3)	(26.3-36.4)	(25.3-34.6)					
Age Group									
<1	0	0	0	0					
Rate*									
95% C.I.									
1-4	0	0	0	0					
Rate*									
95% C.I.									
5-14	0	0	0	0					
Rate*									
95% C.I.									
15-24	0	0	0	0					
Rate*									
95% C.I.									
25-34	0	0	0	0					
Rate*									
95% C.I.									
35-44	0	0	0	0					
Rate*									
95% C.I.									
45-54	19	7	7	5					
Rate*	2.5								
95% C.I.	(1.38-3.64)								
55-64	78	56	9	13					
Rate*	14.5	15.3		15.4					
95% C.I.	(11.28-17.71)	(11.29-19.31)		(7.05-23.83)					
65-74	271	179	45	47					
Rate*	76.7	73.6	86.4	81.1					
95% C.I.	(67.57-85.83)	(62.80-84.36)	(61.14-111.62)	(57.91-104.27)					
75-84	399	262	65	72					
Rate*	214.9	206.4	238.5	229.0					
95% C.I.	(193.82-235.99)	(181.37-231.35)	(180.52-296.48)	(176.06-281.83)					
85+	228	133	47	48					
Rate*	717.7	665.1	839.4	777.9					
95% C.I.	(624.56-810.89)	(552.06-778.13)	(599.43-1,079.40)	(557.81-997.93)					
Unknown	0	0	0	0					

* Rates are per 100,000 age-specific male population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 101. Prostate Cancer Mortality by County of Residence, Nevada Residents,2000-2004

County of	2000-2004 Mortality							
Residence	Cases	Ra	te*	Age-Adjusted Rate**				
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	40	31.9	(22.0-41.8)	30.7	(21.8-42.5)			
Churchill	13	20.8	(9.5-32.1)	28.6	(14.7-51.7)			
Clark	637	16.3	(15.0-17.5)	25.9	(23.8-28.3)			
Douglas	26	23.3	(14.4-32.3)	26.8	(16.9-40.9)			
Elko	14	11.8	(5.6-17.9)	45.6	(22.0-85.7)			
Esmeralda	1							
Eureka	1							
Humboldt	6							
Lander	4							
Lincoln	4							
Lyon	33	33.3	(22.0-44.7)	34.4	(23.3-49.6)			
Mineral	5							
Nye	26	29.0	(17.8-40.1)	26.0	(16.1-40.7)			
Pershing	3							
Storey	1							
Washoe	173	19.0	(16.2-21.8)	31.0	(26.3-36.4)			
White Pine	8							
Unknown	0							
Total	995	17.9	(16.8-19.0)	27.4	(25.6-29.4)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 male population. **Rates are per 100,000 male population and are age-adjusted to the 2000 US Standard population.

Table 102. Prostate Cancer Mortality by Race/Ethnicity and Gender, NevadaResidents, 2000-2004

		Gender					
Race/Ethnicity		Male	Female	Other/ Unknown	Total		
White	Incidence	856	0	0	856		
	Rate*	27.3			11.4		
	95% C.I.	(25.4-29.4)			(10.7-12.2)		
Black	Incidence	86	0	0	86		
	Rate*	52.9			21.2		
	95% C.I.	(40.6-68.6)			(16.7-26.7)		
Native	Incidence	3	0	0	3		
American	Rate*						
	95% C.I.						
Asian	Incidence	16	0	0	16		
	Rate*	12.6			5.2		
	95% C.I.	(6.4-24.2)			(2.7-9.9)		
Hispanic	Incidence	34	0	0	34		
·	Rate*	22.2			8.6		
	95% C.I.	(14.4-33.3)			(5.7-12.5)		
Other/Unkr	nown	0	0	0	0		
Total	Incidence	995	0	0	995		
	Rate*	27.4			11.4		
	95% C.I.	(25.6-29.4)			(10.7-12.1)		

Note: The "---" is used for rates calculated on numbers less than ten.*Rates are per 100,000 male population and are agadjusted to the 2000 US Standard population.

Table 103. Prostate Cancer Mortality by Age Group and Gender, NevadaResidents, 2000-2004

Age	Gender						
Group	Male	Female	Total				
<1	0		0				
Rate*							
95% C.I.							
1-4	0		0				
Rate*							
95% C.I.							
5-14	0		0				
Rate*							
95% C.I.							
15-24	0		0				
Rate*							
95% C.I.							
25-34	0		0				
Rate*							
95% C.I.							
35-44	0		0				
Rate*							
95% C.I.							
45-54	19		19				
Rate*	2.51		1.27				
95% C.I.	(1.38-3.64)		(0.70-1.84)				
55-64	78		78				
Rate*	14.49		7.14				
95% C.I.	(11.28-17.71)		(5.56-8.73)				
65-74	271		271				
Rate*	76.70		37.81				
95% C.I.	(67.57-85.83)		(33.30-42.31)				
75-84	399		399				
Rate*	214.90		97.08				
95% C.I.	(193.82-235.99)		(87.56-106.61)				
85+	228		228				
Rate*	717.72		239.97				
95% C.I.	(624.56-810.89)		(208.82-271.12)				
Unknown	0		0				
Total	995		995				
Rate*	17.90		9.09				
95% C.I.	(16.8-19.0)		(8.5-9.7)				

Note: The "---" is used for rates calculated on numbers less than ten.


* Rates are per 100,000 age-specific population.


Table 104. Median Age at Death from Prostate Cancer by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004

		Gender									
Race/Ethnicity	Male		Fem	ale	Total						
	Cases	Median Age	Cases	Median Age	Cases	Median Age					
White	856	78.0			856	78.0					
Black	86	74.5			86	74.5					
Native American	3				3						
Asian	16	77.0			16	77.0					
Hispanic	34	78.5			34	78.5					
Other/Unknown	0				0						
Total	995	78.0			995	78.0					

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE





Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.






Table 105. Cause-Specific Survival Rates for Prostate Cancer byRace/Ethnicity and Gender, Nevada Residents, 2000-2004

Race/			Cause Specific Survival Rate					
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Median Survival Time (years)	
Total	6,757	95.7%	93.5%	91.9%	90.4%	89.6%	> 5 YEARS	
Male	6,757	95.7%	93.5%	91.9%	90.4%	89.6%	> 5 YEARS	
Female	0							
Race/Ethnicity								
White	5,533	95.6%	93.3%	91.6%	90.0%	89.1%	> 5 YEARS	
Male	5,533	95.6%	93.3%	91.6%	90.0%	89.1%	> 5 YEARS	
Female	0							
Black	458	93.6%	91.5%	90.6%	90.6%	90.6%	> 5 YEARS	
Male	458	93.6%	91.5%	90.6%	90.6%	90.6%	> 5 YEARS	
Female	0							
Native American	12							
Male	12							
Female	0							
Asian	104	95.6%	92.5%	92.5%	88.5%	88.5%	> 5 YEARS	
Male	104	95.6%	92.5%	92.5%	88.5%	88.5%	> 5 YEARS	
Female	0							
Hispanic	293	97.3%	95.4%	94.0%	91.6%	91.6%	> 5 YEARS	
Male	293	97.3%	95.4%	94.0%	91.6%	91.6%	> 5 YEARS	
Female	0							

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Survival Rate of Stage			Gender	
	at Diagnosis	Total	Male	Female
Total	Cases	6,757	6,757	
	One Year	95.7%	95.7%	
	5 Years	89.6%	89.6%	
	Median Survival	> 5 YEARS	> 5 YEARS	
Stage at D	iagnosis			
In situ	Cases			
	One Year			
	5 Years			
	Median Survival			
Localized	Cases	4,863	4,863	
	One Year	99.1%	99.1%	
	5 Years	94.7%	94.7%	
	Median Survival	> 5 YEARS	> 5 YEARS	
Regional	Cases	542	542	
	One Year	99.2%	99.2%	
	5 Years	93.2%	93.2%	
	Median Survival	> 5 YEARS	> 5 YEARS	
Distant	Cases	199	199	
	One Year	64.3%	64.3%	
	5 Years	30.6%	30.6%	
	Median Survival	1.73	1.73	
Unstaged	Cases	1,153	1,153	
	One Year	81.2%	81.2%	
	5 Years	68.4%	68.4%	
	Median Survival	> 5 YEARS	> 5 YEARS	


Table 106. Cause-Specific Survival Rates for Prostate Cancer by Stage ofCancer at Diagnosis and Gender, Nevada Residents, 2000-2004

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

COLORECTAL CANCER

COLORECTAL CANCER GENERAL PROFILE⁴

Figure 75. Anatomy of the Digestive System⁵



General Anatomy: The colon and rectum are parts of the body's digestive system, which removes nutrients from food and stores waste until it passes out of the body. Together, the colon and rectum form a long, muscular tube called the large intestine (also called the large bowel). The colon is the first 6 feet of the large intestine, and the rectum is the last 8 to 10 inches.

Risk Factors: Age, diet, polyps (benign growths on the inner wall of the colon and rectum), personal medical history, family medical history, and ulcerative colitis (the lining of the colon becomes inflamed).

Signs and Symptoms: A change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood (either bright red or very dark) in the stool, stools that are narrower than usual, general abdominal discomfort (frequent gas pains, bloating, fullness, and/or cramps), weight loss with no known reason, constant tiredness, and vomiting.

Diagnosing the Cancer: Fecal occult blood test, sigmoidoscopy, colonscopy, double contrast barium enema (DCBE), polypectomy, biopsy, and a digital rectal exam.

Treatment: Treatment options include: surgery (Colostomy), chemotherapy, radiation therapy, biological therapy, and clinical trials.

HIGHLIGHTS

- The ratio of the age-adjusted incidence rate, 51.4, to the age-adjusted mortality rate, 21.4 (per 100,000 2000 US Standard population), for Colorectal Cancer was 2.4 during the 2000 to 2004 period, which means that for every 241 Colorectal Cancer cases there was 100 deaths due to Colorectal Cancer in Nevada during this period.
- Nevadan females had a higher ratio (2.52) than males (2.28) when the incidence and mortality age-adjusted rates for Colorectal Cancer were compared. Females had a ratio of 2.52 while the ratio for males was 2.28. This means that for every 100 deaths due to Colorectal Cancer there would be 252 female cases while only 228 cases for every male death.
- The median age at diagnosis of Colorectal Cancer for Nevadans was 69 years of age from 2000 to 2004. The median age at time of death due to Colorectal Cancer during this period was 73 years.

CANCER SCREENING

- Of the 2,188 people surveyed in Nevada during the 2001, 2002 and 2004 period, 43.7% responded No to ever having a blood stool test and/or a sigmoidoscopy or colonoscopy to try and detect early signs of Colorectal Cancer.
- Males had a slightly higher percentage of respondents who said yes to ever having a blood stool test and/or a sigmoidoscopy or colonoscopy than females (56.0%) with a percentage of 56.7% when the questions were asked in 2001, 2002 and 2004.
- Each age group showed statistical significance over the next age group for those respondents who said that they had never had a blood stool test and/or a sigmoidoscopy or colonoscopy, with the 45 to 54 age group having the highest percentage at 38.5% (32.5-44.6); being followed by the 55 to 64 and 65 and older age groups with percentages of 56.0% (52.3-59.6) and 66.9% (63.6-70.2), respectively, when these questions were included in the Behavorial Risk Factor Surveillance Survey.

INCIDENCE

- Nevada's incidence rate for Colorectal Cancer 51.4 was slightly lower than the national rate of 53.1 (per 100,000 – 2000 US Standard population) from 2000 to 2004.
- There were 5,173 cases of Colorectal Cancer reported in Nevada from 2000 to 2004. Regional comparisons showed that Clark County's age-adjusted incidence rate, 52.7 (49.1-56.5), was only slightly higher than the rate for Nevada as a whole 51.4 (50.0-52.9), Washoe County 52.7 (49.1-56.5) and the All Other Counties region 44.3 (41.1-47.8) during this period.
- > Nevada's cancer incidence rate for Males diagnosed with Colorectal Cancer (58.9) was

lower than the 2000-2004 national rate of 60.8 (per 100,000 – 2000 US Standard population) from 2000 to 2004, while Nevada's female population had an age-adjusted incidence rate (44.8) that was only slightly above the rate for their national counterparts (44.6) during this period.

The Colorectal Cancer age-adjusted incidence rates for Blacks, 56.0 (49.5-63.4), and Whites, 53.5 (51.9-55.1), showed statistical significance over all other racial/ethnic groups from 2000 to 2004. They were followed by Asians, Hispanics and Native Americans with rates of 43.1 (35.7-52.2), 29.1 (24.6-34.5) and 15.7 (9.0-26.2), respectively.

INPATIENT HOSPITAL DISCHARGES

- There were 4,433 Inpatient Discharges for Colorectal Cancer to Nevada residents in Nevada from 2000 to 2004. Washoe County (45.5) had the highest age-adjusted inpatient discharge rate for Colorectal Cancer in Nevada, followed by Clark County, Nevada Overall, and All Other Counties who had rates of 45.0, 44.1 and 38.5 (per 100,000 – 2000 US Standard population), respectively.
- Total billed charges for Colorectal Cancer inpatient hospital discharges in Nevada totaled 219.1 million dollars from 2000 to 2004. The overall average billed charge per day for a hospital inpatient discharge due to Colorectal Cancer was approximately \$5,755 in Nevada during this period.
- ➤ Washoe County had the highest median total billed amount (\$36,788) and average length of stay (9.1 days) during the 2000 to 2004 period, once regional comparisons were made.

MORTALITY

- There were 2,030 resident deaths due to Colorectal Cancer in Nevada from 2000 to 2004. Males had a higher statistically significant age-adjusted mortality rate, 25.8 (24.2-27.5), than females who had a rate of 17.8 (per 100,000 2000 US Standard population), during this period.
- Racial/ethnic comparisons showed that Blacks and Whites had higher age-adjusted mortality rates for Colorectal Cancer 27.8 and 22.1, respectively, when compared to Asians and Hispanics who had rates of 14.6 and 14.1 (per 100,000 – 2000 US Standard population), respectively, from 2000 to 2004.

SURVIVAL RATE

- The one-year survival rate for Colorectal cancer in Nevada was 79.0% during the 2000 to 2004 period, while the five-year survival rate was 55.3% during this same time. The median survival rate in Nevada was greater than five years during this period.
- Females had a slightly higher one-year survival rate (79.4%) than males (78.7%) for Colorectal Cancer in Nevada from 2000 to 2004. This difference maintained out to the

five-year survival rate where females had a higher rate at 56.5% and males with a rate of 54.3% during this period.

The five-year survival rate for those diagnosed with Colorectal Cancer at the localized stage was 92.7% for Nevada from 2000 to 2004, while those recorded at the regional, distant and unstaged stages had rates of 69.2%, 34.7% and 11.2%, respectively.

SCREENING (BRFSS)

Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender,Education, Age Group, and Income, Nevada Residents, 2001 and 2002 and 2004

				Answers			
Responses		Yes					
	Number	Percent*	95% C.I.	Number	Percent*	95% C.I.	Total
Total							
Responses	2,188	56.3%	(54.0-58.6)	1,678	43.7%	(41.4-46.0)	3,866
County/Region of Resid	dence						
Clark County	695	56.5%	(53.2-59.8)	533	43.5%	(40.2-46.8)	1,228
Washoe County	717	57.5%	(54.3-60.6)	483	42.5%	(39.4-45.7)	1,200
All Other Counties	776	54.4%	(51.3-57.4)	662	45.6%	(42.6-48.7)	1,438
Gender							
Male	1,061	56.7%	(53.2-60.1)	843	43.3%	(39.9-46.8)	1,904
Female	1,127	56.0%	(52.8-59.1)	835	44.0%	(40.9-47.2)	1,962
Education							
Less than High School	153	41.9%	(34.0-49.8)	180	58.1%	(50.2-66.0)	333
High School	577	52.4%	(48.2-56.5)	538	47.6%	(43.5-51.8)	1,115
Some Post High School	695	56.1%	(52.2-60.0)	514	43.9%	(40.0-47.8)	1,209
College Graduate	758	64.8%	(60.6-69.0)	440	35.2%	(31.0-39.4)	1,198
Age Group							
18-24 years old							
25-34 years old							
35-44 years old							
45-54 years old	329	38.5%	(32.5-44.6)	513	61.5%	(55.4-67.5)	842
55-64 years old	760	56.0%	(52.3-59.6)	608	44.0%	(40.4-47.7)	1,368
65+ years old	1,099	66.9%	(63.6-70.2)	557	33.1%	(29.8-36.4)	1,656
Income							
Less than \$15,000	167	42.5%	(35.1-50.0)	194	57.5%	(50.0-64.9)	361
\$15,000-\$24,999	293	49.5%	(43.5-55.4)	263	50.5%	(44.6-56.5)	556
\$25,000-\$34,999	271	53.3%	(47.1-59.6)	216	46.7%	(40.4-52.9)	487
\$35,000-\$49,999	350	59.0%	(53.6-64.4)	262	41.0%	(35.6-46.4)	612
\$50,000 or More	735	57.7%	(53.8-61.6)	507	42.3%	(38.4-46.2)	1,242


*Denominator is persons age 50-65+ and excludes missing, don't know, and refused responses.

Note: This table includes those respondents who answered "Yes" or "No" to either of the following questions:

- 1) A blood stool test is a test that may use a special kit at home to determine whether the stool contains blood. Have you ever had this test using a home kit?
- 2) A sigmoidoscopy or colonoscopy is when a tube is inserted in the rectum to view the bowel for signs of cancer and other health problems. Have you ever had this exam?

INCIDENCE

Figure 76. Colorectal Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 78. Colorectal Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 108. Colorectal Cancer Cases by Gender, Race/Ethnicity and County/Regionof Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)				
Total										
Cases	5,173	3,628	832	710	3	187,391				
Rate*	51.4	52.8	52.7	44.3		53.1				
95% C.I.	(50.0-52.9)	(51.0-54.6)	(49.1-56.5)	(41.1-47.8)		(52.9-53.4)				
Gender										
Male	2,810	1,979	438	393	0	94,459				
Rate*	58.9	60.8	60.1	50.6		62.1				
95% C.I.	(56.6-61.3)	(58.0-63.8)	(54.4-66.5)	(45.5-56.1)		(61.7-62.5)				
Female	2,363	1,649	394	317	3	92,932				
Rate*	44.8	45.9	46.3	38.4		46.2				
95% C.I.	(43.0-46.7)	(43.6-48.2)	(41.9-51.2)	(34.2-42.9)		(45.9-46.5)				
Other/Unknown	0	0	0	0	0	0				
Race/Ethnicity										
White	4,401	2,950	777	673	1	155,076				
Rate*	53.5	54.7	56.5	46.1		52.8				
95% C.I.	(51.9-55.1)	(52.7-56.7)	(52.6-60.7)	(42.6-49.8)		(52.6-53.1)				
Black	296	282	11	2	1	18,551				
Rate*	56.0	57.8	35.9			63.6				
95% C.I.	(49.5-63.4)	(50.8-65.7)	(17.3-70.1)			(62.7-64.6)				
Native American	18	3	2	12	1	849				
Rate*	15.7			27.1		28.8				
95% C.I.	(9.0-26.2)			(13.8-49.6)		(26.8-26.8)				
Asian	184	153	26	5	0	11,668				
Rate*	43.1	45.4	43.2			42.1				
95% C.I.	(35.7-52.2)	(36.4-56.8)	(26.2-73.5)			(41.3-42.9)				
Hispanic	214	190	12	12	0	14,046				
Rate*	29.1	33.1	12.1	20.5		40.4				
95% C.I.	(24.6-34.5)	(27.6-39.8)	(5.9-22.9)	(9.7-40.1)		(39.7-41.1)				
Other/Unknown	60	50	4	6	0	1,247				

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the national (SEER) rates. See Technical Notes for more information.

Table 109. Colorectal Cancer Cases by Age Group and County/Region ofResidence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

			County/Regio	on of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)
Total						
Cases	5,173	3,628	832	710	3	187,391
Rate*	51.4	52.8	52.7	44.3		53.1
95% C.I.	(50.0-52.9)	(51.0-54.6)	(49.1-56.5)	(41.1-47.8)		(52.9-53.4)
Age Group						
<1	0	0	0	0	0	1
Rate*						0.0
95% C.I.						(0.0-0.1)
1-4	0	0	0	0	0	1
Rate*						0.0
95% C.I.						(0.0-0.0)
5-14	1	0	1	0	0	17
Rate*						0.0
95% C.I.						(0.0-0.1)
15-24	5	4	1	0	0	279
Rate*						0.5
95% C.I.						(0.5-0.6)
25-34	42	30	11	1	0	1,634
Rate*	2.6	2.5	4.2			3.0
95% C.I.	(1.81-3.38)	(1.61-3.40)	(1.73-6.75)			(2.9-3.2)
35-44	168	125	19	24	0	7,166
Rate*	9.9	10.4	6.7	11.0		12.0
95% C.I.	(8.36-11.34)	(8.58-12.23)	(3.67-9.65)	(6.59-15.39)		(11.7-12.3)
45-54	563	399	89	74	1	21,470
Rate*	37.7	39.6	34.0	33.1		41.4
95% C.I.	(34.59-40.82)	(35.71-43.48)	(26.90-41.00)	(25.57-40.67)		(40.9-42.0)
55-64	1,080	776	169	134	1	33,445
Rate*	98.9	103.3	97.3	80.5		101.4
95% C.I.	(93.03-104.83)	(95.99-110.52)	(82.63-111.97)	(66.88-94.15)		(100.3-102.5)
65-74	1,539	1,074	226	239	0	47,795
Rate*	214.7	217.1	212.1	206.8		219.2
95% C.I.	(203.97-225.42)	(204.11-230.07)	(184.47-239.78)	(180.58-233.02)		(217.2-221.2)
75-84	1,375	961	235	179	0	52,947
Rate*	334.6	343.4	371.1	263.8		343.8
95% C.I.	(316.87-352.24)	(321.73-365.16)	(323.67-418.57)	(225.14-302.42)		(340.9-346.8)
85+	400	259	81	59	1	22,636
Rate*	421.0	425.4	464.0	353.8		409.7
95% C.I.	(379.74-462.25)	(373.63-477.25)	(362.93-565.02)	(263.51-444.06)		(404.3-415.0)
Unknown	0	0	0	0	0	0

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 110. Colorectal Cancer Cases by County of Residence at Diagnosis, NevadaResidents, 2000-2004

County of	2000-2004 Incidence							
Residence	Cases	Ra	te*	Age-Adjusted Rate**				
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	162	63.4	(53.6-73.1)	53.3	(45.4-62.4)			
Churchill	54	43.2	(31.7-54.8)	45.4	(34.0-59.7)			
Clark	3,628	47.1	(45.6-48.7)	52.8	(51.0-54.6)			
Douglas	110	49.6	(40.4-58.9)	39.5	(32.3-48.2)			
Elko	58	25.4	(18.9-31.9)	41.6	(30.5-56.1)			
Esmeralda	2							
Eureka	4							
Humboldt	23	28.4	(16.8-40.0)	33.8	(21.0-52.6)			
Lander	9							
Lincoln	16	90.8	(46.3-135.3)	74.0	(42.1-123.2)			
Lyon	95	48.5	(38.7-58.2)	41.9	(33.8-51.5)			
Mineral	27	113.8	(70.9-156.8)	80.6	(52.4-122.3)			
Nye	119	67.5	(55.4-79.7)	44.7	(36.7-54.7)			
Pershing	6							
Storey	7							
Washoe	832	46.3	(43.2-49.5)	52.7	(49.1-56.5)			
White Pine	18	47.2	(25.4-69.0)	35.0	(20.5-58.0)			
Unknown	3							
Total	5,173	47.3	(46.0-48.6)	51.4	(50.0-52.9)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 111. Colorectal Cancer Cases by Race/Ethnicity and Gender, NevadaResidents, 2000-2004

Race/Ethnicity			Gender						
		Male	Female	Other/ Unknown	Total				
White	Incidence	2,400	2,001	0	4,401				
	Rate* 95% C.I.	60.9 (58.3-63.5)	46.8 (44.7-48.9)		53.5 (51.9-55.1)				
Black	Incidence	162	134	0	296				
	Rate*	67.7	47.6		56.0				
	95% C.I.	(56.3-81.9)	(39.6-57.0)		(49.5-63.4)				
Native	Incidence	6	12	0	18				
American	Rate*		17.9		15.7				
	95% C.I.		(8.9-33.6)		(9.0-26.2)				
Asian	Incidence	88	96	0	184				
	Rate*	49.6	38.6		43.1				
	95% C.I.	(37.4-66.2)	(29.6-50.5)		(35.7-52.2)				
Hispanic	Incidence	121	93	0	214				
	Rate*	35.4	24.4		29.1				
	95% C.I.	(27.5-45.9)	(19.0-31.1)		(24.6-34.5)				
Other/Unknown		33	27	0	60				
Total	Incidence	2,810	2,363	0	5,173				
	Rate*	58.9	44.8		51.4				
	95% C.I.	(56.6-61.3)	(43.0-46.7)		(50.0-52.9)				

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are ageadjusted to the 2000 US Standard population.

Table 112. Colorectal Cancer Cases by Age Group and Gender, Nevada Residents,2000-2004

Age	Gender							
Group	Male	Female	Unknown	Total				
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	1	0	1				
Rate*								
95% C.I.								
15-24	3	2	0	5				
Rate*								
95% C.I.								
25-34	18	24	0	42				
Rate*	2.13	3.10		2.59				
95% C.I.	(1.15-3.12)	(1.86-4.33)		(1.81-3.38)				
35-44	90	78	0	168				
Rate*	10.17	9.51		9.85				
95% C.I.	(8.07-12.27)	(7.40-11.62)		(8.36-11.34)				
45-54	291	272	0	563				
Rate*	38.45	36.94		37.70				
95% C.I.	(34.03-42.86)	(32.55-41.33)		(34.59-40.82)				
55-64	666	414	0	1,080				
Rate*	123.74	74.80		98.93				
95% C.I.	(114.35-133.14)	(67.59-82.01)		(93.03-104.83)				
65-74	895	644	0	1,539				
Rate*	253.31 (236.72-269.91)	177.16 (163.48-190.84)		214.69 (203.97-225.42)				
95% C.I.		/		/				
75-84 Rate*	695 374.33	680 301.78	0	1,375 334.55				
95% C.I.	(346.50-402.16)	(279.10-324.46)		(316.87-352.24)				
85+ Rate*	152 478.48	248 392.12	0	400 421.00				
95% C.I.	(402.42-554.55)	(343.32-440.92)		(379.74-462.25)				
Unknown	(+02.+2-334.33)	(3+3.32-++0.32)	0	(373.74-402.23)				
Total	2,810	2,363	0	5,173				
Rate*	50.55	43.90		47.28				
95% C.I.	(48.7-52.4)	(42.1-45.7)		(46.0-48.6)				
	()			()				

Note: The "---" is used for rates calculated on numbers less than ten.

* Rates are per 100,000 age-specific population.

Table 113. Colorectal Cancer Cases by Age Group and Stage, Nevada Residents,2000-2004

Age Group		Stage							
		In situ	Localized	Regional	Distant	Unstaged	Total		
<1	Number		0	0	0	0	0		
	Percent								
1-4	Number		0	0	0	0	0		
	Percent								
5-14	Number		0	1	0	0	1		
	Percent			100.0%			100.0%		
15-24	Number		0	2	2	1	5		
	Percent			40.0%	40.0%	20.0%	100.0%		
25-34	Number		12	16	1	13	42		
	Percent		28.6%	38.1%	2.4%	31.0%	100.0%		
35-44	Number		42	67	28	31	168		
	Percent		25.0%	39.9%	16.7%	18.5%	100.0%		
45-54	Number		157	188	105	113	563		
	Percent		27.9%	33.4%	18.7%	20.1%	100.0%		
55-64	Number		314	359	188	219	1,080		
	Percent		29.1%	33.2%	17.4%	20.3%	100.0%		
65-74	Number		460	501	248	330	1,539		
	Percent		29.9%	32.6%	16.1%	21.4%	100.0%		
75-84	Number		425	432	195	323	1,375		
	Percent		30.9%	31.4%	14.2%	23.5%	100.0%		
85+	Number		115	112	48	125	400		
	Percent		28.8%	28.0%	12.0%	31.3%	100.0%		
Unknown	Number		0	0	0	0	0		
	Percent								
Total	Number		1,525	1,678	815	1,155	5,173		
	Percent		29.5%	32.4%	15.8%	22.3%	100.0%		

Table 114. Colorectal Cancer Cases by Stage and Race/Ethnicity, NevadaResidents, 2000-2004

Stage		Race/Ethnicity							
		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total	
In situ	Number								
	Percent								
Localized	Number	1,329	73	7	46	53	17	1,525	
	Percent	30.2%	24.7%	38.9%	25.0%	24.8%	28.3%	29.5%	
Regional	Number	1,438	93	5	73	57	12	1,678	
	Percent	32.7%	31.4%	27.8%	39.7%	26.6%	20.0%	32.4%	
Distant	Number	667	65	0	32	44	7	815	
	Percent	15.2%	22.0%		17.4%	20.6%	11.7%	15.8%	
Unstaged	Number	967	65	6	33	60	24	1,155	
	Percent	22.0%	22.0%	33.3%	17.9%	28.0%	40.0%	22.3%	
Total	Number	4,401	296	18	184	214	60	5,173	
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	


Table 115. Median Age at Diagnosis of Colorectal Cancer by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004

	Gender								
Race/Ethnicity	Male		Fem	ale	Total				
	Cases	Median Age	Cases	Median Age	Cases	Median Age			
White	2,400	69.0	2,001	72.0	4,401	70.0			
Black	162	65.0	134	66.0	296	65.0			
Native American	6	68.0	12	57.0	18	58.5			
Asian	88	66.0	96	65.5	184	66.0			
Hispanic	121	64.0	93	66.0	214	64.5			
Other/Unknown	33	68.0	27	78.0	60	70.5			
Total	2,810	68.0	2,363	71.0	5,173	69.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 79. Colorectal Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical Notes for more information.

Figure 80. Colorectal Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 2000-2004





Figure 81. Median Charges for Colorectal Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 2000-2004








Table 116. Colorectal Cancer Inpatient Discharges by Gender, Charges, Length of
Stay, and County/Region of Residence, Nevada Residents, 2000-2004

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	4,433	3,098	717	617	1
Rate*	44.1	45.0	45.5	38.5	
95% C.I.	(42.8-45.5)	(43.3-46.6)	(42.2-49.1)	(35.5-41.8)	
Gender					
Male	2,300	1,617	342	341	0
Rate*	48.0	49.7	46.7	43.0	
95% C.I.	(46.0-50.1)	(47.2-52.4)	(41.6-52.3)	(38.4-48.0)	
Female	2,133	1,481	375	276	1
Rate*	40.5	41.0	44.2	33.6	
95% C.I.	(38.8-42.2)	(38.9-43.1)	(39.8-48.9)	(29.8-37.9)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$219,084,483	\$160,833,847	\$35,182,584	\$22,990,609	\$77,443
Average Charges	\$49,421	\$51,915	\$49,069	\$37,262	\$77,443
Median Charges	\$34,761	\$35,479	\$36,788	\$29,182	\$77,443
Discharge Length of S	tay (LOS) (Days)				
Total LOS	38,066	27,001	6,519	4,536	10
Average LOS	8.6	8.7	9.1	7.4	10.0
Median LOS	7.0	7.0	7.0	6.0	10.0

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 117. Colorectal Cancer Inpatient Discharges by Age Group and
County/Region of Residence, Nevada Residents, 2000-2004

		County/Region	of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Discharges	4,433	3,098	717	617
Rate*	40.5	40.2	39.9	42.6
95% C.I.	(39.3-41.7)	(38.8-41.7)	(37.0-42.9)	(39.2-45.9)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	1	0	1	0
Rate*				
95% C.I.				
15-24	8	5	3	0
Rate*				
95% C.I.				
25-34	33	24	9	0
Rate*	2.0	2.0		
95% C.I.	(1.34-2.73)	(1.20-2.80)		
35-44	145	108	15	22
Rate*	8.5	9.0	5.3	10.1
95% C.I.	(7.12-9.89)	(7.29-10.68)	(2.60-7.92)	(5.86-14.28)
45-54	493	349	84	60
Rate*	33.0	34.6	32.0	26.9
95% C.I.	(30.10-35.93)	(31.00-38.27)	(25.19-38.90)	(20.06-33.65)
55-64	929	678	147	104
Rate*	85.1	90.2	84.6	62.5
95% C.I.	(79.63-90.57)	(83.42-97.00)	(70.95-98.31)	(50.48-74.50)
65-74	1,310	902	182	226
Rate*	182.8	182.3	170.8	195.6
95% C.I.	(172.85-192.64)	(170.42-194.22)	(146.01-195.65)	(170.06-221.05)
75-84	1,164	816	194	154
Rate*	283.2	291.6	306.4	226.9
95% C.I.	(266.94-299.48)	(271.61-311.63)	(263.26-349.48)	(191.09-262.78)
85+	350	216	82	51
Rate*	368.4	354.8	469.7	305.8
95% C.I.	(329.78-406.96)	(307.49-402.12)	(368.04-571.37)	(221.88-389.75)
Unknown	0	0	0	0

* Rates are per 100,000 age-specific population.

Table 118. Colorectal Cancer Inpatient Discharges by Age Group and Gender,
Nevada Residents, 2000-2004

Age	Gender						
Group	Male	Female	Total				
<1	0	0	0				
Rate*							
95% C.I.							
1-4	0	0	0				
Rate*							
95% C.I.							
5-14	0	1	1				
Rate*							
95% C.I.	<u> </u>						
15-24	4	4	8				
Rate*							
95% C.I.							
25-34	10	23	33				
Rate*	1.19	2.97	2.04				
95% C.I.	(0.45-1.92)	(1.75-4.18)	(1.34-2.73)				
35-44	81	64	145				
Rate*	9.15	7.81	8.50				
95% C.I.	(7.16-11.14)	(5.89-9.72)	(7.12-9.89)				
45-54	252	241	493				
Rate*	33.29	32.73	33.01				
95% C.I.	(29.18-37.40)	(28.59-36.86)	(30.10-35.93)				
55-64	542	387	929				
Rate*	100.70	69.92	85.10				
95% C.I.	(92.23-109.18)	(62.96-76.89)	(79.63-90.57)				
65-74	733	577	1,310				
Rate*	207.46	158.73	182.75				
95% C.I.	(192.44-222.48)	(145.78-171.68)	(172.85-192.64)				
75-84	559	605	1,164				
Rate*	301.08	268.49	283.21				
95% C.I.	(276.12-326.04)	(247.10-289.89)	(266.94-299.48)				
85+	119	231	350				
Rate*	374.60	365.24	368.37				
95% C.I.	(307.30-441.91)	(318.14-412.34)	(329.78-406.96)				
Unknown	0	0	0				
Total Rate*	2,300 41.38	2,133	4,433				
95% C.I.	41.38 (39.7-43.1)	39.63 (37.9-41.3)	40.52 (39.3-41.7)				
JU /0 U.I.	(03.1-+0.1)	(37.3-41.3)	(33.3-41.7)				

* Rates are per 100,000 age-specific population.

Table 119. Colorectal Cancer Inpatient Discharges by County/Region ofResidence, Nevada Residents, 2000-2004

Country of	2000-2004 Inpatient Hospital Discharges						
County of Residence	Rate*			Age-Adjusted Rate**			
	Cases -	Rate	95% C.I.	Rate	95% C.I.		
Carson City	109	42.6	(34.6-50.6)	36.1	(29.6-43.7)		
Churchill	46	36.8	(26.2-47.5)	38.1	(27.8-51.4)		
Clark	3,098	40.2	(38.8-41.7)	45.0	(43.3-46.6)		
Douglas	84	37.9	(29.8-46.0)	29.7	(23.6-37.3)		
Elko	46	20.1	(14.3-26.0)	34.8	(24.6-48.2)		
Esmeralda	1						
Eureka	7						
Humboldt	22	27.2	(15.8-38.5)	34.0	(20.9-53.2)		
Lander	7						
Lincoln	5						
Lyon	133	67.9	(56.3-79.4)	59.5	(49.7-70.9)		
Mineral	27	113.8	(70.9-156.8)	86.3	(55.9-130.6)		
Nye	104	59.0	(47.7-70.4)	39.2	(31.6-48.6)		
Pershing	7						
Storey	4						
Washoe	717	39.9	(37.0-42.9)	45.5	(42.2-49.1)		
White Pine	15	39.3	(19.4-59.3)	28.9	(16.1-48.4)		
Unknown	1						
Total	4,433	40.5	(39.3-41.7)	44.1	(42.8-45.5)		


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 120. Colorectal Cancer Inpatient Discharges by Age Group, Charges and
Length of Stay, Nevada Residents, 2000-2004

Age	Discharges	Charges (\$)			Length of Stay (Days)		
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	1						
15-24	8						
25-34	33	2,067,746	62,659	36,746	339	10.3	7.0
35-44	145	5,885,069	40,587	34,295	1,112	7.7	7.0
45-54	493	24,562,662	49,823	33,290	4,344	8.8	7.0
55-64	929	40,470,628	43,564	33,221	7,231	7.8	6.0
65-74	1,310	62,891,626	48,009	33,818	10,701	8.2	7.0
75-84	1,164	60,938,806	52,353	36,983	10,701	9.2	7.0
85+	350	21,970,894	62,774	37,082	3,585	10.2	8.0
Unknown	0						
Total	4,433	219,084,483	49,421	34,761	38,066	8.6	7.0

MORTALITY

Figure 83. Colorectal Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.







Figure 85. Colorectal Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 2000-2004



	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Mortality	2,030	1,422	322	286			
Rate*	21.4	22.0	21.3	18.9			
95% C.I.	(20.4-22.4)	(20.8-23.2)	(19.0-23.8)	(16.7-21.3)			
Gender							
Male	1,120	778	183	159			
Rate*	25.8	26.6	26.4	22.3			
95% C.I.	(24.2-27.5)	(24.6-28.8)	(22.5-30.9)	(18.8-26.3)			
Female	910	644	139	127			
Rate*	17.8	18.4	16.8	15.9			
95% C.I.	(16.7-19.0)	(17.0-19.9)	(14.1-19.8)	(13.2-18.9)			
Other/Unknown	0	0	0	0			
Race/Ethnicity							
White	1,752	1,194	291	267			
Rate*	22.1	22.9	21.8	19.2			
95% C.I.	(21.1-23.2)	(21.6-24.3)	(19.4-24.6)	(16.9-21.7)			
Black	128	119	6	3			
Rate*	27.8	28.1					
95% C.I.	(22.9-33.8)	(22.8-34.4)					
Native American	9	1	3	5			
Rate*							
95% C.I.							
Asian	59	45	12	2			
Rate*	14.6	12.7	27.1				
95% C.I.	(10.4-20.6)	(8.6-19.4)	(11.6-58.1)				
Hispanic	77	60	9	8			
Rate*	14.1	13.9					
95% C.I.	(10.6-18.5)	(10.0-19.2)					
Other/Unknown	5	3	1	1			

Table 121. Colorectal Cancer Mortality by Gender, Race/Ethnicity and
County/Region of Residence, Nevada Residents, 2000-2004

Note: The "---" is used for rates calculated on numbers less than ten.

*Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 122. Colorectal Cancer Mortality by Age Group and County/Region of
Residence, Nevada Residents, 2000-2004

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Deaths	2,030	1,422	322	286			
Rate*	21.4	22.0	21.3	18.9			
95% C.I.	(20.4-22.4)	(20.8-23.2)	(19.0-23.8)	(16.7-21.3)			
Age Group							
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	0	0	0	0			
Rate*							
95% C.I.							
15-24	0	0	0	0			
Rate*							
95% C.I.							
25-34	7	6	1	0			
Rate*							
95% C.I.							
35-44	46	34	7	5			
Rate*	2.7	2.8					
95% C.I.	(1.92-3.48)	(1.88-3.78)					
45-54	154	114	25	15			
Rate*	10.3	11.3	9.5	6.7			
95% C.I.	(8.68-11.94)	(9.24-13.39)	(5.80-13.28)	(3.32-10.11)			
55-64	330	234	53	43			
Rate*	30.2	31.1	30.5	25.8			
95% C.I.	(26.97-33.49)	(27.15-35.12)	(22.30-38.73)	(18.11-33.56)			
65-74	576	405	89	82			
Rate*	80.4	81.9	83.5	71.0			
95% C.I.	(73.79-86.92)	(73.89-89.84)	(66.18-100.89)	(55.60-86.31)			
75-84	634	449	94	91			
Rate*	154.3	160.5	148.5	134.1			
95% C.I.	(142.25-166.27)	(145.62-175.31)	(118.44-178.46)	(106.55-161.65)			
85+	283	180	53	50			
Rate*	297.9	295.7	303.6	299.8			
95% C.I.	(263.15-332.56)	(252.48-338.87)	(221.85-385.32)	(216.71-382.93)			
Unknown	0	0	0	0			

Note: The "---" is used for rates calculated on numbers less than ten.

* Rates are per 100,000 age-specific population.

Table 123. Colorectal Cancer Mortality by County of Residence, NevadaResidents, 2000-2004

County of						
Residence	Cases	Rat	te*	Age-Adjusted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.	
Carson City	67	26.2	(19.9-32.5)	22.3	(17.3-28.5)	
Churchill	25	20.0	(12.2-27.9)	21.0	(13.5-31.5)	
Clark	1,422	18.5	(17.5-19.4)	22.0	(20.8-23.2)	
Douglas	35	15.8	(10.6-21.0)	13.5	(9.2-19.3)	
Elko	34	14.9	(9.9-19.9)	30.0	(19.9-43.8)	
Esmeralda	1					
Eureka	0					
Humboldt	6					
Lander	2					
Lincoln	5					
Lyon	43	21.9	(15.4-28.5)	19.8	(14.3-27.1)	
Mineral	12	50.6	(22.0-79.2)	35.6	(18.1-64.3)	
Nye	40	22.7	(15.7-29.7)	14.8	(10.4-21.1)	
Pershing	9					
Storey	1					
Washoe	322	17.9	(16.0-19.9)	21.3	(19.0-23.8)	
White Pine	6					
Unknown	0					
Total	2,030	18.6	(17.7-19.4)	21.4	(20.4-22.4)	

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 124. Colorectal Cancer Mortality by Race/Ethnicity and Gender, NevadaResidents, 2000-2004

			Gei	nder	
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total
White	Incidence	978	774	0	1,752
	Rate*	26.7	18.3		22.1
	95% C.I.	(24.9-28.5)	(17.0-19.6)		(21.1-23.2)
Black	Incidence	65	63	0	128
	Rate*	32.3	24.7		27.8
	95% C.I.	(23.7-44.1)	(18.8-32.2)		(22.9-33.8)
Native	Incidence	4	5	0	9
American	Rate*				
	95% C.I.				
Asian	Incidence	24	35	0	59
	Rate*	14.1	14.9		14.6
	95% C.I.	(8.3-24.7)	(9.4-23.7)		(10.4-20.6)
Hispanic	Incidence	45	32	0	77
	Rate*	20.2	10.3		14.1
	95% C.I.	(13.3-30.3)	(6.7-15.4)		(10.6-18.5)
Other/Unkr	nown	4	1	0	5
Total	Incidence	1,120	910	0	2,030
	Rate*	25.8	17.8		21.4
	95% C.I.	(24.2-27.5)	(16.7-19.0)		(20.4-22.4)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 125. Colorectal Cancer Mortality by Age Group and Gender, NevadaResidents, 2000-2004

Age	Gender						
Group	Male	Female	Total				
<1	0	0	0				
Rate*							
95% C.I.							
1-4	0	0	0				
Rate*							
95% C.I.							
5-14	0	0	0				
Rate*							
95% C.I.							
15-24	0	0	0				
Rate*							
95% C.I.							
25-34	3	4	7				
Rate*							
95% C.I.							
35-44	24	22	46				
Rate*	2.71	2.68	2.70				
95% C.I.	(1.63-3.80)	(1.56-3.80)	(1.92-3.48)				
45-54	86	68	154				
Rate*	11.36	9.23	10.31				
95% C.I.	(8.96-13.76)	(7.04-11.43)	(8.68-11.94)				
55-64	202	128	330				
Rate*	37.53	23.13	30.23				
95% C.I.	(32.36-42.71)	(19.12-27.13)	(26.97-33.49)				
65-74	342	234	576				
Rate*	96.80	64.37	80.35				
95% C.I.	(86.54-107.05)	(56.12-72.62)	(73.79-86.92)				
75-84	345	289	634				
Rate*	185.82	128.26	154.26				
95% C.I.	(166.21-205.43)	(113.47-143.04)	(142.25-166.27)				
85+	118	165	283				
Rate*	371.45	260.89	297.85				
95% C.I.	(304.43-438.48)	(221.08-300.69)	(263.15-332.56)				
Unknown	0	0	0				
Total	1,120	910	2,030				
Rate*	20.15	16.91	18.55				
95% C.I.	(19.0-21.3)	(15.8-18.0)	(17.7-19.4)				

Note: The "---" is used for rates calculated on numbers less than ten.

* Rates are per 100,000 age-specific population.


Table 126. Median Age at Death from Colorectal Cancer by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004

	Gender								
Race/Ethnicity	Male		Fem	nale	Total				
	Cases	Median Age	Cases	Median Age	Cases	Median Age			
White	978	72.0	774	75.0	1,752	73.0			
Black	65	69.0	63	68.0	128	69.0			
Native American	4		5	66.0	9	58.0			
Asian	24	68.0	35	66.0	59	67.0			
Hispanic	45	70.0	32	72.5	77	72.0			
Other/Unknown	4		1		5	73.0			
Total	1,120	72.0	910	74.0	2,030	73.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 86. Survival Rates for Colorectal Cancer by Race/Ethnicity, Nevada Residents, 2000-2004



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 87. Survival Rates for Colorectal Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 2000-2004




Table 127. Cause-Specific Survival Rates for Colorectal Cancer by
Race/Ethnicity and Gender, Nevada Residents, 2000-2004

Race/	Newslow		Cause Specific Survival Rate				Median
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	4,121	79.0%	69.7%	63.6%	59.2%	55.3%	> 5 YEARS
Male	2,211	78.7%	68.2%	61.9%	57.5%	54.3%	> 5 YEARS
Female	1,910	79.4%	71.4%	65.5%	61.3%	56.5%	> 5 YEARS
Race/Ethnicity							
White	3,479	78.6%	69.2%	63.3%	59.5%	55.3%	> 5 YEARS
Male	1,885	78.2%	67.7%	61.6%	57.5%	54.5%	> 5 YEARS
Female	1,594	79.0%	70.9%	65.3%	61.8%	56.3%	> 5 YEARS
Black	246	78.4%	67.5%	57.8%	48.3%	44.6%	3.82
Male	127	80.3%	64.5%	53.2%	46.1%	39.9%	3.45
Female	119	76.4%	71.3%	63.8%	51.0%	51.0%	> 5 YEARS
Native American	11						
Male	2						
Female	9						
Asian	154	84.4%	76.4%	69.8%	62.2%	62.2%	> 5 YEARS
Male	72	84.9%	77.1%	77.1%	71.6%	71.6%	> 5 YEARS
Female	82	84.0%	75.7%	63.7%	54.2%	54.2%	> 5 YEARS
Hispanic	176	78.4%	71.3%	64.4%	57.4%	57.4%	> 5 YEARS
Male	98	76.1%	69.9%	62.9%	55.3%	55.3%	> 5 YEARS
Female	78	81.3%	73.1%	66.3%	60.2%	60.2%	> 5 YEARS

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 128. Cause-Specific Survival Rates for Colorectal Cancer by Stage of
Cancer at Diagnosis and Gender, Nevada Residents, 2000-2004

Surviv	al Rate of Stage		Gender	
a	t Diagnosis	Total	Male	Female
Total	Cases	4,121	2,211	1,910
	One Year	79.0%	78.7%	79.4%
	5 Years	55.3%	54.3%	56.5%
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS
Stage at Di	iagnosis			
In situ	Cases			
	One Year			
	5 Years			
	Median Survival			
Localized	Cases	1,189	639	550
	One Year	93.9%	93.8%	94.1%
	5 Years	79.1%	76.6%	82.6%
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS
Regional	Cases	1,346	724	622
	One Year	88.4%	89.9%	86.6%
	5 Years	64.2%	66.2%	62.2%
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS
Distant	Cases	671	384	287
	One Year	45.8%	43.9%	48.4%
	5 Years	10.4%	9.8%	11.6%
	Median Survival	0.92	0.89	0.97
Unstaged	Cases	915	464	451
	One Year	68.4%	67.6%	69.3%
	5 Years	36.4%	33.5%	39.7%
	Median Survival	2.89	2.59	3.34


Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

URINARY BLADDER CANCER

URINARY BLADDER CANCER

GENERAL PROFILE⁴

Figure 88. Anatomy of the Urinary System⁵



General Anatomy: The bladder is a hollow organ in the lower abdomen. It stores urine, the liquid waste produced by the kidneys. Urine passes from each kidney into the bladder through a tube called a ureter. An outer layer of muscle surrounds the inner lining of the bladder. When the bladder is full, the muscles in the bladder wall can tighten to allow urination. Urine leaves the bladder through another tube, the urethra.

Risk Factors: Age, tobacco use, occupation (due to amount of carcinogens in the workplace), infection, treatment with cyclophosphamide or arsenic, race, being a man, family history, and personal history with Bladder Cancer.

Signs and Symptoms: Blood in the urine (making the urine slightly rusty to deep red), pain during urination, and frequent urination, or feeling the need to urinate without results.

Diagnosing the Cancer: Physical exams, urine tests, intravenous pyelogram, and cystoscopy.

Treatment: Treatment options include: surgery (Transurethral resection, Radical cystectomy, and Segmental cystectomy), radiation therapy (internal or external), chemotherapy, and biological therapy.

HIGHLIGHTS

- From 2000 to 2004, Nevadan males had a higher ratio than females when the incidence and mortality age-adjusted rates for Urinary Bladder Cancer were compared. Males had a ratio of 5.10 while the ratio for females was 4.17. This means that for every 100 deaths due to Urinary Bladder Cancer there would be 510 male cases and 417 female cases.
- The median age at diagnosis of Urinary Bladder Cancer for Nevadans was 71 years of age from 2000 to 2004. The median age at time of death due to Urinary Bladder Cancer during this period was 76 years.

INCIDENCE

- There were 2,567 cases of Urinary Bladder Cancer reported in Nevada from 2000 to 2004. Nevada's age-adjusted incidence rate, 25.7 (24.7-26.7), for Urinary Bladder Cancer showed statistical significance over the national rate of 21.13 (21.0-21.3, per 100,000 2000 US Standard population).
- While there was little regional variation between All Other Counties (28.2), Washoe County (25.2), and Clark County (25.1) in the age-adjusted incidence rate for Urinary Bladder Cancer, the rate for males, 43.2, was 3.9 times as the rate for Nevada females, 11.1, (per 100,000 2000 US Standard population) for the 2000 to 2004 period.

INPATIENT HOSPITAL DISCHARGES

- Billed charges from Urinary Bladder Cancer inpatient hospital discharges accounted for approximately 43.0 million dollars from 2000 to 2004. Nevadans in the 65-74 and 75-84 age groups accounted for 66.5% of the total inpatient discharges and 70.1% of the total billed charges during this period. The overall daily billed amount for these discharges was approximately \$6,261 in Nevada during this period.
- There were 1,033 Inpatient Discharges for Urinary Bladder Cancer to Nevada residents in Nevada from 2000 to 2004. Clark County (11.2) had the highest age-adjusted inpatient discharge rate for Urinary Bladder Cancer in Nevada, followed by Nevada overall, Washoe County, and All Other Counties who had rates of 10.5, 9.5 and 8.7 (per 100,000 – 2000 US Standard population), respectively.
- Washoe County had the highest median total billed amount (\$25,720) and average length of stay (7.3 days) during the 2000 to 2004 period for Urinary Bladder Cancer inpatient hospital discharges, once regional comparisons were made.

MORTALITY

There were 474 resident deaths due to Urinary Bladder Cancer from 2000 to 2004. Regional comparisons were fairly similar between All Other Counties, as a region, Clark County and Washoe County with rates of 5.2, 5.1 and 5.1 (per 100,000 – 2000 US Standard population), respectively.


Nevadan males had a statistically significant higher age-adjusted mortality rate, 8.5 (7.5-9.5), for Urinary Bladder Cancer that was more than 3.1 times the female mortality rate of 2.7 (2.2-3.2) (per 100,000 – 2000 US Standard population) for the 2000 to 2004 period.

SURVIVAL RATE


- Nevada's one-year survival rate for males with Urinary Bladder Cancer was higher than the rate for females during the 2000 to 2004 period, with rates of 89.5% and 84.5%, respectively, and remained at approximately the same ratio at the five-year rate where males had a rate of 73.6% and females had a rate of 71.0%.
- The one-year survival rate for those diagnosed with Urinary Bladder Cancer at the in situ stage was 100.0% for Nevada from 2000 to 2004. The rate for those at the localized stage was 99.0%, while those recorded at the regional, distant and unstaged stages had rates of 97.7%, 57.5% and 85.4%, respectively.
- The Median Survival time for those diagnosed at the in situ, localized, regional, and unstaged stages was over five years, while those diagnosed at the distant level had a median survival time of 1.56 years, respectively, during the 2000 to 2004 period.

INCIDENCE

Figure 89. Urinary Bladder Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 91. Urinary Bladder Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 129. Urinary Bladder Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

	County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)			
Total									
Cases	2,567	1,727	394	445	1	73,919			
Rate*	25.7	25.1	25.2	28.2		21.1			
95% C.I.	(24.7-26.7)	(23.9-26.4)	(22.8-28.0)	(25.6-31.0)		(21.0-21.3)			
Gender									
Male	1,981	1,322	300	359	0	55,067			
Rate*	43.2	41.6	43.0	48.9		37.3			
95% C.I.	(41.2-45.2)	(39.2-44.1)	(38.0-48.6)	(43.7-54.5)		(37.0-37.6)			
Female	586	405	94	86	1	18,852			
Rate*	11.1	11.2	11.2	10.3		9.4			
95% C.I.	(10.2-12.1)	(10.1-12.4)	(9.0-13.7)	(8.3-12.8)		(9.2-9.5)			
Other/Unknown	0	0	0	0	0	0			
Race/Ethnicity									
White	2,322	1,519	374	428	1	67,096			
Rate*	28.1	27.8	27.4	29.5		23.0			
95% C.I.	(26.9-29.3)	(26.4-29.2)	(24.6-30.4)	(26.8-32.6)		(22.8-23.1)			
Black	65	62	1	2	0	3,528			
Rate*	13.7	14.0				12.6			
95% C.I.	(10.4-18.0)	(10.5-18.6)				(12.2-13.1)			
Native American	5	2	2	1	0	151			
Rate*						5.3			
95% C.I.						(4.5-4.5)			
Asian	32	28	4	0	0	2,412			
Rate*	7.0	6.7				9.2			
95% C.I.	(4.5-11.4)	(4.3-10.0)				(8.9-9.6)			
Hispanic	72	55	10	7	0	3,715			
Rate*	10.0	9.8	11.4			11.6			
95% C.I.	(7.5-13.4)	(7.1-13.8)	(4.5-27.0)			(11.3-12.0)			
Other/Unknown	71	61	3	7	0	732			

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the national (SEER) rates. See Technical Notes for more information.

Table 130. Urinary Bladder Cancer Cases by Age Group and County/Region ofResidence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)			
Total									
Cases	2,567	1,727	394	445	1	73,919			
Rate*	25.7	25.1	25.2	28.2		21.1			
95% C.I.	(24.7-26.7)	(23.9-26.4)	(22.8-28.0)	(25.6-31.0)		(21.0-21.3)			
Age Group									
<1	2	0	2	0	0	3			
Rate*						0.1			
95% C.I.						(0.0-0.2)			
1-4	0	0	0	0	0	11			
Rate*						0.1			
95% C.I.						(0.0-0.1)			
5-14	0	0	0	0	0	12			
Rate*						0.0			
95% C.I.						(0.0-0.0)			
15-24	5	3	2	0	0	85			
Rate*						0.2			
95% C.I.						(0.1-0.2)			
25-34	10	8	2	0	0	351			
Rate*	0.6					0.7			
95% C.I.	(0.23-1.00)					(0.6-0.7)			
35-44	58	34	10	14	0	1,580			
Rate*	3.4	2.8	3.5	6.4		2.6			
95% C.I.	(2.53-4.28)	(1.88-3.78)	(1.33-5.68)	(3.05-9.77)		(2.5-2.8)			
45-54	173	116	31	26	0	5,780			
Rate*	11.6	11.5	11.8	11.6		11.2			
95% C.I.	(9.86-13.31)	(9.42-13.61)	(7.66-15.99)	(7.16-16.11)		(10.9-11.5)			
55-64	492	344	75	73	0	12,720			
Rate*	45.1	45.8	43.2	43.9		38.6			
95% C.I.	(41.09-49.05)	(40.93-50.61)	(33.41-52.95)	(33.80-53.92)		(37.9-39.3)			
65-74	870	584	134	152	0	21,066			
Rate*	121.4	118.1	125.8	131.5		96.7			
95% C.I.	(113.30-129.43)	(108.47-127.62)	(104.48-147.07)	(110.61-152.43)		(95.4-98.0)			
75-84	771	536	97	137	1	23,599			
Rate*	187.6	191.6	153.2	201.9		153.4			
95% C.I.	(174.35-200.83)	(175.34-207.77)	(122.70-183.67)	(168.08-235.69)		(151.4-155.4)			
85+	186	102	41	43	0	8,712			
Rate*	195.8	167.6	234.9	257.8		157.7			
95% C.I.	(167.63-223.90)	(135.03-200.06)	(162.96-306.74)	(180.78-334.91)		(154.4-161.0)			
Unknown	0	0	0	0	0	0			

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 131. Urinary Bladder Cancer Cases by County of Residence at Diagnosis,Nevada Residents, 2000-2004

County of	County of 2000-2004 Incidence				
Residence	Casaa	Ra	te*	Age-Adjus	ted Rate**
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.
Carson City	118	46.2	(37.8-54.5)	38.6	(31.9-46.4)
Churchill	32	25.6	(16.7-34.5)	26.8	(18.3-38.4)
Clark	1,727	22.4	(21.4-23.5)	25.1	(23.9-26.4)
Douglas	76	34.3	(26.6-42.0)	28.1	(21.9-35.8)
Elko	24	10.5	(6.3-14.7)	19.4	(11.7-30.8)
Esmeralda	1				
Eureka	3				
Humboldt	10	12.4	(4.7-20.0)	14.7	(6.8-28.8)
Lander	9				
Lincoln	7				
Lyon	67	34.2	(26.0-42.4)	30.8	(23.8-39.5)
Mineral	9				
Nye	67	38.0	(28.9-47.1)	26.2	(20.0-34.1)
Pershing	7				
Storey	7				
Washoe	394	21.9	(19.8-24.1)	25.2	(22.8-28.0)
White Pine	8				
Unknown	1				
Total	2,567	23.5	(22.6-24.4)	25.7	(24.7-26.7)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 132. Urinary Bladder Cancer Cases by Race/Ethnicity and Gender, NevadaResidents, 2000-2004

		Gender				
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total	
White	Incidence	1,785	537	0	2,322	
	Rate*	46.4	12.5		28.1	
	95% C.I.	(44.2-48.7)	(11.4-13.6)		(26.9-29.3)	
Black	Incidence	50	15	0	65	
	Rate*	24.1	5.9		13.7	
	95% C.I.	(16.9-34.4)	(3.2-10.2)		(10.4-18.0)	
Native	Incidence	4	1	0	5	
American	Rate*					
	95% C.I.					
Asian	Incidence	23	9	0	32	
	Rate*	13.1			7.0	
	95% C.I.	(7.6-23.6)			(4.5-11.4)	
Hispanic	Incidence	63	9	0	72	
	Rate*	19.5			10.0	
	95% C.I.	(13.9-27.8)			(7.5-13.4)	
Other/Unkr	nown	56	15	0	71	
Total	Incidence	1,981	586	0	2,567	
	Rate*	43.2	11.1		25.7	
	95% C.I.	(41.2-45.2)	(10.2-12.1)		(24.7-26.7)	

Note: The "---" is used for rates calculated on numbers less than ten.

*Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 133. Urinary Bladder Cancer Cases by Age Group and Gender, NevadaResidents, 2000-2004

Age	Gender						
Group	Male	Female	Unknown	Total			
<1	2	0	0	2			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	0	0	0	0			
Rate*							
95% C.I.							
15-24	1	4	0	5			
Rate*							
95% C.I.							
25-34	7	3	0	10			
Rate*				0.62			
95% C.I.				(0.23-1.00)			
35-44	43	15	0	58			
Rate*	4.86	1.83		3.40			
95% C.I.	(3.41-6.31)	(0.90-2.76)		(2.53-4.28)			
45-54	130	43	0	173			
Rate*	17.18	5.84		11.58			
95% C.I.	(14.22-20.13)	(4.09-7.58)		(9.86-13.31)			
55-64 Rate*	402 74.69	90	0	492			
95% C.I.	(67.39-81.99)	16.26 (12.90-19.62)		45.07 (41.09-49.05)			
65-74	665	205		870			
Rate*	188.21	56.39	0	121.37			
95% C.I.	(173.91-202.52)	(48.67-64.11)		(113.30-129.43)			
75-84	600	171	0	771			
Rate*	323.16	75.89		187.59			
95% C.I.	(297.30-349.02)	(64.51-87.26)		(174.35-200.83)			
85+	131	55	0	186			
Rate*	412.38	86.96		195.76			
95% C.I.	(341.76-482.99)	(63.98-109.95)		(167.63-223.90)			
Unknown	0	0	0	0			
Total	1,981	586	0	2,567			
Rate*	35.64	10.89		23.46			
95% C.I.	(34.1-37.2)	(10.0-11.8)		(22.6-24.4)			

Note: The "---" is used for rates calculated on numbers less than ten.

* Rates are per 100,000 age-specific population.

Table 134. Urinary Bladder Cancer Cases by Age Group and Stage, NevadaResidents, 2000-2004

Arro	Crown	Stage						
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total	
<1	Number	0	2	0	0	0	2	
	Percent		100.0%				100.0%	
1-4	Number	0	0	0	0	0	0	
	Percent							
5-14	Number	0	0	0	0	0	0	
	Percent							
15-24	Number	2	3	0	0	0	5	
	Percent	40.0%	60.0%				100.0%	
25-34	Number	6	2	0	1	1	10	
	Percent	60.0%	20.0%		10.0%	10.0%	100.0%	
35-44	Number	20	25	3	1	9	58	
	Percent	34.5%	43.1%	5.2%	1.7%	15.5%	100.0%	
45-54	Number	89	46	15	8	15	173	
	Percent	51.4%	26.6%	8.7%	4.6%	8.7%	100.0%	
55-64	Number	193	163	38	20	78	492	
	Percent	39.2%	33.1%	7.7%	4.1%	15.9%	100.0%	
65-74	Number	339	272	75	30	154	870	
	Percent	39.0%	31.3%	8.6%	3.4%	17.7%	100.0%	
75-84	Number	291	274	48	22	136	771	
	Percent	37.7%	35.5%	6.2%	2.9%	17.6%	100.0%	
85+	Number	54	68	15	3	46	186	
	Percent	29.0%	36.6%	8.1%	1.6%	24.7%	100.0%	
Unknown	Number	0	0	0	0	0	0	
	Percent							
Total	Number Percent	994 38.7%	855 33.3%	194 7.6%	85 3.3%	439 17.1%	2,567 100.0%	

Table 135. Urinary Bladder Cancer Cases by Stage and Race/Ethnicity, NevadaResidents, 2000-2004

		Race/Ethnicity						
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total
In situ	Number	900	21	2	15	32	24	994
	Percent	38.8%	32.3%	40.0%	46.9%	44.4%	33.8%	38.7%
Localized	Number	786	24	3	7	23	12	855
	Percent	33.9%	36.9%	60.0%	21.9%	31.9%	16.9%	33.3%
Regional	Number	181	8	0	4	1	0	194
	Percent	7.8%	12.3%		12.5%	1.4%		7.6%
Distant	Number	77	4	0	2	2	0	85
	Percent	3.3%	6.2%		6.3%	2.8%		3.3%
Unstaged	Number	378	8	0	4	14	35	439
	Percent	16.3%	12.3%		12.5%	19.4%	49.3%	17.1%
Total	Number	2,322	65	5	32	72	71	2,567
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%


Table 136. Median Age at Diagnosis of Urinary Bladder Cancer by Race/Ethnicityand Gender, Nevada Residents, 2000-2004

		Gender							
Race/Ethnicity	Ма	le	Fem	nale	Total				
	Cases	Median Age	Cases	Median Age	Cases	Median Age			
White	1,785	71.0	537	72.0	2,322	72.0			
Black	50	69.0	15	66.0	65	68.0			
Native American	4		1		5	60.0			
Asian	23	71.0	9	58.0	32	68.5			
Hispanic	63	63.0	9	68.0	72	65.0			
Other/Unknown	56	70.0	15	73.0	71	70.0			
Total	1,981	71.0	586	71.0	2,567	71.0			


Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 92. Urinary Bladder Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical Notes for more information.








Figure 94. Median Charges for Urinary Bladder Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 2000-2004








Table 137. Urinary Bladder Cancer Inpatient Discharges by Gender, Charges,Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	1,033	746	145	140	2			
Rate*	10.5	11.2	9.5	8.7				
95% C.I.	(9.9-11.2)	(10.4-12.0)	(8.0-11.2)	(7.3-10.4)				
Gender								
Male	803	590	97	114	2			
Rate*	18.0	19.5	14.4	15.1				
95% C.I.	(16.7-19.4)	(17.8-21.3)	(11.5-17.8)	(12.4-18.5)				
Female	230	156	48	26	0			
Rate*	4.4	4.4	5.8	3.1				
95% C.I.	(3.9-5.0)	(3.7-5.2)	(4.3-7.7)	(2.0-4.6)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Ch	narges (\$)							
Total Charges	\$42,953,616	\$31,125,311	\$6,532,031	\$5,236,420	\$59,854			
Average Charges	\$41,581	\$41,723	\$45,048	\$37,403	\$29,927			
Median Charges	\$22,690	\$22,511	\$25,720	\$20,708	\$29,927			
Discharge Length of S	tay (LOS) (Days)							
Total LOS	6,860	4,886	1,063	895	16			
Average LOS	6.6	6.5	7.3	6.4	8.0			
Median LOS	4.0	4.0	6.0	4.0	8.0			

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 138. Urinary Bladder Cancer Inpatient Discharges by Age Group and
County/Region of Residence, Nevada Residents, 2000-2004

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Discharges	1,033	746	145	140				
Rate*	9.4	9.7	8.1	9.7				
95% C.I.	(8.9-10.0)	(9.0-10.4)	(6.8-9.4)	(8.1-11.3)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	2	2	0	0				
Rate*								
95% C.I.								
25-34	4	4	0	0				
Rate*								
95% C.I.								
35-44	12	9	2	1				
Rate*	0.7							
95% C.I.	(0.31-1.10)							
45-54	56	40	11	5				
Rate*	3.8	4.0	4.2					
95% C.I.	(2.77-4.73)	(2.74-5.20)	(1.72-6.68)					
55-64	188	136	19	33				
Rate*	17.2	18.1	10.9	19.8				
95% C.I.	(14.76-19.68)	(15.05-21.14)	(6.02-15.86)	(13.06-26.59)				
65-74	307	215	49	43				
Rate*	42.8	43.5	46.0	37.2				
95% C.I.	(38.04-47.62)	(37.65-49.27)	(33.11-58.87)	(26.09-48.33)				
75-84	380	283	50	45				
Rate*	92.5	101.1	79.0	66.3				
95% C.I.	(83.16-101.75)	(89.36-112.92)	(57.07-100.85)	(46.94-85.69)				
85+	84	57	14	13				
Rate*	88.4	93.6	80.2	78.0				
95% C.I.	(69.50-107.32)	(69.32-117.94)	(38.19-122.20)	(35.58-120.33)				
Unknown	0	0	0	0				

* Rates are per 100,000 age-specific population.

Table 139. Urinary Bladder Cancer Inpatient Discharges by Age Group and
Gender, Nevada Residents, 2000-2004

Age	Gender				
Group	Male	Female	Total		
<1	0	0	0		
Rate*					
95% C.I.					
1-4	0	0	0		
Rate*					
95% C.I.					
5-14	0	0	0		
Rate*					
95% C.I.					
15-24	2	0	2		
Rate*					
95% C.I.					
25-34	2	2	4		
Rate*					
95% C.I.					
35-44	8	4	12		
Rate*			0.70		
95% C.I.			(0.31-1.10)		
45-54	45	11	56		
Rate*	5.95	1.49	3.75		
95% C.I.	(4.21-7.68)	(0.61-2.38)	(2.77-4.73)		
55-64	163	25	188		
Rate*	30.29	4.52	17.22		
95% C.I.	(25.64-34.93)	(2.75-6.29)	(14.76-19.68)		
65-74	233	74	307		
Rate*	65.95	20.36	42.83		
95% C.I.	(57.48-74.41)	(15.72-25.00)	(38.04-47.62)		
75-84	289	91	380		
Rate* 95% C.I.	155.66 (137.71-173.60)	40.39 (32.09-48.68)	92.46 (83.16-101.75)		
	, , ,	<u>`</u>	· · · · · · · · · · · · · · · · · · ·		
85+ Rate*	61 102 02	23 36.37	84 88.41		
95% C.I.	192.02 (143.83-240.21)	36.37 (21.50-51.23)	(69.50-107.32)		
Unknown	(143.03-240.21)	(21.30-31.23)	(09.30-107.32)		
Total	803	230	1,033		
Rate*	14.45	4.27	9.44		
95% C.I.	(13.4-15.4)	(3.7-4.8)	(8.9-10.0)		
	(((

* Rates are per 100,000 age-specific population.

Table 140. Urinary Bladder Cancer Inpatient Discharges by County/Region of
Residence, Nevada Residents, 2000-2004

Querte et	2000-2004 Inpatient Hospital Discharges						
County of Residence	0	Rate*		Age-Adjusted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	18	7.0	(3.8-10.3)	5.6	(3.3-9.0)		
Churchill	15	12.0	(5.9-18.1)	12.1	(6.8-20.6)		
Clark	746	9.7	(9.0-10.4)	11.2	(10.4-12.0)		
Douglas	13	5.9	(2.7-9.1)	5.0	(2.6-9.2)		
Elko	18	7.9	(4.2-11.5)	18.3	(10.4-30.3)		
Esmeralda	0						
Eureka	0						
Humboldt	5						
Lander	4						
Lincoln	1						
Lyon	33	16.8	(11.1-22.6)	15.1	(10.3-21.6)		
Mineral	2						
Nye	22	12.5	(7.3-17.7)	7.8	(4.9-12.1)		
Pershing	2						
Storey	3						
Washoe	145	8.1	(6.8-9.4)	9.5	(8.0-11.2)		
White Pine	4						
Unknown	2						
Total	1,033	9.4	(8.9-10.0)	10.5	(9.9-11.2)		


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 141. Urinary Bladder Cancer Inpatient Discharges by Age Group, Chargesand Length of Stay, Nevada Residents, 2000-2004


Age Group	Discharges	Charges (\$)			Length of Stay (Days)		
		Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	0						
15-24	2						
25-34	4						
35-44	12	463,557	38,630	35,920	79	6.6	6.5
45-54	56	2,533,597	45,243	25,937	389	7.0	6.0
55-64	188	7,332,986	39,005	27,522	1,137	6.1	4.0
65-74	307	13,950,889	45,443	25,135	2,168	7.1	5.0
75-84	380	16,193,529	42,615	21,796	2,612	6.9	4.0
85+	84	2,265,334	26,968	18,902	430	5.1	4.0
Unknown	0						
Total	1,033	42,953,616	41,581	22,690	6,860	6.6	4.0

MORTALITY

Figure 96. Urinary Bladder Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.







Figure 98. Urinary Bladder Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 2000-2004



	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Mortality	474	321	75	78			
Rate*	5.1	5.1	5.1	5.2			
95% C.I.	(4.7-5.6)	(4.6-5.8)	(4.0-6.4)	(4.1-6.5)			
Gender							
Male	339	229	48	62			
Rate*	8.5	8.5	7.7	9.1			
95% C.I.	(7.5-9.5)	(7.3-9.8)	(5.6-10.6)	(6.9-12.0)			
Female	135	92	27	16			
Rate*	2.7	2.7	3.2	2.0			
95% C.I.	(2.2-3.2)	(2.2-3.3)	(2.1-4.7)	(1.1-3.3)			
Other/Unknown	0	0	0	0			
Race/Ethnicity							
White	432	286	69	77			
Rate*	5.5	5.6	5.2	5.6			
95% C.I.	(5.0-6.1)	(5.0-6.3)	(4.0-6.6)	(4.4-7.0)			
Black	16	15	1	0			
Rate*	3.5	3.5					
95% C.I.	(2.0-6.2)	(1.9-6.4)					
Native American	3	1	2	0			
Rate*							
95% C.I.							
Asian	8	6	2	0			
Rate*							
95% C.I.							
Hispanic	14	12	1	1			
Rate*	3.5	3.9					
95% C.I.	(1.8-6.4)	(1.8-7.5)					
Other/Unknown	1	1	0	0			

Table 142. Urinary Bladder Cancer Mortality by Gender, Race/Ethnicity and
County/Region of Residence, Nevada Residents, 2000-2004

Note: The "---" is used for rates calculated on numbers less than ten.

*Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 143. Urinary Bladder Cancer Mortality by Age Group and County/Regionof Residence, Nevada Residents, 2000-2004

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Deaths	474	321	75	78			
Rate*	5.1	5.1	5.1	5.2			
95% C.I.	(4.7-5.6)	(4.6-5.8)	(4.0-6.4)	(4.1-6.5)			
Age Group							
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	0	0	0	0			
Rate*							
95% C.I.							
15-24	0	0	0	0			
Rate*							
95% C.I.							
25-34	2	2	0	0			
Rate*							
95% C.I.							
35-44	5	2	1	2			
Rate*							
95% C.I.							
45-54	18	13	2	3			
Rate*	1.2	1.3					
95% C.I.	(0.65-1.76)	(0.59-1.99)					
55-64	73	47	14	12			
Rate*	6.7	6.3	8.1	7.2			
95% C.I.	(5.15-8.22)	(4.47-8.04)	(3.84-12.28)	(3.13-11.29)			
65-74	123	82	17	24			
Rate*	17.2	16.6	16.0	20.8			
95% C.I.	(14.13-20.19)	(12.99-20.16)	(8.37-23.54)	(12.46-29.08)			
75-84	175	125	28	22			
Rate*	42.6	44.7	44.2	32.4			
95% C.I.	(36.27-48.89)	(36.84-52.50)	(27.84-60.60)	(18.87-45.97)			
85+	78	50	13	15			
Rate*	82.1	82.1	74.5	90.0			
95% C.I.	(63.88-100.31)	(59.37-104.90)	(33.99-114.94)	(44.43-135.46)			
Unknown	0	0	0	0			

Note: The "---" is used for rates calculated on numbers less than ten.

* Rates are per 100,000 age-specific population.

Table 144. Urinary Bladder Cancer Mortality by County of Residence, NevadaResidents, 2000-2004

County of	2000-2004 Mortality						
Residence	Cases	Ra	te*	Age-Adjus	sted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	22	8.6	(5.0-12.2)	7.3	(4.5-11.1)		
Churchill	4						
Clark	321	4.2	(3.7-4.6)	5.1	(4.6-5.8)		
Douglas	15	6.8	(3.3-10.2)	6.2	(3.3-10.8)		
Elko	4						
Esmeralda	0						
Eureka	0						
Humboldt	4						
Lander	2						
Lincoln	0						
Lyon	14	7.1	(3.4-10.9)	6.9	(3.7-11.9)		
Mineral	3						
Nye	7						
Pershing	1						
Storey	0						
Washoe	75	4.2	(3.2-5.1)	5.1	(4.0-6.4)		
White Pine	2						
Unknown	0						
Total	474	4.3	(3.9-4.7)	5.1	(4.7-5.6)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 145. Urinary Bladder Cancer Mortality by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004

		Gender					
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total		
White	Incidence	314	118	0	432		
	Rate*	9.1	2.8		5.5		
	95% C.I.	(8.1-10.3)	(2.3-3.4)		(5.0-6.1)		
Black	Incidence	10	6	0	16		
	Rate*	5.5			3.5		
	95% C.I.	(2.3-12.5)			(2.0-6.2)		
Native	Incidence	2	1	0	3		
American	Rate*						
	95% C.I.						
Asian	Incidence	5	3	0	8		
	Rate*						
	95% C.I.						
Hispanic	Incidence	8	6	0	14		
	Rate*				3.5		
	95% C.I.				(1.8-6.4)		
Other/Unkr	nown	0	1	0	1		
Total	Incidence	339	135	0	474		
	Rate*	8.5	2.7		5.1		
	95% C.I.	(7.5-9.5)	(2.2-3.2)		(4.7-5.6)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are ageadjusted to the 2000 US Standard population.

Table 146. Urinary Bladder Cancer Mortality by Age Group and Gender, NevadaResidents, 2000-2004

Age	Gender						
Group	Male	Female	Total				
<1	0 =	0	0				
Rate*							
95% C.I.							
1-4	0	0	0				
Rate*							
95% C.I.	<u> </u>						
5-14	0	0	0				
Rate*							
95% C.I.							
15-24	0	0	0				
Rate*							
95% C.I.							
25-34	2	0	2				
Rate*							
95% C.I.							
35-44	1	4	5				
Rate*							
95% C.I.							
45-54	10	8	18				
Rate*	1.32		1.21				
95% C.I.	(0.50-2.14)		(0.65-1.76)				
55-64	54	19	73				
Rate* 95% C.I.	10.03 (7.36-12.71)	3.43 (1.89-4.98)	6.69 (5.15-8.22)				
65-74	91	32	· · · · · · · · · · · · · · · · · · ·				
Rate*	25.76	8.80	123 17.16				
95% C.I.	(20.46-31.05)	(5.75-11.85)	(14.13-20.19)				
75-84	129	46	175				
Rate*	69.48	20.41	42.58				
95% C.I.	(57.49-81.47)	(14.51-26.31)	(36.27-48.89)				
85+	52	26	78				
Rate*	163.69	41.11	82.09				
95% C.I.	(119.20-208.18)	(25.31-56.91)	(63.88-100.31)				
Unknown	0	0	0				
Total	339	135	474				
Rate*	6.10	2.51	4.33				
95% C.I.	(5.4-6.7)	(2.1-2.9)	(3.9-4.7)				

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.


Table 147. Median Age at Death from Urinary Bladder Cancer by Race/Ethnicityand Gender, Nevada Residents, 2000-2004

	Gender							
Race/Ethnicity	Male		Fem	ale	Total			
	Cases	Median Age	Cases	Median Age	Cases	Median Age		
White	314	76.0	118	75.5	432	76.0		
Black	10	74.5	6	69.5	16	73.0		
Native American	2		1		3			
Asian	5	70.0	3		8	67.0		
Hispanic	8	80.5	6	82.0	14	80.5		
Other/Unknown	0		1		1			
Total	339	76.0	135	76.0	474	76.0		

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 99. Survival Rates for Urinary Bladder Cancer by Race/Ethnicity, Nevada Residents, 2000-2004



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 100. Survival Rates for Urinary Bladder Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 2000-2004




Table 148. Cause-Specific Survival Rates for Urinary Bladder Cancer byRace/Ethnicity and Gender, Nevada Residents, 2000-2004

Race/			Cause Specific Survival Rate				Median
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	2,031	88.3%	82.7%	79.0%	76.7%	73.0%	> 5 YEARS
Male	1,561	89.5%	84.4%	80.2%	77.9%	73.6%	> 5 YEARS
Female	470	84.5%	76.7%	75.0%	73.0%	71.0%	> 5 YEARS
Race/Ethnicity							
White	1,821	88.2%	82.5%	78.8%	76.5%	73.0%	> 5 YEARS
Male	1,394	89.2%	84.0%	79.7%	77.4%	73.3%	> 5 YEARS
Female	427	84.8%	77.7%	75.9%	73.7%	71.6%	> 5 YEARS
Black	52	83.5%	68.6%	62.0%	56.6%	40.5%	4.41
Male	40						
Female	12						
Native American	3						
Male	2						
Female	1						
Asian	28						
Male	20						
Female	8						
Hispanic	62	89.7%	87.6%	87.6%	87.6%	87.6%	> 5 YEARS
Male	54	92.0%	89.5%	89.5%	89.5%	89.5%	> 5 YEARS
Female	8						<u> </u>

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 149. Cause-Specific Survival Rates for Urinary Bladder Cancer by Stage of
Cancer at Diagnosis and Gender, Nevada Residents, 2000-2004

Survival Rate of Stage at Diagnosis			Gender					
		Total	Male	Female				
Total	Cases	2,031	1,561	470				
	One Year	88.3%	89.5%	84.5%				
	5 Years	73.0%	73.6%	71.0%				
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS				
Stage at Di	iagnosis							
In situ	Cases	788	595	193				
	One Year	99.2%	99.5%	98.3%				
	5 Years	92.7%	92.3%	93.7%				
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS				
Localized	Cases	678	540	138				
	One Year	89.6%	90.0%	87.9%				
	5 Years	69.2%	69.2%	69.0%				
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS				
Regional	Cases	152	112	40				
	One Year	70.5%	75.5%					
	5 Years	34.7%	39.8%					
	Median Survival	2.17	3.02	<u> </u>				
Distant	Cases	72	56	16				
	One Year	17.5%	20.7%					
	5 Years	11.2%	14.7%					
	Median Survival	0.61	0.63					
Unstaged	Cases	341	258	83				
	One Year	84.7%	87.6%	75.6%				
	5 Years	75.6%	80.1%	60.9%				
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS				


Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

NON-HODGKIN'S LYMPHOMA

NON-HODGKIN'S LYMPHOMA

GENERAL PROFILE⁴

Figure 101. Anatomy of the Lymphatic System



General Anatomy: Lymphoma is a general term for cancers that develop in the lymphatic system. The lymphatic system is part of the body's immune system that helps the body fight disease and infection and includes a network of thin tubes (lymphatic vessels) that branch, like blood vessels, into tissues throughout the body. Lymphatic vessels carry lymph, a colorless, watery fluid that contains infection-fighting cells called lymphocytes. Along this network of vessels are small organs called lymph nodes that are found in the underarms, groin, neck, chest, and abdomen. Other parts of the lymphatic system are the spleen, thymus, tonsils, and bone marrow. Lymphatic tissue is also found in other parts of the body, including the stomach, intestines, and skin.

In Non-Hodgkin's Lymphoma, cells in the lymphatic system become abnormal. They divide and grow without any order or control, or old cells do not die as cells normally do. Non-Hodgkin's lymphoma can start almost anywhere in the body and may occur in a single lymph node, a group of lymph nodes, or in another organ. This type of cancer can spread to almost any part of the body, including the liver, bone marrow, and spleen.

Risk Factors: Age, male gender, weakened immune system, viruses (Human T-lymphotropic virus type I (HTLV-1) and Epstein-Barr virus), and environment (chemical exposure).

Signs and Symptoms: Unexplained fever, night sweats, constant fatigue, unexplained weight loss, itchy skin, and reddened patches on the skin.

Diagnosing the Cancer: X-rays, computed tomography (CAT) scan, magnetic resonance imaging (MRI), and lymphangiogram.

Treatment: Treatment options include: chemotherapy, radiation therapy, bone marrow transplantation (BMT), biological therapy, surgery, and clinical trials.

HIGHLIGHTS

- The ratio of the age-adjusted incidence rate, 17.7, to the age-adjusted mortality rate, 6.6 (per 100,000 2000 US Standard population), for Non-Hodgkin's Lymphoma in Nevada was 2.7 during the 2000 to 2004 period, which means that for every 269 Non-Hodgkin's Lymphoma cases there was 100 deaths due to Non-Hodgkin's Lymphoma in Nevada during this period.
- Nevadan females had a higher ratio (2.76) than males (2.58) when the incidence and mortality age-adjusted rates for Non-Hodgkin's Lymphoma were compared. This means that for every 100 deaths due to Non-Hodgkin's Lymphoma there was 276 female cases while only 258 cases for every male death during the 2000 to 2004 period.
- The median age at diagnosis of Non-Hodgkin's Lymphoma for Nevadans was 66 years of age from 2000 to 2004. The median age at time of death due to Non-Hodgkin's Lymphoma during this period was 73 years.

INCIDENCE

- There were 1,815 cases of Non-Hodgkin's Lymphoma in Nevada from 2000 to 2004. Nevada's higher incidence rate, 21.2 (19.9-22.7), for Non-Hodgkin's Lymphoma showed statistical significance when compared to the national rate, 19.34 (19.2), per 100,000 – 2000 US Standard population.
- Regional comparisons showed that Clark County's age-adjusted incidence rate, 18.2, was higher than the rate for Washoe County and All Other Counties who had rates of 17.6 and 15.5 (per 100,000 2000 US Standard population) from 2000 to 2004.
- Males had a statistically significant higher age-adjusted incidence rate, 21.2 (19.9-22.7), for Non-Hodgkin's Lymphoma than females from 2000 to 2004 who had a rate of 14.6 (13.6-15.7), (per 100,000 2000 US Standard population).
- Whites had the highest age-adjusted incidence rate, 18.7, for Non-Hodgkin's Lymphoma of all racial/ethnic groups and were followed by Blacks, Asians and Hispanics with rates of 13.5, 11.0, and 9.1 (per 100,000 2000 US Standard population), respectively, during this period.

INPATIENT HOSPITAL DISCHARGES

Statistical regional comparisons indicate that Washoe County had the highest ageadjusted inpatient discharge rate for Non-Hodgkin's Lymphoma, 11.8 (10.2-13.6), and was followed by Clark County, 10.3 (9.6-11.1), and All Other Counties, 7.9 (6.5-9.4), (per 100,000 – 2000 US Standard population) from 2000 to 2004.

- Clark County had the highest median total charge (\$36,352) for Non-Hodgkin's Lymphoma inpatient hospital discharges during the 2000 to 2004 period and was followed by Washoe County (\$25,024) and All Other Counties (\$21,433).
- Total billed charges for Non-Hodgkin's Lymphoma inpatient hospital discharges in Nevada totaled 59.7 million dollars from 2000 to 2004. The overall average billed charge per day for a hospital inpatient discharge due to Non-Hodgkin's Lymphoma was approximately \$5,991 in Nevada during this period.

MORTALITY


- There were 630 resident deaths due to Non-Hodgkin's Lymphoma from 2000 to 2004. Regional comparisons were fairly similar between Washoe County, All Other Counties, as a region, and Clark County with rates of 7.1, 7.1 and 6.3 (per 100,000 – 2000 US Standard population), respectively.
- While racial/ethnic comparisons showed that Whites had highest age-adjusted mortality rate (6.9) for Non-Hodgkin's Lymphoma, and were followed by Blacks, Hispanics, and Asians with rates of 5.6, 5.4 and 3.9 (per 100,000 2000 US Standard population), respectively; statistical analysis does not show any statistical significance between any of the racial/ethnic groups during the 2000 to 2004 period.

SURVIVAL RATE


- Females had a slightly higher one-year survival rate (78.8%) than males (78.4%) for Non-Hodgkin's Lymphoma in Nevada from 2000 to 2004. This difference increased at the five-year survival rate where females had a higher rate at 64.6% and males with a rate of 60.3% during this period.
- The Non-Hodgkin's Lymphoma survival rate varies greatly by the stage of the cancer at time of diagnosis. Those diagnosed at the localized stage had the highest one- and five-year survival rates with 85.6% and 71.2%, respectively. This was followed by those with regional and then distant diagnoses with rates of 84.4% and 72.8% for the one year period and 55.8% and 58.5% for the five year period.

INCIDENCE

Figure 102. Non-Hodgkin's Lymphoma Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 104. Non-Hodgkin's Lymphoma Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 150. Non-Hodgkin's Lymphoma Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)		
Total								
Cases	1,815	1,274	293	247	1	69,044		
Rate*	17.7	18.2	17.6	15.5		19.3		
95% C.I.	(16.9-18.6)	(17.2-19.3)	(15.6-19.8)	(13.6-17.6)		(19.2-19.5)		
Gender								
Male	1,035	728	174	132	1	36,882		
Rate*	21.2	22.0	21.9	17.2		23.2		
95% C.I.	(19.9-22.7)	(20.3-23.9)	(18.6-25.8)	(14.3-20.6)		(23.0-23.5)		
Female	780	546	119	115	0	32,162		
Rate*	14.6	15.0	13.8	13.9		16.3		
95% C.I.	(13.6-15.7)	(13.7-16.3)	(11.4-16.5)	(11.5-16.8)		(16.1-16.4)		
Other/Unknown	0	0	0	0	0	0		
Race/Ethnicity								
White	1,515	1,030	259	226	0	59,191		
Rate*	18.7	19.5	18.3	15.8		20.2		
95% C.I.	(17.7-19.7)	(18.3-20.8)	(16.1-20.7)	(13.8-18.1)		(20.0-20.3)		
Black	75	70	3	1	1	4,864		
Rate*	13.5	13.5				14.6		
95% C.I.	(10.5-17.5)	(10.4-17.8)				(14.2-15.0)		
Native American	6	3	1	2	0	252		
Rate*						7.7		
95% C.I.						(6.7-6.7)		
Asian	50	36	11	3	0	3,784		
Rate*	11.0	9.4	18.7			13.2		
95% C.I.	(7.5-16.3)	(5.8-15.7)	(7.4-45.4)			(12.8-13.6)		
Hispanic	94	73	11	10	0	6,648		
Rate*	9.1	9.6	5.6	10.3		16.5		
95% C.I.	(7.0-12.0)	(7.1-13.3)	(2.3-12.0)	(4.4-22.3)		(16.1-16.9)		
Other/Unknown	75	62	8	5	0	953		

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the national (SEER) rates. See Technical Notes for more information.

Table 151. Non-Hodgkin's Lymphoma Cases by Age Group and County/Region ofResidence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)			
Total									
Cases	1,815	1,274	293	247	1	69,044			
Rate*	17.7	18.2	17.6	15.5		19.3			
95% C.I.	(16.9-18.6)	(17.2-19.3)	(15.6-19.8)	(13.6-17.6)		(19.2-19.5)			
Age Group									
<1	1	1	0	0	0	8			
Rate*						0.2			
95% C.I.						(0.1-0.3)			
1-4	3	2	1	0	0	121			
Rate*						0.6			
95% C.I.						(0.5-0.7)			
5-14	16	10	4	2	0	584			
Rate*	1.0	0.9				1.1			
95% C.I.	(0.53-1.54)	(0.35-1.48)				(1.0-1.1)			
15-24	23	18	4	1	0	1,118			
Rate*	1.5	1.6				2.1			
95% C.I.	(0.87-2.07)	(0.88-2.40)				(2.0-2.2)			
25-34	61	43	11	7	0	2,266			
Rate*	3.8	3.6	4.2			4.2			
95% C.I.	(2.82-4.71)	(2.51-4.66)	(1.73-6.75)			(4.0-4.4)			
35-44	131	93	25	13	0	5,326			
Rate*	7.7	7.7	8.8	6.0		8.9			
95% C.I.	(6.37-9.00)	(6.17-9.31)	(5.33-12.20)	(2.72-9.19)		(8.7-9.2)			
45-54	222	154	38	30	0	9,736			
Rate*	14.9	15.3	14.5	13.4		18.8			
95% C.I.	(12.91-16.82)	(12.87-17.70)	(9.89-19.10)	(8.62-18.23)		(18.4-19.2)			
55-64	384	263	73	48	0	12,486			
Rate*	35.2	35.0	42.0	28.8		37.8			
95% C.I.	(31.66-38.69)	(30.76-39.22)	(32.39-51.67)	(20.68-37.00)		(37.1-38.5)			
65-74	463	329	64	70	0	15,571			
Rate*	64.6	66.5	60.1	60.6		71.4			
95% C.I.	(58.71-70.47)	(59.32-73.69)	(45.35-74.79)	(46.38-74.76)		(70.3-72.5)			
75-84	398	281	55	61	1	16,193			
Rate*	96.8	100.4	86.9	89.9		105.3			
95% C.I.	(87.32-106.35)	(88.68-112.17)	(63.90-109.81)	(67.33-112.45)		(103.7-106.9)			
85+	113	80	18	15	0	5,635			
Rate*	118.9	131.4	103.1	90.0		102.0			
95% C.I.	(97.00-140.86)	(102.61-160.21)	(55.47-150.74)	(44.43-135.46)		(99.3-104.7)			
Unknown	0	0	0	0	0	0			

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 152. Non-Hodgkin's Lymphoma Cases by County of Residence at Diagnosis,Nevada Residents, 2000-2004

County of	2000-2004 Incidence						
Residence	Cases	Rat	te*	Age-Adjus	ted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	54	21.1	(15.5-26.8)	18.7	(14.0-24.7)		
Churchill	25	20.0	(12.2-27.9)	20.6	(13.3-30.9)		
Clark	1,274	16.6	(15.6-17.5)	18.2	(17.2-19.3)		
Douglas	44	19.9	(14.0-25.7)	15.0	(10.8-20.7)		
Elko	24	10.5	(6.3-14.7)	17.8	(10.8-28.4)		
Esmeralda	0						
Eureka	3						
Humboldt	9						
Lander	4						
Lincoln	2						
Lyon	28	14.3	(9.0-19.6)	12.4	(8.2-18.3)		
Mineral	7						
Nye	38	21.6	(14.7-28.4)	15.6	(10.8-22.5)		
Pershing	3						
Storey	0						
Washoe	293	16.3	(14.5-18.2)	17.6	(15.6-19.8)		
White Pine	6						
Unknown	1						
Total	1,815	16.6	(15.8-17.4)	17.7	(16.9-18.6)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 153. Non-Hodgkin's Lymphoma Cases by Race/Ethnicity and Gender,Nevada Residents, 2000-2004

		Gender				
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total	
White	Incidence	846	669	0	1,515	
	Rate*	21.9	15.8		18.7	
	95% C.I.	(20.3-23.5)	(14.7-17.1)		(17.7-19.7)	
Black	Incidence	46	29	0	75	
	Rate*	16.1	10.6		13.5	
	95% C.I.	(11.6-22.0)	(6.9-15.7)		(10.5-17.5)	
Native	Incidence	3	3	0	6	
American	Rate*					
	95% C.I.					
Asian	Incidence	30	20	0	50	
	Rate*	15.9	7.2		11.0	
	95% C.I.	(9.4-27.4)	(3.9-14.0)		(7.5-16.3)	
Hispanic	Incidence	57	37	0	94	
	Rate*	13.0	6.2		9.1	
	95% C.I.	(8.9-19.8)	(4.2-9.2)		(7.0-12.0)	
Other/Unkr	nown	53	22	0	75	
Total	Incidence	1,035	780	0	1,815	
	Rate*	21.2	14.6		17.7	
	95% C.I.	(19.9-22.7)	(13.6-15.7)		(16.9-18.6)	

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are ageadjusted to the 2000 US Standard population.

Table 154. Non-Hodgkin's Lymphoma Cases by Age Group and Gender, Nevada Residents, 2000-2004

Age	Gender							
Group	Male	Female	Unknown	Total				
<1	1	0	0	1				
Rate*								
95% C.I.								
1-4	1	2	0	3				
Rate*								
95% C.I.								
5-14	12	4	0	16				
Rate*	1.50			1.03				
95% C.I.	(0.65-2.35)			(0.53-1.54)				
15-24	12	11	0	23				
Rate*	1.48	1.46		1.47				
95% C.I.	(0.64-2.32)	(0.60-2.33)		(0.87-2.07)				
25-34	40	21	0	61				
Rate*	4.74	2.71		3.77				
95% C.I.	(3.27-6.21)	(1.55-3.87)		(2.82-4.71)				
35-44	85	46	0	131				
Rate*	9.60	5.61		7.68				
95% C.I.	(7.56-11.64)	(3.99-7.23)		(6.37-9.00)				
45-54	130	92	0	222				
Rate*	17.18	12.49		14.87				
95% C.I.	(14.22-20.13)	(9.94-15.05)		(12.91-16.82)				
55-64	244	140	0	384				
Rate*	45.34	25.29		35.18				
95% C.I.	(39.65-51.02)	(21.10-29.48)		(31.66-38.69)				
65-74	257	206	0	463				
Rate*	72.74	56.67		64.59				
95% C.I.	(63.85-81.63)	(48.93-64.41)		(58.71-70.47)				
75-84	198	200	0	398				
Rate*	106.64	88.76		96.84				
95% C.I.	(91.79-121.50)	(76.46-101.06)		(87.32-106.35)				
85+	55	58	0	113				
Rate* 95% C.I.	173.14 (127.38-218.89)	91.71 (68.10-115.31)		118.93 (97.00-140.86)				
		(00.10-110.31)	0	(97.00-140.66)				
<u>Unknown</u> Total	0 1,035	780	0	1,815				
Rate*	1,035	14.49	0	1,815				
95% C.I.	(17.5-19.8)	(13.5-15.5)		(15.8-17.4)				
	(11.6 10.0)	(10.0 10.0)		(1010 111)				

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 155. Non-Hodgkin's Lymphoma Cases by Age Group and Stage, NevadaResidents, 2000-2004

Age Group		Stage								
		In situ	Localized	Regional	Distant	Unstaged	Total			
<1	Number		0	0	0	1	1			
	Percent					100.0%	100.0%			
1-4	Number		1	0	1	1	3			
	Percent		33.3%		33.3%	33.3%	100.0%			
5-14	Number		2	2	5	7	16			
	Percent		12.5%	12.5%	31.3%	43.8%	100.0%			
15-24	Number		7	2	7	7	23			
	Percent		30.4%	8.7%	30.4%	30.4%	100.0%			
25-34	Number		16	11	12	22	61			
	Percent		26.2%	18.0%	19.7%	36.1%	100.0%			
35-44	Number		36	8	40	47	131			
	Percent		27.5%	6.1%	30.5%	35.9%	100.0%			
45-54	Number		53	21	65	83	222			
	Percent		23.9%	9.5%	29.3%	37.4%	100.0%			
55-64	Number		81	36	126	141	384			
	Percent		21.1%	9.4%	32.8%	36.7%	100.0%			
65-74	Number		99	30	139	195	463			
	Percent		21.4%	6.5%	30.0%	42.1%	100.0%			
75-84	Number		70	31	130	167	398			
	Percent		17.6%	7.8%	32.7%	42.0%	100.0%			
85+	Number		22	6	29	56	113			
	Percent		19.5%	5.3%	25.7%	49.6%	100.0%			
Unknown	Number		0	0	0	0	0			
	Percent									
Total	Number		387	147	554	727	1,815			
	Percent		21.3%	8.1%	30.5%	40.1%	100.0%			

Table 156. Non-Hodgkin's Lymphoma Cases by Stage and Race/Ethnicity, Nevada Residents, 2000-2004

		Race/Ethnicity							
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total	
In situ	Number								
	Percent								
Localized	Number	317	27	2	9	22	10	387	
	Percent	20.9%	36.0%	33.3%	18.0%	23.4%	13.3%	21.3%	
Regional	Number	126	5	0	3	8	5	147	
	Percent	8.3%	6.7%		6.0%	8.5%	6.7%	8.1%	
Distant	Number	464	20	3	18	29	20	554	
	Percent	30.6%	26.7%	50.0%	36.0%	30.9%	26.7%	30.5%	
Unstaged	Number	608	23	1	20	35	40	727	
	Percent	40.1%	30.7%	16.7%	40.0%	37.2%	53.3%	40.1%	
Total	Number	1,515	75	6	50	94	75	1,815	
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	


Table 157. Median Age at Diagnosis of Non-Hodgkin's Lymphoma by
Race/Ethnicity and Gender, Nevada Residents, 2000-2004

	Gender								
Race/Ethnicity	Male		Fem	ale	Total				
	Cases	Median Age	Cases	Median Age	Cases	Median Age			
White	846	65.5	669	69.0	1,515	67.0			
Black	46	57.0	29	63.0	75	58.0			
Native American	3		3		6	68.5			
Asian	30	61.5	20	53.5	50	57.0			
Hispanic	57	57.0	37	52.0	94	55.0			
Other/Unknown	53	62.0	22	70.5	75	65.0			
Total	1,035	64.0	780	68.0	1,815	66.0			


Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 105. Non-Hodgkin's Lymphoma Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical Notes for more information.








Figure 107. Median Charges for Non-Hodgkin's Lymphoma Discharges by County/Region of Residence, Nevada Residents, 2000-2004








Table 158. Non-Hodgkin's Lymphoma Discharges by Gender, Charges, Length of
Stay, and County/Region of Residence, Nevada Residents, 2000-2004

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	1,055	736	196	122	1
Rate*	10.2	10.3	11.8	7.9	
95% C.I.	(9.6-10.9)	(9.6-11.1)	(10.2-13.6)	(6.5-9.4)	
Gender					
Male	583	430	98	55	0
Rate*	11.6	12.4	12.0	7.4	
95% C.I.	(10.6-12.7)	(11.2-13.8)	(9.6-14.9)	(5.5-9.9)	
Female	472	306	98	67	1
Rate*	8.9	8.4	11.4	8.3	
95% C.I.	(8.1-9.8)	(7.4-9.4)	(9.2-13.9)	(6.4-10.6)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$59,713,417	\$44,479,958	\$10,040,841	\$4,786,891	\$405,727
Average Charges	\$56,600	\$60,435	\$51,229	\$39,237	\$405,727
Median Charges	\$31,614	\$36,352	\$25,024	\$21,433	\$405,727
Discharge Length of S	tay (LOS) (Days)				
Total LOS	9,968	7,233	1,750	949	36
Average LOS	9.4	9.8	8.9	7.8	36.0
Median LOS	6.0	7.0	6.0	4.0	36.0

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 159. Non-Hodgkin's Lymphoma Discharges by Age Group and
County/Region of Residence, Nevada Residents, 2000-2004

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Discharges	1,055	736	196	122				
Rate*	9.6	9.6	10.9	8.4				
95% C.I.	(9.1-10.2)	(8.9-10.3)	(9.4-12.4)	(6.9-9.9)				
Age Group								
<1	1	1	0	0				
Rate*								
95% C.I.								
1-4	1	1	0	0				
Rate*								
95% C.I.								
5-14	24	19	3	1				
Rate*	1.6	1.7						
95% C.I.	(0.93-2.16)	(0.95-2.52)						
15-24	31	26	4	1				
Rate*	2.0	2.4						
95% C.I.	(1.29-2.68)	(1.46-3.28)						
25-34	44	37	4	3				
Rate*	2.7	3.1						
95% C.I.	(1.91-3.52)	(2.09-4.08)						
35-44	77	59	10	8				
Rate*	4.5	4.9	3.5					
95% C.I.	(3.51-5.52)	(3.66-6.16)	(1.33-5.68)					
45-54	153	110	33	10				
Rate*	10.3	10.9	12.6	4.5				
95% C.I.	(8.62-11.87)	(8.88-12.96)	(8.29-16.88)	(1.70-7.25)				
55-64	199	140	41	18				
Rate*	18.2	18.6	23.6	10.8				
95% C.I.	(15.70-20.76)	(15.54-21.71)	(16.38-30.83)	(5.82-15.81)				
65-74	257	169	52	36				
Rate*	35.9	34.2	48.8	31.2				
95% C.I.	(31.47-40.24)	(29.01-39.31)	(35.54-62.07)	(20.97-41.33)				
75-84	213	140	39	34				
Rate*	51.8	50.0	61.6	50.1				
95% C.I.	(44.87-58.79)	(41.75-58.32)	(42.26-80.92)	(33.26-66.94)				
85+	55	34	10	11				
Rate*	57.9	55.9	57.3	66.0				
95% C.I.	(42.59-73.19)	(37.08-74.62)	(21.78-92.78)	(26.98-104.94)				
Unknown	0	0	0	0				

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 160. Non-Hodgkin's Lymphoma Discharges by Age Group and Gender,
Nevada Residents, 2000-2004

Age	Gender						
Group	Male	Female	Total				
<1	0	1	1				
Rate*							
95% C.I.							
1-4	1	0	1				
Rate*							
95% C.I.							
5-14	16	8	24				
Rate*	2.01		1.55				
95% C.I.	(1.02-2.99)		(0.93-2.16)				
15-24	18	13	31				
Rate*	2.22	1.73	1.99				
95% C.I.	(1.19-3.25)	(0.79-2.67)	(1.29-2.68)				
25-34	28	16	44				
Rate*	3.32	2.06	2.72				
95% C.I.	(2.09-4.55)	(1.05-3.08)	(1.91-3.52)				
35-44	57	20	77				
Rate*	6.44	2.44	4.52				
95% C.I.	(4.77-8.11)	(1.37-3.51)	(3.51-5.52)				
45-54	89	64	153				
Rate*	11.76	8.69	10.25				
95% C.I.	(9.32-14.20)	(6.56-10.82)	(8.62-11.87)				
55-64 Datat	126	73	199				
Rate*	23.41 (19.32-27.50)	13.19 (10.16-16.22)	18.23 (15.70-20.76)				
95% C.I.							
65-74 Rate*	129 36.51	128 35.21	257 35.85				
95% C.I.	(30.21-42.81)	(29.11-41.31)	(31.47-40.24)				
75-84	96	117	213				
Rate*	51.71	51.92	51.83				
95% C.I.	(41.36-62.05)	(42.51-61.33)	(44.87-58.79)				
85+	23	32	55				
Rate*	72.40	50.60	57.89				
95% C.I.	(42.81-101.99)	(33.07-68.13)	(42.59-73.19)				
Unknown		0	0				
Total	583	472	1,055				
Rate*	10.49	8.77	9.64				
95% C.I.	(9.6-11.3)	(8.0-9.6)	(9.1-10.2)				

 \ast Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 161. Non-Hodgkin's Lymphoma Discharges by County/Region of Residence,
Nevada Residents, 2000-2004

O	2000-2004 Inpatient Hospital Discharges							
County of Residence	Casaa	Rat	te*	Age-Adjus	Age-Adjusted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	30	11.7	(7.5-15.9)	9.9	(6.7-14.4)			
Churchill	8							
Clark	736	9.6	(8.9-10.3)	10.3	(9.6-11.1)			
Douglas	25	11.3	(6.9-15.7)	9.1	(5.7-14.0)			
Elko	3							
Esmeralda	0							
Eureka	1							
Humboldt	3							
Lander	2							
Lincoln	2							
Lyon	30	15.3	(9.8-20.8)	14.3	(9.6-20.7)			
Mineral	3							
Nye	15	8.5	(4.2-12.8)	5.6	(3.1-9.6)			
Pershing	0							
Storey	0							
Washoe	196	10.9	(9.4-12.4)	11.8	(10.2-13.6)			
White Pine	0							
Unknown	1							
Total	1,055	9.6	(9.1-10.2)	10.2	(9.6-10.9)			


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 162. Non-Hodgkin's Lymphoma Discharges by Age Group, Charges and
Length of Stay, Nevada Residents, 2000-2004


Age	Discharges	Charges (\$)			Length of Stay (Days)		
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	1						
1-4	1						
5-14	24	1,937,559	80,732	40,577	242	10.1	6.0
15-24	31	3,465,050	111,776	43,081	457	14.7	8.0
25-34	44	2,081,594	47,309	33,678	436	9.9	7.0
35-44	77	5,222,710	67,827	36,318	808	10.5	6.0
45-54	153	8,297,838	54,234	29,598	1,371	9.0	6.0
55-64	199	11,465,202	57,614	33,409	2,003	10.1	7.0
65-74	257	14,259,591	55,485	32,341	2,329	9.1	6.0
75-84	213	10,530,766	49,440	27,359	1,806	8.5	6.0
85+	55	2,378,787	43,251	28,658	503	9.2	7.0
Unknown	0						
Total	1,055	59,713,417	56,600	31,614	9,968	9.4	6.0

MORTALITY

Figure 109. Non-Hodgkin's Lymphoma Age-Adjusted (2000) Mortality Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 111. Non-Hodgkin's Lymphoma Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 163. Non-Hodgkin's Lymphoma Mortality by Gender, Race/Ethnicity and
County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	630	415	109	106				
Rate*	6.6	6.3	7.1	7.1				
95% C.I.	(6.0-7.1)	(5.7-7.0)	(5.8-8.6)	(5.8-8.6)				
Gender								
Male	357	245	60	52				
Rate*	8.2	8.5	8.5	7.2				
95% C.I.	(7.3-9.2)	(7.3-9.8)	(6.3-11.2)	(5.3-9.7)				
Female	273	170	49	54				
Rate*	5.3	4.8	5.9	6.8				
95% C.I.	(4.7-6.0)	(4.1-5.6)	(4.4-7.8)	(5.1-8.9)				
Other/Unknown	0	0	0	0				
Race/Ethnicity								
White	548	352	97	99				
Rate*	6.9	6.8	7.2	7.2				
95% C.I.	(6.3-7.5)	(6.0-7.5)	(5.8-8.8)	(5.8-8.8)				
Black	24	21	2	1				
Rate*	5.6	5.4						
95% C.I.	(3.4-8.9)	(3.1-9.0)						
Native American	4	0	2	2				
Rate*								
95% C.I.								
Asian	19	16	2	1				
Rate*	3.9	3.8						
95% C.I.	(2.3-6.4)	(2.1-6.5)						
Hispanic	34	25	6	3				
Rate*	5.4	5.5						
95% C.I.	(3.5-8.4)	(3.2-9.2)						
Other/Unknown	1	1	0	0				

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 164. Non-Hodgkin's Lymphoma Mortality by Age Group and
County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence				
Category	Nevada Total	Clark	Washoe	All Other Counties	
Total					
Deaths	630	415	109	106	
Rate*	6.6	6.3	7.1	7.1	
95% C.I.	(6.0-7.1)	(5.7-7.0)	(5.8-8.6)	(5.8-8.6)	
Age Group					
<1	0	0	0	0	
Rate*					
95% C.I.					
1-4	0	0	0	0	
Rate*					
95% C.I.					
5-14	1	1	0	0	
Rate*					
95% C.I.					
15-24	5	4	1	0	
Rate*					
95% C.I.					
25-34	5	5	0	0	
Rate*					
95% C.I.					
35-44	24	15	6	3	
Rate*	1.4	1.3			
95% C.I.	(0.84-1.97)	(0.62-1.88)			
45-54	38	29	5	4	
Rate*	2.5	2.9			
95% C.I.	(1.74-3.35)	(1.83-3.93)			
55-64	107	77	19	11	
Rate*	9.8	10.3	10.9	6.6	
95% C.I.	(7.94-11.66)	(7.96-12.53)	(6.02-15.86)	(2.70-10.52)	
65-74	177	117	31	29	
Rate*	24.7	23.7	29.1	25.1	
95% C.I.	(21.05-28.33)	(19.36-27.93)	(18.85-39.34)	(15.96-34.23)	
75-84	193	117	35	41	
Rate*	47.0	41.8	55.3	60.4	
95% C.I.	(40.33-53.58)	(34.24-49.39)	(36.96-73.58)	(41.92-78.91)	
85+	80	50	12	18	
Rate*	84.2	82.1	68.7	107.9	
95% C.I.	(65.75-102.65)	(59.37-104.90)	(29.85-107.63)	(58.07-157.80)	
Unknown	0	0	0	0	

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 165. Non-Hodgkin's Lymphoma Mortality by County of Residence, Nevada Residents, 2000-2004

County of	2000-2004 Mortality				
Residence	Cases	Rat	te*	Age-Adjusted Rate**	
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.
Carson City	29	11.3	(7.2-15.5)	9.6	(6.4-14.0)
Churchill	3				
Clark	415	5.4	(4.9-5.9)	6.3	(5.7-7.0)
Douglas	16	7.2	(3.7-10.8)	6.0	(3.4-10.4)
Elko	12	5.3	(2.3-8.2)	12.0	(5.9-22.3)
Esmeralda	0				
Eureka	0				
Humboldt	6				
Lander	1				
Lincoln	1				
Lyon	14	7.1	(3.4-10.9)	6.8	(3.6-11.7)
Mineral	4				
Nye	16	9.1	(4.6-13.5)	6.8	(3.7-12.0)
Pershing	0				
Storey	0				
Washoe	109	6.1	(4.9-7.2)	7.1	(5.8-8.6)
White Pine	4				
Unknown	0				
Total	630	5.8	(5.3-6.2)	6.6	(6.0-7.1)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 166. Non-Hodgkin's Lymphoma Mortality by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004

Race/Ethnicity			Gender					
		Male	Female	Other/ Unknown	Total			
White	Incidence	314	234	0	548			
	Rate*	8.7	5.5		6.9			
	95% C.I.	(7.7-9.9)	(4.8-6.2)		(6.3-7.5)			
Black	Incidence	12	12	0	24			
	Rate*	4.5	5.6		5.6			
	95% C.I.	(2.2-8.4)	(2.8-10.2)		(3.4-8.9)			
Native	Incidence	2	2	0	4			
American	Rate*							
	95% C.I.							
Asian	Incidence	9	10	0	19			
	Rate*		3.6		3.9			
	95% C.I.		(1.7-7.1)		(2.3-6.4)			
Hispanic	Incidence	20	14	0	34			
	Rate*	7.7	3.9		5.4			
	95% C.I.	(4.0-14.7)	(2.0-7.5)		(3.5-8.4)			
Other/Unknown		0	1	0	1			
Total	Incidence	357	273	0	630			
	Rate*	8.2	5.3		6.6			
	95% C.I.	(7.3-9.2)	(4.7-6.0)		(6.0-7.1)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are ageadjusted to the 2000 US Standard population.

Table 167. Non-Hodgkin's Lymphoma Mortality by Age Group and Gender,
Nevada Residents, 2000-2004

$\begin{tabular}{ c c c c c c c } \hline \hline Group & Male & Female & Total & \hline $	Age		Gender			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Group	Male	Female	Total		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	<1	0	0	0		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Rate*					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	95% C.I.					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	1-4	0	0	0		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Rate*					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	95% C.I.					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	5-14	1	0	1		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	95% C.I.					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		4	1	5		
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		3	2	5		
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			8			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		/		<u>`</u>		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		· · · · · · · · · · · · · · · · · · ·	<u>`</u>	(1.74-3.35)		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $, ,		,		
95% C.I.(20.46-31.05)(18.66-28.66)(21.05-28.33)75-8410786193Rate*57.6338.1746.9695% C.I.(46.71-68.55)(30.10-46.23)(40.33-53.58)85+394180Rate*122.7764.8384.2095% C.I.(84.24-161.30)(44.98-84.67)(65.75-102.65)Unknown000Total357273630Rate*6.425.075.76						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
Rate*57.6338.1746.9695% C.I.(46.71-68.55)(30.10-46.23)(40.33-53.58)85+394180Rate*122.7764.8384.2095% C.I.(84.24-161.30)(44.98-84.67)(65.75-102.65)Unknown000Total357273630Rate*6.425.075.76				`		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
85+ 39 41 80 Rate* 122.77 64.83 84.20 95% C.I. (84.24-161.30) (44.98-84.67) (65.75-102.65) Unknown 0 0 0 0 0 Total 357 273 630 Rate* 6.42 5.07 5.76						
Rate*122.7764.8384.2095% C.I.(84.24-161.30)(44.98-84.67)(65.75-102.65)Unknown000Total357273630Rate*6.425.075.76			/			
95% C.I.(84.24-161.30)(44.98-84.67)(65.75-102.65)Unknown000Total357273630Rate*6.425.075.76						
Unknown 0 </td <td></td> <td></td> <td></td> <td></td>						
Total 357 273 630 Rate* 6.42 5.07 5.76		, , ,				
Rate* 6.42 5.07 5.76						
	95% C.I.	(5.8-7.1)	(4.5-5.7)	(5.3-6.2)		

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.


Table 168. Median Age at Death from Non-Hodgkin's Lymphoma by
Race/Ethnicity and Gender, Nevada Residents, 2000-2004

	Gender					
Race/Ethnicity	Male		Female		Total	
	Cases	Median Age	Cases	Median Age	Cases	Median Age
White	314	71.0	234	74.0	548	73.0
Black	12	59.0	12	79.5	24	67.0
Native American	2		2		4	
Asian	9	64.0	10	73.0	19	71.0
Hispanic	20	67.0	14	70.5	34	70.0
Other/Unknown	0		1		1	
Total	357	71.0	273	74.0	630	73.0

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE





Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 113. Survival Rates for Non-Hodgkin's Lymphoma by Stage of Cancer at Diagnosis, Nevada Residents, 2000-2004




Table 169. Cause-Specific Survival Rates for Non-Hodgkin's Lymphoma byRace/Ethnicity and Gender, Nevada Residents, 2000-2004

Race/			Cause	Specific Surviv	ecific Survival Rate			
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Median Survival Time (years)	
Total	1,494	78.6%	72.3%	68.4%	65.7%	62.3%	> 5 YEARS	
Male	839	78.4%	71.8%	66.9%	64.2%	60.3%	> 5 YEARS	
Female	655	78.8%	72.9%	70.2%	67.6%	64.6%	> 5 YEARS	
Race/Ethnicity								
White	1,233	77.7%	71.2%	67.7%	65.5%	61.5%	> 5 YEARS	
Male	677	77.0%	69.9%	65.3%	63.2%	58.7%	> 5 YEARS	
Female	556	78.4%	72.7%	70.6%	68.2%	64.8%	> 5 YEARS	
Black	68	80.3%	71.9%	62.5%	51.6%	51.6%	> 5 YEARS	
Male	41							
Female	27							
Native American	2							
Male	0							
Female	2							
Asian	41							
Male	24							
Female	17							
Hispanic	83	78.1%	76.2%	71.2%	66.6%	66.6%	> 5 YEARS	
Male	50	79.6%	76.5%	67.2%	56.9%	56.9%	> 5 YEARS	
Female	33						<u> </u>	

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 170. Cause-Specific Survival Rates for Non-Hodgkin's Lymphoma by Stageof Cancer at Diagnosis and Gender, Nevada Residents, 2000-2004

Surviv	al Rate of Stage		Gender		
	t Diagnosis	Total	Male	Female	
Total	Cases	1,494	839	655	
	One Year	78.6%	78.4%	78.8%	
	5 Years	62.3%	60.3%	64.6%	
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS	
Stage at D	iagnosis				
In situ	Cases				
	One Year				
	5 Years				
	Median Survival				
Localized	Cases	319	178	141	
	One Year	85.6%	83.6%	88.2%	
	5 Years	71.2%	68.7%	74.4%	
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS	
Regional	Cases	127	68	59	
	One Year	84.4%	84.5%	84.3%	
	5 Years	55.8%	42.7%	76.4%	
	Median Survival	> 5 YEARS	4.62	> 5 YEARS	
Distant	Cases	448	261	187	
	One Year	72.8%	71.4%	74.8%	
	5 Years	58.5%	56.6%	61.3%	
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS	
Unstaged	Cases	600	332	268	
	One Year	77.8%	80.0%	75.2%	
	5 Years	61.0%	64.8%	56.2%	
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS	

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

KIDNEY AND RENAL PELVIS CANCER

KIDNEY AND RENAL PELVIS CANCER

GENERAL PROFILE⁴




Figure 114. Anatomy of the Urinary System⁵

General Anatomy: The kidneys are two reddish-brown, bean-shaped organs located just above the waist, one on each side of the spine. They are part of the urinary system. Their main function is to filter blood and produce urine to rid the body of waste. As blood flows through the kidneys, they remove waste products and unneeded water. The resulting liquid, urine, collects in the middle of each kidney in an area called the renal pelvis. Urine drains from each kidney through a long tube, the ureter, into the bladder, where it is stored. Urine leaves the body through another tube, called the urethra. The kidneys also produce substances that help control blood pressure and regulate the formation of red blood cells.

Risk Factors: Tobacco use, obesity, occupational exposure, radiation, phenacetin (prolonged heavy use of this painkiller), dialysis, and Von Hippel-Lindau (VHL) disease.

Signs and Symptoms: Blood in the urine, a lump or mass in the kidney area, and other less common symptoms may include: fatigue, loss of appetite, weight loss, recurrent fevers, a pain in the side that doesn't go away, or a general feeling of poor health.

Diagnosing the Cancer: Health exams, intravenous pyelogram (IVP), arteriography, computed tomography (CAT) scan, magnetic resonance imaging (MRI), and ultrasonography.

Treatment: Surgery (Simple or Radical Nephrectomy), arterial embolization, radiation therapy, biological therapy, chemotherapy, and hormone therapy.

HIGHLIGHTS

- The ratio of the age-adjusted incidence rate, 12.3, to the age-adjusted mortality rate, 3.9 (per 100,000 2000 US Standard population), for Kidney and Renal Pelvis Cancer was 3.1 during the 2000 to 2004 period, which means that for every 312 Kidney and Renal Pelvis Cancer cases there was 100 deaths due to Kidney and Renal Pelvis Cancer in Nevada during this period.
- Nevadan females had a higher ratio (3.35) than males (2.96) when the incidence and mortality age-adjusted rates for Kidney and Renal Pelvis Cancer were compared. For every female death due to this type of cancer there were 3.35 female cases while there were 2.96 male cases for every male Kidney and Renal Pelvis Cancer death in Nevada from 2000 to 2004.
- The median age at diagnosis of Kidney and Renal Pelvis Cancer for Nevada residents was 64 years of age from 2000 to 2004. For females and males both, the median age was 64 years. The median age at time of death due to Kidney and Renal Pelvis Cancer was 68 years for Nevada overall, 66 years of age for males and 72 years of age for females.

INCIDENCE

- There were 1,310 cases of Kidney and Renal Pelvis Cancer in Nevada from 2000 to 2004. Nevada's Incidence rate for Kidney and Renal Pelvis Cancer (12.3) was only slightly higher than the national rate of 12.8 (per 100,000 2000 US Standard population). Regional comparisons showed little variation between Washoe County (13.4), Clark County (12.4) and All Other Counties (10.8) from 2000 to 2004.
- The higher age-adjusted incidence rate for male Kidney and Renal Pelvis Cancer, 16.6 (15.5-17.9), was statistically significant over the female rate of 8.5 (7.8-9.3), per 100,000 2000 US Standard population, during the 2000 to 2004 period.
- Blacks had the highest age-adjusted incidence rate, 12.9, for Kidney and Renal Pelvis Cancer of all racial/ethnic groups and were followed by Whites, Hispanics and Asians with rates of 12.9, 9.7 and 5.7 (per 100,000 – 2000 US Standard population), respectively, during the 2000 to 2004 period.
- The median age at diagnosis for Asians (58 years) was the lowest of any specific racial/ethnic group and was considerably lower than the statewide median age of 65 years for the 2000 to 2004 period.

INPATIENT HOSPITAL DISCHARGES

There were 1,070 hospital inpatient discharges for a primary diagnosis of Kidney and Renal Pelvis Cancer to Nevada residents from 2000 to 2004. Regional comparisons showed little difference between the age-adjusted inpatient discharge rates between Washoe County (10.3), Clark County (10.1) and All Other Counties (8.7 per 100,000 – 2000 US Standard population).

- Total billed charges for Kidney and Renal Pelvis Cancer inpatient hospital discharges in Nevada totaled 41.6 million dollars from 2000 to 2004. The overall average billed charge per day for a hospital inpatient discharge due to Kidney and Renal Pelvis Cancer was approximately \$6,481 in Nevada during this period.
- Washoe County had the highest median total billed amount (\$36,764), while the statewide median billed amount was \$28,622 from 2000 to 2004; with Clark County and All Other Counties with median billed amounts of \$27,771 and \$21,419, respectively.

MORTALITY


- There were 400 resident deaths due to Kidney and Renal Pelvis Cancer from 2000 to 2004. Males had a statistically significant age-adjusted mortality rate, 5.6 (4.9-6.4), more than double the female rate of 2.5 (2.1-3.0), per 100,000 2000 US Standard population, during this period.
- Blacks, as a racial/ethnic group, had the highest age-adjusted mortality rate for Kidney and Renal Pelvis Cancer of any racial/ethnic group, 4.3, and were followed by Whites, Hispanics and Asians with rates of 4.1, 2.8 and 2.5, (per 100,000 – 2000 US Standard population) respectively, from 2000 to 2004.
- Males had a median age at death from Kidney and Renal Pelvis Cancer six years earlier than females in Nevada from 2000 to 2004 with a median age at death of 66 and 72 years, respectively.

SURVIVAL RATE

- The one-year survival rate for Kidney and Renal Pelvis Cancer in Nevada was 77.9% during the 2000 to 2004 period, while the five-year survival rate was 61.7% during this same time. The median survival rate in Nevada was greater than five years for Kidney and Renal Pelvis Cancer for this period.
- Females in Nevada had a slightly higher one-year survival rate (79.9%) than males (76.8%) for Kidney and Renal Pelvis Cancer during the 2000 to 2004 period and this difference remained approximately the same for the five-year survival rate with females and males at 62.6% and 61.1%, respectively.
- The Kidney and Renal Pelvis Cancer Survival Rate varies greatly by the stage of the cancer at time of diagnosis. Those diagnosed at the localized stage had the highest one-and five-year survival rates with 97.3% and 82.7%, respectively. This was followed by those with Regional and then Distant diagnoses with rates of 77.4% and 32.5% for the one year period and 55.8% and 14.1% for the five year period.

INCIDENCE

Figure 115. Kidney and Renal Pelvis Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.

Figure 116. Kidney and Renal Pelvis Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 2000-2004




Figure 117. Kidney and Renal Pelvis Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 171. Kidney and Renal Pelvis Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

			County/Region	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)
Total						
Cases	1,310	909	225	176	0	45,784
Rate*	12.3	12.4	13.4	10.8		12.8
95% C.I.	(11.6-13.0)	(11.6-13.3)	(11.7-15.3)	(9.2-12.6)		(12.7-12.9)
Gender						
Male	843	570	142	131	0	28,447
Rate*	16.6	16.4	17.7	16.6		17.8
95% C.I.	(15.5-17.9)	(15.0-17.9)	(14.8-21.2)	(13.8-20.0)		(17.6-18.0)
Female	467	339	83	45	0	17,337
Rate*	8.5	9.0	9.6	5.4		8.9
95% C.I.	(7.8-9.3)	(8.0-10.0)	(7.6-11.9)	(3.9-7.4)		(8.7-9.0)
Other/Unknown	0	0	0	0	0	0
Race/Ethnicity						
White	1,088	727	204	157	0	38,859
Rate*	12.9	13.1	14.3	10.7		13.3
95% C.I.	(12.1-13.7)	(12.2-14.1)	(12.3-16.4)	(9.1-12.6)		(13.1-13.4)
Black	76	71	5	0	0	4,506
Rate*	12.9	12.9				14.3
95% C.I.	(10.1-16.6)	(10.0-16.9)				(13.8-14.7)
Native American	10	2	2	6	0	316
Rate*	9.6					9.8
95% C.I.	(4.4-18.8)					(8.7-8.7)
Asian	30	25	3	2	0	1,840
Rate*	5.7	5.9				6.3
95% C.I.	(3.5-9.8)	(3.3-11.2)				(6.1-6.6)
Hispanic	85	66	11	8	0	4,856
Rate*	9.7	9.6	10.2			12.4
95% C.I.	(7.4-12.8)	(7.1-13.2)	(3.8-25.1)			(12.0-12.8)
Other/Unknown	21	18	0	3	0	263

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the national (SEER) rates. See Technical Notes for more information.

Table 172. Kidney and Renal Pelvis Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

			County/Region	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)
Total						
Cases	1,310	909	225	176	0	45,784
Rate*	12.3	12.4	13.4	10.8		12.8
95% C.I.	(11.6-13.0)	(11.6-13.3)	(11.7-15.3)	(9.2-12.6)		(12.7-12.9)
Age Group						
<1	0	0	0	0	0	92
Rate*						1.7
95% C.I.						(1.4-2.1)
1-4	10	8	2	0	0	383
Rate*	1.6					1.8
95% C.I.	(0.60-2.56)					(1.6-2.0)
5-14	8	4	3	1	0	158
Rate*						0.3
95% C.I.						(0.2-0.3)
15-24	1	1	0	0	0	115
Rate*						0.2
95% C.I.						(0.2-0.3)
25-34	11	9	1	1	0	622
Rate*	0.7					1.2
95% C.I.	(0.28-1.08)					(1.1-1.2)
35-44	81	51	17	13	0	2,913
Rate*	4.8	4.3	6.0	6.0		4.9
95% C.I.	(3.72-5.79)	(3.08-5.41)	(3.13-8.79)	(2.72-9.19)		(4.7-5.1)
45-54	200	137	35	28	0	7,445
Rate*	13.4	13.6	13.4	12.5		14.4
95% C.I.	(11.54-15.25)	(11.32-15.87)	(8.93-17.77)	(7.89-17.17)		(14.1-14.7)
55-64	362	257	57	48	0	10,765
Rate*	33.2	34.2	32.8	28.8		32.6
95% C.I.	(29.74-36.58)	(30.01-38.38)	(24.30-41.34)	(20.68-37.00)		(32.0-33.2)
65-74	366	265	56	45	0	11,503
Rate*	51.1	53.6	52.6	38.9		52.7
95% C.I.	(45.83-56.29)	(47.12-60.01)	(38.80-66.33)	(27.56-50.31)		(51.7-53.7)
75-84	228	150	47	31	0	9,294
Rate*	55.5	53.6	74.2	45.7		60.6
95% C.I.	(48.27-62.68)	(45.03-62.19)	(53.00-95.44)	(29.60-61.76)		(59.4-61.9)
85+	43	27	7	9	0	2,494
Rate*	45.3	44.4				45.1
95% C.I.	(31.73-58.78)	(27.62-61.08)				(43.4-46.9)
Unknown	0	0	0	0	0	0

* Rates are per 100,000 age-specific population. Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 173. Kidney and Renal Pelvis Cancer Cases by County of Residence at
Diagnosis, Nevada Residents, 2000-2004

County of	2000-2004 Incidence					
Residence	Casas	Ra	te*	Age-Adjus	ted Rate**	
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.	
Carson City	34	13.3	(8.8-17.8)	10.9	(7.5-15.3)	
Churchill	20	16.0	(9.0-23.0)	16.0	(9.7-25.2)	
Clark	909	11.8	(11.0-12.6)	12.4	(11.6-13.3)	
Douglas	30	13.5	(8.7-18.4)	10.1	(6.8-14.7)	
Elko	17	7.4	(3.9-11.0)	11.6	(6.2-20.8)	
Esmeralda	1					
Eureka	3					
Humboldt	8					
Lander	3					
Lincoln	3					
Lyon	25	12.8	(7.8-17.8)	11.0	(7.1-16.5)	
Mineral	2					
Nye	27	15.3	(9.5-21.1)	11.1	(7.1-17.4)	
Pershing	1					
Storey	1					
Washoe	225	12.5	(10.9-14.2)	13.4	(11.7-15.3)	
White Pine	1					
Unknown	0					
Total	1,310	12.0	(11.3-12.6)	12.3	(11.6-13.0)	

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 174. Kidney and Renal Pelvis Cancer Cases by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004

			Ger	nder	
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total
White	Incidence	706	382	0	1,088
	Rate*	17.3	8.9		12.9
	95% C.I.	(16.0-18.7)	(8.0-9.9)		(12.1-13.7)
Black	Incidence	47	29	0	76
	Rate*	16.2	9.7		12.9
	95% C.I.	(11.8-22.0)	(6.4-14.4)		(10.1-16.6)
Native	Incidence	7	3	0	10
American	Rate*				9.6
	95% C.I.				(4.4-18.8)
Asian	Incidence	19	11	0	30
	Rate*	9.5	3.1		5.7
	95% C.I.	(4.9-19.3)	(1.5-5.6)		(3.5-9.8)
Hispanic	Incidence	55	30	0	85
	Rate*	15.5	5.4		9.7
	95% C.I.	(10.6-23.1)	(3.5-8.2)		(7.4-12.8)
Other/Unkr	nown	9	12	0	21
Total	Incidence	843	467	0	1,310
	Rate*	16.6	8.5		12.3
	95% C.I.	(15.5-17.9)	(7.8-9.3)		(11.6-13.0)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 175. Kidney and Renal Pelvis Cancer Cases by Age Group and Gender,Nevada Residents, 2000-2004

Age		Gender							
Group	Male	Female	Unknown	Total					
<1	0	0	0	0					
Rate*									
95% C.I.									
1-4	7	3	0	10					
Rate*				1.58					
95% C.I.				(0.60-2.56)					
5-14	4	4	0	8					
Rate*									
95% C.I.									
15-24	0	1	0	1					
Rate*									
95% C.I.									
25-34	7	4	0	11					
Rate*				0.68					
95% C.I.				(0.28-1.08)					
35-44	44	37	0	81					
Rate*	4.97	4.51		4.75					
95% C.I.	(3.50-6.44)	(3.06-5.97)		(3.72-5.79)					
45-54	129	71	0	200					
Rate*	17.04	9.64		13.39					
95% C.I.	(14.10-19.98)	(7.40-11.88)		(11.54-15.25)					
55-64	246	116	0	362					
Rate*	45.71	20.96		33.16					
95% C.I.	(40.00-51.42)	(17.14-24.77)		(29.74-36.58)					
65-74	230	136	0	366					
Rate*	65.10	37.41		51.06					
95% C.I.	(56.68-73.51)	(31.12-43.70)		(45.83-56.29)					
75-84	149	79	0	228					
Rate*	80.25	35.06		55.48					
95% C.I.	(67.37-93.14)	(27.33-42.79)		(48.27-62.68)					
85+	27	16	0	43					
Rate*	84.99	25.30		45.26					
95% C.I.	(52.93-117.05)	(12.90-37.69)		(31.73-58.78)					
Unknown	0	0	0	0					
Total	843	467	0	1,310					
Rate* 95% C.I.	15.17 (14.1-16.2)	8.68 (7.9-9.5)		11.97 (11.3-12.6)					
90 /0 U.I.	(14.1-10.2)	(7.9-9.3)		(11.3-12.0)					

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 176. Kidney and Renal Pelvis Cancer Cases by Age Group and Stage,
Nevada Residents, 2000-2004

A	Group	Stage						
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total	
<1	Number		0	0	0	0	0	
	Percent							
1-4	Number		4	1	3	2	10	
	Percent		40.0%	10.0%	30.0%	20.0%	100.0%	
5-14	Number		2	2	1	3	8	
	Percent		25.0%	25.0%	12.5%	37.5%	100.0%	
15-24	Number		1	0	0	0	1	
	Percent		100.0%				100.0%	
25-34	Number		9	0	2	0	11	
	Percent		81.8%		18.2%		100.0%	
35-44	Number		54	6	7	14	81	
	Percent		66.7%	7.4%	8.6%	17.3%	100.0%	
45-54	Number		108	33	17	42	200	
	Percent		54.0%	16.5%	8.5%	21.0%	100.0%	
55-64	Number		177	48	61	76	362	
	Percent		48.9%	13.3%	16.9%	21.0%	100.0%	
65-74	Number		176	53	53	84	366	
	Percent		48.1%	14.5%	14.5%	23.0%	100.0%	
75-84	Number		84	31	39	74	228	
	Percent		36.8%	13.6%	17.1%	32.5%	100.0%	
85+	Number		9	4	11	19	43	
	Percent		20.9%	9.3%	25.6%	44.2%	100.0%	
Unknown	Number		0	0	0	0	0	
	Percent							
Total	Number Percent		624 47.6%	178 13.6%	194 14.8%	314 24.0%	1,310 100.0%	

Table 177. Kidney and Renal Pelvis Cancer Cases by Stage and Race/Ethnicity,Nevada Residents, 2000-2004

		Race/Ethnicity						
\$	Stage		Black	Native American	Asian	Hispanic	Other/ Unknown	Total
In situ	Number							
	Percent							
Localized	Number	505	50	3	12	48	6	624
	Percent	46.4%	65.8%	30.0%	40.0%	56.5%	28.6%	47.6%
Regional	Number	158	4	0	9	6	0	178
	Percent	14.5%	5.3%		30.0%	7.1%		13.6%
Distant	Number	172	6	0	3	12	1	194
	Percent	15.8%	7.9%	<u> </u>	10.0%	14.1%	4.8%	14.8%
Unstaged	Number	253	16	7	6	19	14	314
	Percent	23.3%	21.1%	70.0%	20.0%	22.4%	66.7%	24.0%
Total	Number	1,088	76	10	30	85	21	1,310
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%


Table 178. Median Age at Diagnosis of Kidney and Renal Pelvis Cancer by
Race/Ethnicity and Gender, Nevada Residents, 2000-2004

	Gender								
Race/Ethnicity	Ma	Male		ale	То	tal			
	Cases	Median Age	Cases	Median Age	Cases	Median Age			
White	706	64.0	382	65.0	1,088	65.0			
Black	47	60.0	29	64.0	76	61.0			
Native American	7	71.0	3		10	70.0			
Asian	19	60.0	11	57.0	30	58.0			
Hispanic	55	64.0	30	53.0	85	60.0			
Other/Unknown	9	65.0	12	64.0	21	65.0			
Total	843	64.0	467	64.0	1,310	64.0			


Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 118. Kidney and Renal Pelvis Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical Notes for more information.








Figure 120. Median Charges for Kidney and Renal Pelvis Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 2000-2004








Table 179. Kidney and Renal Pelvis Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	1,070	749	176	145	0
Rate*	9.9	10.1	10.3	8.7	
95% C.I.	(9.3-10.5)	(9.4-10.9)	(8.8-11.9)	(7.4-10.3)	
Gender					
Male	694	471	115	108	0
Rate*	13.3	13.1	14.0	13.4	
95% C.I.	(12.3-14.4)	(11.9-14.5)	(11.4-17.1)	(11.0-16.4)	
Female	376	278	61	37	0
Rate*	6.8	7.4	6.9	4.4	
95% C.I.	(6.1-7.6)	(6.5-8.3)	(5.3-8.9)	(3.1-6.1)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$41,562,878	\$29,908,136	\$7,508,010	\$4,146,732	\$0
Average Charges	\$38,844	\$39,931	\$42,659	\$28,598	\$0
Median Charges	\$28,622	\$27,771	\$36,764	\$21,419	\$0
Discharge Length of S	tay (LOS) (Days)				
Total LOS	6,413	4,702	1,020	691	0
Average LOS	6.0	6.3	5.8	4.8	0.0
Median LOS	4.0	5.0	5.0	4.0	0.0

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 180. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group
and County/Region of Residence, Nevada Residents, 2000-2004

		County/Region	of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Discharges	1,070	749	176	145
Rate*	9.8	9.7	9.8	10.0
95% C.I.	(9.2-10.4)	(9.0-10.4)	(8.4-11.3)	(8.4-11.6)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	13	12	1	0
Rate*	2.1	2.6		
95% C.I.	(0.94-3.18)	(1.13-4.08)		
5-14	7	7	0	0
Rate*				
95% C.I.				
15-24	1	1	0	0
Rate*				
95% C.I.				
25-34	9	7	1	1
Rate*				
95% C.I.				
35-44	66	41	13	12
Rate*	3.9	3.4	4.6	5.5
95% C.I.	(2.94-4.80)	(2.37-4.46)	(2.08-7.03)	(2.39-8.60)
45-54	173	124	27	22
Rate*	11.6	12.3	10.3	9.9
95% C.I.	(9.86-13.31)	(10.14-14.47)	(6.41-14.18)	(5.73-13.96)
55-64	305	211	51	43
Rate*	27.9	28.1	29.4	25.8
95% C.I.	(24.80-31.07)	(24.29-31.86)	(21.30-37.42)	(18.11-33.56)
65-74	303	216	54	33
Rate*	42.3	43.7	50.7	28.6
95% C.I.	(37.51-47.03)	(37.84-49.48)	(37.17-64.20)	(18.81-38.30)
75-84	169	111	26	32
Rate*	41.1	39.7	41.1	47.2
95% C.I.	(34.92-47.32)	(32.29-47.05)	(25.28-56.84)	(30.82-63.49)
85+	24	19	3	2
Rate*	25.3	31.2		
95% C.I.	(15.15-35.37)	(17.18-45.24)		
Unknown	0	0	0	0

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 181. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group
and Gender, Nevada Residents, 2000-2004

Age		Gender	
Group	Male	Female	Total
<1	0	0	0
Rate*			
95% C.I.			
1-4	12	1	13
Rate*	3.71		2.06
95% C.I.	(1.61-5.81)		(0.94-3.18)
5-14	6	1	7
Rate*			
95% C.I.			
15-24	0	1	1
Rate*			
95% C.I.			
25-34	5	4	9
Rate*			
95% C.I.			
35-44	38	28	66
Rate*	4.29	3.42	3.87
95% C.I.	(2.93-5.66)	(2.15-4.68)	(2.94-4.80)
45-54	108	65	173
Rate*	14.27	8.83	11.58
95% C.I.	(11.58-16.96)	(6.68-10.97)	(9.86-13.31)
55-64	205	100	305
Rate*	38.09	18.07	27.94
95% C.I.	(32.88-43.30)	(14.53-21.61)	(24.80-31.07)
65-74	198	105	303
Rate*	56.04	28.88	42.27
95% C.I.	(48.23-63.85)	(23.36-34.41)	(37.51-47.03)
75-84	109	60	169
Rate*	58.71	26.63	41.12
95% C.I.	(47.69-69.73)	(19.89-33.37)	(34.92-47.32)
85+	13	11	24
Rate*	40.92	17.39	25.26
95% C.I.	(18.68-63.17)	(7.11-27.67)	(15.15-35.37)
Unknown	0	0	0
Total	694	376	1,070
Rate*	12.49 (11 6 12 4)	6.99	9.78
95% C.I.	(11.6-13.4)	(6.3-7.7)	(9.2-10.4)

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 182. Kidney and Renal Pelvis Cancer Inpatient Discharges by
County/Region of Residence, Nevada Residents, 2000-2004

	2000-2004 Inpatient Hospital Discharges						
County of Residence	Casaa	Ra	te*	Age-Adjusted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	21	8.2	(4.7-11.7)	6.8	(4.2-10.5)		
Churchill	13	10.4	(4.8-16.1)	10.4	(5.5-18.4)		
Clark	749	9.7	(9.0-10.4)	10.1	(9.4-10.9)		
Douglas	23	10.4	(6.1-14.6)	7.8	(4.9-12.0)		
Elko	13	5.7	(2.6-8.8)	8.2	(4.0-15.7)		
Esmeralda	0						
Eureka	5						
Humboldt	6						
Lander	2						
Lincoln	1						
Lyon	27	13.8	(8.6-19.0)	11.9	(7.8-17.5)		
Mineral	3						
Nye	27	15.3	(9.5-21.1)	11.1	(7.0-17.3)		
Pershing	1						
Storey	1						
Washoe	176	9.8	(8.4-11.3)	10.3	(8.8-11.9)		
White Pine	2						
Unknown	0						
Total	1,070	9.8	(9.2-10.4)	9.9	(9.3-10.5)		


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 183. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group,Charges and Length of Stay, Nevada Residents, 2000-2004

Age	Discharges	Charges (\$)		Length of Stay (Days)		ays)	
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	13	647,468	49,805	47,229	112	8.6	8.0
5-14	7						
15-24	1						
25-34	9						
35-44	66	2,423,214	36,715	28,566	364	5.5	4.0
45-54	173	6,331,049	36,596	25,821	951	5.5	4.0
55-64	305	11,685,632	38,314	29,255	1,832	6.0	4.0
65-74	303	11,036,935	36,426	28,006	1,707	5.6	4.0
75-84	169	7,724,349	45,706	29,919	1,154	6.8	5.0
85+	24	944,353	39,348	26,908	182	7.6	5.5
Unknown	0						
Total	1,070	41,562,878	38,844	28,622	6,413	6.0	4.0

MORTALITY

Figure 122. Kidney and Renal Pelvis Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.

Figure 123. Kidney and Renal Pelvis Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 2000-2004




Figure 124. Kidney and Renal Pelvis Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 184. Kidney and Renal Pelvis Cancer Mortality by Gender, Race/Ethnicityand County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence						
Category	Nevada Total Clark		Washoe	All Other Counties			
Total							
Mortality	400	272	63	65			
Rate*	3.9	3.9	4.0	4.0			
95% C.I.	(3.6-4.4)	(3.4-4.4)	(3.1-5.2)	(3.0-5.1)			
Gender							
Male	265	179	42	44			
Rate*	5.6	5.5	6.1	5.6			
95% C.I.	(4.9-6.4)	(4.7-6.5)	(4.3-8.6)	(4.0-7.8)			
Female	135	93	21	21			
Rate*	2.5	2.6	2.5	2.5			
95% C.I.	(2.1-3.0)	(2.1-3.2)	(1.6-3.9)	(1.5-3.8)			
Other/Unknown	0	0	0	0			
Race/Ethnicity							
White	338	224	56	58			
Rate*	4.1	4.1	4.1	3.9			
95% C.I.	(3.6-4.5)	(3.6-4.7)	(3.1-5.3)	(2.9-5.1)			
Black	23	21	2	0			
Rate*	4.3	4.3					
95% C.I.	(2.6-7.0)	(2.5-7.1)					
Native American	6	0	2	4			
Rate*							
95% C.I.							
Asian	10	10	0	0			
Rate*	2.5	3.2					
95% C.I.	(0.9-6.4)	(1.1-8.4)					
Hispanic	22	16	3	3			
Rate*	2.8	2.2					
95% C.I.	(1.6-5.1)	(1.2-3.9)					
Other/Unknown	1	1	0	0			

*Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 185. Kidney and Renal Pelvis Cancer Mortality by Age Group and
County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Deaths	400	272	63	65			
Rate*	3.9	3.9	4.0	4.0			
95% C.I.	(3.6-4.4)	(3.4-4.4)	(3.1-5.2)	(3.0-5.1)			
Age Group							
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	1	0	1	0			
Rate*							
95% C.I.							
15-24	0	0	0	0			
Rate*							
95% C.I.							
25-34	1	1	0	0			
Rate*							
95% C.I.							
35-44	8	6	0	2			
Rate*							
95% C.I.							
45-54	37	26	6	5			
Rate*	2.5	2.6					
95% C.I.	(1.68-3.28)	(1.59-3.57)					
55-64	113	76	16	21			
Rate*	10.4	10.1	9.2	12.6			
95% C.I.	(8.44-12.26)	(7.84-12.39)	(4.70-13.73)	(7.22-18.01)			
65-74	109	76	13	20			
Rate*	15.2	15.4	12.2	17.3			
95% C.I.	(12.35-18.06)	(11.91-18.82)	(5.57-18.84)	(9.72-24.89)			
75-84	99	68	19	12			
Rate*	24.1	24.3	30.0	17.7			
95% C.I.	(19.34-28.83)	(18.53-30.08)	(16.51-43.50)	(7.68-27.69)			
85+	32	19	8	5			
Rate*	33.7	31.2					
95% C.I.	(22.01-45.35)	(17.18-45.24)					
Unknown	0	0	0	0			

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 186. Kidney and Renal Pelvis Cancer Mortality by County of Residence,Nevada Residents, 2000-2004

County of	2000-2004 Mortality						
Residence	Rate*			Age-Adjus	sted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	15	5.9	(2.9-8.8)	5.0	(2.8-8.4)		
Churchill	7		(210 010)		(2.0 0.1)		
Clark	272	3.5	(3.1-4.0)	3.9	(3.4-4.4)		
Douglas	9						
Elko	4						
Esmeralda	0						
Eureka	1						
Humboldt	4						
Lander	2						
Lincoln	0						
Lyon	9						
Mineral	1						
Nye	12	6.8	(3.0-10.7)	4.6	(2.2-9.0)		
Pershing	0						
Storey	0						
Washoe	63	3.5	(2.6-4.4)	4.0	(3.1-5.2)		
White Pine	1						
Unknown	0						
Total	400	3.7	(3.3-4.0)	3.9	(3.6-4.4)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 187. Kidney and Renal Pelvis Cancer Mortality by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004

		Gender					
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total		
White	Incidence	222	116	0	338		
	Rate*	5.7	2.7		4.1		
	95% C.I.	(4.9-6.6)	(2.2-3.2)		(3.6-4.5)		
Black	Incidence	12	11	0	23		
	Rate*	4.0	4.2		4.3		
	95% C.I.	(2.1-7.1)	(2.1-8.1)		(2.6-7.0)		
Native	Incidence	3	3	0	6		
American	Rate*						
	95% C.I.						
Asian	Incidence	9	1	0	10		
	Rate*				2.5		
	95% C.I.				(0.9-6.4)		
Hispanic	Incidence	19	3	0	22		
•	Rate*	5.9			2.8		
	95% C.I.	(2.9-12.0)			(1.6-5.1)		
Other/Unkn	own	0	1	0	1		
Total	Incidence	265	135	0	400		
	Rate*	5.6	2.5		3.9		
	95% C.I.	(4.9-6.4)	(2.1-3.0)		(3.6-4.4)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 188. Kidney and Renal Pelvis Cancer Mortality by Age Group and Gender,
Nevada Residents, 2000-2004

Age	Gender					
Group	Male	Female	Total			
<1	0	0	0			
Rate*						
95% C.I.						
1-4	0	0	0			
Rate*						
95% C.I.						
5-14	0	1	1			
Rate*						
95% C.I.						
15-24	0	0	0			
Rate*						
95% C.I.						
25-34	1	0	1			
Rate*						
95% C.I.						
35-44	6	2	8			
Rate*						
95% C.I.						
45-54	28	9	37			
Rate*	3.70		2.48			
95% C.I.	(2.33-5.07)		(1.68-3.28)			
55-64	85	28	113			
Rate*	15.79	5.06	10.35			
95% C.I.	(12.44-19.15)	(3.19-6.93)	(8.44-12.26)			
65-74	67	42	109			
Rate*	18.96	11.55	15.21			
95% C.I.	(14.42-23.50)	(8.06-15.05)	(12.35-18.06)			
75-84	59	40	99			
Rate*	31.78	17.75	24.09			
95% C.I.	(23.67-39.89)	(12.25-23.25)	(19.34-28.83)			
85+	19	13	32			
Rate*	59.81	20.55	33.68			
95% C.I.	(32.92-86.70)	(9.38-31.73)	(22.01-45.35)			
Unknown	0	0	0			
Total	265	135	400			
Rate*	4.77	2.51	3.66			
95% C.I.	(4.2-5.3)	(2.1-2.9)	(3.3-4.0)			

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.


Table 189. Median Age at Death from Kidney and Renal Pelvis Cancer by
Race/Ethnicity and Gender, Nevada Residents, 2000-2004

	Gender							
Race/Ethnicity	Male		Fem	ale	Total			
	Cases	Median Age	Cases	Median Age	Cases	Median Age		
White	222	66.0	116	72.0	338	69.0		
Black	12	62.0	11	67.0	23	64.0		
Native American	3		3		6	69.5		
Asian	9	70.0	1		10	71.0		
Hispanic	19	63.0	3		22	60.5		
Other/Unknown	0		1		1			
Total	265	66.0	135	72.0	400	68.0		

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE





Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 126. Survival Rates for Kidney and Renal Pelvis Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 2000-2004




Table 190. Cause-Specific Survival Rates for Kidney and Renal Pelvis Cancer by
Race/Ethnicity and Gender, Nevada Residents, 2000-2004

Race/	Number	Cause Specific Survival Rate				Median	
Ethnicity and Gender	thnicity of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	1,046	77.9%	73.3%	68.6%	64.9%	61.7%	> 5 YEARS
Male	660	76.8%	72.2%	67.1%	64.5%	61.1%	> 5 YEARS
Female	386	79.9%	75.3%	71.3%	65.6%	62.6%	> 5 YEARS
Race/Ethnicity							
White	861	77.3%	72.3%	67.8%	64.2%	60.3%	> 5 YEARS
Male	546	76.8%	71.6%	66.9%	65.0%	60.7%	> 5 YEARS
Female	315	78.2%	73.5%	69.5%	63.1%	59.7%	> 5 YEARS
Black	65	81.2%	76.8%	73.9%	69.4%	69.4%	> 5 YEARS
Male	40						
Female	25						
Native American	3						
Male	2						
Female	1						
Asian	25						
Male	16						
Female	9						
Hispanic	73	79.4%	79.4%	70.1%	64.2%	64.2%	> 5 YEARS
Male	47						
Female	26						<u> </u>

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 191. Cause-Specific Survival Rates for Kidney and Renal Pelvis Cancer byStage of Cancer at Diagnosis and Gender, Nevada Residents, 2000-2004

Survival Rate of Stage at Diagnosis			Gender				
		Total	Male	Female			
Total	Cases	1,046	660	386			
	One Year	77.9%	76.8%	79.9%			
	5 Years	61.7%	61.1%	62.6%			
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS			
Stage at Di	iagnosis						
In situ	Cases						
	One Year						
	5 Years						
	Median Survival						
Localized	Cases	503	306	197			
	One Year	97.3%	96.9%	97.8%			
	5 Years	82.7%	82.0%	83.7%			
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS			
Regional	Cases	143	92	51			
	One Year	77.4%	77.9%	76.3%			
	5 Years	55.8%	57.1%	54.7%			
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS			
Distant	Cases	164	110	54			
	One Year	32.5%	32.7%	32.1%			
	5 Years	14.1%	18.6%	8.6%			
	Median Survival	0.74	0.74	0.74			
Unstaged	Cases	236	152	84			
	One Year	67.7%	66.0%	70.8%			
	5 Years	51.8%	50.5%	54.2%			
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS			


Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

LIP, ORAL CAVITY AND PHARYNYX CANCER

LIP, ORAL CAVITY AND PHARYNX CANCER

GENERAL PROFILE⁴

Figure 127. Anatomy of the Oral Cavity⁵



General Anatomy: The oral cavity includes many parts: the lips; the lining inside the lips and cheeks, called the buccal mucosa; the teeth; the bottom (floor) of the mouth under the tongue; the front two-thirds of the tongue; the bony top of the mouth (hard palate); the gums; and the small area behind the wisdom teeth. The oropharynx includes the back one-third of the tongue, the soft palate, the tonsils, and the part of the throat behind the mouth. Salivary glands throughout the oral cavity make saliva, which keeps the mouth moist and helps digest food.

Risk Factors: Tobacco use (especially smokeless tobacco), chronic and/or heavy alcohol use, sun exposure (Lip), history of leukoplakia (whitish patch inside the mouth associated with tobacco use), and erythroplakia (reddish patches usually in those over 60 years old)

Signs and Symptoms: Oral cancer usually occurs in people over the age of 45 but can develop at any age. These are some symptoms to watch for: A sore on the lip or in the mouth that does not heal, a lump on the lip or in the mouth or throat, a white or red patch on the gums, tongue, or lining of the mouth, unusual bleeding, pain, or numbness in the mouth, a sore throat that does not go away, or a feeling that something is caught in the throat, difficulty or pain with chewing or swallowing, swelling of the jaw that causes dentures to fit poorly or become uncomfortable, a change in the voice, and/or, pain in the ear.

Diagnosing the Cancer: Health exam, dental x-rays, head and chest x-rays, computed tomography (CAT) scan, ultrasonography, magnetic resonance imaging (MRI).

Treatment: Surgery, radiation therapy, chemotherapy, and clinical trials.

HIGHLIGHTS

- The ratio of the age-adjusted incidence rate, 10.85, to the age-adjusted mortality rate, 3.75 (per 100,000 – 2000 US Standard population), for Lip, Oral Cavity and Pharynx Cancer was 3.75 during the 2000 to 2004 period, which means that for every 100 deaths due to this type of cancer there were 375 cases in Nevada of Lip, Oral Cavity and Pharynx Cancer during this period.
- Nevadan males had a higher ratio (3.73) than females (3.60) when the incidence and mortality age-adjusted rates for Lip, Oral Cavity and Pharynx Cancer were compared. This means that for every 100 deaths due to Lip, Oral Cavity and Pharynx Cancer there would be 373 male cases while only 360 cases for every female death for the 2000 to 2004 period.
- The median age at diagnosis of Lip, Oral Cavity and Pharynx Cancer for Nevada residents was 62 years of age from 2000 to 2004 while the median age for males and females was 61 and 65 years, respectively. The median age at time of death due to Lip, Oral Cavity and Pharynx Cancer was 69 years statewide, 67 years of age for males and 72 years of age for females.

INCIDENCE

- Nevada's incidence rate for Lip, Oral Cavity and Pharynx Cancer 10.8 was slightly higher than the national rate of 10.5 (per 100,000 – 2000 US Standard population) from 2000 to 2004.
- The statistically significant age-adjusted incidence rate for male Lip, Oral Cavity and Pharynx Cancer, 16.1 (15.0-17.3), was more than double the rate for females, 6.0 (5.3-6.7), per 100,000 – 2000 US Standard population, during the 2000 to 2004 period.
- Regional comparisons showed that Clark County's age-adjusted incidence rate for Lip, Oral Cavity and Pharynx Cancer, 11.1, was slightly higher than the rates for Washoe County and All Other Counties who had rates of 10.6 and 10.0 (per 100,000 – 2000 US Standard population) from 2000 to 2004.
- Whites, as a racial/ethnic group, had the highest age-adjusted incidence rate, 11.8, for Lip, Oral Cavity and Pharynx Cancer during the 2000 to 2004 period and were followed by Blacks, Asians and Hispanics with rates of 8.5, 6.7 and 4.0 (per 100,000 – 2000 US Standard population), respectively.

INPATIENT HOSPITAL DISCHARGES

There were 526 Lip, Oral Cavity and Pharynx Cancer inpatient discharges in Nevada from 2000 to 2004. The statistically significant age-adjusted inpatient discharge rate for males, 5.7 (4.1-7.9), was almost twice the inpatient discharge rate for females, 2.9 (2.4-3.5), per 100,000 – 2000 US Standard population, in Nevada during this period.

- Total billed charges for hospital inpatient discharges from Lip, Oral Cavity and Pharynx Cancer in Nevada totaled 23.1 million dollars from 2000 to 2004. Clark County had the highest median total charge (\$25,921), while Washoe County had the longest average length of stay (7.1 days) during this time; once regional comparisons were made.
- The overall average billed charge per day for a inpatient hospital discharge for Lip, Oral Cavity and Pharynx Cancer in Nevada was approximately \$6,480 from 2000 to 2004.

MORTALITY


- There were 296 deaths due to Lip, Oral Cavity and Pharynx Cancer in Nevada from 2000 to 2004. While the All Other Counties region had the highest age-adjusted mortality rate, 3.2, and was followed by Clark County and Washoe County with rates of 3.0 and 2.2, respectively, statistical analysis shows that there is not a statistically significant difference between the three regions.
- Males had a statistically significant higher age-adjusted mortality rate due to Lip, Oral Cavity and Pharynx Cancer, 4.3 (3.7-5.0), than their female counterparts who had an ageadjusted mortality rate of 1.7 (1.3-2.1) (per 100,000 – 2000 US Standard population) during the 2000 to 2004 period.

SURVIVAL RATE


- Females had a slightly higher one-year survival rate (80.0%) than males (78.8%) for Lip, Oral Cavity and Pharynx Cancer in Nevada from 2000 to 2004. This difference maintained out to the five-year survival rate where females had a higher rate at 59.8% and males with a rate of 57.5% during this period.
- The one-year survival rate for those diagnosed with Lip, Oral Cavity and Pharynx Cancer at the localized stage was 90.6% for Nevada from 2000 to 2004, while those recorded at the regional, distant and unstaged stages had rates of 78.5%, 46.1% and 78.2%, respectively.
- The five-year survival rate for those diagnosed with Lip, Oral Cavity and Pharynx Cancer at the localized stage was 78.8% for Nevada from 2000 to 2004, while those recorded at the regional, distant and unstaged stages had rates of 56.3%, 27.7% and 46.1%, respectively.

INCIDENCE

Figure 128. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 130. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 192. Lip, Oral Cavity and Pharynx Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)		
Total								
Cases	1,171	820	182	168	1	37,869		
Rate*	10.8	11.1	10.6	10.0		10.5		
95% C.I.	(10.2-11.5)	(10.3-11.9)	(9.1-12.3)	(8.6-11.7)		(10.4-10.6)		
Gender								
Male	846	617	115	113	1	25,795		
Rate*	16.1	17.2	13.9	13.4		15.7		
95% C.I.	(15.0-17.3)	(15.8-18.8)	(11.4-17.1)	(11.0-16.3)		(15.5-15.9)		
Female	325	203	67	55	0	12,074		
Rate*	6.0	5.4	7.7	6.6		6.1		
95% C.I.	(5.3-6.7)	(4.7-6.2)	(5.9-9.8)	(5.0-8.7)		(6.0-6.2)		
Other/Unknown	0	0	0	0	0	0		
Race/Ethnicity								
White	1,006	671	172	162	1	31,197		
Rate*	11.8	12.0	11.7	10.8		10.6		
95% C.I.	(11.1-12.5)	(11.1-13.0)	(10.0-13.7)	(9.2-12.6)		(10.5-10.7)		
Black	49	44	5	0	0	3,685		
Rate*	8.5	8.2				11.2		
95% C.I.	(6.2-11.8)	(5.9-11.6)				(10.8-11.6)		
Native American	2	0	2	0	0	194		
Rate*						5.6		
95% C.I.						(4.8-4.8)		
Asian	35	34	0	1	0	2,413		
Rate*	6.7	8.1				7.9		
95% C.I.	(4.3-10.9)	(5.1-13.7)				(7.6-8.2)		
Hispanic	40	34	3	3	0	2,484		
Rate*	4.0	4.5				6.2		
95% C.I.	(2.7-5.8)	(2.9-6.8)				(6.0-6.5)		
Other/Unknown	39	37	0	2	0	380		

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the national (SEER) rates. See Technical Notes for more information.

Table 193. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)			
Total									
Cases	1,171	820	182	168	1	37,869			
Rate*	10.8	11.1	10.6	10.0		10.5			
95% C.I.	(10.2-11.5)	(10.3-11.9)	(9.1-12.3)	(8.6-11.7)		(10.4-10.6)			
Age Group									
<1	0	0	0	0	0	2			
Rate*						0.0			
95% C.I.						(0.0-0.1)			
1-4	0	0	0	0	0	11			
Rate*						0.1			
95% C.I.						(0.0-0.1)			
5-14	4	3	0	1	0	85			
Rate*						0.2			
95% C.I.						(0.1-0.2)			
15-24	7	4	3	0	0	263			
Rate*						0.5			
95% C.I.						(0.4-0.6)			
25-34	15	11	2	2	0	791			
Rate*	0.9	0.9				1.5			
95% C.I.	(0.46-1.40)	(0.38-1.46)				(1.4-1.6)			
35-44	68	55	8	5	0	2,729			
Rate*	4.0	4.6				4.6			
95% C.I.	(3.04-4.94)	(3.37-5.79)				(4.4-4.7)			
45-54	222	151	41	29	1	7,784			
Rate*	14.9	15.0	15.6	13.0		15.0			
95% C.I.	(12.91-16.82)	(12.59-17.37)	(10.85-20.43)	(8.26-17.70)		(14.7-15.4)			
55-64	355	251	54	50	0	9,328			
Rate*	32.5	33.4	31.1	30.0		28.2			
95% C.I.	(29.14-35.90)	(29.27-37.53)	(22.80-39.38)	(21.72-38.37)		(27.6-28.8)			
65-74	304	215	40	49	0	8,421			
Rate*	42.4	43.5	37.5	42.4		38.6			
95% C.I.	(37.64-47.18)	(37.65-49.27)	(25.91-49.18)	(30.53-54.27)		(37.7-39.4)			
75-84	160	108	25	27	0	6,308			
Rate*	38.9	38.6	39.5	39.8		41.1			
95% C.I.	(32.90-44.96)	(31.32-45.88)	(24.00-54.96)	(24.78-54.80)		(40.1-42.1)			
85+	36	22	9	5	0	2,147			
Rate*	37.9	36.1				38.9			
95% C.I.	(25.51-50.27)	(21.04-51.24)				(37.2-40.5)			
Unknown	0	0	0	0	0	0			

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 194. Lip, Oral Cavity and Pharynx Cancer Cases by County of Residence at
Diagnosis, Nevada Residents, 2000-2004

County of	2000-2004 Incidence							
Residence	Cases	Rat	te*	Age-Adjusted Rate**				
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	39	15.3	(10.5-20.0)	12.9	(9.2-17.8)			
Churchill	21	16.8	(9.6-24.0)	16.6	(10.3-25.5)			
Clark	820	10.7	(9.9-11.4)	11.1	(10.3-11.9)			
Douglas	17	7.7	(4.0-11.3)	5.6	(3.2-9.4)			
Elko	8							
Esmeralda	1							
Eureka	2							
Humboldt	5							
Lander	2							
Lincoln	4							
Lyon	31	15.8	(10.3-21.4)	12.9	(8.7-18.5)			
Mineral	3							
Nye	26	14.8	(9.1-20.4)	9.5	(6.1-14.6)			
Pershing	2							
Storey	1							
Washoe	182	10.1	(8.7-11.6)	10.6	(9.1-12.3)			
White Pine	6							
Unknown	1							
Total	1,171	10.7	(10.1-11.3)	10.8	(10.2-11.5)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 195. Lip, Oral Cavity and Pharynx Cancer Cases by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004

			nder		
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total
White	Incidence	725	281	0	1,006
	Rate*	17.3	6.5		11.8
	95% C.I.	(16.0-18.6)	(5.8-7.4)		(11.1-12.5)
Black	Incidence	33	16	0	49
	Rate*	12.5	5.4		8.5
	95% C.I.	(8.1-19.9)	(3.0-9.1)		(6.2-11.8)
Native	Incidence	2	0	0	2
American	Rate*				
	95% C.I.				
Asian	Incidence	23	12	0	35
	Rate*	11.5	3.3		6.7
_	95% C.I.	(6.5-21.6)	(1.7-5.8)		(4.3-10.9)
Hispanic	Incidence	31	9	0	40
	Rate*	6.4			4.0
_	95% C.I.	(4.0-10.0)			(2.7-5.8)
Other/Unknown		32	7	0	39
Total	Incidence	846	325	0	1,171
	Rate*	16.1	6.0		10.8
	95% C.I.	(15.0-17.3)	(5.3-6.7)		(10.2-11.5)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 196. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and
Gender, Nevada Residents, 2000-2004

Age	Gender						
Group	Male	Female	Unknown	Total			
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.			<u> </u>	<u> </u>			
5-14	3	1	0	4			
Rate*							
95% C.I.							
15-24	3	4	0	7			
Rate*							
95% C.I.							
25-34	10	5	0	15			
Rate*	1.19			0.93			
95% C.I.	(0.45-1.92)			(0.46-1.40)			
35-44	46	22	0	68			
Rate*	5.20	2.68		3.99			
95% C.I.	(3.69-6.70)	(1.56-3.80)		(3.04-4.94)			
45-54 Rate*	172	50	0	222			
95% C.I.	22.72 (19.33-26.12)	6.79 (4.91-8.67)		14.87 (12.91-16.82)			
55-64		<i>,</i>					
Rate*	277 51.47	78 14.09	0	355 32.52			
95% C.I.	(45.41-57.53)	(10.97-17.22)		(29.14-35.90)			
65-74	215	89	0	304			
Rate*	60.85	24.48		42.41			
95% C.I.	(52.72-68.99)	(19.40-29.57)		(37.64-47.18)			
75-84	98	62	0	160			
Rate*	52.78	27.52		38.93			
95% C.I.	(42.33-63.23)	(20.67-34.36)		(32.90-44.96)			
85+	22	14	0	36			
Rate*	69.25	22.14		37.89			
95% C.I.	(40.31-98.19)	(10.54-33.73)		(25.51-50.27)			
Unknown	0	0	0	0			
Total	846	325	0	1,171			
Rate*	15.22	6.04		10.70			
95% C.I.	(14.2-16.2)	(5.4-6.7)		(10.1-11.3)			

* Rates are per 100,000 age-specific population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 197. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and Stage,
Nevada Residents, 2000-2004

A	0	Stage					
Age	Age Group		Localized	Regional	Distant	Unstaged	Total
<1	Number		0	0	0	0	0
	Percent						
1-4	Number		0	0	0	0	0
	Percent						
5-14	Number		2	2	0	0	4
	Percent		50.0%	50.0%			100.0%
15-24	Number		2	3	0	2	7
	Percent		28.6%	42.9%		28.6%	100.0%
25-34	Number		5	4	0	6	15
	Percent		33.3%	26.7%		40.0%	100.0%
35-44	Number		24	21	5	18	68
	Percent		35.3%	30.9%	7.4%	26.5%	100.0%
45-54	Number		59	83	15	65	222
	Percent		26.6%	37.4%	6.8%	29.3%	100.0%
55-64	Number		107	124	35	89	355
	Percent		30.1%	34.9%	9.9%	25.1%	100.0%
65-74	Number		80	107	22	95	304
	Percent		26.3%	35.2%	7.2%	31.3%	100.0%
75-84	Number		45	46	14	55	160
	Percent		28.1%	28.8%	8.8%	34.4%	100.0%
85+	Number		7	10	1	18	36
	Percent		19.4%	27.8%	2.8%	50.0%	100.0%
Unknown	Number		0	0	0	0	0
	Percent						
Total	Number Percent		331 28.3%	400 34.2%	92 7.9%	348 29.7%	1,171 100.0%

Table 198. Lip, Oral Cavity and Pharynx Cancer Cases by Stage and
Race/Ethnicity, Nevada Residents, 2000-2004

			Race/Ethnicity								
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total			
In situ	Number										
	Percent										
Localized	Number	287	11	0	12	11	10	331			
	Percent	28.5%	22.4%		34.3%	27.5%	25.6%	28.3%			
Regional	Number	351	19	0	10	14	6	400			
	Percent	34.9%	38.8%		28.6%	35.0%	15.4%	34.2%			
Distant	Number	79	5	0	5	3	0	92			
	Percent	7.9%	10.2%	<u> </u>	14.3%	7.5%		7.9%			
Unstaged	Number	289	14	2	8	12	23	348			
	Percent	28.7%	28.6%	100.0%	22.9%	30.0%	59.0%	29.7%			
Total	Number	1,006	49	2	35	40	39	1,171			
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%			


Table 199. Median Age at Diagnosis of Lip, Oral Cavity and Pharynx Cancer by
Race/Ethnicity and Gender, Nevada Residents, 2000-2004

	Gender								
Race/Ethnicity	Male		Fem	nale	Total				
	Cases	Median Age	Cases	Median Age	Cases	Median Age			
White	725	62.0	281	65.0	1,006	63.0			
Black	33	62.0	16	62.0	49	62.0			
Native American	2		0		2				
Asian	23	56.0	12	55.0	35	56.0			
Hispanic	31	56.0	9	45.0	40	51.5			
Other/Unknown	32	58.5	7	58.0	39	58.0			
Total	846	61.0	325	65.0	1,171	62.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 131. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical Notes for more information.

Figure 132. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 2000-2004






Figure 133. Median Charges for Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 2000-2004








Table 200. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown				
Total									
Discharges	526	371	82	72	1				
Rate*	4.8	4.9	4.8	4.2					
95% C.I.	(4.4-5.2)	(4.4-5.4)	(3.8-6.0)	(3.3-5.3)					
Gender									
Male	362	259	48	54	1				
Rate*	6.7	7.0	5.7	6.1					
95% C.I.	(6.0-7.4)	(6.1-8.0)	(4.1-7.9)	(4.5-8.0)					
Female	164	112	34	18	0				
Rate*	3.0	2.9	3.9	2.2					
95% C.I.	(2.5-3.5)	(2.4-3.5)	(2.7-5.5)	(1.3-3.5)					
Other/Unknown	0	0	0	0	0				
Inpatient Discharge Ch	narges (\$)								
Total Charges	\$23,050,151	\$17,108,903	\$3,326,185	\$2,597,955	\$17,108				
Average Charges	\$43,822	\$46,116	\$40,563	\$36,083	\$17,108				
Median Charges	\$25,322	\$25,921	\$25,633	\$21,410	\$17,108				
Discharge Length of S	tay (LOS) (Days)								
Total LOS	3,557	2,552	581	423	1				
Average LOS	6.8	6.9	7.1	5.9	1.0				
Median LOS	4.0	4.0	4.0	3.0	1.0				

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 201. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by AgeGroup and County/Region of Residence, Nevada Residents, 2000-2004

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Discharges	526	371	82	72
Rate*	4.8	4.8	4.6	5.0
95% C.I.	(4.4-5.2)	(4.3-5.3)	(3.6-5.6)	(3.8-6.1)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	1	1	0	0
Rate*				
95% C.I.				
5-14	2	2	0	0
Rate*				
95% C.I.				
15-24	3	2	1	0
Rate*				
95% C.I.				
25-34	4	4	0	0
Rate*				
95% C.I.				
35-44	34	24	8	2
Rate*	2.0	2.0		
95% C.I.	(1.32-2.66)	(1.20-2.80)		
45-54	93	62	12	19
Rate*	6.2	6.2	4.6	8.5
95% C.I.	(4.96-7.49)	(4.62-7.68)	(1.99-7.17)	(4.68-12.33)
55-64	178	124	25	29
Rate*	16.3	16.5	14.4	17.4
95% C.I.	(13.91-18.70)	(13.59-19.40)	(8.75-20.04)	(11.08-23.77)
65-74	141	108	19	13
Rate*	19.7	21.8	17.8	11.3
95% C.I.	(16.42-22.92)	(17.71-25.95)	(9.81-25.85)	(5.13-17.36)
75-84	62	40	14	8
Rate*	15.1	14.3	22.1	
95% C.I.	(11.33-18.84)	(9.87-18.73)	(10.53-33.69)	
85+	8	4	3	1
Rate*				
95% C.I.				
Unknown	0	0	0	0

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 202. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by AgeGroup and Gender, Nevada Residents, 2000-2004

Age	Gender						
Group	Male	Female	Total				
<1	0	0	0				
Rate*							
95% C.I.							
1-4	1	0	1				
Rate*							
95% C.I.							
5-14	1	1	2				
Rate*							
95% C.I.							
15-24	1	2	3				
Rate*							
95% C.I.							
25-34	4	0	4				
Rate*							
95% C.I.							
35-44	24	10	34				
Rate*	2.71	1.22	1.99				
95% C.I.	(1.63-3.80)	(0.46-1.98)	(1.32-2.66)				
45-54	75	18	93				
Rate*	9.91	2.44	6.23				
95% C.I.	(7.67-12.15)	(1.32-3.57)	(4.96-7.49)				
55-64	133	45	178				
Rate*	24.71	8.13	16.31				
95% C.I.	(20.51-28.91)	(5.75-10.51)	(13.91-18.70)				
65-74	93	48	141				
Rate*	26.32	13.20	19.67				
95% C.I.	(20.97-31.67)	(9.47-16.94)	(16.42-22.92)				
75-84	24	38	62				
Rate*	12.93	16.86	15.09				
95% C.I.	(7.75-18.10)	(11.50-22.23)	(11.33-18.84)				
85+	6	2	8				
Rate*							
95% C.I.							
Unknown	0	0	0				
Total Rate*	362	164	526				
95% C.I.	6.51 (5.8-7.2)	3.05 (2.6-3.5)	4.81 (4.4-5.2)				
5576 0.1.	(0.0-7.2)	(2.0-3.3)	(+.+-3.2)				

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 203. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by
County/Region of Residence, Nevada Residents, 2000-2004

0	2000-2004 Inpatient Hospital Discharges							
County of Residence	Casas	Ra	te*	Age-Adjus	ted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	14	5.5	(2.6-8.3)	4.6	(2.5-7.7)			
Churchill	6							
Clark	371	4.8	(4.3-5.3)	4.9	(4.4-5.4)			
Douglas	5							
Elko	3							
Esmeralda	0							
Eureka	0							
Humboldt	10	12.4	(4.7-20.0)	11.6	(5.4-23.8)			
Lander	0							
Lincoln	0							
Lyon	17	8.7	(4.6-12.8)	6.9	(4.0-11.1)			
Mineral	2							
Nye	12	6.8	(3.0-10.7)	4.5	(2.3-8.2)			
Pershing	0							
Storey	2							
Washoe	82	4.6	(3.6-5.6)	4.8	(3.8-6.0)			
White Pine	1							
Unknown	1							
Total	526	4.8	(4.4-5.2)	4.8	(4.4-5.2)			


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 204. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by AgeGroup, Charges and Length of Stay, Nevada Residents, 2000-2004


Age	Discharges	(Charges (\$)		Len	gth of Stay (Da	ays)
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	1						
5-14	2						
15-24	3						
25-34	4						
35-44	34	1,185,901	34,879	23,664	201	5.9	3.5
45-54	93	3,986,681	42,868	24,849	592	6.4	4.0
55-64	178	8,416,354	47,283	26,145	1,434	8.1	4.0
65-74	141	6,895,896	48,907	30,936	926	6.6	4.0
75-84	62	2,098,619	33,849	20,942	305	4.9	3.0
85+	8						
Unknown	0						
Total	526	23,050,151	43,822	25,322	3,557	6.8	4.0

MORTALITY

Figure 135. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.







Figure 137. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 2000-2004



	County/Region of Residence							
Category	Nevada Total	Total Clark Washoe		All Other Counties				
Total								
Mortality	296	209	36	51				
Rate*	2.9	3.0	2.2	3.2				
95% C.I.	(2.6-3.3)	(2.6-3.4)	(1.6-3.2)	(2.3-4.2)				
Gender								
Male	209	147	24	38				
Rate*	4.3	4.5	3.1	4.7				
95% C.I.	(3.7-5.0)	(3.8-5.5)	(2.0-5.0)	(3.3-6.8)				
Female	87	62	12	13				
Rate*	1.7	1.7	1.4	1.6				
95% C.I.	(1.3-2.1)	(1.3-2.2)	(0.7-2.5)	(0.9-2.8)				
Other/Unknown	0	0	0	0				
Race/Ethnicity								
White	259	178	31	50				
Rate*	3.1	3.2	2.2	3.4				
95% C.I.	(2.7-3.5)	(2.8-3.8)	(1.5-3.2)	(2.5-4.6)				
Black	18	17	1	0				
Rate*	3.6	3.6						
95% C.I.	(2.1-6.2)	(2.0-6.4)						
Native American	1	0	1	0				
Rate*								
95% C.I.								
Asian	10	10	0	0				
Rate*	2.5	3.1						
95% C.I.	(0.9-6.3)	(1.1-8.3)						
Hispanic	7	4	3	0				
Rate*								
95% C.I.								
Other/Unknown	1	0	0	1				

Table 205. Lip, Oral Cavity and Pharynx Cancer Mortality by Gender,Race/Ethnicity and County/Region of Residence, Nevada Residents, 2000-2004

*Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 206. Lip, Oral Cavity and Pharynx Cancer Mortality by Age Group and
County/Region of Residence, Nevada Residents, 2000-2004

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties					
Total									
Deaths	296	209	36	51					
Rate*	2.9	3.0	2.2	3.2					
95% C.I.	(2.6-3.3)	(2.6-3.4)	(1.6-3.2)	(2.3-4.2)					
Age Group									
<1	0	0	0	0					
Rate*									
95% C.I.									
1-4	0	0	0	0					
Rate*									
95% C.I.									
5-14	0	0	0	0					
Rate*									
95% C.I.									
15-24	1	1	0	0					
Rate*									
95% C.I.									
25-34	2	2	0	0					
Rate*									
95% C.I.									
35-44	5	5	0	0					
Rate*									
95% C.I.									
45-54	31	22	2	7					
Rate*	2.1	2.2							
95% C.I.	(1.35-2.81)	(1.27-3.10)							
55-64	73	50	10	13					
Rate*	6.7	6.7	5.8	7.8					
95% C.I.	(5.15-8.22)	(4.81-8.50)	(2.19-9.33)	(3.56-12.06)					
65-74	95	71	11	13					
Rate*	13.3	14.4	10.3	(5.42.47.20)					
95% C.I.	(10.59-15.92)	(11.01-17.69)	(4.22-16.43)	(5.13-17.36)					
75-84	69 16 8	45	11	13					
Rate*	(12 82 20 75)	16.1 (11.38-20.78)	(7 11 27 64)	(8 74 20 57)					
95% C.I.	(12.83-20.75)		(7.11-27.64)	(8.74-29.57)					
85+ Poto*	20	13	2	5					
Rate*	21.1	21.4							
95% C.I.	(11.82-30.28)	(9.75-32.96)							
Unknown	0	0	0	0					

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 207. Lip, Oral Cavity and Pharynx Cancer Mortality by County ofResidence, Nevada Residents, 2000-2004

County of	2000-2004 Mortality							
Residence	Cases	Rat	te*	Age-Adjus	ted Rate**			
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	12	4.7	(2.0-7.3)	3.9	(2.0-6.9)			
Churchill	2							
Clark	209	2.7	(2.3-3.1)	3.0	(2.6-3.4)			
Douglas	2							
Elko	3							
Esmeralda	0							
Eureka	0							
Humboldt	3							
Lander	0							
Lincoln	2							
Lyon	7							
Mineral	1							
Nye	11	6.2	(2.6-9.9)	4.3	(2.1-8.0)			
Pershing	1							
Storey	3							
Washoe	36	2.0	(1.4-2.7)	2.2	(1.6-3.2)			
White Pine	4							
Unknown	0							
Total	296	2.7	(2.4-3.0)	2.9	(2.6-3.3)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 208. Lip, Oral Cavity and Pharynx Cancer Mortality by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004

		Gender					
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total		
White	Incidence	188	71	0	259		
	Rate*	4.7	1.7		3.1		
	95% C.I.	(4.0-5.5)	(1.3-2.1)		(2.7-3.5)		
Black	Incidence	10	8	0	18		
	Rate*	3.5			3.6		
	95% C.I.	(1.7-7.0)			(2.1-6.2)		
Native	Incidence	1	0	0	1		
American	Rate*						
	95% C.I.						
Asian	Incidence	5	5	0	10		
	Rate*				2.5		
	95% C.I.				(0.9-6.3)		
Hispanic	Incidence	5	2	0	7		
	Rate*						
	95% C.I.						
Other/Unkr	nown	0	1	0	1		
Total	Incidence	209	87	0	296		
	Rate*	4.3	1.7		2.9		
	95% C.I.	(3.7-5.0)	(1.3-2.1)		(2.6-3.3)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 209. Lip, Oral Cavity and Pharynx Cancer Mortality by Age Group and
Gender, Nevada Residents, 2000-2004

Age		Gender	
Group	Male	Female	Total
<1	0	0	0
Rate*			
95% C.I.			
1-4	0	0	0
Rate*			
95% C.I.			
5-14	0	0	0
Rate*			
95% C.I.			
15-24	1	0	1
Rate*			
95% C.I.			
25-34	1	1	2
Rate*			
95% C.I.			
35-44	3	2	5
Rate* 95% C.I.			
45-54	22		31
45-54 Rate*	22 2.91	9	2.08
95% C.I.	(1.69-4.12)		(1.35-2.81)
55-64	62	11	73
Rate*	11.52	1.99	6.69
95% C.I.	(8.65-14.39)	(0.81-3.16)	(5.15-8.22)
65-74	69	26	95
Rate*	19.53	7.15	13.25
95% C.I.	(14.92-24.14)	(4.40-9.90)	(10.59-15.92)
75-84	38	31	69
Rate*	20.47	13.76	16.79
95% C.I.	(13.96-26.97)	(8.91-18.60)	(12.83-20.75)
85+	13	7	20
Rate*	40.92		21.05
95% C.I.	(18.68-63.17)		(11.82-30.28)
Unknown	0	0	0
Total	209	87	296
Rate*	3.76	1.62	2.71
95% C.I.	(3.3-4.3)	(1.3-2.0)	(2.4-3.0)

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.


Table 210. Median Age at Death from Lip, Oral Cavity and Pharynx Cancer by
Race/Ethnicity and Gender, Nevada Residents, 2000-2004

			Gen	der		
Race/Ethnicity	Male		Fem	ale	Total	
	Cases	Median Age	Cases	Median Age	Cases	Median Age
White	188	67.5	71	74.0	259	70.0
Black	10	58.5	8	76.5	18	64.0
Native American	1		0		1	
Asian	5	59.0	5	48.0	10	53.5
Hispanic	5	60.0	2		7	63.0
Other/Unknown	0		1		1	
Total	209	67.0	87	72.0	296	69.0

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE





Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 139. Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 2000-2004




Table 211. Cause-Specific Survival Rates for Lip, Oral Cavity and Pharynx Cancerby Race/Ethnicity and Gender, Nevada Residents, 2000-2004

Race/		Cause Specific Survival Rate					Median
Ethnicity and Gender	of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	950	79.1%	71.0%	65.0%	62.2%	58.1%	> 5 YEARS
Male	689	78.8%	70.1%	63.5%	60.6%	57.5%	> 5 YEARS
Female	261	80.0%	73.2%	68.8%	66.5%	59.8%	> 5 YEARS
Race/Ethnicity							
White	806	79.0%	71.6%	65.3%	62.5%	59.1%	> 5 YEARS
Male	585	78.4%	70.3%	63.4%	60.6%	58.9%	> 5 YEARS
Female	221	80.8%	75.3%	70.3%	67.7%	60.2%	> 5 YEARS
Black	42						
Male	28						
Female	14						•
Native American	1						
Male	1						
Female	0						
Asian	33						
Male	21						
Female	12						
Hispanic	34						
Male	26						
Female	8						<u> </u>

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 212. Cause-Specific Survival Rates for Lip, Oral Cavity and Pharynx Cancerby Stage of Cancer at Diagnosis and Gender, Nevada Residents, 2000-2004

Surviv	al Rate of Stage		Gender					
a	t Diagnosis	Total	Male	Female				
Total	Cases	950	689	261				
	One Year	79.1%	78.8%	80.0%				
	5 Years	58.1%	57.5%	59.8%				
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS				
Stage at Di	iagnosis							
In situ	Cases							
	One Year							
	5 Years							
	Median Survival							
Localized	Cases	267	184	83				
	One Year	90.6%	91.5%	88.8%				
	5 Years	78.8%	83.8%	71.3%				
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS				
Regional	Cases	335	249	86				
	One Year	78.5%	76.7%	83.5%				
	5 Years	56.3%	53.8%	63.1%				
	Median Survival	> 5 YEARS	> 5 YEARS	> 5 YEARS				
Distant	Cases	77	59	18				
	One Year	46.1%	46.6%					
	5 Years	27.7%	27.1%					
	Median Survival	0.93	0.94					
Unstaged	Cases	271	197	74				
	One Year	78.2%	79.8%	73.7%				
	5 Years	46.1%	44.6%	50.0%				
	Median Survival	4.72	4.58	5.00				


Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

LEUKEMIA

LEUKEMIA

GENERAL PROFILE⁴

Figure 140. Anatomy of Stem Cell Maturation



General Anatomy: Blood cells form in the bone marrow, which is the soft material in the center of most bones. Immature blood cells are called stem cells and blasts. Most blood cells mature in the bone marrow and then move into the blood vessels. The bone marrow makes different types of blood cells; each with a special function: White blood cells fight infection, red blood cells carry oxygen to body tissues, and platelets help form blood clots to speed healing. In people with leukemia, the bone marrow produces abnormal white blood cells. At first, leukemia cells function almost normally. In time, they may crowd out normal white blood cells, red blood cells, and platelets.

Risk Factors: Very high levels of radiation, working with certain chemicals (e.g. Benzene, Formaldehyde), chemotherapy, down syndrome, human T-cell leukemia virus-I (HTLV-I), and myelodysplastic syndrome.

Signs and Symptoms: Fevers or night sweats, frequent infections, feeling weak or tired, headache, bleeding and bruising easily (bleeding gums, purplish patches in the skin, or tiny red spots under the skin), pain in the bones or joints, swelling or discomfort in the abdomen (from an enlarged spleen), swollen lymph nodes, especially in the neck or armpit, and weight loss.

Diagnosing the Cancer: Health exams, blood tests (High level of white blood cells, low levels of red blood cells and platelets), bone marrow aspiration, bone marrow biopsy, cytogenetics, spinal tap, and chest x-ray.

Treatment: chemotherapy (intrathecal), biological therapy, radiation therapy, or stem cell transplantation (Bone Marrow, Peripheral stem cell and Umbilical cord blood transplantations).

HIGHLIGHTS

- The ratio of the age-adjusted incidence rate, 12.0, to the age-adjusted mortality rate, 7.3 (per 100,000 2000 US Standard population), for Leukemia in Nevada was 1.6 during the 2000 to 2004 period, which means that for every 164 Leukemia cases there was 100 deaths due to Leukemia in Nevada during this period.
- Nevadan females had a higher ratio (1.76) than males (1.57) when the incidence and mortality age-adjusted rates for Leukemia were compared. This means that for every 100 deaths due to Leukemia there was 176 female cases while only 157 cases for every male death during the 2000 to 2004 period.
- The median age at diagnosis of Leukemia for Nevadans was 67 years of age from 2000 to 2004. The median age at time of death due to Leukemia during this period was 72 years.

INCIDENCE

- There were 1,201 cases of Leukemia in Nevada from 2000 to 2004. While regional comparisons showed Clark County (13.3) as having a higher incidence rate than All Other Counties (10.0), Washoe County (8.4) and the national incidence rate 12.3 (per 100,000 2000 US Standard population) from 2000 to 2004, statistical analysis shows a significant difference only for the Washoe County region.
- The age-adjusted incidence rate for male Leukemia, 14.9 (13.8-16.2), was statistically significant over the rate for females, 9.6 (8.7-10.5), during the 2000 to 2004 period.
- Whites, as a racial/ethnic group had the highest age-adjusted incidence rate, (12.5), from Leukemia of all racial/ethnic groups during the 2000 to 2004 period. They were followed by Blacks, Asians and Hispanics with rates of 9.0, 7.7, and 6.7 (per 100,000 – 2000 US Standard population), respectively, during this period.

INPATIENT HOSPITAL DISCHARGES

- Statistical regional comparisons indicate that Clark County had the highest age-adjusted inpatient discharge rate for Leukemia, 10.8 (10.0-11.6), and was followed by All Other Counties, 8.5 (7.1-10.1), and Washoe County, 8.0 (6.7-9.5), (per 100,000 – 2000 US Standard population) from 2000 to 2004.
- Clark County had by far the highest median total charge (\$47,611) for Leukemia inpatient hospital discharges during the 2000 to 2004 period and was followed by Washoe County (\$22,628) and All Other Counties (\$22,518). This was similar to the average length of stay (days) where Clark County had a value of 14.7 days, while All Other Counties, as a region, and Washoe County had average values of 11.6 and 10.4 days, respectively.

Total billed charges for Leukemia inpatient hospital discharges in Nevada totaled 91.9 million dollars from 2000 to 2004. The overall average billed charge per day for a hospital inpatient discharge due to Leukemia was approximately \$6,421 in Nevada during this period.

MORTALITY


- There were 699 resident deaths due to Leukemia from 2000 to 2004. Regional comparisons were fairly similar between All Other Counties, Washoe County and Clark County with rates of 8.1, 7.4 and 7.2 (per 100,000 2000 US Standard population), respectively.
- Males had a statistically significant higher age-adjusted mortality rate due to Leukemia, 9.5 (8.6-10.6), than their female counterparts who had an age-adjusted mortality rate of 5.4 (4.8-6.1) (per 100,000 – 2000 US Standard population) during the 2000 to 2004 period.

SURVIVAL RATE

- The one-year survival rate for Leukemia in Nevada was 62.3% during the 2000 to 2004 period, while the five-year survival rate was 43.4% during this same time. The median survival rate in Nevada was 3.20 years for Leukemia for this period.
- Females had a slightly higher one-year survival rate (63.7%) than males (61.4%) for Leukemia in Nevada from 2000 to 2004. This difference increased at the five-year survival rate where females had a higher rate at 46.5% and males with a rate of 42.3% during this period.
- Nevadan males' median survival time for Leukemia was 3.09 years versus 3.32 years for their female counterparts during the 2000 to 2004 period.

INCIDENCE

Figure 141. Leukemia Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 143. Leukemia Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 213. Leukemia Cases by Gender, Race/Ethnicity and County/Region ofResidence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

			County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)			
Total									
Cases	1,201	910	136	153	2	44,045			
Rate*	12.0	13.3	8.4	10.0		12.3			
95% C.I.	(11.3-12.7)	(12.5-14.3)	(7.0-10.0)	(8.4-12.5)		(12.2-12.4)			
Gender									
Male	700	528	70	100	2	25,145			
Rate*	14.9	16.8	9.2	13.3		16.0			
95% C.I.	(13.8-16.2)	(15.3-18.5)	(7.1-11.9)	(10.5-17.7)		(15.8-16.2)			
Female	500	382	66	52	0	18,900			
Rate*	9.6	10.6	7.8	6.7		9.5			
95% C.I.	(8.7-10.5)	(9.6-11.8)	(6.0-10.2)	(5.0-8.8)		(9.4-9.7)			
Other/Unknown	1	0	0	1	0	0			
Race/Ethnicity									
White	978	714	121	142	1	37,581			
Rate*	12.5	14.0	9.1	10.1		12.8			
95% C.I.	(11.7-13.4)	(13.0-15.2)	(7.5-11.0)	(8.5-12.0)		(12.7-12.9)			
Black	55	51	2	2	0	3,249			
Rate*	9.0	9.0				10.2			
95% C.I.	(6.7-12.4)	(6.6-12.6)				(9.8-10.6)			
Native American	2	1	0	1	0	180			
Rate*						4.6			
95% C.I.						(3.9-3.9)			
Asian	35	30	5	0	0	2,205			
Rate*	7.7	7.5				7.4			
95% C.I.	(4.9-12.5)	(4.6-13.1)				(7.1-7.7)			
Hispanic	89	75	7	6	1	5,011			
Rate*	6.7	7.5				9.7			
95% C.I.	(4.9-9.4)	(5.2-11.0)				(9.4-10.0)			
Other/Unknown	42	39	1	2	0	830			

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the national (SEER) rates. See Technical Notes for more information.

Table 214. Leukemia Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

			County/Region	of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)
Total						
Cases	1,201	910	136	153	2	44,045
Rate*	12.0	13.3	8.4	10.0		12.3
95% C.I.	(11.3-12.7)	(12.5-14.3)	(7.0-10.0)	(8.4-12.5)		(12.2-12.4)
Age Group						
<1	6	4	1	1	0	242
Rate*						4.5
95% C.I.						(3.9-5.1)
1-4	46	34	6	6	0	1,876
Rate*	7.3	7.4				8.9
95% C.I.	(5.18-9.39)	(4.90-9.87)				(8.5-9.3)
5-14	46	31	9	6	0	1,889
Rate*	3.0	2.8				3.4
95% C.I.	(2.11-3.82)	(1.83-3.83)				(3.2-3.6)
15-24	29	21	3	5	0	1,400
Rate*	1.9	1.9				2.6
95% C.I.	(1.18-2.53)	(1.10-2.73)				(2.5-2.8)
25-34	37	28	5	3	1	1,490
Rate*	2.3	2.3				2.8
95% C.I.	(1.55-3.02)	(1.47-3.20)				(2.6-2.9)
35-44	67	55	7	5	0	2,490
Rate*	3.9	4.6				4.2
95% C.I.	(2.99-4.87)	(3.37-5.79)				(4.0-4.3)
45-54	104	70	18	16	0	4,356
Rate*	7.0	7.0	6.9	7.2		8.4
95% C.I.	(5.63-8.30)	(5.32-8.57)	(3.69-10.04)	(3.65-10.67)		(8.2-8.7)
55-64	212	164	21	26	1	6,405
Rate*	19.4	21.8	12.1	15.6		19.4
95% C.I.	(16.81-22.03)	(18.48-25.16)	(6.92-17.26)	(9.62-21.63)		(18.9-19.9)
65-74	281	215	26	40	0	8,967
Rate*	39.2	43.5	24.4	34.6		41.1
95% C.I.	(34.62-43.78)	(37.65-49.27)	(15.02-33.78)	(23.89-45.34)		(40.3-42.0)
75-84	275	205	31	39	0	10,452
Rate*	66.9	73.3	49.0	57.5		67.9
95% C.I.	(59.00-74.82)	(63.23-83.29)	(31.72-66.19)	(39.43-75.51)		(66.6-69.2)
85+	97	82	9	6	0	4,478
Rate*	102.1	134.7				81.0
95% C.I.	(81.77-122.41)	(105.54-163.85)				(78.7-83.5)
Unknown	1	1	0	0	0	0

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 215. Leukemia Cases by County of Residence at Diagnosis, Nevada Residents, 2000-2004

County of	2000-2004 Incidence							
Residence	Cases	Rat	te*	Age-Adjusted Rate**				
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	33	12.9	(8.5-17.3)	11.2	(7.7-16.0)			
Churchill	21	16.8	(9.6-24.0)	16.7	(10.3-26.2)			
Clark	910	11.8	(11.1-12.6)	13.3	(12.5-14.3)			
Douglas	15	6.8	(3.3-10.2)	5.6	(3.0-9.9)			
Elko	17	7.4	(3.9-11.0)	15.2	(5.7-39.7)			
Esmeralda	0							
Eureka	1							
Humboldt	10	12.4	(4.7-20.0)	15.8	(7.4-30.5)			
Lander	4							
Lincoln	1							
Lyon	18	9.2	(4.9-13.4)	8.3	(4.9-13.4)			
Mineral	2							
Nye	22	12.5	(7.3-17.7)	8.0	(4.9-12.7)			
Pershing	4							
Storey	2							
Washoe	136	7.6	(6.3-8.8)	8.4	(7.0-10.0)			
White Pine	3							
Unknown	2							
Total	1,201	11.0	(10.4-11.6)	12.0	(11.3-12.7)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 216. Leukemia Cases by Race/Ethnicity and Gender, Nevada Residents,2000-2004

			Gender						
Race/Ethnicity		Male	Female	Other/ Unknown	Total				
White	Incidence	582	395	1	978				
	Rate*	15.7	9.8		12.5				
	95% C.I.	(14.4-17.1)	(8.9-10.9)		(11.7-13.4)				
Black	Incidence	28	27	0	55				
	Rate*	10.6	8.0		9.0				
	95% C.I.	(6.5-17.8)	(5.1-12.3)		(6.7-12.4)				
Native	Incidence	0	2	0	2				
American	Rate*								
	95% C.I.								
Asian	Incidence	12	23	0	35				
	Rate*	4.7	9.9		7.7				
	95% C.I.	(2.3-8.9)	(5.5-17.6)		(4.9-12.5)				
Hispanic	Incidence	52	37	0	89				
	Rate*	9.9	4.6		6.7				
	95% C.I.	(5.9-16.8)	(3.0-7.2)		(4.9-9.4)				
Other/Unknown		26	16	0	42				
Total	Incidence	700	500	1	1,201				
	Rate*	14.9	9.6		12.0				
	95% C.I.	(13.8-16.2)	(8.7-10.5)		(11.3-12.7)				

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 217. Leukemia Cases by Age Group and Gender, Nevada Residents,2000-2004

Age	Gender								
Group	Male	Female	Unknown	Total					
<1	2	4	0	6					
Rate*									
95% C.I.									
1-4	27	19	0	46					
Rate*	8.35	6.16		7.28					
95% C.I.	(5.20-11.51)	(3.39-8.93)		(5.18-9.39)					
5-14	22	24	0	46					
Rate*	2.76	3.18		2.96					
95% C.I.	(1.61-3.91)	(1.91-4.45)		(2.11-3.82)					
15-24	15	14	0	29					
Rate*	1.85	1.86		1.86					
95% C.I.	(0.91-2.79)	(0.89-2.84)		(1.18-2.53)					
25-34	16	21	0	37					
Rate*	1.90	2.71		2.29					
95% C.I.	(0.97-2.83)	(1.55-3.87)		(1.55-3.02)					
35-44	36	31	0	67					
Rate*	4.07	3.78		3.93					
95% C.I.	(2.74-5.40)	(2.45-5.11)		(2.99-4.87)					
45-54	64	40	0	104					
Rate*	8.46	5.43		6.96					
95% C.I.	(6.38-10.53)	(3.75-7.12)	 	(5.63-8.30)					
55-64	124	87	1	212					
Rate*	23.04	15.72		19.42					
95% C.I.	(18.98-27.09)	(12.42-19.02)		(16.81-22.03)					
65-74 Rate*	185 52.36	96 26.41	0	281 39.20					
95% C.I.	(44.82-59.91)	(21.13-31.69)		(34.62-43.78)					
75-84	161	114	0	275					
Rate*	86.72	50.59	0	66.91					
95% C.I.	(73.32-100.11)	(41.31-59.88)		(59.00-74.82)					
85+	47	50	0	97					
Rate*	147.95	79.06		102.09					
95% C.I.	(105.65-190.25)	(57.14-100.97)		(81.77-122.41)					
Unknown	1	0	0	1					
Total	700	500	1	1,201					
Rate*	12.59	9.29		10.98					
95% C.I.	(11.7-13.5)	(8.5-10.1)	<u> </u>	(10.4-11.6)					

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 218. Leukemia Incidence by Age Group and Stage, Nevada Residents,2000-2004

	0	Stage								
Age	Age Group		Localized	Regional	Distant	Unstaged	Total			
<1	Number		0	0	5	1	6			
	Percent				83.3%	16.7%	100.0%			
1-4	Number		0	0	45	1	46			
	Percent				97.8%	2.2%	100.0%			
5-14	Number		0	0	46	0	46			
	Percent				100.0%		100.0%			
15-24	Number		0	0	28	1	29			
	Percent				96.6%	3.4%	100.0%			
25-34	Number		0	0	35	2	37			
	Percent				94.6%	5.4%	100.0%			
35-44	Number		0	0	64	3	67			
	Percent				95.5%	4.5%	100.0%			
45-54	Number		0	0	101	3	104			
	Percent				97.1%	2.9%	100.0%			
55-64	Number		0	0	202	10	212			
	Percent				95.3%	4.7%	100.0%			
65-74	Number		0	0	256	25	281			
	Percent				91.1%	8.9%	100.0%			
75-84	Number		0	0	254	21	275			
	Percent				92.4%	7.6%	100.0%			
85+	Number		0	0	86	11	97			
	Percent				88.7%	11.3%	100.0%			
Unknown	Number		0	0	1	0	1			
	Percent				100.0%		100.0%			
Total	Number		0	0	1,123	78	1,201			
	Percent				93.5%	6.5%	100.0%			

Table 219. Leukemia Cases by Stage and Race/Ethnicity,
Nevada Residents, 2000-2004

		Race/Ethnicity								
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total		
In situ	Number									
	Percent									
Localized	Number									
	Percent									
Regional	Number									
	Percent									
Distant	Number	915	53	2	32	86	35	1,123		
	Percent	93.6%	96.4%	100.0%	91.4%	96.6%	83.3%	93.5%		
Unstaged	Number	63	2	0	3	3	7	78		
	Percent	6.4%	3.6%		8.6%	3.4%	16.7%	6.5%		
Total	Number	978	55	2	35	89	42	1,201		
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		


Table 220. Median Age at Diagnosis of Leukemia by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004

	Gender								
Race/Ethnicity	Ма	le	Fem	ale	Total				
	Cases	Median Age	Cases	Median Age	Cases	Median Age			
White	582	69.0	395	69.0	977	69.0			
Black	28	57.0	27	43.0	55	53.0			
Native American			2		2				
Asian	12	48.0	23	62.0	35	58.0			
Hispanic	52	32.0	37	24.0	89	28.0			
Other/Unknown	25	69.0	16	63.0	41	65.0			
Total	699	67.0	500	66.0	1,199	67.0			


Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 144. Leukemia Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical Notes for more information.






Figure 146. Median Charges for Leukemia Inpatient Discharges by County/Region of Residence, Nevada Residents, 2000-2004




Figure 147. Average Length of Stay for Leukemia Inpatient Discharges by County/Region of Residence, Nevada Residents, 2000-2004




Table 221. Leukemia Inpatient Discharges by Gender, Charges, Length of Stay,
and County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Discharges	1,041	780	130	131	0		
Rate*	10.0	10.8	8.0	8.5			
95% C.I.	(9.4-10.7)	(10.0-11.6)	(6.7-9.5)	(7.1-10.1)			
Gender							
Male	597	447	66	84	0		
Rate*	11.8	12.7	8.8	10.7			
95% C.I.	(10.9-12.9)	(11.5-14.1)	(6.7-11.5)	(8.5-13.4)			
Female	443	332	64	47	0		
Rate*	8.4	9.0	7.5	6.2			
95% C.I.	(7.6-9.2)	(8.1-10.1)	(5.7-9.6)	(4.6-8.4)			
Other/Unknown	1	1	0	0	0		
Inpatient Discharge Cl	narges (\$)						
Total Charges	\$91,884,609	\$76,079,829	\$7,579,182	\$8,225,598	\$0		
Average Charges	\$88,266	\$97,538	\$58,301	\$62,791	\$0		
Median Charges	\$40,522	\$47,611	\$22,628	\$22,518	\$0		
Discharge Length of Stay (LOS) (Days)							
Total LOS	14,309	11,434	1,357	1,518	0		
Average LOS	13.7	14.7	10.4	11.6	0.0		
Median LOS	7.0	8.0	6.0	5.0	0.0		

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 222. Leukemia Inpatient Discharges by Age Group and County/Region of
Residence, Nevada Residents, 2000-2004

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties		
Total						
Discharges	1,041	780	130	131		
Rate*	9.5	10.1	7.2	9.0		
95% C.I.	(8.9-10.1)	(9.4-10.8)	(6.0-8.5)	(7.5-10.6)		
Age Group						
<1	4	4	0	0		
Rate*						
95% C.I.						
1-4	83	68	5	10		
Rate*	13.1	14.8		14.2		
95% C.I.	(10.31-15.97)	(11.26-18.29)		(5.38-22.94)		
5-14	118	104	11	3		
Rate*	7.6	9.5	4.4			
95% C.I.	(6.23-8.97)	(7.67-11.32)	(1.79-6.97)			
15-24	55	38	4	13		
Rate*	3.5	3.5		6.5		
95% C.I.	(2.59-4.45)	(2.36-4.57)		(2.97-10.06)		
25-34	66	58	6	2		
Rate*	4.1	4.8				
95% C.I.	(3.09-5.06)	(3.59-6.08)				
35-44	59	51	5	3		
Rate*	3.5	4.3				
95% C.I.	(2.58-4.34)	(3.08-5.41)				
45-54	104	68	12	24		
Rate*	7.0	6.8	4.6	10.7		
95% C.I.	(5.63-8.30)	(5.14-8.35)	(1.99-7.17)	(6.44-15.04)		
55-64	142	99	23	20		
Rate*	13.0	13.2	13.2	12.0		
95% C.I.	(10.87-15.15)	(10.58-15.77)	(7.83-18.65)	(6.75-17.28)		
65-74	192	144	24	24		
Rate*	26.8	29.1	22.5	20.8		
95% C.I.	(23.00-30.57)	(24.35-33.86)	(13.51-31.54)	(12.46-29.08)		
75-84	167	113	30	24		
Rate*	40.6	40.4	47.4	35.4		
95% C.I.	(34.47-46.80)	(32.94-47.83)	(30.42-64.33)	(21.22-49.52)		
85+	51	33	10	8		
Rate*	53.7	54.2	57.3			
95% C.I.	(38.95-68.41)	(35.71-72.70)	(21.78-92.78)			
Unknown	0	0	0	0		

* Rates are per 100,000 age-specific population.

Table 223. Leukemia Inpatient Discharges by Age Group and Gender, Nevada					
Residents, 2000-2004					

Age	Gender					
Group	Male	Female	Total			
<1	1	3	4			
Rate*						
95% C.I.						
1-4	47	36	83			
Rate*	14.54	11.67	13.14			
95% C.I.	(10.38-18.70)	(7.86-15.49)	(10.31-15.97)			
5-14	65	52	118			
Rate*	8.15	6.89	7.60			
95% C.I.	(6.17-10.13)	(5.01-8.76)	(6.23-8.97)			
15-24	32	23	55			
Rate*	3.95	3.06	3.52			
95% C.I.	(2.58-5.32)	(1.81-4.31)	(2.59-4.45)			
25-34	29	37	66			
Rate*	3.44	4.77	4.08			
95% C.I.	(2.19-4.69)	(3.23-6.31)	(3.09-5.06)			
35-44	28	31	59			
Rate*	3.16	3.78	3.46			
95% C.I.	(1.99-4.33)	(2.45-5.11)	(2.58-4.34)			
45-54	82	22	104			
Rate*	10.83	2.99	6.96			
95% C.I.	(8.49-13.18)	(1.74-4.24)	(5.63-8.30)			
55-64	78	64	142			
Rate*	14.49	11.56	13.01			
95% C.I.	(11.28-17.71)	(8.73-14.40)	(10.87-15.15)			
65-74	115	77	192			
Rate*	32.55	21.18	26.78			
95% C.I.	(26.60-38.50)	(16.45-25.91)	(23.00-30.57)			
75-84	100	67	167			
Rate*	53.86	29.73	40.63			
95% C.I.	(43.30-64.42)	(22.61-36.85)	(34.47-46.80)			
85+	20	31	51			
Rate*	62.96	49.02	53.68			
95% C.I.	(35.37-90.55)	(31.76-66.27)	(38.95-68.41)			
Unknown	0	0	0			
Total	597	443	1,041			
Rate*	10.74	8.23	9.51			
95% C.I.	(9.9-11.6)	(7.5-9.0)	(8.9-10.1)			

* Rates are per 100,000 age-specific population.

Table 224. Leukemia Inpatient Discharges by County/Region of Residence, NevadaResidents, 2000-2004

O such as t	2000-2004 Inpatient Hospital Discharges						
County of Residence	Rate*			Age-Adjusted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	31	12.1	(7.9-16.4)	11.2	(7.6-16.0)		
Churchill	20	16.0	(9.0-23.0)	15.9	(9.7-25.2)		
Clark	780	10.1	(9.4-10.8)	10.8	(10.0-11.6)		
Douglas	12	5.4	(2.4-8.5)	4.3	(2.2-7.8)		
Elko	3						
Esmeralda	2						
Eureka	3						
Humboldt	6						
Lander	2						
Lincoln	1						
Lyon	30	15.3	(9.8-20.8)	13.9	(9.3-20.2)		
Mineral	0						
Nye	14	7.9	(3.8-12.1)	5.3	(2.8-9.6)		
Pershing	3						
Storey	1						
Washoe	130	7.2	(6.0-8.5)	8.0	(6.7-9.5)		
White Pine	3						
Unknown	0						
Total	1,041	9.5	(8.9-10.1)	10.0	(9.4-10.7)		


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 225. Leukemia Inpatient Discharges by Age Group, Charges and Length ofStay, Nevada Residents, 2000-2004

Age	Discharges	Charges (\$)			Length of Stay (Days)		
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	4						
1-4	83	4,759,863	57,348	35,711	889	10.7	8.0
5-14	118	8,032,471	68,072	29,058	1,104	9.4	6.0
15-24	55	6,397,266	116,314	73,885	1,008	18.3	14.0
25-34	66	9,856,674	149,344	85,359	1,331	20.2	14.5
35-44	59	6,520,287	110,513	97,058	1,106	18.8	11.0
45-54	104	10,101,303	97,128	56,685	1,760	16.9	10.0
55-64	142	16,961,814	119,449	77,707	2,539	17.9	10.5
65-74	192	16,865,519	87,841	41,407	2,549	13.3	7.0
75-84	167	10,257,697	61,423	28,326	1,639	9.8	7.0
85+	51	1,473,849	28,899	23,927	335	6.6	6.0
Unknown	0						
Total	1,041	91,884,609	88,266	40,522	14,309	13.7	7.0

MORTALITY

Figure 148. Leukemia Age-Adjusted (2000) Mortality Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.







Figure 150. Leukemia Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 2000-2004



	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Mortality	699	471	112	116			
Rate*	7.3	7.2	7.4	8.1			
95% C.I.	(6.8-7.9)	(6.5-7.9)	(6.1-9.0)	(6.4-10.6)			
Gender							
Male	421	289	56	76			
Rate*	9.5	9.8	7.9	11.3			
95% C.I.	(8.6-10.6)	(8.6-11.1)	(5.8-10.5)	(8.3-15.9)			
Female	278	182	56	40			
Rate*	5.4	5.2	6.8	5.0			
95% C.I.	(4.8-6.1)	(4.4-6.0)	(5.1-8.9)	(3.6-6.9)			
Other/Unknown	0	0	0	0			
Race/Ethnicity							
White	609	397	102	110			
Rate*	7.9	7.9	7.8	8.1			
95% C.I.	(7.2-8.6)	(7.1-8.8)	(6.3-9.5)	(6.4-10.8)			
Black	32	28	3	1			
Rate*	5.8	5.3					
95% C.I.	(3.8-8.7)	(3.4-8.4)					
Native American	1	1	0	0			
Rate*							
95% C.I.							
Asian	24	21	3	0			
Rate*	5.4	5.0					
95% C.I.	(3.2-9.6)	(3.0-8.0)					
Hispanic	32	23	4	5			
Rate*	3.4	3.0					
95% C.I.	(2.1-5.2)	(1.7-5.0)					
Other/Unknown	1	1	0	0			

Table 226. Leukemia Mortality by Gender, Race/Ethnicity and County/Region ofResidence, Nevada Residents, 2000-2004

*Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 227. Leukemia Mortality by Age Group and County/Region of Residence,Nevada Residents, 2000-2004

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Deaths	699	471	112	116			
Rate*	7.3	7.2	7.4	8.1			
95% C.I.	(6.8-7.9)	(6.5-7.9)	(6.1-9.0)	(6.4-10.6)			
Age Group							
<1	3	1	0	2			
Rate*							
95% C.I.							
1-4	5	3	1	1			
Rate*							
95% C.I.							
5-14	11	9	2	0			
Rate*	0.7						
95% C.I.	(0.29-1.13)						
15-24	10	8	1	1			
Rate*	0.6						
95% C.I.	(0.24-1.04)						
25-34	19	15	3	1			
Rate*	1.2	1.3					
95% C.I.	(0.65-1.70)	(0.62-1.88)					
35-44	23	22	1	0			
Rate*	1.4	1.8					
95% C.I.	(0.80-1.90)	(1.07-2.60)					
45-54	48	31	9	8			
Rate*	3.2	3.1					
95% C.I.	(2.30-4.12)	(1.99-4.16)					
55-64	101	63	17	21			
Rate*	9.3	8.4	9.8	12.6			
95% C.I.	(7.45-11.06)	(6.31-10.45)	(5.13-14.44)	(7.22-18.01)			
65-74	175	126	19	30			
Rate*	24.4	25.5	17.8	26.0			
95% C.I.	(20.80-28.03)	(21.02-29.92)	(9.81-25.85)	(16.67-35.25)			
75-84	219	137	41	41			
Rate*	53.3	49.0	64.8	60.4			
95% C.I.	(46.23-60.34)	(40.76-57.16)	(44.93-84.57)	(41.92-78.91)			
85+	85	56	18	11			
Rate*	89.5	92.0	103.1	66.0			
95% C.I.	(70.44-108.48)	(67.89-116.08)	(55.47-150.74)	(26.98-104.94)			
Unknown	0	0	0	0			

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 228. Leukemia Mortality by County of Residence, Nevada Residents,2000-2004

County of	2000-2004 Mortality						
Residence	Cases	Rat	te*	Age-Adjus	Age-Adjusted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	20	7.8	(4.4-11.3)	6.6	(4.0-10.3)		
Churchill	13	10.4	(4.8-16.1)	11.0	(5.8-19.5)		
Clark	471	6.1	(5.6-6.7)	7.2	(6.5-7.9)		
Douglas	14	6.3	(3.0-9.6)	5.5	(2.9-9.8)		
Elko	10	4.4	(1.7-7.1)	12.8	(3.8-37.6)		
Esmeralda	0						
Eureka	0						
Humboldt	6						
Lander	2						
Lincoln	3						
Lyon	21	10.7	(6.1-15.3)	11.6	(5.9-24.1)		
Mineral	1						
Nye	21	11.9	(6.8-17.0)	8.0	(4.8-13.1)		
Pershing	1						
Storey	2						
Washoe	112	6.2	(5.1-7.4)	7.4	(6.1-9.0)		
White Pine	2						
Unknown	0						
Total	699	6.4	(5.9-6.9)	7.3	(6.8-7.9)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 229. Leukemia Mortality by Race/Ethnicity and Gender, Nevada Residents,2000-2004

			Gender					
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total			
White	Incidence	364	245	0	609			
	Rate*	10.1	6.0		7.9			
	95% C.I.	(9.0-11.3)	(5.2-6.8)		(7.2-8.6)			
Black	Incidence	22	10	0	32			
	Rate*	9.2	3.1		5.8			
	95% C.I.	(5.3-16.5)	(1.5-6.1)		(3.8-8.7)			
Native	Incidence	0	1	0	1			
American	Rate*							
	95% C.I.							
Asian	Incidence	11	13	0	24			
	Rate*	5.1	5.6		5.4			
	95% C.I.	(2.4-9.8)	(2.5-12.2)		(3.2-9.6)			
Hispanic	Incidence	23	9	0	32			
	Rate*	5.3			3.4			
	95% C.I.	(3.0-8.8)			(2.1-5.2)			
Other/Unkr	nown	1	0	0	1			
Total	Incidence	421	278	0	699			
	Rate*	9.5	5.4		7.3			
	95% C.I.	(8.6-10.6)	(4.8-6.1)		(6.8-7.9)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 230. Leukemia Mortality by Age Group and Gender, Nevada Residents,2000-2004

Age	Gender					
Group	Male	Female	Total			
<1	3	0	3			
Rate*						
95% C.I.						
1-4	2	3	5			
Rate*						
95% C.I.						
5-14	2	9	11			
Rate*			0.71			
95% C.I.			(0.29-1.13)			
15-24	8	2	10			
Rate*			0.64			
95% C.I.			(0.24-1.04)			
25-34	12	7	19			
Rate*	1.42		1.17			
95% C.I.	(0.62-2.23)		(0.65-1.70)			
35-44	9	14	23			
Rate*		1.71	1.35			
95% C.I.		(0.81-2.60)	(0.80-1.90)			
45-54 Data*	38	10	48			
Rate*	5.02 (3.42-6.62)	1.36 (0.52-2.20)	3.21 (2.30-4.12)			
95% C.I.		`				
55-64 Rate*	60 11.15	41 7.41	101 9.25			
95% C.I.	(8.33-13.97)	(5.14-9.68)	(7.45-11.06)			
65-74	114	61	175			
Rate*	32.27	16.78	24.41			
95% C.I.	(26.34-38.19)	(12.57-20.99)	(20.80-28.03)			
75-84	138	81	219			
Rate*	74.33	35.95	53.29			
95% C.I.	(61.93-86.73)	(28.12-43.78)	(46.23-60.34)			
85+	35	50	85			
Rate*	110.18	79.06	89.46			
95% C.I.	(73.68-146.68)	(57.14-100.97)	(70.44-108.48)			
Unknown	0	0	0			
Total	421	278	699			
Rate*	7.57	5.17	6.39			
95% C.I.	(6.9-8.3)	(4.6-5.8)	(5.9-6.9)			

* Rates are per 100,000 age-specific population.


Note: The "---" is used for rates calculated on numbers less than ten.


Table 231. Median Age at Death from Leukemia by Race/Ethnicity and Gender,
Nevada Residents, 2000-2004

	Gender							
Race/Ethnicity	Male		Fem	nale	Total			
	Cases	Median Age	Cases	Median Age	Cases	Median Age		
White	364	72.0	245	75.0	609	73.0		
Black	22	62.5	10	59.5	32	62.5		
Native American	0		1		1			
Asian	11	66.0	13	67.0	24	66.5		
Hispanic	23	61.0	9	59.0	32	60.0		
Other/Unknown	1		0		1			
Total	421	71.0	278	73.0	699	72.0		

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE





Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 152. Survival Rates for Leukemia by Stage of Cancer at Diagnosis, Nevada Residents, 2000-2004




Table 232. Cause-Specific Survival Rates for Leukemia by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004

Race/			Cause	Specific Surviv	val Rate		Median
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	951	62.3%	54.4%	50.8%	46.9%	43.4%	3.20
Male	565	61.4%	53.0%	50.3%	47.1%	42.3%	3.09
Female	385	63.7%	56.6%	51.7%	46.5%	46.5%	3.32
Race/Ethnicity							
White	759	60.5%	53.1%	49.7%	45.9%	42.0%	2.90
Male	460	59.7%	52.1%	49.7%	46.5%	41.1%	2.86
Female	298	62.0%	54.9%	49.8%	45.1%	45.1%	2.97
Black	47						
Male	24						
Female	23						
Native American	1						
Male	0						
Female	1						
Asian	33						
Male	13						
Female	20						
Hispanic	79	69.3%	58.7%	58.7%	58.7%	58.7%	> 5 YEARS
Male	50	68.5%	56.6%	56.6%	56.6%	56.6%	> 5 YEARS
Female	29						<u> </u>

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 233. Cause-Specific Survival Rates for Leukemia by Stage of Cancer atDiagnosis and Gender, Nevada Residents, 2000-2004


Surviv	al Rate of Stage		Gender	
а	at Diagnosis	Total	Male	Female
Total	Cases	951	565	385
	One Year	62.3%	61.4%	63.7%
	5 Years	43.4%	42.3%	46.5%
	Median Survival	3.20	3.09	3.32
Stage at D	iagnosis			
In situ	Cases			
	One Year			
	5 Years			
	Median Survival			
Localized	Cases			
	One Year			
	5 Years			
	Median Survival			
Regional	Cases			
	One Year			
	5 Years			
	Median Survival			
Distant	Cases	903	544	358
	One Year	61.9%	61.1%	63.4%
	5 Years	43.1%	42.0%	46.2%
	Median Survival	3.13	3.01	3.26
Unstaged	Cases	47	21	26
	One Year			
	5 Years			
	Median Survival	<u> </u>	<u> </u>	<u> </u>

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

PANCREATIC CANCER

PANCREATIC CANCER GENERAL PROFILE⁴

Figure 153. Anatomy of the Endocrine System⁵



General Anatomy: The pancreas is a gland located deep in the abdomen between the stomach and the spine (backbone). The pancreas is about 6 inches long and is shaped like a flat pear. The pancreas makes insulin and other hormones that travel throughout the body to help the body use or store the energy that comes from food.

Risk Factors: Age, smoking, diabetes, being male, being African American, family history of pancreatic cancer, and Chronic pancreatitis.

Signs and Symptoms: Pancreatic cancer is sometimes called a "silent disease" because early pancreatic cancer often does not cause symptoms. But, as the cancer grows, symptoms may include: Pain in the upper abdomen or upper back, yellow skin and eyes, and dark urine from jaundice, weakness, loss of appetite, nausea and vomiting, and weight loss.

Diagnosing the Cancer: Physical exam, blood, stool and urine tests (Bilirubin levels), computed tomography (CAT) scan, ultrasonography (Transabdominal, Endoscopic), endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), and fine-needle aspiration.

Treatment: Surgery (Whipple procedure, Distal pancreatectomy, Total pancreatectomy, bypass), radiation therapy, and chemotherapy.

HIGHLIGHTS

- Nevadan females had a higher ratio (1.06) than males (1.01) when the incidence and mortality age-adjusted rates for Pancreatic Cancer were compared. For every female death due to this type of cancer there were 1.06 female cases while there were 1.01 male cases for every male Pancreatic Cancer death in Nevada from 2000 to 2004.
- The median age at diagnosis of Pancreatic Cancer for Nevada residents was 69 years of age from 2000 to 2004. For females the median age was 72 years, while for males it was 67 years. The median age at time of death due to Pancreatic Cancer was 71 years for Nevada overall, 69 years of age for males and 73 years of age for females.

INCIDENCE

- There were 1,075 cases of Pancreatic Cancer reported in Nevada from 2000 to 2004. Nevada's age-adjusted incidence rate for Pancreatic Cancer (10.6) was only slightly lower than the national rate of 11.4 (per 100,000 – 2000 US Standard population) from 2000 to 2004.
- While regional comparisons showed only slight variations between the age-adjusted incidence rates of Pancreatic Cancer for Washoe County (11.4), Clark County (10.7) and All Other Counties (9.3) from 2000 to 2004, statistical analysis shows no statistically significant difference between the three regions.
- The age-adjusted incidence rate for male Pancreatic Cancer, 11.5 (10.5-12.6), was higher, although not statistically significant, over the female rate of 9.8 (9.0-10.7), per 100,000 2000 US Standard population, during the 2000 to 2004 period.
- Blacks had the highest age-adjusted incidence rate, 14.7, for Pancreatic Cancer of all racial/ethnic groups and were followed by Whites, Hispanics and Asians with rates of 11.0, 7.0 and 7.4 (per 100,000 2000 US Standard population), respectively, during the 2000 to 2004 period.

INPATIENT HOSPITAL DISCHARGES

- Billed charges from Pancreatic Cancer inpatient hospital discharges accounted for approximately 46.1 million dollars from 2000 to 2004. Nevadans in the 55-64, 65-74 and 75-84 age groups accounted for 76.4% of the total billed charges during this period. The overall daily billed amount for these discharges was approximately \$5,717 in Nevada during this period.
- There were 848 hospital inpatient discharges for a primary diagnosis of Pancreatic Cancer to Nevada residents from 2000 to 2004. Regional comparisons showed little difference between the age-adjusted inpatient discharge rates between Washoe County (9.8), Clark County (8.2) and All Other Counties (7.1 per 100,000 – 2000 US Standard population).

The median total billed charges in Nevada for inpatient discharges due to Cancer of the Pancreas were \$30,150 during the 2000 to 2004 period.

MORTALITY


- There were 1,017 resident Pancreatic Cancer deaths from 2000 to 2004. Regional comparisons found no statistical differences between the three regions where All Other Counties, Washoe County and Clark County had rates of10.5, 10.4 and 10.1 (per 100,000 2000 US Standard population), respectively.
- Blacks, as a racial/ethnic group, had the highest age-adjusted mortality rate for Pancreatic Cancer of any racial/ethnic group, 14.1, and were followed by Whites, Hispanics and Asians with rates of 10.4, 8.3 and 7.1, (per 100,000 – 2000 US Standard population) respectively, from 2000 to 2004.

SURVIVAL RATE

- Males in Nevada had a slightly higher one-year survival rate (23.2%) than females (23.2%) for Pancreatic during the 2000 to 2004 period and this difference slightly increased for the five-year survival rate with males and females at 9.7% and 8.7%, respectively.
- The one-year survival rate for those diagnosed with Pancreatic Cancer at the regional stage was 37.8%, while those diagnosed at the distant and unstaged stages had rates of 12.2% and 23.5%, respectively, during the 2000 to 2004 period.
- From 2000 to 2004, the median survival time for Pancreatic Cancer overall was 0.65 years. Those diagnosed at the localized, regional, distant and unstaged levels had median survival times of 0.77, 0.80, 0.57, and 0.65 years, respectively.

INCIDENCE

Figure 154. Pancreatic Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.






Figure 156. Pancreatic Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 2000-2004




Table 234. Pancreatic Cancer Cases by Gender, Race/Ethnicity and County/Regionof Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)				
Total										
Cases	1,075	746	181	147	1	39,881				
Rate*	10.6	10.7	11.4	9.3		11.4				
95% C.I.	(10.0-11.3)	(9.9-11.5)	(9.8-13.2)	(7.9-11.1)		(11.2-11.5)				
Gender										
Male	552	394	85	73	0	19,553				
Rate*	11.5	11.8	11.7	9.7		12.9				
95% C.I.	(10.5-12.6)	(10.6-13.1)	(9.2-14.8)	(7.5-12.5)		(12.7-13.1)				
Female	522	352	95	74	1	20,328				
Rate*	9.8	9.7	11.1	9.0		10.1				
95% C.I.	(9.0-10.7)	(8.7-10.8)	(8.9-13.5)	(7.1-11.4)		(10.0-10.2)				
Other/Unknown	1	0	1	0	0	0				
Race/Ethnicity										
White	907	606	160	140	1	32,883				
Rate*	11.0	11.1	11.6	9.7		11.2				
95% C.I.	(10.2-11.7)	(10.2-12.0)	(9.9-13.6)	(8.2-11.6)		(11.1-11.3)				
Black	76	69	7	0	0	4,280				
Rate*	14.7	14.2				15.0				
95% C.I.	(11.4-19.0)	(10.9-18.6)				(14.6-15.5)				
Native American	3	1	0	2	0	198				
Rate*						6.9				
95% C.I.						(6.0-6.0)				
Asian	33	27	5	1	0	2,409				
Rate*	7.4	8.1				9.0				
95% C.I.	(4.6-12.1)	(4.7-14.3)				(8.7-9.4)				
Hispanic	51	38	9	4	0	3,403				
Rate*	7.0	6.5				10.5				
95% C.I.	(4.9-10.2)	(4.3-10.1)				(10.1-10.9)				
Other/Unknown	5	5	0	0	0	111				

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the national (SEER) rates. See Technical Notes for more information.

Table 235. Pancreatic Cancer Cases by Age Group and County/Region ofResidence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

			County/Regio	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)
Total						
Cases	1,075	746	181	147	1	39,881
Rate*	10.6	10.7	11.4	9.3		11.4
95% C.I.	(10.0-11.3)	(9.9-11.5)	(9.8-13.2)	(7.9-11.1)		(11.2-11.5)
Age Group						
<1	0	0	0	0	0	1
Rate*						0.0
95% C.I.						(0.0-0.1)
1-4	0	0	0	0	0	2
Rate*						0.0
95% C.I.						(0.0-0.0)
5-14	0	0	0	0	0	6
Rate*						0.0
95% C.I.						(0.0-0.0)
15-24	2	2	0	0	0	29
Rate*						0.1
95% C.I.						(0.0-0.1)
25-34	6	4	1	1	0	157
Rate*						0.3
95% C.I.						(0.3-0.3)
35-44	29	16	9	4	0	1,004
Rate*	1.7	1.3				1.7
95% C.I.	(1.08-2.32)	(0.68-1.98)				(1.6-1.8)
45-54	119	83	23	13	0	3,848
Rate*	8.0	8.2	8.8	5.8		7.4
95% C.I.	(6.54-9.40)	(6.46-10.01)	(5.19-12.36)	(2.66-8.98)		(7.2-7.7)
55-64	243	166	42	35	0	7,234
Rate*	22.3	22.1	24.2	21.0		22.0
95% C.I.	(19.46-25.06)	(18.73-25.45)	(16.87-31.49)	(14.06-28.00)		(21.5-22.5)
65-74	310	233	37	39	1	10,852
Rate*	43.3	47.1	34.7	33.8		49.8
95% C.I.	(38.43-48.06)	(41.05-53.14)	(23.54-45.92)	(23.15-44.34)		(48.9-50.7)
75-84	287	200	50	37	0	11,840
Rate*	69.8	71.5	79.0	54.5		76.9
95% C.I.	(61.75-77.91)	(61.57-81.38)	(57.07-100.85)	(36.96-72.09)		(75.5-78.3)
85+	79	42	19	18	0	4,908
Rate*	83.2	69.0	108.8	107.9		88.8
95% C.I.	(64.81-101.48)	(48.13-89.86)	(59.90-157.77)	(58.07-157.80)		(86.4-91.3)
Unknown	0	0	0	0	0	0

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 236. Pancreatic Cancer Cases by County of Residence at Diagnosis, NevadaResidents, 2000-2004

County of	2000-2004 Incidence						
Residence	Cases	Ra	te*	Age-Adjus	ted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	25	9.8	(5.9-13.6)	8.3	(5.3-12.3)		
Churchill	10	8.0	(3.0-13.0)	8.7	(4.1-16.5)		
Clark	746	9.7	(9.0-10.4)	10.7	(9.9-11.5)		
Douglas	23	10.4	(6.1-14.6)	10.0	(6.2-15.5)		
Elko	14	6.1	(2.9-9.3)	8.0	(3.9-15.9)		
Esmeralda	0						
Eureka	2						
Humboldt	3						
Lander	3						
Lincoln	0						
Lyon	22	11.2	(6.5-15.9)	10.1	(6.3-15.7)		
Mineral	2						
Nye	33	18.7	(12.3-25.1)	13.1	(8.8-19.6)		
Pershing	3						
Storey	3						
Washoe	181	10.1	(8.6-11.6)	11.4	(9.8-13.2)		
White Pine	4						
Unknown	1						
Total	1,075	9.8	(9.2-10.4)	10.6	(10.0-11.3)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 237. Pancreatic Cancer Cases by Race/Ethnicity and Gender, NevadaResidents, 2000-2004

			Ger	nder	
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total
White	Incidence	469	437	1	907
	Rate*	11.8	10.1		11.0
	95% C.I.	(10.7-13.0)	(9.1-11.1)		(10.2-11.7)
Black	Incidence	37	39	0	76
	Rate*	14.3	14.9		14.7
	95% C.I.	(9.6-22.1)	(10.5-20.9)		(11.4-19.0)
Native	Incidence	3	0	0	3
American	Rate*				
	95% C.I.				
Asian	Incidence	14	19	0	33
	Rate*	7.4	7.5		7.4
	95% C.I.	(3.2-16.9)	(4.0-14.3)		(4.6-12.1)
Hispanic	Incidence	28	23	0	51
	Rate*	9.6	5.6		7.0
	95% C.I.	(5.2-17.1)	(3.3-9.3)		(4.9-10.2)
Other/Unkr	nown	1	4	0	5
Total	Incidence	552	522	1	1,075
	Rate*	11.5	9.8		10.6
	95% C.I.	(10.5-12.6)	(9.0-10.7)		(10.0-11.3)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are ageadjusted to the 2000 US Standard population.

Table 238. Pancreatic Cancer Cases by Age Group and Gender, Nevada Residents,2000-2004

Age	Gender							
Group	Male	Female	Unknown	Total				
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	2	0	0	2				
Rate*								
95% C.I.								
25-34 Rate*	3	3	0	6				
95% C.I.								
35-44	14	15	0	29				
Rate*	1.58	1.83		1.70				
95% C.I.	(0.75-2.41)	(0.90-2.76)		(1.08-2.32)				
45-54	81	38	0	119				
Rate*	10.70	5.16		7.97				
95% C.I.	(8.37-13.03)	(3.52-6.80)		(6.54-9.40)				
55-64	128	114	1	243				
Rate*	23.78	20.60		22.26				
95% C.I.	(19.66-27.90)	(16.82-24.38)		(19.46-25.06)				
65-74	165	145	0	310				
Rate*	46.70	39.89		43.25				
95% C.I.	(39.57-53.83)	(33.40-46.38)		(38.43-48.06)				
75-84	131	156	0	287				
Rate*	70.56	69.23		69.83				
95% C.I.	(58.47-82.64)	(58.37-80.10)		(61.75-77.91)				
85+	28	51	0	79				
Rate* 95% C.I.	88.14 (55.49-120.79)	80.64 (58.51-102.77)		83.15 (64.81-101.48)				
Unknown	(33.49-120.79)	0	0	0				
Total	552	522	1	1,075				
Rate*	9.93	9.70		9.83				
95% C.I.	(9.1-10.8)	(8.9-10.5)		(9.2-10.4)				

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 239. Pancreatic Cancer Cases by Age Group and Stage, Nevada Residents,2000-2004

•				Si	tage		
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number		0	0	0	0	0
	Percent						
1-4	Number		0	0	0	0	0
	Percent						
5-14	Number		0	0	0	0	0
	Percent						
15-24	Number		0	1	1	0	2
	Percent			50.0%	50.0%		100.0%
25-34	Number		0	1	2	3	6
	Percent			16.7%	33.3%	50.0%	100.0%
35-44	Number		0	8	12	9	29
	Percent			27.6%	41.4%	31.0%	100.0%
45-54	Number		9	35	44	31	119
	Percent		7.6%	29.4%	37.0%	26.1%	100.0%
55-64	Number		8	55	94	86	243
	Percent		3.3%	22.6%	38.7%	35.4%	100.0%
65-74	Number		21	66	117	106	310
	Percent		6.8%	21.3%	37.7%	34.2%	100.0%
75-84	Number		24	35	84	144	287
	Percent		8.4%	12.2%	29.3%	50.2%	100.0%
85+	Number		9	9	22	39	79
	Percent		11.4%	11.4%	27.8%	49.4%	100.0%
Unknown	Number		0	0	0	0	0
	Percent						
Total	Number		71	210	376	418	1,075
	Percent		6.6%	19.5%	35.0%	38.9%	100.0%

Table 240. Pancreatic Cancer Cases by Stage and Race/Ethnicity, NevadaResidents, 2000-2004

		Race/Ethnicity						
s	Stage		Black	Native American	Asian	Hispanic	Other/ Unknown	Total
In situ	Number							
	Percent							
Localized	Number	67	2	0	0	2	0	71
	Percent	7.4%	2.6%			3.9%		6.6%
Regional	Number	173	13	1	10	13	0	210
	Percent	19.1%	17.1%	33.3%	30.3%	25.5%		19.5%
Distant	Number	307	32	0	13	20	4	376
	Percent	33.8%	42.1%		39.4%	39.2%	80.0%	35.0%
Unstaged	Number	360	29	2	10	16	1	418
	Percent	39.7%	38.2%	66.7%	30.3%	31.4%	20.0%	38.9%
Total	Number	907	76	3	33	51	5	1,075
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%


Table 241. Median Age at Diagnosis of Pancreatic Cancer by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004

	Gender								
Race/Ethnicity	Ма	le	Fem	ale	То	Total			
	Cases	Median Age	Cases	Median Age	Cases	Median Age			
White	469	68.0	437	72.0	906	70.0			
Black	37	62.0	39	68.0	76	66.5			
Native American	3		0		3				
Asian	14	58.5	19	66.0	33	65.0			
Hispanic	28	61.0	23	63.0	51	62.0			
Other/Unknown	1		4		5	57.0			
Total	552	67.0	522	72.0	1,074	69.0			


Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 157. Pancreatic Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical Notes for more information.








Figure 159. Median Charges for Pancreatic Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 2000-2004








Table 242. Pancreatic Cancer Inpatient Discharges by Gender, Charges, Length of
Stay, and County/Region of Residence, Nevada Residents, 2000-2004

		Count	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	848	578	158	112	0
Rate*	8.3	8.2	9.8	7.1	
95% C.I.	(7.7-8.9)	(7.5-8.9)	(8.3-11.5)	(5.8-8.6)	
Gender					
Male	418	288	72	58	0
Rate*	8.7	8.5	9.8	7.8	
95% C.I.	(7.8-9.6)	(7.5-9.7)	(7.5-12.7)	(5.9-10.4)	
Female	430	290	86	54	0
Rate*	8.0	7.9	9.9	6.5	
95% C.I.	(7.3-8.8)	(7.0-8.9)	(7.9-12.2)	(4.9-8.6)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$46,086,152	\$32,552,720	\$9,665,330	\$3,868,102	\$0
Average Charges	\$54,347	\$56,320	\$61,173	\$34,537	\$0
Median Charges	\$30,150	\$32,446	\$25,734	\$20,566	\$0
Discharge Length of S	tay (LOS) (Days)				
Total LOS	8,061	5,521	1,762	778	0
Average LOS	9.5	9.6	11.2	6.9	0.0
Median LOS	7.0	7.0	7.0	5.0	0.0

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 243. Pancreatic Cancer Inpatient Discharges by Age Group and
County/Region of Residence, Nevada Residents, 2000-2004

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Discharges	848	578	158	112
Rate*	7.8	7.5	8.8	7.7
95% C.I.	(7.2-8.3)	(6.9-8.1)	(7.4-10.2)	(6.3-9.2)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	4	4	0	0
Rate*				
95% C.I.				
25-34	5	3	2	0
Rate*				
95% C.I.				
35-44	27	12	11	4
Rate*	1.6	1.0	3.9	
95% C.I.	(0.99-2.18)	(0.43-1.56)	(1.58-6.13)	
45-54	100	75	17	8
Rate*	6.7	7.4	6.5	
95% C.I.	(5.38-8.01)	(5.76-9.13)	(3.40-9.57)	
55-64	211	140	45	26
Rate*	19.3	18.6	25.9	15.6
95% C.I.	(16.72-21.94)	(15.54-21.71)	(18.34-33.48)	(9.62-21.63)
65-74	255	185	34	36
Rate*	35.6	37.4	31.9	31.2
95% C.I.	(31.21-39.94)	(32.01-42.78)	(21.19-42.64)	(20.97-41.33)
75-84	182	127	32	23
Rate*	44.3	45.4	50.5	33.9
95% C.I.	(37.85-50.72)	(37.49-53.28)	(33.03-68.04)	(20.04-47.75)
85+	64	32	17	15
Rate*	67.4	52.6	97.4	90.0
95% C.I.	(50.86-83.86)	(34.35-70.78)	(51.09-143.67)	(44.43-135.46)
Unknown	0	0	0	0

* Rates are per 100,000 age-specific population.

Table 244. Pancreatic Cancer Inpatient Discharges by Age Group and Gender,Nevada Residents, 2000-2004

Age	Gender					
Group	Male	Female	Total			
<1	0	0	0			
Rate*						
95% C.I.						
1-4	0	0	0			
Rate*						
95% C.I.						
5-14	0	0	0			
Rate*						
95% C.I.						
15-24	4	0	4			
Rate*						
95% C.I.						
25-34	4	1	5			
Rate*						
95% C.I.						
35-44	11	16	27			
Rate*	1.24	1.95	1.58			
95% C.I.	(0.51-1.98)	(1.00-2.91)	(0.99-2.18)			
45-54	60	40	100			
Rate*	7.93	5.43	6.70			
95% C.I.	(5.92-9.93)	(3.75-7.12)	(5.38-8.01)			
55-64	112	99	211			
Rate*	20.81	17.89	19.33			
95% C.I.	(16.96-24.66)	(14.36-21.41)	(16.72-21.94)			
65-74	121	134	255			
Rate*	34.25	36.86	35.57			
95% C.I.	(28.14-40.35)	(30.62-43.10)	(31.21-39.94)			
75-84	81	101	182			
Rate*	43.63	44.82	44.28			
95% C.I.	(34.13-53.13)	(36.08-53.56)	(37.85-50.72)			
85+	25	39	64			
Rate*	78.70	61.66	67.36			
95% C.I.	(47.85-109.55)	(42.31-81.02)	(50.86-83.86)			
Unknown	0	0	0			
Total	418	430	848			
Rate* 95% C.I.	7.52 (6.8-8.2)	7.99 (7.2-8.7)	7.75 (7.2-8.3)			
90% U.I.	(0.0-0.2)	(1.2-0.1)	(1.2-0.3)			

* Rates are per 100,000 age-specific population.

Table 245. Pancreatic Cancer Inpatient Discharges by County/Region ofResidence, Nevada Residents, 2000-2004

0 miles (2000-2004 Inpatient Hospital Discharges						
County of Residence	Casaa	Rate*		Age-Adjusted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	13	5.1	(2.3-7.8)	4.3	(2.3-7.4)		
Churchill	5						
Clark	578	7.5	(6.9-8.1)	8.2	(7.5-8.9)		
Douglas	17	7.7	(4.0-11.3)	7.6	(4.3-12.8)		
Elko	12	5.3	(2.3-8.2)	6.3	(3.0-12.8)		
Esmeralda	0						
Eureka	0						
Humboldt	6						
Lander	1						
Lincoln	2						
Lyon	26	13.3	(8.2-18.4)	12.5	(8.1-18.6)		
Mineral	3						
Nye	19	10.8	(5.9-15.6)	7.7	(4.5-13.0)		
Pershing	2						
Storey	0						
Washoe	158	8.8	(7.4-10.2)	9.8	(8.3-11.5)		
White Pine	6						
Unknown	0						
Total	848	7.8	(7.2-8.3)	8.3	(7.7-8.9)		


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 246. Pancreatic Cancer Inpatient Discharges by Age Group, Charges andLength of Stay, Nevada Residents, 2000-2004

Age Group	Discharges	Charges (\$)			Length of Stay (Days)		
		Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	0						
15-24	4						
25-34	5						
35-44	27	1,137,322	42,123	23,317	238	8.8	6.0
45-54	100	6,040,413	60,404	29,397	1,029	10.3	7.0
55-64	211	10,534,750	49,928	31,744	1,955	9.3	7.0
65-74	255	16,438,292	64,464	30,739	2,605	10.2	6.0
75-84	182	8,504,322	46,727	28,507	1,591	8.7	7.0
85+	64	2,620,330	40,943	26,024	499	7.8	6.0
Unknown	0						
Total	848	46,086,152	54,347	30,150	8,061	9.5	7.0

MORTALITY

Figure 161. Pancreatic Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 2000-2004



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical Notes for more information.







Figure 163. Pancreatic Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 2000-2004



	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	1,017	693	160	164				
Rate*	10.2	10.1	10.4	10.5				
95% C.I.	(9.6-10.9)	(9.3-10.9)	(8.8-12.2)	(8.9-12.3)				
Gender								
Male	529	376	72	81				
Rate*	11.4	11.6	10.2	11.3				
95% C.I.	(10.4-12.5)	(10.3-12.9)	(7.9-13.2)	(8.9-14.3)				
Female	488	317	88	83				
Rate*	9.3	8.8	10.5	10.1				
95% C.I.	(8.5-10.2)	(7.8-9.8)	(8.4-12.9)	(8.0-12.6)				
Other/Unknown	0	0	0	0				
Race/Ethnicity								
White	859	568	141	150				
Rate*	10.4	10.3	10.4	10.5				
95% C.I.	(9.7-11.2)	(9.5-11.3)	(8.8-12.4)	(8.8-12.4)				
Black	69	63	5	1				
Rate*	14.1	13.7						
95% C.I.	(10.7-18.3)	(10.3-18.1)						
Native American	3	1	0	2				
Rate*								
95% C.I.								
Asian	27	22	4	1				
Rate*	7.1	7.0						
95% C.I.	(4.1-12.1)	(3.7-13.2)						
Hispanic	55	35	10	10				
Rate*	8.3	6.3	8.9	20.3				
95% C.I.	(5.9-11.7)	(4.1-9.9)	(3.7-18.7)	(9.1-40.5)				
Other/Unknown	4	4	0	0				

Table 247. Pancreatic Cancer Mortality by Gender, Race/Ethnicity and
County/Region of Residence, Nevada Residents, 2000-2004

*Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 248. Pancreatic Cancer Mortality by Age Group and County/Region of
Residence, Nevada Residents, 2000-2004

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Deaths	1,017	693	160	164			
Rate*	10.2	10.1	10.4	10.5			
95% C.I.	(9.6-10.9)	(9.3-10.9)	(8.8-12.2)	(8.9-12.3)			
Age Group							
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	0	0	0	0			
Rate*							
95% C.I.							
15-24	1	1	0	0			
Rate*							
95% C.I.							
25-34	3	1	1	1			
Rate*							
95% C.I.							
35-44	16	8	6	2			
Rate*	0.9						
95% C.I.	(0.48-1.40)						
45-54	86	61	14	11			
Rate*	5.8	6.1	5.3	4.9			
95% C.I.	(4.54-6.98)	(4.53-7.57)	(2.54-8.14)	(2.01-7.83)			
55-64	210	147	32	31			
Rate*	19.2	19.6	18.4	18.6			
95% C.I.	(16.63-21.84)	(16.40-22.72)	(12.04-24.81)	(12.07-25.18)			
65-74	307	219	39	49			
Rate*	42.8	44.3	36.6	42.4			
95% C.I.	(38.04-47.62)	(38.40-50.13)	(25.12-48.09)	(30.53-54.27)			
75-84	309	215	45	49			
Rate*	75.2	76.8	71.1	72.2			
95% C.I.	(66.80-83.57)	(66.57-87.11)	(50.30-91.83)	(51.99-92.43)			
85+	85	41	23	21			
Rate*	89.5	67.4	131.8	125.9			
95% C.I.	(70.44-108.48)	(46.73-87.96)	(77.90-185.59)	(72.07-179.78)			
Unknown	0	0	0	0			

* Rates are per 100,000 age-specific population.

Table 249. Pancreatic Cancer Mortality by County of Residence, NevadaResidents, 2000-2004

County of	2000-2004 Mortality					
Residence	Cases	Ra	te*	Age-Adjus	Age-Adjusted Rate**	
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.	
Carson City	38	14.9	(10.1-19.6)	12.5	(8.9-17.3)	
Churchill	11	8.8	(3.6-14.0)	9.3	(4.6-17.2)	
Clark	693	9.0	(8.3-9.7)	10.1	(9.3-10.9)	
Douglas	15	6.8	(3.3-10.2)	6.4	(3.4-11.0)	
Elko	17	7.4	(3.9-11.0)	12.8	(6.9-22.5)	
Esmeralda	0					
Eureka	0					
Humboldt	3					
Lander	2					
Lincoln	2					
Lyon	25	12.8	(7.8-17.8)	11.6	(7.4-17.5)	
Mineral	4					
Nye	32	18.2	(11.9-24.5)	12.2	(8.1-18.4)	
Pershing	2					
Storey	5					
Washoe	160	8.9	(7.5-10.3)	10.4	(8.8-12.2)	
White Pine	8					
Unknown	0					
Total	1,017	9.3	(8.7-9.9)	10.2	(9.6-10.9)	

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 250. Pancreatic Cancer Mortality by Race/Ethnicity and Gender, NevadaResidents, 2000-2004

		Gender					
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total		
White	Incidence	450	409	0	859		
	Rate*	11.5	9.4		10.4		
	95% C.I.	(10.4-12.7)	(8.5-10.4)		(9.7-11.2)		
Black	Incidence	33	36	0	69		
	Rate*	14.3	14.1		14.1		
	95% C.I.	(9.1-22.6)	(9.8-20.1)		(10.7-18.3)		
Native	Incidence	2	1	0	3		
American	Rate*						
	95% C.I.						
Asian	Incidence	11	16	0	27		
	Rate*	8.1	6.4		7.1		
	95% C.I.	(3.0-19.0)	(3.2-13.1)		(4.1-12.1)		
Hispanic	Incidence	31	24	0	55		
	Rate*	11.3	6.3		8.3		
	95% C.I.	(6.7-19.1)	(3.8-10.4)		(5.9-11.7)		
Other/Unknown		2	2	0	4		
Total	Incidence	529	488	0	1,017		
	Rate*	11.4	9.3		10.2		
	95% C.I.	(10.4-12.5)	(8.5-10.2)		(9.6-10.9)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are ageadjusted to the 2000 US Standard population.

Table 251. Pancreatic Cancer Mortality by Age Group and Gender, NevadaResidents, 2000-2004

Age	Gender					
Group	Male	Female	Total			
<1	0	0	0			
Rate*						
95% C.I.						
1-4	0	0	0			
Rate*						
95% C.I.						
5-14	0	0	0			
Rate*						
95% C.I.						
15-24	1	0	1			
Rate*						
95% C.I.	<u> </u>					
25-34	1	2	3			
Rate*						
95% C.I.	<u> </u>					
35-44	6	10	16			
Rate*		1.22	0.94			
95% C.I.		(0.46-1.98)	(0.48-1.40)			
45-54	57	29	86			
Rate*	7.53	3.94	5.76			
95% C.I.	(5.58-9.49)	(2.50-5.37)	(4.54-6.98)			
55-64	124	86	210			
Rate*	23.04	15.54	19.24			
95% C.I.	(18.98-27.09)	(12.25-18.82)	(16.63-21.84)			
65-74	161	146	307			
Rate*	45.57	40.16	42.83			
95% C.I.	(38.53-52.61)	(33.65-46.68)	(38.04-47.62)			
75-84	144	165	309			
Rate*	77.56	73.23	75.18			
95% C.I.	(64.89-90.23)	(62.05-84.40)	(66.80-83.57)			
85+	35	50	85			
Rate*	110.18	79.06	89.46			
95% C.I.	(73.68-146.68)	(57.14-100.97)	(70.44-108.48)			
Unknown	0	0	0			
Total	529	488	1,017			
Rate* 95% C.I.	9.52 (8 7-10 3)	9.07 (8 3-0 0)	9.30 (8 7-9 9)			
90% U.I.	(8.7-10.3)	(8.3-9.9)	(8.7-9.9)			


* Rates are per 100,000 age-specific population.


Table 252. Median Age at Death from Pancreatic Cancer by Race/Ethnicity and
Gender, Nevada Residents, 2000-2004

	Gender							
Race/Ethnicity	Male		Fem	nale	Total			
	Cases	Median Age	Cases	Median Age	Cases	Median Age		
White	450	70.0	409	74.0	859	72.0		
Black	33	62.0	36	69.0	69	68.0		
Native American	2		1		3			
Asian	11	67.0	16	68.5	27	68.0		
Hispanic	31	66.0	24	65.0	55	66.0		
Other/Unknown	2		2		4			
Total	529	69.0	488	73.0	1,017	71.0		

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE





Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 165. Survival Rates for Pancreatic Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 2000-2004




Table 253. Cause-Specific Survival Rates for Pancreatic Cancer by Race/Ethnicityand Gender, Nevada Residents, 2000-2004

Race/		Cause Specific Survival Rate					Median
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	863	23.1%	13.9%	11.0%	9.3%	9.3%	0.65
Male	443	23.2%	14.9%	12.3%	9.7%	9.7%	0.65
Female	420	23.0%	12.7%	9.4%	8.7%	8.7%	0.65
Race/Ethnicity							
White	716	22.7%	13.2%	10.0%	8.8%	8.8%	0.65
Male	369	22.4%	14.4%	11.6%	9.2%	9.2%	0.64
Female	347	23.0%	11.6%	7.9%	7.9%	7.9%	0.65
Black	61	17.7%	12.2%	12.2%	12.2%	0.0%	0.61
Male	29						
Female	32						
Native American	0						
Male	0						
Female	0						
Asian	31						
Male	13						
Female	18						
Hispanic	48						
Male	28						
Female	20						<u> </u>

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 254. Cause-Specific Survival Rates for Pancreatic Cancer by Stage of
Cancer at Diagnosis and Gender, Nevada Residents, 2000-2004

Surviv	al Rate of Stage	Gender					
a	t Diagnosis	Total	Male	Female			
Total	Cases	863	443	420			
	One Year	23.1%	23.2%	23.0%			
	5 Years	9.3%	9.7%	8.7%			
	Median Survival	0.65	0.65	0.65			
Stage at Di	iagnosis						
In situ	Cases						
	One Year						
	5 Years						
	Median Survival						
Localized	Cases	52	19	33			
	One Year	35.4%					
	5 Years	19.0%					
	Median Survival	0.77		<u> </u>			
Regional	Cases	183	101	82			
	One Year	37.8%	42.1%	32.5%			
	5 Years	15.8%	15.8%	15.4%			
	Median Survival	0.80	0.86	0.74			
Distant	Cases	314	166	148			
	One Year	12.2%	12.9%	11.3%			
	5 Years	2.9%	4.0%	0.0%			
	Median Survival	0.57	0.57	0.56			
Unstaged	Cases	314	157	157			
	One Year	23.5%	19.9%	27.3%			
	5 Years	10.2%	10.1%	9.9%			
	Median Survival	0.65	0.62	0.69			

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

ALL OTHER CANCERS


Table 255. Cancer Incidence, Inpatient Hospital Discharges and Mortality by Typeof Cancer, Nevada Residents, 2000-2004

Type of Cancer		Incidence	Hospital Admissions	Mortality
Total		49,963	34,796	19,379
	Rate*	480.0	330.0	197.0
	95% C.I.	(475.6-484.2)	(326.9-334.0)	(193.7-199.4)
Skin		2,023	93	298
	Rate*	19.0	0.9	2.8
	95% C.I.	(18.4-20.1)	(0.7-1.1)	(2.5-3.2)
Corpus Uteri & U	terus NOS	1,033	946	156
	Rate*	9.7	8.8	1.6
	95% C.I.	(9.1-10.3)	(8.3-9.4)	(1.4-1.9)
Ovary		734	721	457
	Rate*	7.0	6.7	4.5
	95% C.I.	(6.5-7.5)	(6.2-7.2)	(4.1-5.0)
Thyroid Gland		1,126	1,570	29
	Rate*	10.0	14.0	0.3
	95% C.I.	(9.5-10.7)	(13.4-14.8)	(0.2-0.4)
Brain and Other	Central Nervous		0.40	445
System	D / *	663	946	415
	Rate*	6.3	8.8	4.0
Oto was a sh	95% C.I.	(5.8-6.8)	(8.2-9.4)	(3.6-4.4)
Stomach	Dete*	639 6.4	597	346
	Rate* 95% C.I.	-	5.8	3.6
Liver and Introke		(5.9-6.9)	(5.3-6.3)	(3.2-4.0)
Liver and Intrahe		555	379	501
	Rate* 95% C.I.	5.4	3.6	4.9 (4 5 5 4)
Convix Litori	95% C.I.	(4.9-5.8) 514	(3.3-4.0) 609	(4.5-5.4)
Cervix Uteri	Rate*	4.7	5.5	149 1.4
	95% C.I.			
Feenbague	95% C.I.	(4.3-5.2)	(5.1-6.0) 302	(1.2-1.7) 459
Esophagus	Rate*	545 5.2	2.9	4.4
	95% C.I.	(4.8-5.7)	(2.5-3.2)	(4.0-4.9)
Larynx	95% C.I.	(4.8-5.7)	(2.5-3.2)	(4.0-4.9)
Larynx	Rate*	391	1.6	1.1
	95% C.I.	(3.3-4.1)	(1.3-1.8)	(0.9-1.3)
Multiple Myeloma		(3.3-4.1)	373	(0.9-1.3)
	Rate*	4.4	3.6	3.4
	95% C.I.	(4.0-4.9)	(3.2-4.0)	(3.1-3.8)
Hodgkin's Lymph		(4.0-4.9)	(3.2-4.0)	(3.1-3.8)
Houghin's Lymph	Rate*	2.5	1.1	0.4
	95% C.I.	(2.2-2.8)	(0.9-1.3)	(0.2-0.5)
All Other Sites	5576 0.1.	3,464	8,238	(0.2-0.3) 2,180
All Other Oiles	Rate*	34.0	78.0	2,180
	95% C.I.	(32.7-35.1)	(76.2-79.7)	(21.4-23.4)
	3570 0.1.	(32.7-33.1)	(10.2-19.1)	(21.4-23.4)

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender-specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten.

SKIN CANCER GENERAL PROFILE⁴

Figure 166. Anatomy of the Skin⁴



General Anatomy: The skin is the body's largest organ. It protects against heat, sunlight, injury, and infection. It helps regulate body temperature, stores water and fat, and produces vitamin D. The skin has two main layers: the outer epidermis and the inner dermis. The epidermis is mostly made up of flat, scalelike cells called squamous cells. Round cells called basal cells lie under the squamous cells in the epidermis. The lower part of the epidermis also contains melanocytes. The dermis contains blood vessels, lymph vessels, hair follicles, and glands. Some of these glands produce sweat, which helps regulate body temperature. Other glands produce sebum, an oily substance that helps keep the skin from drying out. Sweat and sebum reach the skin's surface through tiny openings called pores. Melanoma is one of the most common cancers and occurs when melanocytes (pigment cells) become malignant.

Risk Factors: Dysplastic nevi moles, many (more than 50) ordinary moles, fair skin, personal history of melanoma or skin cancer, family history of melanoma, weakened immune system, severe blistering sunburns, and ultraviolet (UV) radiation.

Signs and Symptoms: Asymetrical, border, color, and diameter changes in a mole, and Dysplastic Nevi moles are common signs and symptoms.

Diagnosing the Cancer: Excisional biopsy.

Treatment: Treatment options include: surgery (Sentinel lymph node biopsy, Lymph node dissection), chemotherapy (Orally or injection or Isolated limb perfusion), biological therapy, or radiation therapy.

Table 256. Skin Cancer Cases by Gender, Race/Ethnicity and County/Region ofResidence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)		
Total								
Cases	2,023	1,505	301	215	2	67,272		
Rate*	19.2	20.8	17.5	13.8		18.5		
95% C.I.	(18.4-20.1)	(19.7-21.9)	(15.5-19.7)	(12.0-15.9)		(18.4-18.7)		
Gender								
Male	1,227	933	162	131	1	38,221		
Rate*	24.5	27.3	19.8	16.9		23.6		
95% C.I.	(23.0-26.0)	(25.4-29.2)	(16.8-23.5)	(14.1-20.3)		(23.4-23.9)		
Female	795	571	139	84	1	29,051		
Rate*	14.7	15.3	15.6	10.9		14.9		
95% C.I.	(13.7-15.8)	(14.0-16.6)	(13.1-18.7)	(8.7-13.6)		(14.8-15.1)		
Other/Unknown	1	1	0	0	0	0		
Race/Ethnicity								
White	1,926	1,420	295	210	1	63,542		
Rate*	24.1	27.2	20.8	15.6		21.6		
95% C.I.	(23.0-25.2)	(25.7-28.7)	(18.4-23.4)	(13.5-18.0)		(21.4-21.7)		
Black	15	14	0	1	0	309		
Rate*	3.1	3.0				1.0		
95% C.I.	(1.6-5.6)	(1.6-5.7)				(0.9-1.1)		
Native American	2	1	0	1	0	83		
Rate*						2.3		
95% C.I.						(1.8-1.8)		
Asian	6	6	0	0	0	440		
Rate*						1.5		
95% C.I.						(1.3-1.6)		
Hispanic	33	29	3	1	0	2,013		
Rate*	3.2	3.5				4.5		
95% C.I.	(1.9-5.4)	(2.0-6.4)				(4.3-4.7)		
Other/Unknown	41	35	3	2	1	2,898		

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 257. Skin Cancer Inpatient Discharges by Gender, Charges, Length of Stay,
and County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	93	63	14	16	0			
Rate*	0.9	0.8	0.8	1.0				
95% C.I.	(0.7-1.1)	(0.6-1.1)	(0.4-1.4)	(0.6-1.6)				
Gender								
Male	63	45	11	7	0			
Rate*	1.2	1.2	1.4					
95% C.I.	(0.9-1.5)	(0.9-1.6)	(0.7-2.6)					
Female	30	18	3	9	0			
Rate*	0.6	0.5						
95% C.I.	(0.4-0.8)	(0.3-0.8)						
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Ch	narges (\$)							
Total Charges	\$2,273,481	\$1,652,293	\$360,763	\$260,425	\$0			
Average Charges	\$24,446	\$26,227	\$25,769	\$16,277	\$0			
Median Charges	\$15,620	\$14,513	\$23,518	\$13,906	\$0			
Discharge Length of Stay (LOS) (Days)								
Total LOS	328	230	42	56	0			
Average LOS	3.5	3.7	3.0	3.5	0.0			
Median LOS	2.0	2.0	2.0	2.0	0.0			

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.


Table 258. Skin Cancer Mortality by Age Group and County/Region of Residence,Nevada Residents, 2000-2004

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Deaths	298	197	51	50			
Rate*	2.8	2.7	3.0	3.1			
95% C.I.	(2.5-3.2)	(2.4-3.2)	(2.2-4.0)	(2.3-4.1)			
Age Group							
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	0	0	0	0			
Rate*							
95% C.I.							
15-24	3	1	2	0			
Rate*							
95% C.I.							
25-34	7	6	1	0			
Rate*							
95% C.I.							
35-44	31	18	7	6			
Rate*	1.8	1.5					
95% C.I.	(1.18-2.46)	(0.81-2.19)					
45-54	58	32	17	9			
Rate*	3.9	3.2	6.5				
95% C.I.	(2.88-4.88)	(2.08-4.28)	(3.40-9.57)				
55-64	63	46	7	10			
Rate*	5.8	6.1		6.0			
95% C.I.	(4.35-7.20)	(4.35-7.89)		(2.28-9.73)			
65-74	73	49	7	17			
Rate*	10.2	9.9		14.7			
95% C.I.	(7.85-12.52)	(7.13-12.68)		(7.72-21.70)			
75-84	49	36	7	6			
Rate*	11.9	12.9					
95% C.I.	(8.58-15.26)	(8.66-17.07)					
85+	14	9	3	2			
Rate*	14.7						
95% C.I.	(7.02-22.45)						
Unknown	0	0	0	0			

* Rates are per 100,000 age-specific population.

UTERINE CANCER GENERAL PROFILE⁴

Figure 167. Anatomical Drawing of Female Reproductive System⁴



General Anatomy: The uterus is part of a woman's reproductive system. It is the hollow, pear-shaped organ where a baby grows. The uterus is in the pelvis between the bladder and the rectum. The narrow, lower portion of the uterus is the cervix. The broad, middle part of the uterus is the body, or corpus. The dome-shaped top of the uterus is the fundus. The fallopian tubes extend from either side of the top of the uterus to the ovaries.

The wall of the uterus has two layers of tissue. The inner layer, or lining, is the endometrium. The outer layer is muscle tissue called the myometrium. In women of childbearing age, the lining of the uterus grows and thickens each month to prepare for pregnancy. If a woman does not become pregnant, the thick, bloody lining flows out of the body through the vagina. This flow is called menstruation.

Risk Factors: Age (Women over 50), Endometrial hyperplasia, Hormone replacement therapy (HRT), Obesity and related conditions, Women taking the drug Tamoxifen, Race (White Females), and Inherited form of Colorectal Cancer.

Signs and Symptoms: Unusual vaginal bleeding or discharge, difficult or painful urination, pain during intercourse, and pain in the pelvic area.

Diagnosing the Cancer: Pelvic exam, Pap test, transvaginal ultrasound, and biopsy.

Treatment: Treatment options include: surgery (Hysterectomy), radiation therapy and hormonal therapy.

Table 259. Uterine Cancer Cases by Gender, Race/Ethnicity and County/Region ofResidence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)	
Total							
Cases	1,033	717	159	157	0	45,110	
Rate*	9.7	9.8	9.4	9.6		12.5	
95% C.I.	(9.1-10.3)	(9.1-10.6)	(8.0-11.0)	(8.1-11.2)		(12.4-12.7)	
Gender							
Male							
Rate*							
95% C.I.							
Female	1,033	717	159	157	0	45,110	
Rate*	18.8	18.9	18.0	18.6		23.1	
95% C.I.	(17.6-20.0)	(17.6-20.4)	(15.3-21.1)	(15.8-21.8)		(22.9-23.3)	
Other/Unknown	0	0	0	0	0	0	
Race/Ethnicity							
White	880	592	142	146	0	38,338	
Rate*	20.5	21.3	19.1	19.1		24.2	
95% C.I.	(19.2-21.9)	(19.6-23.1)	(16.1-22.6)	(16.1-22.7)		(23.9-24.4)	
Black	38	36	1	1	0	3,423	
Rate*	13.1	13.3				19.4	
95% C.I.	(9.2-18.5)	(9.2-19.1)				(18.8-20.1)	
Native American	7	0	5	2	0	201	
Rate*						10.8	
95% C.I.						(9.3-12.6)	
Asian	45	35	6	4	0	2,758	
Rate*	12.1	11.3				16.1	
95% C.I.	(8.7-16.6)	(7.8-16.2)				(15.5-16.7)	
Hispanic	50	41	5	4	0	3,860	
Rate*	9.4	9.3				17.3	
95% C.I.	(6.7-13.3)	(6.5-13.2)				(16.7-17.9)	
Other/Unknown	13	13	0	0	0	390	

* Rates are per 100,000 age-specific female population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 260. Uterine Cancer Inpatient Discharges by Gender, Charges, Length of
Stay, and County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	946	652	161	133	0			
Rate*	8.8	8.8	9.5	8.1				
95% C.I.	(8.3-9.4)	(8.1-9.5)	(8.1-11.1)	(6.8-9.6)				
Gender								
Male								
Rate*								
95% C.I.								
Female	946	652	161	133	0			
Rate*	17.1	17.1	18.3	15.7				
95% C.I.	(16.1-18.3)	(15.8-18.5)	(15.6-21.4)	(13.1-18.7)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Ch	narges (\$)							
Total Charges	\$32,282,509	\$21,957,763	\$5,534,909	\$4,789,837	\$0			
Average Charges	\$34,125	\$33,678	\$34,378	\$36,014	\$0			
Median Charges	\$26,896	\$25,680	\$34,123	\$28,690	\$0			
Discharge Length of S	tay (LOS) (Days)							
Total LOS	4,306	3,039	670	597	0			
Average LOS	4.6	4.7	4.2	4.5	0.0			
Median LOS	3.0	3.5	3.0	3.0	0.0			

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.


Table 261. Uterine Cancer Mortality by Age Group and County/Region ofResidence, Nevada Residents, 2000-2004

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Deaths	155	119	17	19			
Rate*	3.0	3.4	2.1	2.3			
95% C.I.	(2.5-3.5)	(2.8-4.0)	(1.2-3.3)	(1.4-3.7)			
Age Group							
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	0	0	0	0			
Rate*							
95% C.I.							
15-24	0	0	0	0			
Rate*							
95% C.I.							
25-34	2	2	0	0			
Rate*							
95% C.I.							
35-44	7	7	0	0			
Rate*							
95% C.I.							
45-54	18	16	1	1			
Rate*	2.4	3.2					
95% C.I.	(1.32-3.57)	(1.64-4.80)					
55-64	26	20	2	4			
Rate*	4.7	5.2					
95% C.I.	(2.89-6.50)	(2.91-7.46)					
65-74	41	32	5	4			
Rate*	11.3	12.7					
95% C.I.	(7.83-14.73)	(8.32-17.13)					
75-84	36	25	4	7			
Rate*	16.0	16.4					
95% C.I.	(10.76-21.20)	(9.94-22.77)					
85+	25	17	5	3			
Rate*	39.5	41.6					
95% C.I.	(24.03-55.02)	(21.82-61.35)					
Unknown	0	0	0	0			

* Rates are per 100,000 age-specific female population.

OVARIAN CANCER GENERAL PROFILE⁴

Figure 168. Anatomical Drawing of Female Reproductive System⁴



General Anatomy: The ovaries are a pair of organs in the female reproductive system. They are located in the pelvis, one on each side of the uterus. Each ovary is about the size and shape of an almond. The ovaries have two functions: they produce eggs and female hormones (chemicals that control the way certain cells or organs function).

Every month, during the menstrual cycle, an egg is released from one ovary in a process called ovulation. The egg travels from the ovary through the fallopian tube to the uterus. The ovaries are also the main source of the female hormones estrogen and progesterone, which influence the development of a woman's breasts, body shape, and body hair. They also regulate the menstrual cycle and pregnancy.

Risk Factors: Family History, Age (Women over 50, especially over 60), Women who never had children, Personal history of Breast or Colorectal Cancer, Use of Fertility drugs, Use of Talc, and Hormone replacement therapy (HRT).

Signs and Symptoms: General abdominal discomfort and/or pain (gas, indigestion, pressure, swelling, bloating, cramps), Nausea, diarrhea, constipation, or frequent urination, Loss of appetite, Feeling of fullness even after a light meal, Weight gain or loss with no known reason, and Abnormal bleeding from the vagina.

Diagnosing the Cancer: Pelvic exam, ultrasound, CA-125 assay blood test, lower gastrointestinal (GI) series, or barium enema (Colon and Rectum X-rays), CT (or CAT) scan, and biopsy.

Treatment: Surgery (hysterectomy with bilateral Salpingo-oophorectomy), chemotherapy, radiation therapy, and clinical trials.

Table 262. Ovarian Cancer Cases by Gender, Race/Ethnicity and County/Regionof Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)	
Total							
Cases	734	516	123	94	1	26,546	
Rate*	7.0	7.1	7.4	6.0		7.4	
95% C.I.	(6.5-7.5)	(6.5-7.8)	(6.1-8.9)	(4.8-7.4)		(7.3-7.5)	
Gender							
Male							
Rate*							
95% C.I.							
Female	734	516	123	94	1	26,546	
Rate*	13.4	13.8	14.1	11.7		13.5	
95% C.I.	(12.5-14.5)	(12.6-15.0)	(11.7-16.8)	(9.5-14.5)		(13.4-13.7)	
Other/Unknown	0	0	0	0	0	0	
Race/Ethnicity							
White	617	428	106	83	0	22,790	
Rate*	14.6	15.5	14.3	11.7		14.3	
95% C.I.	(13.4-15.8)	(14.0-17.1)	(11.7-17.4)	(9.2-14.6)		(14.1-14.5)	
Black	28	23	4	1	0	1,833	
Rate*	10.6	8.8				10.1	
95% C.I.	(6.9-15.9)	(5.5-13.9)				(9.7-10.6)	
Native American	5	0	0	5	0	141	
Rate*						7.8	
95% C.I.						(6.5-9.3)	
Asian	32	28	3	1	0	1,644	
Rate*	8.8	9.1				9.7	
95% C.I.	(6.0-12.9)	(6.0-13.3)				(9.3-10.2)	
Hispanic	49	35	10	4	0	2,594	
Rate*	8.2	7.7	13.9			11.5	
95% C.I.	(5.9-11.5)	(5.1-11.4)	(6.2-29.6)			(11.0-12.0)	
Other/Unknown	3	2	0	0	1	138	

* Rates are per 100,000 age-specific female population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 263. Ovarian Cancer Inpatient Discharges by Gender, Charges, Length of
Stay, and County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	721	491	145	84	1			
Rate*	6.7	6.7	8.5	5.3				
95% C.I.	(6.2-7.2)	(6.1-7.3)	(7.2-10.1)	(4.2-6.7)				
Gender								
Male								
Rate*								
95% C.I.								
Female	721	491	145	84	1			
Rate*	13.1	12.9	16.4	10.6				
95% C.I.	(12.1-14.1)	(11.8-14.2)	(13.9-19.4)	(8.4-13.2)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Ch	narges (\$)							
Total Charges	\$44,972,093	\$28,517,658	\$12,067,132	\$4,308,828	\$78,475			
Average Charges	\$62,375	\$58,081	\$83,222	\$51,296	\$78,475			
Median Charges	\$40,741	\$36,256	\$60,309	\$39,423	\$78,475			
Discharge Length of S	tay (LOS) (Days)							
Total LOS	6,217	3,811	1,726	657	23			
Average LOS	8.6	7.8	11.9	7.8	23.0			
Median LOS	6.0	6.0	9.0	7.0	23.0			

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.


Table 264. Ovarian Cancer Mortality by Age Group and County/Region ofResidence, Nevada Residents, 2000-2004

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Deaths	456	321	77	58				
Rate*	8.5	8.7	9.1	6.9				
95% C.I.	(7.7-9.3)	(7.8-9.7)	(7.1-11.4)	(5.2-9.0)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	0	0	0	0				
Rate*								
95% C.I.								
25-34	2	1	1	0				
Rate*								
95% C.I.								
35-44	17	13	2	2				
Rate*	2.1	2.3						
95% C.I.	(1.09-3.06)	(1.04-3.51)						
45-54	52	42	7	3				
Rate*	7.1	8.5						
95% C.I.	(5.14-8.98)	(5.90-11.02)						
55-64	106	71	15	20				
Rate*	19.2	18.4	17.5	24.3				
95% C.I.	(15.51-22.80)	(14.13-22.70)	(8.65-26.38)	(13.66-34.98)				
65-74	128	95	22	11				
Rate*	35.2	37.8	40.4	19.1				
95% C.I.	(29.11-41.31)	(30.18-45.38)	(23.52-57.29)	(7.81-30.38)				
75-84	117	82	20	15				
Rate*	51.9	53.7	(24, 45, 70, 75)	41.2				
95% C.I.	(42.51-61.33)	(42.04-65.26)	(31.15-79.75)	(20.35-62.04)				
85+	34	17	10	7				
Rate*	53.8	41.6	84.3					
95% C.I.	(35.69-71.83)	(21.82-61.35)	(32.06-136.59)					
Unknown	0	0	0	0				

* Rates are per 100,000 age-specific female population.

THYROID GLAND CANCER <u>GENERAL PROFILE⁴</u>

Figure 169. Anatomical Drawing of the Thyroid Gland⁴



General Anatomy: The thyroid is a gland in the neck. It has two kinds of cells that make hormones. Follicular cells make thyroid hormone, which affects heart rate, body temperature, and energy level. C cells make calcitonin, a hormone that helps control the level of calcium in the blood. The thyroid is shaped like a butterfly and lies at the front of the neck, beneath the voice box (larynx). It has two parts, or lobes. The two lobes are separated by a thin section called the isthmus. A healthy thyroid is a little larger than a quarter. It usually cannot be felt through the skin. A swollen lobe might look or feel like a lump in the front of the neck. A swollen thyroid is called a goiter. Most goiters are caused by not enough iodine in the diet.

Risk Factors: Exposure to radiation, Family history, Being female, Age (over 40), Race (Whites are more likely to be diagnosed with Thyroid Cancer than Blacks, as a racial/ethnic group,), and not enough iodine in the diet.

Signs and Symptoms: A lump, or nodule, in the front of the neck near the Adam's apple, hoarseness or difficulty speaking in a normal voice, swollen lymph nodes, especially in the neck, difficulty swallowing or breathing, or pain in the throat or neck.

Diagnosing the Cancer: Physical exam, blood tests, ultrasonography, radionuclide scanning, and fineneedle aspiration.

Treatment: surgery (Total thyroidectomy, Lobectomy), radioactive iodine, hormone treatment, external radiation, and chemotherapy.

Table 265. Thyroid Gland Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)	
Total							
Cases	1,126	814	196	115	1	31,505	
Rate*	10.1	10.5	10.7	7.4		8.5	
95% C.I.	(9.5-10.7)	(9.8-11.3)	(9.2-12.3)	(6.1-8.9)		(8.4-8.6)	
Gender							
Male	245	172	41	31	1	7,579	
Rate*	4.4	4.6	4.3	3.8		4.4	
95% C.I.	(3.9-5.1)	(3.9-5.4)	(3.1-5.9)	(2.6-5.5)		(4.3-4.5)	
Female	881	642	155	84	0	23,926	
Rate*	16.0	16.7	17.2	11.1		12.5	
95% C.I.	(15.0-17.1)	(15.4-18.1)	(14.6-20.1)	(8.8-13.9)		(12.3-12.6)	
Other/Unknown	0	0	0	0	0	0	
Race/Ethnicity							
White	881	608	167	105	1	26,249	
Rate*	11.4	12.0	11.9	8.2		8.9	
95% C.I.	(10.6-12.2)	(11.1-13.0)	(10.1-13.9)	(6.6-10.0)		(8.8-9.0)	
Black	43	39	4	0	0	1,867	
Rate*	6.3	6.2				5.1	
95% C.I.	(4.5-8.7)	(4.3-8.6)				(4.9-5.3)	
Native American	3	0	2	1	0	163	
Rate*						3.7	
95% C.I.						(3.2-3.2)	
Asian	83	66	15	2	0	2,872	
Rate*	12.9	12.9	14.6			8.5	
95% C.I.	(10.0-17.5)	(9.5-18.7)	(8.1-24.4)			(8.2-8.8)	
Hispanic	95	83	6	6	0	4,229	
Rate*	6.0	6.8				7.5	
95% C.I.	(4.7-7.6)	(5.2-8.7)				(7.2-7.7)	
Other/Unknown	21	18	2	1	0	354	

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 266. Thyroid Gland Cancer Inpatient Discharges by Gender, Charges,	
Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004	

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	1,570	1,312	161	97	0			
Rate*	14.1	16.9	8.8	6.2				
95% C.I.	(13.4-14.8)	(16.0-17.9)	(7.4-10.2)	(5.0-7.7)				
Gender								
Male	332	272	34	26	0			
Rate*	6.0	7.2	3.6	3.1				
95% C.I.	(5.4-6.8)	(6.3-8.2)	(2.5-5.0)	(2.0-4.7)				
Female	1,238	1,040	127	71	0			
Rate*	22.5	27.1	14.1	9.4				
95% C.I.	(21.3-23.8)	(25.5-28.8)	(11.7-16.7)	(7.3-11.9)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Ch	narges (\$)							
Total Charges	\$23,968,521	\$19,591,628	\$2,892,023	\$1,484,870	\$0			
Average Charges	\$15,267	\$14,933	\$17,963	\$15,308	\$0			
Median Charges	\$12,740	\$11,990	\$15,993	\$13,963	\$0			
Discharge Length of S	tay (LOS) (Days)							
Total LOS	3,179	2,644	349	186	0			
Average LOS	2.0	2.0	2.2	1.9	0.0			
Median LOS	2.0	2.0	2.0	2.0	0.0			

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.


Table 267. Thyroid Gland Cancer Mortality by Age Group and County/Region of
Residence, Nevada Residents, 2000-2004

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Deaths	29	24	3	2			
Rate*	0.3	0.4	0.0	0.0			
95% C.I.	(0.2-0.4)	(0.2-0.6)					
Age Group							
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	0	0	0	0			
Rate*							
95% C.I.							
15-24	0	0	0	0			
Rate*							
95% C.I.							
25-34	0	0	0	0			
Rate*							
95% C.I.							
35-44	1	1	0	0			
Rate*							
95% C.I.							
45-54	3	2	0	1			
Rate*							
95% C.I.							
55-64	6	4	2	0			
Rate*							
95% C.I. 65-74							
Rate*	8	7	0	1			
95% C.I.							
75-84	9	8		0			
Rate*				0			
95% C.I.							
85+	2	2	0	0			
Rate*							
95% C.I.							
Unknown	0	0	0	0			

* Rates are per 100,000 age-specific population.

BRAIN AND OTHER CENTRAL NERVOUS SYSTEM CANCER GENERAL PROFILE⁴

Figure 170. Anatomical Drawing of the Brain and Nearby Structures⁴



General Anatomy: The brain is a soft, spongy mass of tissue. It is protected by the bones of the skull and three thin membranes called meninges. Watery fluid called cerebrospinal fluid cushions the brain. This fluid flows through spaces between the meninges and through spaces within the brain called ventricles. A network of nerves carries messages back and forth between the brain and the rest of the body. Some nerves go directly from the brain to the eyes, ears, and other parts of the head. Other nerves run through the spinal cord to connect the brain with the other parts of the body. Within the brain and spinal cord, glial cells surround nerve cells and hold them in place.

Risk Factors: Being male, being white, age (over 70 years of age), family history, and exposure to: radiation or certain chemicals: formaldehyde, vinyl chloride, and acrylonitrile.

Signs and Symptoms: Headaches (usually worse in the morning), nausea or vomiting, changes in speech, vision, or hearing, problems balancing or walking, changes in mood, personality, or ability to concentrate, problems with memory, muscle jerking or twitching (seizures or convulsions), and numbness or tingling in the arms or legs.

Diagnosing the Cancer: Physical exam, neurologic exam, computed tomography (CAT) scan, magnetic resonance imaging (MRI), angiogram, skull x-ray, spinal tap, myelogram, and biopsy.

Treatment: surgery (Craniotomy), radiation therapy (Fractionation, Hyperfractionation, Stereotactic, 3-dimensional conformal, and Proton beam), and chemotherapy

Table 268. Brain and Other Central Nervous System Cancer Cases by Gender,Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents(2000-2004) and SEER-17 (2000-2004)

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)	
Total							
Cases	663	430	118	115	0	23,505	
Rate*	6.3	5.9	7.0	7.5		6.4	
95% C.I.	(5.8-6.8)	(5.3-6.5)	(5.8-8.5)	(6.0-9.8)		(6.4-6.5)	
Gender							
Male	385	242	76	67	0	12,996	
Rate*	7.5	6.8	9.1	8.5		7.7	
95% C.I.	(6.7-8.3)	(6.0-7.9)	(7.1-11.7)	(6.6-11.1)		(7.5-7.8)	
Female	278	188	42	48	0	10,509	
Rate*	5.2	5.1	4.8	6.5		5.4	
95% C.I.	(4.6-5.9)	(4.4-5.9)	(3.5-6.5)	(4.4-10.7)		(5.3-5.5)	
Other/Unknown	0	0	0	0	0	0	
Race/Ethnicity							
White	545	336	102	107	0	20,695	
Rate*	6.9	6.5	7.4	7.6		7.1	
95% C.I.	(6.3-7.5)	(5.8-7.3)	(6.0-9.0)	(6.2-9.3)		(7.0-7.1)	
Black	29	26	2	1	0	1,484	
Rate*	4.7	4.6				4.1	
95% C.I.	(3.0-7.3)	(2.9-7.5)				(3.9-4.3)	
Native American	0	0	0	0	0	85	
Rate*						2.2	
95% C.I.						(1.7-1.7)	
Asian	20	17	2	1	0	1,073	
Rate*	3.2	3.2				3.4	
95% C.I.	(1.9-5.2)	(1.8-5.3)				(3.2-3.6)	
Hispanic	59	43	12	4	0	2,869	
Rate*	4.8	3.8	7.6			5.3	
95% C.I.	(3.3-7.1)	(2.5-5.7)	(2.3-21.9)			(5.1-5.5)	
Other/Unknown	10	8	0	2	0	168	

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 269. Brain and Other Central Nervous System Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Discharges	946	676	129	141	0		
Rate*	8.8	9.1	7.4	8.8			
95% C.I.	(8.2-9.4)	(8.4-9.8)	(6.2-8.8)	(7.4-10.5)			
Gender							
Male	524	359	85	80	0		
Rate*	9.8	9.7	9.7	10.2			
95% C.I.	(9.0-10.8)	(8.7-10.8)	(7.7-12.3)	(8.0-12.9)			
Female	422	317	44	61	0		
Rate*	7.8	8.5	5.0	7.6			
95% C.I.	(7.1-8.6)	(7.6-9.5)	(3.6-6.7)	(5.8-9.8)			
Other/Unknown	0	0	0	0	0		
Inpatient Discharge Ch	arges (\$)						
Total Charges	\$47,679,851	\$36,154,520	\$5,551,517	\$5,973,814	\$0		
Average Charges	\$50,402	\$53,483	\$43,035	\$42,367	\$0		
Median Charges	\$37,562	\$38,316	\$37,060	\$31,538	\$0		
Discharge Length of Stay (LOS) (Days)							
Total LOS	7,068	5,113	978	977	0		
Average LOS	7.5	7.6	7.6	6.9	0.0		
Median LOS	5.0	5.0	5.0	5.0	0.0		

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.


Table 270. Brain and Other Central Nervous System Cancer Mortality by AgeGroup and County/Region of Residence, Nevada Residents, 2000-2004

		County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Deaths	415	277	63	75			
Rate*	4.0	3.9	3.8	4.7			
95% C.I.	(3.6-4.4)	(3.4-4.4)	(2.9-4.9)	(3.7-6.0)			
Age Group							
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	6	4	1	1			
Rate*							
95% C.I.							
5-14	6	3	2	1			
Rate*							
95% C.I.							
15-24	11	7	3	1			
Rate*	0.7						
95% C.I.	(0.29-1.12)						
25-34	13	10	2	1			
Rate*	0.8	0.8					
95% C.I.	(0.37-1.24)	(0.32-1.35)					
35-44	29	16	7	6			
Rate*	1.7	1.3					
95% C.I.	(1.08-2.32)	(0.68-1.98)					
45-54	58	43	8	7			
Rate*	3.9	4.3					
95% C.I.	(2.88-4.88)	(2.99-5.54)					
55-64	90	60	13	17			
Rate*	8.2	8.0	7.5	10.2			
95% C.I.	(6.54-9.95)	(5.96-10.00)	(3.42-11.55)	(5.36-15.07)			
65-74	96	67	14	15			
Rate*	13.4	13.5	13.1	13.0			
95% C.I.	(10.71-16.07)	(10.30-16.79)	(6.26-20.02)	(6.41-19.55)			
75-84	85	56	7	22			
Rate*	20.7	20.0		32.4			
95% C.I.	(16.28-25.08)	(14.77-25.26)		(18.87-45.97)			
85+	21	11	6	4			
Rate*	22.1	18.1					
95% C.I.	(12.65-31.56)	(7.39-28.75)					
Unknown	0	0	0	0			

* Rates are per 100,000 age-specific population.

STOMACH CANCER <u>GENERAL PROFILE⁴</u>

Figure 171. Anatomical Drawing of the Esophagus and Stomach⁵



General Anatomy: The stomach is part of the digestive system. It is located in the upper abdomen, under the ribs. The upper part of the stomach connects to the esophagus, and the lower part leads into the small intestine. When food enters the stomach, muscles in the stomach wall create a rippling motion that mixes and mashes the food. At the same time, juices made by glands in the lining of the stomach help digest the food. After about 3 hours, the food becomes a liquid and moves into the small intestine, where digestion continues.

Risk Factors: While the cause of Stomach Cancer is still unknown, some people are more likely to be diagnosed with Stomach Cancer. It is more common in: people over 55 years of age, males, Blacks as a racial/ethnic group, and people who have had stomach surgery or have pernicious anemia, achlorhydria, or gastric atrophy (which generally result in lower than normal amounts of digestive juices) have an increased risk. Stomach Cancer is also more common in parts of the world like Japan, Korea, parts of Eastern Europe, and Latin America than in the United States.

Signs and Symptoms: Indigestion or a burning sensation (heartburn), discomfort or pain in the abdomen, nausea and vomiting, diarrhea or constipation, bloating of the stomach after meals, loss of appetite, weakness and fatigue, and bleeding (vomiting blood or having blood in the stool).

Diagnosing the Cancer: Fecal occult blood test, upper gastrointestinal (GI) x-ray series, and endoscopy are some of the common ways of diagnosing Stomach Cancer.

Treatment: surgery (Gastrectomy), chemotherapy, radiation therapy, and biological therapy.

Table 271. Stomach Cancer Cases by Gender, Race/Ethnicity and County/Regionof Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)		
Total	Total							
Cases	639	462	102	74	1	28,598		
Rate*	6.4	6.8	6.4	4.7		8.1		
95% C.I.	(5.9-6.9)	(6.2-7.5)	(5.2-7.8)	(3.7-6.0)		(8.0-8.2)		
Gender								
Male	421	300	71	50	0	17,355		
Rate*	8.9	9.3	9.8	6.2		11.4		
95% C.I.	(8.0-9.9)	(8.2-10.6)	(7.5-12.7)	(4.6-8.4)		(11.3-11.6)		
Female	218	162	31	24	1	11,243		
Rate*	4.2	4.6	3.6	3.0		5.6		
95% C.I.	(3.7-4.8)	(3.9-5.3)	(2.5-5.2)	(1.9-4.6)		(5.5-5.7)		
Other/Unknown	0	0	0	0	0	0		
Race/Ethnicity								
White	478	329	81	68	0	20,827		
Rate*	5.9	6.2	5.9	4.7		7.1		
95% C.I.	(5.4-6.4)	(5.5-6.9)	(4.7-7.4)	(3.6-6.1)		(7.0-7.2)		
Black	58	54	4	0	0	3,568		
Rate*	11.6	11.6				12.5		
95% C.I.	(8.7-15.5)	(8.5-15.7)				(12.1-13.0)		
Native American	1	0	1	0	0	221		
Rate*						7.8		
95% C.I.						(6.8-6.8)		
Asian	39	33	4	1	1	3,835		
Rate*	7.7	8.2				14.3		
95% C.I.	(5.4-10.8)	(5.5-11.9)				(13.8-14.7)		
Hispanic	56	42	9	5	0	4,338		
Rate*	7.8	7.5				12.3		
95% C.I.	(5.5-11.0)	(5.0-11.3)				(11.9-12.7)		
Other/Unknown	7	4	3	0	0	147		

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 272. Stomach Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	
Total						
Discharges	597	448	91	58	0	
Rate*	5.8	6.3	5.6	3.8		
95% C.I.	(5.3-6.3)	(5.7-7.0)	(4.5-6.9)	(2.8-4.9)		
Gender						
Male	409	312	58	39	0	
Rate*	8.2	9.2	7.5	5.0		
95% C.I.	(7.4-9.1)	(8.1-10.4)	(5.6-10.0)	(3.5-7.0)		
Female	188	136	33	19	0	
Rate*	3.6	3.7	3.9	2.4		
95% C.I.	(3.1-4.1)	(3.1-4.4)	(2.7-5.5)	(1.4-3.8)		
Other/Unknown	0	0	0	0	0	
Inpatient Discharge Ch	narges (\$)					
Total Charges	\$40,467,096	\$31,023,880	\$5,894,195	\$3,549,021	\$0	
Average Charges	\$67,784	\$69,250	\$64,771	\$61,190	\$0	
Median Charges	\$46,095	\$47,289	\$44,733	\$36,127	\$0	
Discharge Length of Stay (LOS) (Days)						
Total LOS	6,669	5,040	1,047	582	0	
Average LOS	11.2	11.3	11.5	10.0	0.0	
Median LOS	9.0	9.0	9.0	8.0	0.0	

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.


Table 273. Stomach Cancer Mortality by Age Group and County/Region ofResidence, Nevada Residents, 2000-2004

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties		
Total						
Deaths	346	253	52	41		
Rate*	3.6	3.9	3.3	2.7		
95% C.I.	(3.2-4.0)	(3.4-4.4)	(2.5-4.4)	(1.9-3.7)		
Age Group						
<1	0	0	0	0		
Rate*						
95% C.I.						
1-4	0	0	0	0		
Rate*						
95% C.I.						
5-14	0	0	0	0		
Rate*						
95% C.I.						
15-24	2	1	0	1		
Rate*						
95% C.I.						
25-34	5	5	0	0		
Rate*						
95% C.I.						
35-44	11	10	1	0		
Rate*	0.7	0.8				
95% C.I.	(0.26-1.03)	(0.32-1.35)				
45-54	35	25	6	4		
Rate*	2.3	2.5				
95% C.I.	(1.57-3.12)	(1.51-3.45)				
55-64	51	30	11	10		
Rate*	4.7	4.0	6.3	6.0		
95% C.I.	(3.39-5.95)	(2.56-5.42)	(2.59-10.08)	(2.28-9.73)		
65-74	91	70	14	7		
Rate*	12.7	14.2	13.1			
95% C.I.	(10.09-15.30)	(10.83-17.46)	(6.26-20.02)			
75-84	107	82	13	12		
Rate*	26.0 (21 10 20 07)	(22.06.25.65)	20.5	(7 68 27 60)		
95% C.I.	(21.10-30.97)	(22.96-35.65)	(9.37-31.69)	(7.68-27.69)		
85+ Poto*	44	30	7	7		
Rate* 95% C.I.	46.3	49.3				
95% C.I. Unknown	(32.63-59.99)	(31.64-66.91)				
UNKNOWN	0	0	0	0		

* Rates are per 100,000 age-specific population.

LIVER AND INTRAHEPATIC BILE DUCTS CANCER <u>GENERAL PROFILE⁴</u>

Figure 172. Anatomical Drawing of the Digestive System⁵



General Anatomy: The liver is the largest organ in the body. It is found behind the ribs on the right side of the abdomen. The liver has two parts, a right lobe and a smaller left lobe. The liver has many important functions that keep a person healthy. It removes harmful material from the blood. It makes enzymes and bile that help digest food. It also converts food into substances needed for life and growth. The liver gets its supply of blood from two vessels. Most of its blood comes from the hepatic portal vein. The rest comes from the hepatic artery.

Risk Factors: Chronic liver infection (hepatitis), cirrhosis, Aflatoxin (type of mold), being male, family history, and age (over 60 years of age).

Signs and Symptoms: Pain in the upper abdomen on the right side; the pain may extend to the back and shoulder, swollen abdomen (bloating), weight loss, loss of appetite and feelings of fullness, weakness or feeling very tired, nausea and vomiting, yellow skin and eyes and dark urine from jaundice, and fever.

Diagnosing the Cancer: Physical exam, blood tests, computed tomography (CAT) scan, ultrasound test, magnetic resonance imaging (MRI), angiogram, and biopsy.

Treatment: surgery (Hepatectomy, Transplantation), radio frequency ablation, percutaneous ethanol injection, cryosurgery, hepatic arterial infusion, chemoembolization, chemotherapy, and radiation therapy.

Table 274. Liver and Intrahepatic Bile Ducts Cancer Cases by Gender,Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents(2000-2004) and SEER-17 (2000-2004)

			County/Region	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)
Total						
Cases	555	398	90	67	0	22,078
Rate*	5.4	5.6	5.5	4.5		6.2
95% C.I.	(4.9-5.8)	(5.0-6.2)	(4.4-6.8)	(3.3-6.6)		(6.1-6.3)
Gender						
Male	392	277	70	45	0	15,363
Rate*	7.7	8.0	8.9	6.2		9.5
95% C.I.	(7.0-8.6)	(7.1-9.1)	(6.9-11.5)	(4.2-10.0)		(9.4-9.7)
Female	163	121	20	22	0	6,715
Rate*	3.1	3.4	2.4	2.7		3.4
95% C.I.	(2.7-3.7)	(2.8-4.1)	(1.5-3.7)	(1.7-4.2)		(3.3-3.5)
Other/Unknown	0	0	0	0	0	0
Race/Ethnicity						
White	402	262	76	64	0	15,267
Rate*	4.9	4.8	5.3	4.9		5.2
95% C.I.	(4.4-5.4)	(4.3-5.5)	(4.2-6.7)	(3.5-7.3)		(5.1-5.3)
Black	32	31	1	0	0	2,432
Rate*	5.2	5.4				7.6
95% C.I.	(3.5-7.6)	(3.6-7.9)				(7.3-8.0)
Native American	2	1	0	1	0	232
Rate*						7.1
95% C.I.						(6.2-6.2)
Asian	63	55	7	1	0	4,021
Rate*	13.1	13.8				13.9
95% C.I.	(9.5-18.6)	(9.7-20.4)				(13.5-14.4)
Hispanic	51	44	6	1	0	3,593
Rate*	7.0	7.5				9.7
95% C.I.	(5.0-9.9)	(5.2-11.2)				(9.4-10.0)
Other/Unknown	5	5	0	0	0	126

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 275. Liver and Intrahepatic Bile Ducts Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004

		Coun	ty/Region of Resid	lence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	379	297	58	23	1
Rate*	3.6	4.1	3.5	1.5	
95% C.I.	(3.3-4.0)	(3.7-4.7)	(2.7-4.6)	(0.9-2.2)	
Gender					
Male	257	206	38	12	1
Rate*	4.9	5.7	4.8	1.4	
95% C.I.	(4.3-5.6)	(4.9-6.6)	(3.4-6.9)	(0.7-2.6)	
Female	122	91	20	11	0
Rate*	2.4	2.6	2.4	1.4	
95% C.I.	(2.0-2.9)	(2.1-3.3)	(1.4-3.7)	(0.7-2.5)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	arges (\$)				
Total Charges	\$12,734,532	\$10,877,493	\$1,230,212	\$577,331	\$49,496
Average Charges	\$33,600	\$36,625	\$21,211	\$25,101	\$49,496
Median Charges	\$22,134	\$24,422	\$17,305	\$12,643	\$49,496
Discharge Length of S	tay (LOS) (Days)				
Total LOS	2,374	1,913	321	127	13
Average LOS	6.3	6.4	5.5	5.5	13.0
Median LOS	5.0	5.0	4.0	4.0	13.0

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 276. Liver and Intrahepatic Bile Ducts Cancer Mortality by Age Group and
County/Region of Residence, Nevada Residents, 2000-2004


		County/Regior	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties						
Total										
Deaths	501	352	80	69						
Rate*	4.9	5.1	5.0	4.4						
95% C.I.	(4.5-5.4)	(4.5-5.6)	(3.9-6.2)	(3.4-5.7)						
Age Group										
<1	1	1	0	0						
Rate*										
95% C.I.										
1-4	1	1	0	0						
Rate*										
95% C.I.										
5-14	2	2	0	0						
Rate*										
95% C.I.										
15-24	3	3	0	0						
Rate*										
95% C.I.										
25-34	3	2	0	1						
Rate*										
95% C.I.										
35-44	16	13	1	2						
Rate*	0.9	1.1								
95% C.I.	(0.48-1.40)	(0.49-1.67)								
45-54	84	62	17	5						
Rate*	5.6	6.2	6.5							
95% C.I.	(4.42-6.83)	(4.62-7.68)	(3.40-9.57)							
55-64	83	64	8	11						
Rate*	7.6	8.5		6.6						
95% C.I.	(5.97-9.24)	(6.43-10.60)		(2.70-10.52)						
65-74	152	103	33	16						
Rate*	21.2	20.8	31.0	13.8						
95% C.I.	(17.83-24.58)	(16.80-24.84)	(20.41-41.54)	(7.06-20.63)						
75-84	125	81	16	28						
Rate*	30.4	29.0	25.3	41.3						
95% C.I.	(25.08-35.75)	(22.64-35.25)	(12.89-37.65)	(25.98-56.54)						
85+	31	20	5	6						
Rate*	32.6	32.9								
95% C.I.	(21.14-44.11)	(18.45-47.25)								
Unknown	0	0	0	0						

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

CERVICAL CANCER <u>GENERAL PROFILE⁴</u>

Figure 173. Anatomical Drawing of the Female Reproductive System⁴



General Anatomy: The cervix is the lower, narrow part of the uterus (womb). The uterus, a hollow, pear-shaped organ, is located in a woman's lower abdomen, between the bladder and the rectum. The cervix forms a canal that opens into the vagina, which leads to the outside of the body. Cells on the surface of the cervix sometimes appear abnormal but not cancerous. Scientists believe that some abnormal changes in cells on the cervix are the first step in a series of slow changes that can lead to cancer years later. If these changes form abnormal cells that spread deeper into the cervix or to other tissues or organs, the disease is then called cervical cancer, or invasive cervical cancer.

Risk Factors: Researchers believe that, in many cases, cervical cancer develops when two or more risk factors act together. These include: women who began having sexual intercourse before age 18, women who have had many sexual partners, women whose partners began having sexual intercourse at a young age, have had many sexual partners, or were previously married to women who had cervical cancer, some sexually transmitted human papillomaviruses (HPVs), smoking, women whose mothers were given the drug diethylstilbestrol (DES) during pregnancy to prevent miscarriage, weakened immune systems, and the use of oral contraceptives (the pill).

Signs and Symptoms: Precancerous changes of the cervix usually do not cause pain. In fact, they generally do not cause any symptoms until abnormal cervical cells become cancerous and invade nearby tissue, unless a woman has a pelvic exam and a Pap test. Symptoms include: abnormal bleeding (longer and heavier than usual), bleeding after menopause, and increased vaginal discharge is another symptom of cervical cancer.

Diagnosing the Cancer: Pap Smear tests (Early Detection), colposcopy, endocervical curettage, conization, dilation and curettage,

Treatment: Surgery (Hysterectomy), cryosurgery, cauterization, laser surgery, conization, radiation therapy, and chemotherapy.

Table 277. Cervical Cancer Screening by County/Region of Residence, Education,Age Group, and Income, Nevada Residents, 2000, 2002 and 2004

	Answers							
Responses		Yes		No				
	Number	Percent*	95% C.I.	Number	Percent*	95% C.I.	Total	
Total								
Responses	3,942	94.7%	(93.6-95.8)	177	5.3%	(4.2-6.4)	4,119	
County/Region of Resid	dence							
Clark County	1,289	95.3%	(93.8-96.7)	50	4.7%	(3.3-6.2)	1,339	
Washoe County	1,295	95.8%	(94.5-97.1)	52	4.2%	(2.9-5.5)	1,347	
All Other Counties	1,358	91.3%	(88.0-94.6)	75	8.7%	(5.4-12.0)	1,433	
Education								
Less than High School	370	89.9%	(85.0-94.8)	36	10.1%	(5.2-15.0)	406	
High School	1,212	93.4%	(91.3-95.5)	73	6.6%	(4.5-8.7)	1,285	
Some Post High School	1,337	95.7%	(94.0-97.4)	46	4.3%	(2.6-6.0)	1,383	
College Graduate	1,014	97.5%	(95.7-99.2)	21	2.5%	(0.8-4.3)	1,035	
Age Group								
18-24 years old	280	76.8%	(70.1-83.4)	62	23.2%	(16.6-29.9)	342	
25-34 years old	639	96.8%	(94.9-98.8)	20	3.2%	(1.2-5.1)	659	
35-44 years old	825	97.6%	(96.0-99.2)	15	2.4%	(0.8-4.0)	840	
45-54 years old	803	98.8%	(97.6-100.0)	11	1.2%	(0.0-2.4)	814	
55-64 years old	594	97.5%	(95.6-99.4)	13	2.5%	(0.6-4.4)	607	
65+ years old	796	94.0%	(91.2-96.8)	56	6.0%	(3.2-8.8)	852	
Income								
Less than \$15,000	367	87.4%	(81.7-93.2)	43	12.6%	(6.8-18.3)	410	
\$15,000-\$24,999	636	93.4%	(90.2-96.7)	36	6.6%	(3.3-9.8)	672	
\$25,000-\$34,999	530	95.0%	(92.2-97.8)	22	5.0%	(2.2-7.8)	552	
\$35,000-\$49,999	688	96.9%	(95.0-98.8)	20	3.1%	(1.2-5.0)	708	
\$50,000 or More	1,200	97.7%	(96.1-99.3)	15	2.3%	(0.7-3.9)	1,215	

*Denominator is persons age 18-65+ and excludes missing, don't know, and refused responses.

Note: This table includes those respondents who answered "Yes" or "No" to the following question:

1) A Pap smear is a test for cancer of the cervix. Have you ever had a Pap smear?

Table 278. Cervical Cancer Cases by Gender, Race/Ethnicity and County/Regionof Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)			
Total									
Cases	514	383	85	46	0	16,674			
Rate*	4.7	5.1	4.8	3.1		4.5			
95% C.I.	(4.3-5.2)	(4.6-5.6)	(3.8-6.0)	(2.2-4.1)		(4.4-4.6)			
Gender									
Male									
Rate*									
95% C.I.									
Female	514	383	85	46	0	16,674			
Rate*	9.4	10.1	9.4	6.1		8.7			
95% C.I.	(8.6-10.3)	(9.1-11.2)	(7.5-11.7)	(4.5-8.2)		(8.5-8.8)			
Other/Unknown	0	0	0	0	0	0			
Race/Ethnicity									
White	371	266	64	41	0	12,762			
Rate*	9.5	10.5	9.0	6.3		8.5			
95% C.I.	(8.6-10.6)	(9.3-11.9)	(6.9-11.6)	(4.5-8.7)		(8.3-8.6)			
Black	31	29	2	0	0	2,235			
Rate*	9.4	9.5				11.4			
95% C.I.	(6.3-14.0)	(6.3-14.3)				(10.9-11.9)			
Native American	2	1	1	0	0	106			
Rate*						5.0			
95% C.I.						(4.1-6.2)			
Asian	40	33	5	2	0	1,387			
Rate*	11.5	11.9				8.0			
95% C.I.	(7.7-18.3)	(7.4-20.6)				(7.6-8.4)			
Hispanic	58	43	13	2	0	3,794			
Rate*	9.1	8.0	20.3			13.8			
95% C.I.	(6.7-12.4)	(5.6-11.6)	(10.0-38.7)			(13.3-14.3)			
Other/Unknown	12	11	0	1	0	184			

* Rates are per 100,000 age-specific female population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 279. Cervical Cancer Inpatient Discharges by Gender, Charges, Length ofStay, and County/Region of Residence, Nevada Residents, 2000-2004

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	609	418	110	81	0
Rate*	5.5	5.4	6.0	5.2	
95% C.I.	(5.1-6.0)	(4.9-6.0)	(4.9-7.3)	(4.1-6.5)	
Gender					
Male					
Rate*					
95% C.I.					
Female	609	418	110	81	0
Rate*	11.1	11.0	12.0	10.4	
95% C.I.	(10.2-12.0)	(10.0-12.1)	(9.9-14.5)	(8.2-13.0)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$20,427,803	\$13,756,202	\$4,140,247	\$2,531,354	\$0
Average Charges	\$33,543	\$32,910	\$37,639	\$31,251	\$0
Median Charges	\$24,485	\$23,788	\$31,221	\$18,854	\$0
Discharge Length of S	itay (LOS) (Days)				
Total LOS	2,981	2,063	494	424	0
Average LOS	4.9	4.9	4.5	5.2	0.0
Median LOS	3.0	4.0	3.0	3.0	0.0

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 280. Cervical Cancer Mortality by Age Group and County/Region ofResidence, Nevada Residents, 2000-2004


		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Deaths	149	110	22	17				
Rate*	2.8	3.0	2.5	2.1				
95% C.I.	(2.3-3.3)	(2.5-3.6)	(1.5-3.8)	(1.2-3.4)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	0	0	0	0				
Rate*								
95% C.I.								
25-34	9	8	1	0				
Rate*								
95% C.I.								
35-44	24	18	3	3				
Rate*	2.9	3.2						
95% C.I.	(1.76-4.10)	(1.69-4.60)						
45-54	35	28	3	4				
Rate*	4.8	5.6						
95% C.I.	(3.18-6.33)	(3.55-7.73)						
55-64	29	17	8	4				
Rate*	5.2	4.4						
95% C.I.	(3.33-7.15)	(2.31-6.50)						
65-74	24	18	2	4				
Rate*	6.6	7.2						
95% C.I.	(3.96-9.24)	(3.85-10.47)						
75-84	20	14	4	2				
Rate*	8.9	9.2						
95% C.I.	(4.99-12.77)	(4.36-13.96)						
85+	8	7	1	0				
Rate*								
95% C.I.								
Unknown	0	0	0	0				

* Rates are per 100,000 age-specific female population.

Note: The "---" is used for rates calculated on numbers less than ten.

ESOPHAGEAL CANCER GENERAL PROFILE⁴

Figure 174. Anatomical Drawing of the Esophagus and Stomach⁵



General Anatomy: The esophagus is a hollow tube that carries food and liquids from the throat to the stomach. When a person swallows, the muscular walls of the esophagus contract to push food down into the stomach. Glands in the lining of the esophagus produce mucus, which keeps the passageway moist and makes swallowing easier. The esophagus is located just behind the trachea (windpipe). In an adult, the esophagus is about 10 inches long.

Risk Factors: Age, (over 60 years of age), being male, tobacco use, chronic and/or heavy alcohol use, Barrett's Esophagus (Long-term irritation from gastric reflux), medical history, and other types of irritation that cause significant irritation or damage to the lining of the esophagus (swallowing lye or other caustic substances) can increase the risk of developing esophageal cancer.

Signs and Symptoms: Difficult or painful swallowing, severe weight loss, pain in the throat or back, behind the breastbone or between the shoulder blades, hoarseness or chronic cough, vomiting, and coughing up blood are some common symptoms of Esophageal Cancer.

Diagnosing the Cancer: Barium swallow x-rays (also called an Esophagram), biopsy procedures (Esophagoscopy/Endoscopy), computed tomography (CAT) scan, bone scan, and bronchoscopy are common ways of diagnosing this type of cancer.

Treatment: Surgery (Esophagectomy), radiation therapy, chemotherapy, laser therapy, and photodynamic therapy (PDT).

Table 281. Esophageal Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)			
Total									
Cases	545	370	81	94	0	16,227			
Rate*	5.2	5.1	5.0	5.6		4.6			
95% C.I.	(4.8-5.7)	(4.6-5.7)	(4.0-6.3)	(4.5-7.0)		(4.5-4.7)			
Gender									
Male	425	291	60	74	0	12,213			
Rate*	8.5	8.4	8.2	9.1		7.9			
95% C.I.	(7.7-9.4)	(7.4-9.5)	(6.2-10.8)	(7.1-11.7)		(7.7-8.0)			
Female	120	79	21	20	0	4,014			
Rate*	2.2	2.2	2.5	2.4		2.0			
95% C.I.	(1.9-2.7)	(1.7-2.7)	(1.5-3.8)	(1.5-3.8)		(2.0-2.1)			
Other/Unknown	0	0	0	0	0	0			
Race/Ethnicity									
White	475	309	75	91	0	13,524			
Rate*	5.5	5.5	5.3	6.0		4.6			
95% C.I.	(5.1-6.1)	(4.9-6.2)	(4.2-6.7)	(4.8-7.4)		(4.5-4.7)			
Black	33	29	3	1	0	1,878			
Rate*	6.5	6.2				6.2			
95% C.I.	(4.4-9.7)	(4.0-9.6)				(5.9-6.5)			
Native American	0	0	0	0	0	75			
Rate*						2.7			
95% C.I.						(2.1-2.1)			
Asian	11	10	1	0	0	691			
Rate*	2.0	2.3				2.5			
95% C.I.	(1.0-3.8)	(1.1-4.5)				(2.3-2.7)			
Hispanic	17	14	2	1	0	1,011			
Rate*	2.5	2.8				3.0			
95% C.I.	(1.3-4.7)	(1.4-5.7)				(2.8-3.2)			
Other/Unknown	9	8	0	1	0	59			

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 282. Esophageal Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	302	216	43	43	0
Rate*	2.9	3.0	2.6	2.6	
95% C.I.	(2.5-3.2)	(2.6-3.4)	(1.9-3.6)	(1.8-3.5)	
Gender					
Male	227	162	33	32	0
Rate*	4.5	4.6	4.5	3.9	
95% C.I.	(3.9-5.2)	(3.9-5.5)	(3.1-6.7)	(2.6-5.7)	
Female	75	54	10	11	0
Rate*	1.4	1.5	1.2	1.3	
95% C.I.	(1.1-1.7)	(1.1-1.9)	(0.6-2.1)	(0.6-2.3)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$16,603,106	\$12,097,988	\$1,996,242	\$2,508,876	\$0
Average Charges	\$54,977	\$56,009	\$46,424	\$58,346	\$0
Median Charges	\$31,245	\$33,147	\$25,413	\$24,912	\$0
Discharge Length of S	tay (LOS) (Days)				
Total LOS	2,781	2,052	324	405	0
Average LOS	9.2	9.5	7.5	9.4	0.0
Median LOS	7.0	7.0	6.0	7.0	0.0

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 283. Esophageal Cancer Mortality by Age Group and County/Region of
Residence, Nevada Residents, 2000-2004


		County/Region	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties						
Total										
Deaths	459	327	54	78						
Rate*	4.4	4.6	3.4	4.7						
95% C.I.	(4.0-4.9)	(4.1-5.1)	(2.5-4.4)	(3.7-6.0)						
Age Group										
<1	0	0	0	0						
Rate*										
95% C.I.										
1-4	0	0	0	0						
Rate*										
95% C.I.										
5-14	0	0	0	0						
Rate*										
95% C.I.										
15-24	0	0	0	0						
Rate*										
95% C.I.										
25-34	0	0	0	0						
Rate*										
95% C.I.										
35-44	12	10	1	1						
Rate*	0.7	0.8								
95% C.I.	(0.31-1.10)	(0.32-1.35)								
45-54	45	33	5	7						
Rate*	3.0	3.3								
95% C.I.	(2.13-3.89)	(2.16-4.39)								
55-64	130	99	12	19						
Rate*	11.9	13.2	6.9	11.4						
95% C.I.	(9.86-13.96)	(10.58-15.77)	(3.00-10.82)	(6.28-16.55)						
65-74	135	88	22	25						
Rate*	18.8	17.8	20.7	21.6						
95% C.I.	(15.66-22.01)	(14.07-21.50)	(12.02-29.28)	(13.15-30.11)						
75-84	113	82	9	22						
Rate*	27.5	29.3		32.4						
95% C.I.	(22.42-32.56)	(22.96-35.65)		(18.87-45.97)						
85+	24	15	5	4						
Rate*	25.3	24.6								
95% C.I.	(15.15-35.37)	(12.17-37.11)								
Unknown	0	0	0	0						

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

LARYNX CANCER GENERAL PROFILE⁴

Figure 175. Anatomy of the Oral Cavity⁵



General Anatomy: The larynx, also called the voice box, is a 2-inch-long, tube-shaped organ made of cartilage in the neck. We use the larynx when we breathe, talk, or swallow. The larynx is at the top of the windpipe (trachea). The large cartilage that forms the front of the larynx is sometimes called the Adam's apple. The vocal cords, two bands of muscle, form a "V" inside the larynx.

Risk Factors: Cancer of the larynx occurs most often in people over the age of 55, men, Blacks as a racial/ethnic group, smokers, and those who work with asbestos.

Signs and Symptoms: The symptoms of cancer of the larynx depend mainly on the size and location of the tumor. Most cancers of the larynx begin on the vocal cords. These tumors are seldom painful, but they almost always cause hoarseness or other changes in the voice. Tumors in the area above the vocal cords may cause a lump on the neck, a sore throat, or an earache. Tumors that begin in the area below the vocal cords are rare. They can make it hard to breathe, and breathing may be noisy.

A cough that doesn't go away or the feeling of a lump in the throat may also be warning signs of cancer of the larynx. As the tumor grows, it may cause pain, weight loss, bad breath, and frequent choking on food. In some cases, a tumor in the larynx can make it hard to swallow.

Diagnosing the Cancer: Direct and indirect laryngoscopy, computed tomography (CAT) scan, and magnetic resonance imaging (MRI) are some common ways of diagnosing cancer of the larynx.

Treatment: Radiation therapy, surgery (Partial or Total Laryngectomy), and chemotherapy are the most common treatment options for those diagnosed with Larynx Cancer.

Table 284. Larynx Cancer Cases by Gender, Race/Ethnicity and County/Region ofResidence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)			
Total									
Cases	391	273	66	52	0	13,226			
Rate*	3.7	3.7	4.0	3.1		3.7			
95% C.I.	(3.3-4.1)	(3.3-4.2)	(3.1-5.1)	(2.3-4.1)		(3.7-3.8)			
Gender									
Male	305	213	47	45	0	10,581			
Rate*	6.0	6.1	5.9	5.3		6.6			
95% C.I.	(5.3-6.7)	(5.3-7.1)	(4.3-8.2)	(3.8-7.3)		(6.5-6.8)			
Female	86	60	19	7	0	2,645			
Rate*	1.6	1.6	2.2			1.4			
95% C.I.	(1.3-2.0)	(1.2-2.1)	(1.3-3.5)			(1.3-1.4)			
Other/Unknown	0	0	0	0	0	0			
Race/Ethnicity									
White	355	240	64	51	0	10,801			
Rate*	4.1	4.3	4.4	3.3		3.7			
95% C.I.	(3.7-4.6)	(3.7-4.8)	(3.4-5.7)	(2.5-4.4)		(3.6-3.8)			
Black	15	13	2	0	0	1,892			
Rate*	2.8	2.5				6.0			
95% C.I.	(1.6-4.9)	(1.3-4.4)				(5.8-6.3)			
Native American	0	0	0	0	0	43			
Rate*						1.3			
95% C.I.						(0.9-0.9)			
Asian	4	4	0	0	0	409			
Rate*						1.5			
95% C.I.						(1.3-1.6)			
Hispanic	11	11	0	0	0	952			
Rate*	1.4	1.8				2.7			
95% C.I.	(0.7-2.8)	(0.9-3.6)				(2.5-2.8)			
Other/Unknown	6	5	0	1	0	81			

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 285. Larynx Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	166	120	23	23	0
Rate*	1.6	1.7	1.4	1.3	
95% C.I.	(1.3-1.8)	(1.4-2.0)	(0.9-2.2)	(0.8-2.0)	
Gender					
Male	125	96	11	18	0
Rate*	2.5	2.9	1.3	1.9	
95% C.I.	(2.0-3.0)	(2.3-3.7)	(0.6-2.4)	(1.2-3.1)	
Female	41	24	12	5	0
Rate*	0.8	0.7	1.4		
95% C.I.	(0.6-1.1)	(0.4-1.0)	(0.7-2.5)		
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$10,039,307	\$7,276,794	\$1,226,554	\$1,535,959	\$0
Average Charges	\$60,478	\$60,640	\$53,328	\$66,781	\$0
Median Charges	\$42,372	\$43,241	\$44,226	\$36,996	\$0
Discharge Length of S	tay (LOS) (Days)				
Total LOS	1,716	1,238	199	279	0
Average LOS	10.3	10.3	8.7	12.1	0.0
Median LOS	8.0	8.0	8.0	9.0	0.0

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 286. Larynx Cancer Mortality by Age Group and County/Region of
Residence, Nevada Residents, 2000-2004


		County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Deaths	108	73	19	16			
Rate*	1.1	1.1	1.1	1.0			
95% C.I.	(0.9-1.3)	(0.8-1.3)	(0.7-1.8)	(0.5-1.6)			
Age Group							
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	0	0	0	0			
Rate*							
95% C.I.							
15-24	0	0	0	0			
Rate*							
95% C.I.							
25-34	0	0	0	0			
Rate*							
95% C.I.							
35-44	1	1	0	0			
Rate*							
95% C.I.							
45-54	8	5	1	2			
Rate*							
95% C.I.							
55-64	38	25	10	3			
Rate*	3.5	3.3	5.8				
95% C.I.	(2.37-4.59)	(2.02-4.63)	(2.19-9.33)				
65-74	28	19	2	7			
Rate*	3.9	3.8					
95% C.I.	(2.46-5.35)	(2.11-5.57)					
75-84	24	17	4	3			
Rate*	5.8	6.1					
95% C.I.	(3.50-8.18)	(3.19-8.96)					
85+	9	6	2	1			
Rate*							
95% C.I.							
Unknown	0	0	0	0			

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

MULTIPLE MYELOMA GENERAL PROFILE⁴

Figure 176. Picture of Myeloma Cells⁴



General Anatomy: Multiple Myeloma affects certain white blood cells called plasma cells that are part of the body's immune system. Plasma cells begin their development in the bone marrow and help the immune system fight infection and disease by producing antibodies. When cancer involves plasma cells, the body keeps producing more and more of these cells. The unneeded plasma cells -- all abnormal and all exactly alike -- are called myeloma cells. Myeloma cells tend to collect in the bone marrow and in the hard, outer part of bones. Sometimes they collect in only one bone and form a single mass, or tumor, called a plasmacytoma. In most cases, however, the myeloma cells collect in many bones, often forming many tumors and causing other problems. When this happens, the disease is called multiple myeloma.

Risk Factors: While the cause is unknown most multiple myeloma patients are between 50 and 70 years of age and affects Blacks, as a racial/ethnic group, more often than whites and men more often than women. Those with a family history of multiple myeloma and those exposed to certain chemicals and radiation seem to have a slightly higher increase in the risk of developing this type of cancer. In most cases, people who develop multiple myeloma have no clear risk factors. The disease may be the result of several factors (known and/or unknown) acting together.

Signs and Symptoms: Symptoms of multiple myeloma depend on how advanced the disease is. In the earliest stage of the disease, there may be no symptoms. When symptoms do occur, patients commonly have: bone pain in the back or ribs, broken bones, weakness, fatigue, weight loss, or repeated infections. When the disease is advanced, symptoms may include nausea, vomiting, constipation, problems with urination, and weakness or numbness in the legs.

Diagnosing the Cancer: X-rays, blood and urine tests (high levels of antibody proteins), bone marrow aspiration and/or bone marrow biopsy.

Treatment: chemotherapy, radiation therapy, and secondary surgical procedures to help the individual recover from these types of therapy include: bone marrow transplantation, peripheral stem cell support, and treatment with colony-stimulating factors.

Table 287. Multiple Myeloma Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)
Total						
Cases	453	298	89	66	0	19,650
Rate*	4.4	4.3	5.5	4.1		5.6
95% C.I.	(4.0-4.9)	(3.8-4.8)	(4.4-6.8)	(3.1-5.2)		(5.5-5.7)
Gender						
Male	264	168	49	47	0	10,621
Rate*	5.5	5.1	6.5	6.1		7.0
95% C.I.	(4.8-6.3)	(4.3-6.1)	(4.7-8.9)	(4.4-8.3)		(6.8-7.1)
Female	189	130	40	19	0	9,029
Rate*	3.5	3.6	4.7	2.2		4.5
95% C.I.	(3.0-4.1)	(3.0-4.2)	(3.4-6.4)	(1.3-3.5)		(4.5-4.6)
Other/Unknown	0	0	0	0	0	0
Race/Ethnicity						
White	360	224	76	60	0	15,118
Rate*	4.3	4.1	5.3	4.1		5.2
95% C.I.	(3.9-4.8)	(3.6-4.7)	(4.2-6.7)	(3.1-5.3)		(5.1-5.3)
Black	40	37	2	1	0	3,284
Rate*	7.7	7.6				11.3
95% C.I.	(5.4-10.9)	(5.3-11.0)				(10.9-11.7)
Native American	4	1	0	3	0	106
Rate*						3.9
95% C.I.						(3.1-3.1)
Asian	15	8	7	0	0	914
Rate*	3.8					3.3
95% C.I.	(1.9-7.8)					(3.1-3.5)
Hispanic	21	16	3	2	0	1,953
Rate*	2.7	2.7				5.7
95% C.I.	(1.6-4.4)	(1.4-4.7)				(5.4-5.9)
Other/Unknown	13	12	1	0	0	228

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 288. Multiple Myeloma Inpatient Discharges by Gender, Charges, Length of
Stay, and County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	
Total						
Discharges	373	255	74	44	0	
Rate*	3.6	3.6	4.4	2.6		
95% C.I.	(3.2-4.0)	(3.2-4.1)	(3.5-5.6)	(1.9-3.6)		
Gender						
Male	213	150	41	22	0	
Rate*	4.3	4.6	5.1	2.6		
95% C.I.	(3.7-5.0)	(3.8-5.5)	(3.6-7.3)	(1.6-4.0)		
Female	160	105	33	22	0	
Rate*	2.9	2.8	3.9	2.6		
95% C.I.	(2.5-3.4)	(2.3-3.4)	(2.6-5.4)	(1.6-4.0)		
Other/Unknown	0	0	0	0	0	
Inpatient Discharge Ch	narges (\$)					
Total Charges	\$20,511,188	\$15,682,775	\$3,334,873	\$1,493,540	\$0	
Average Charges	\$54,990	\$61,501	\$45,066	\$33,944	\$0	
Median Charges	\$33,120	\$35,636	\$27,761	\$27,031	\$0	
Discharge Length of Stay (LOS) (Days)						
Total LOS	3,637	2,541	785	311	0	
Average LOS	9.8	10.0	10.6	7.1	0.0	
Median LOS	7.0	7.0	8.0	7.0	0.0	

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 289. Multiple Myeloma Mortality by Age Group and County/Region ofResidence, Nevada Residents, 2000-2004


	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties		
Total						
Deaths	341	228	70	43		
Rate*	3.4	3.4	4.4	2.7		
95% C.I.	(3.1-3.8)	(3.0-3.9)	(3.5-5.7)	(1.9-3.6)		
Age Group						
<1	0	0	0	0		
Rate*						
95% C.I.						
1-4	0	0	0	0		
Rate*						
95% C.I.						
5-14	0	0	0	0		
Rate*						
95% C.I.						
15-24	0	0	0	0		
Rate*						
95% C.I.						
25-34	0	0	0	0		
Rate*						
95% C.I.						
35-44	4	4	0	0		
Rate*						
95% C.I.						
45-54	28	21	4	3		
Rate*	1.9	2.1				
95% C.I.	(1.18-2.57)	(1.19-2.98)				
55-64	77	50	13	14		
Rate*	7.1	6.7	7.5	8.4		
95% C.I.	(5.48-8.63)	(4.81-8.50)	(3.42-11.55)	(4.01-12.82)		
65-74	102	62	27	13		
Rate*	14.2	12.5	25.3	11.3		
95% C.I.	(11.47-16.99)	(9.41-15.65)	(15.78-34.90)	(5.13-17.36)		
75-84	101	71	22	8		
Rate*	24.6	25.4	34.7			
95% C.I.	(19.78-29.37)	(19.47-31.28)	(20.22-49.26)			
85+	29	20	4	5		
Rate*	30.5	32.9				
95% C.I.	(19.41-41.63)	(18.45-47.25)				
Unknown	0	0	0	0		

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

HODGKIN'S LYMPHOMA GENERAL PROFILE⁴

Figure 177. Anatomy of the Lymphatic System⁴



General Anatomy: Lymphoma is a general term for cancers that develop in the lymphatic system. The lymphatic system is part of the body's immune system that helps the body fight disease and infection and includes a network of thin tubes (lymphatic vessels) that branch, like blood vessels, into tissues throughout the body. These vessels carry lymph, a colorless, watery fluid that contains infection-fighting cells called lymphocytes. Along this network of vessels are small organs called lymph nodes that are found in the underarms, groin, neck, chest, and abdomen. Other parts of the lymphatic system are the spleen, thymus, tonsils, and bone marrow. Lymphatic tissue is also found in other parts of the body, including the stomach, intestines, and skin.

Hodgkin's disease, an uncommon lymphoma, accounts for less than 1 percent of all cases of cancer in the United States. This type of cancer tends to spread in a fairly orderly way from one group of lymph nodes to the next group. For example, Hodgkin's disease that arises in the lymph nodes in the neck spreads first to the nodes above the collarbones, and then to the lymph nodes under the arms and within the chest. Eventually, it can spread to almost any other part of the body.

Risk Factors: Common risk factors that are believed to be associated with the development of Hodgkin's Lymphoma are: age (between 15 and 34 and over 55 years of age), being male, family history, and certain viruses (Epstein-Barr virus).

Signs and Symptoms: A painless swelling in the lymph nodes in the neck, underarm, or groin, unexplained recurrent fevers, night sweats, unexplained weight loss, and itchy skin are some common symptoms that can be associated with Hodgkin's Lymphoma.

Diagnosing the Cancer: X-rays, computed tomography (CAT) scan, and magnetic resonance imaging (MRI), and biopsy (Reed-Sternberg cells in lymph node tissue).

Treatment: Radiation therapy and chemotherapy are the most common treatments, but others include: bone marrow transplantation, peripheral stem cell transplantation, and biological therapies are being studied in clinical trials.

Table 290. Hodgkin's Lymphoma Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

		County/Region of Residence				
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)
Total						
Cases	279	206	49	24	0	10,117
Rate*	2.5	2.6	2.7	1.6		2.7
95% C.I.	(2.2-2.8)	(2.3-3.0)	(2.0-3.6)	(1.0-2.5)		(2.6-2.8)
Gender						
Male	151	111	30	10	0	5,517
Rate*	2.7	2.8	3.4	1.2		3.0
95% C.I.	(2.3-3.1)	(2.3-3.4)	(2.3-4.9)	(0.6-2.4)		(3.0-3.1)
Female	128	95	19	14	0	4,600
Rate*	2.3	2.5	2.1	2.0		2.4
95% C.I.	(2.0-2.8)	(2.0-3.0)	(1.3-3.4)	(1.1-3.4)		(2.3-2.5)
Other/Unknown	0	0	0	0	0	0
Race/Ethnicity						
White	221	156	44	21	0	8,555
Rate*	3.0	3.2	3.3	1.8		2.9
95% C.I.	(2.6-3.4)	(2.7-3.7)	(2.4-4.4)	(1.1-2.8)		(2.8-3.0)
Black	22	22	0	0	0	1,000
Rate*	3.1	3.4				2.4
95% C.I.	(1.9-5.0)	(2.1-5.3)				(2.3-2.6)
Native American	1	0	1	0	0	34
Rate*						0.8
95% C.I.						(0.5-0.5)
Asian	11	10	1	0	0	417
Rate*	1.6	1.8				1.2
95% C.I.	(0.8-2.9)	(0.8-3.4)				(1.1-1.3)
Hispanic	17	13	1	3	0	1,379
Rate*	0.9	0.9				2.2
95% C.I.	(0.4-1.6)	(0.4-1.8)				(2.1-2.4)
Other/Unknown	7	5	2	0	0	111

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Discharges	118	91	19	8	0		
Rate*	1.1	1.1	1.1				
95% C.I.	(0.9-1.3)	(0.9-1.4)	(0.6-1.7)				
Gender							
Male	63	50	11	2	0		
Rate*	1.1	1.2	1.2				
95% C.I.	(0.8-1.4)	(0.9-1.6)	(0.6-2.2)				
Female	54	40	8	6	0		
Rate*	1.0	1.0					
95% C.I.	(0.7-1.3)	(0.7-1.4)					
Other/Unknown	1	1	0	0	0		
Inpatient Discharge Ch	arges (\$)						
Total Charges	\$5,352,582	\$4,228,715	\$792,825	\$331,042	\$0		
Average Charges	\$45,361	\$46,469	\$41,728	\$41,380	\$0		
Median Charges	\$31,299	\$31,043	\$34,998	\$27,653	\$0		
Discharge Length of St	tay (LOS) (Days)						
Total LOS	873	693	131	49	0		
Average LOS	7.4	7.6	6.9	6.1	0.0		
Median LOS	5.0	5.0	5.0	5.5	0.0		

Table 291. Hodgkin's Lymphoma Inpatient Discharges by Gender, Charges,Length of Stay, and County/Region of Residence, Nevada Residents, 2000-2004

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 292. Hodgkin's Lymphoma Mortality by Age Group and County/Region of
Residence, Nevada Residents, 2000-2004

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties		
Total						
Deaths	37	25	7	5		
Rate*	0.4	0.3	0.0	0.0		
95% C.I.	(0.2-0.5)	(0.2-0.5)				
Age Group						
<1	0	0	0	0		
Rate*						
95% C.I.						
1-4	0	0	0	0		
Rate*						
95% C.I.						
5-14	0	0	0	0		
Rate*						
95% C.I.						
15-24	1	0	0	1		
Rate*						
95% C.I.						
25-34	2	2	0	0		
Rate*						
95% C.I.						
35-44	4	3	0	1		
Rate*						
95% C.I.						
45-54	7	3	3	1		
Rate*						
95% C.I.						
55-64	4	3	0	1		
Rate*						
95% C.I.						
65-74	13	10	3	0		
Rate*	1.8	2.0				
95% C.I.	(0.83-2.80)	(0.77-3.27)				
75-84	4	3	1	0		
Rate*						
95% C.I.						
85+	2	1	0	1		
Rate*						
95% C.I.						
Unknown	0	0	0	0		

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

ALL OTHER SITES

Table 293. Cancer Cases for All Other Sites by Gender, County/Region of Residence at Diagnosis and Race/Ethnicity, Nevada Residents (2000-2004) and SEER-17 (2000-2004)

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 17 (2000-2004)
Total						
Cases	3,464	2,408	567	488	1	117,455
Rate*	33.9	34.2	34.8	31.2		32.8
95% C.I.	(32.7-35.1)	(32.8-35.6)	(31.9-37.9)	(28.4-34.1)		(32.6-32.9)
Gender						
Male	1,995	1,363	337	294	1	63,222
Rate*	40.2	40.0	42.4	38.5		39.4
95% C.I.	(38.4-42.1)	(37.8-42.4)	(37.8-47.6)	(34.1-43.4)		(39.1-39.7)
Female	1,468	1,044	230	194	0	54,233
Rate*	27.8	28.7	27.2	24.0		27.1
95% C.I.	(26.3-29.3)	(26.9-30.5)	(23.8-31.0)	(20.7-27.7)		(26.9-27.4)
Other/Unknown	1	1	0	0	0	0
Race/Ethnicity						
White	2,838	1,883	505	449	1	98,916
Rate*	35.6	35.9	37.4	32.2		33.6
95% C.I.	(34.3-37.0)	(34.3-37.6)	(34.2-41.0)	(29.2-35.4)		(33.4-33.8)
Black	182	167	10	5	0	10,370
Rate*	31.2	30.7	32.9			32.7
95% C.I.	(26.6-36.6)	(26.0-36.4)	(15.3-66.3)			(32.0-33.3)
Native American	13	2	1	10	0	623
Rate*	9.5			20.3		19.4
95% C.I.	(5.0-16.7)			(9.6-38.1)		(17.8-17.8)
Asian	102	83	19	0	0	6,203
Rate*	21.6	22.1	26.9			21.7
95% C.I.	(16.8-28.2)	(16.5-30.1)	(13.9-54.0)			(21.2-22.3)
Hispanic	230	188	27	15	0	13,154
Rate*	21.4	22.4	19.9	14.5		31.1
95% C.I.	(18.0-25.6)	(18.4-27.6)	(12.2-31.8)	(7.0-28.2)		(30.5-31.7)
Other/Unknown	99	85	5	9	0	1,343

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 294. Inpatient Discharges for All Other Sites by Gender, Charges, Length of
Stay, and County/Region of Residence, Nevada Residents, 2000-2004

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	
Total						
Discharges	8,238	5,881	1,351	1,003	3	
Rate*	77.9	80.7	80.9	61.9		
95% C.I.	(76.2-79.7)	(78.6-82.9)	(76.6-85.4)	(58.0-66.4)		
Gender						
Male	3,729	2,620	599	507	3	
Rate*	75.1	76.3	78.0	66.0		
95% C.I.	(72.6-77.7)	(73.2-79.5)	(71.6-85.0)	(60.1-73.2)		
Female	4,508	3,260	752	496	0	
Rate*	82.2	86.3	85.9	59.2		
95% C.I.	(79.8-84.7)	(83.3-89.4)	(79.8-92.3)	(54.0-64.7)		
Other/Unknown	1	1	0	0	0	
Inpatient Discharge Ch	narges (\$)					
Total Charges	\$339,550,160	\$254,132,975	\$52,420,532	\$32,877,477	\$119,176	
Average Charges	\$41,218	\$43,213	\$38,801	\$32,779	\$39,725	
Median Charges	\$26,975	\$28,368	\$26,135	\$22,672	\$26,925	
Discharge Length of Stay (LOS) (Days)						
Total LOS	61,414	44,391	10,458	6,525	40	
Average LOS	7.5	7.5	7.7	6.5	13.3	
Median LOS	5.0	5.0	6.0	5.0	10.0	

* Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 295. All Other Sites Cancer Mortality by Age Group and County/Region ofResidence, Nevada Residents, 2000-2004

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties		
Total						
Deaths	2,180	1,434	359	387		
Rate*	22.4	21.5	23.3	25.1		
95% C.I.	(21.4-23.4)	(20.3-22.7)	(20.9-26.0)	(22.7-27.8)		
Age Group						
<1	1	1	0	0		
Rate*						
95% C.I.						
1-4	1	0	0	1		
Rate*						
95% C.I.						
5-14	5	5	0	0		
Rate*						
95% C.I.						
15-24	17	12	3	2		
Rate*	1.1	1.1				
95% C.I.	(0.57-1.61)	(0.48-1.71)				
25-34	36	30	3	3		
Rate*	2.2	2.5				
95% C.I.	(1.50-2.95)	(1.61-3.40)				
35-44	53	34	8	11		
Rate*	3.1	2.8		5.0		
95% C.I.	(2.27-3.95)	(1.88-3.78)		(2.06-8.01)		
45-54	187	132	28	27		
Rate*	12.5	13.1	10.7	12.1		
95% C.I.	(10.73-14.32)	(10.86-15.33)	(6.72-14.64)	(7.53-16.64)		
55-64	420	295	61	64		
Rate*	38.5	39.3	35.1	38.5		
95% C.I.	(34.79-42.15)	(34.77-43.73)	(26.31-43.93)	(29.03-47.88)		
65-74	588	381	101	106		
Rate*	82.0	77.0	94.8	91.7		
95% C.I.	(75.40-88.66)	(69.28-84.75)	(76.31-113.29)	(74.26-109.18)		
75-84	622	391	109	122		
Rate*	151.3	139.7	172.1	179.8		
95% C.I.	(139.45-163.23)	(125.89-153.59)	(139.82-204.45)	(147.88-211.68)		
85+	250	153	46	51		
Rate*	263.1	251.3	263.5	305.8		
95% C.I.	(230.51-295.74)	(211.50-291.14)	(187.35-339.64)	(221.88-389.75)		
Unknown	0	0	0	0		

* Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

APPENDIX A – CODES USED FOR GROUPING

One of the challenges of this report was to combine information on cancer from several different sources and develop a comprehensive report that details the burden and risk of cancer in the State of Nevada. To add to the complexity of it all, each data source did not use identical coding to identify each type of cancer.

The Nevada Central Cancer Registry uses the International Classification of Diseases – Oncology (ICD-O) coding system that is then broken down into the Topography, or Primary Site, as well as the Morphology of the specific cancer. The Topography section of the ICD-O coding structure is fairly comparable to the ICD-10 mortality classification system, with very little variation between the two systems. However, there are some variations, so this report uses the ICD-O coding structure as the primary source for identifying the type of cancer for this report.

Furthermore, the cancer incidence data for 2001 and beyond that are included in this report were classified using the ICD-O3 coding classification structure, while data in previous years were classified using the ICD-O2 coding system. However, this classification change is done within the Cancer Registry. Therefore, this report only shows the classification of the ICD-O code system.

The ICD-10 structure was implemented in 2000 for the coding of the underlying cause of death. However, for this report, due to the variations between the ICD-O and ICD-10 coding structures and the fact that the ICD-O system is the primary one used, there have not been any adjustments made to account for potential coding differences that may have occurred due to the change from the ICD-9 to the ICD-10 system in 2000 for all mortality data used in this report.

The inpatient hospital discharge (UB92) database that was used to provide the inpatient hospital discharge statistics for this report uses the ICD-9 coding structure.

The following pages detail the codes used for each type of coding structure present in the data used for this report. The codes used to identify the leading types of cancer for this report are highlighted. Those not falling under any of the highlighted leading groups were categorized into the All Other Sites grouping.

Table 296. ICD-O Codes Used

	ICD-O2 Codes			
Type of Cancer	Topography	Morphology	Excluding (M = Morphology)	
Total	Sum	Sum		
Lip, Oral Cavity and Pharynx	Sum of subgroups			
Lip	C00		M-9590:9989	
Base of Tongue	C01		M-9590:9989	
Other & Unspecified Parts of Tongue	C02		M-9590:9989	
Parotid Gland	C07		M-9590:9989	
Other & Unspecified Major Salivary glands	C08		M-9590:9989	
Floor of Mouth	C04		M-9590:9989	
Gum	C03		M-9590:9989	
Palate	C05		M-9590:9989	
Other & Unspecified Parts of Mouth	C06		M-9590:9989	
Nasopharynx	C11		M-9590:9989	
Tonsil	C09		M-9590:9989	
Oropharynx	C10		M-9590:9989	
Pyriform Sinus	C12		M-9590:9989	
Hypopharynx	C13		M-9590:9989	
Other & Unspecified Oral (Buccal) Cavity & Pharynx	C14		M-9590:9989	
Digestive System	Sum of Subgroups			
Esophagus	C15		M-9590:9989	
Stomach	C16		M-9590:9989	
Small Intestine	C17			
Colorectal	Sum of Colon, Rectum, Recto	osigmoid Junction, Anus, A	Anal Canal and Anorectum	
Colon (excluding Rectum)	Sum of Subgroups			
Cecum	C18.0		M-9590:9989	
Appendix	C18.1		M-9590:9989	
Ascending Colon	C18.2		M-9590:9989	
Hepatic Flexure	C18.3		M-9590:9989	
Transverse Colon	C18.4		M-9590:9989	
Splenic Flexure	C18.5		M-9590:9989	
Descending Colon	C18.6		M-9590:9989	
Sigmoid Colon	C18.7		M-9590:9989	
Large Intestine, NOS	C18.8-C18.9, C26.0		M-9590:9989	
Rectum	C20		M-9590:9989	
Rectosigmoid Junction	C19		M-9590:9989	
Anus, Anal Canal and Anorectum	C21		M-9590:9989	
Liver	C22.0		M-9590:9989	
Intrahepatic Bile Ducts	C22.1		M-9590:9989	
Gallbladder	C23		M-9590:9989	
Other & Unspecified Biliary Tract	C24		M-9590:9989	
Pancreas	C25		M-9590:9989	
Retroperitoneum	C48.0		M-9590:9989	
Peritoneum, Omentum and Mesentery	C48.1-C48.2		M-9590:9989	
Other Digestive Organs	C26.8-C26.9, C48.8		M-9590:9989	
Respiratory System	Sum of Subgroups			
Nasal Cavity and Middle Ear	C30		M-9590:9989	
Accessory Sinuses	C31		M-9590:9989	
Larynx	C32		M-9590:9989	
Lung and Bronchus	C34		M-9590:9989	
Pleura	C38.4		M-9590:9989	
Trachea	C33		M-9590:9989	
Mediastinum and Other Respiratory Organs	C38.1, C38.3, C38.8, C39		M-9590:9989	
Bones, Joints and Articular Cartilage	Sum of Subgroups			
Bones, Joints & Articular Cartilage of Limbs	C40		M-9590:9989	
Bones, Joints & Articular Cartilage of Other & Unspec Sites	C41		M-9590:9989	
Soft Tissue (Including Heart)	Sum of Subgroups			
Heart	C38.0		M-9590:9989	
Peripheral Nerves & Autonomic Nervous System	C47		M-9590:9989	
Connective, Subcutaneous & Other Soft Tissues	C49		M-9590:9989	

Table 296. ICD-O Codes Used (Continued)

	ICD-02 Codes			
Type of Cancer	Topography	Morphology	Excluding (M = Morphology)	
Skin (Excluding Basal And Squamous)	Sum of Subgroups			
Melanomas Of The Skin	C44	M-8720-8790		
Other Non-Epithelial Skin Breast	C44 C50		M-8000:8004 8010:8045, 8050:8082 8090:8110, 8720:8790 M-9590:9989	
Female Genital System	Sum of Subgroups			
Cervix Uteri	C53		M-9590:9989	
Corpus Uteri & Uterus, NOS	Sum of Corpus Uteri and U	terus, NOS		
Corpus Uteri	C54		M-9590:9989	
Uterus, NOS	C55		M-9590:9989	
Ovary	C56		M-9590:9989	
Vagina	C52		M-9590:9989	
Vulva	C51		M-9590:9989	
Placenta	C58		M-9590:9989	
Other Female Genital Organs	C57		M-9590:9989	
Male Genital System	Sum of Subgroups			
Prostate	C61		M-9590:9989	
Testis	C62		M-9590:9989	
Penis	C60		M-9590:9989	
Other Male Genital Organs	C63		M-9590:9989	
Urinary System	Sum of Subgroups		M 0000.0000	
Urinary Bladder	C67		M-9590:9989	
Kidney and Renal Pelvis	Sum of Kidney and Renal F	Pelvis		
Kidney	C64		M-9590:9989	
Renal Pelvis	C65		M-9590:9989	
Ureter	C66		M-9590:9989	
Other Urinary Organs	C68		M-9590:9989	
Eye and Orbit	C69			
Brain and Other Central Nervous System	Sum of Subgroups			
Brain	C71		M-9530:9539, 9590:9989	
Meninges	C70		M-9590.9989	
Spinal Cord, Cranial Nerves, & Other Parts of CNS	C72	C71 & M-9530:9539	M-9590:9989	
Endocrine System	Sum of Subgroups			
Thyroid Gland	C73			
Adrenal Gland	C74			
Other Endocrine (Including Thymus)	C37, C75		M-9590:9989	
Hodgkin's Lymphoma		M-9650:9667		
Non-Hodgkin's Lymphoma Multiple Myeloma		M-9590-9595, 9670- 9677, 9680-9688, 9690- 9698, 9700-9717, 9823, 000-9731-9732	C42.0, C42.1, C42.4	
Leukemia	Sum of subgroups			
Lymphocytic	Sum of subgroups			
Acute Lymphocytic		M-9821, 9826, 9828		
Chronic Lymphocytic	C42.0, C42.1, C42.4	M-9823		
Other Lymphocytic	, - ,	M-9820, 9822, 9824-		
		9825, 9850, 9940-9941		
Myeloid and Monocytic	Sum of subgroups	,,		
Acute Myeloid Leukemia	2	9866, 9867, 9871-9874,		
Acuto Managutia Laukamia		9910 M-9891		
Acute Monocytic Leukemia Chronic Myeloid Leukemia				
Other Myeloid Leukemia		M-9863, 9868 9880, 9890, 9892-9894, 9930		
Other	Sum of subgroups	9930		
Other Acute	Sum of subgroups	M-0801 0021 0022		
Aleukemic, Subleukemic and NOS		M-9801, 9931, 9932 M-9800, 9802-9804, 9830, 9842, 9870, 9900		
	C42.0, C42.1, C42.4	M-9827		
Mesothelioma	072.0, 072.1, 072.4	M-9050-9055		
Kaposi's Sarcoma		M-9030-9033 M-9140		
Other, III-Defined and Unspecified Sites	All Others			
	711 011013			

Table 297. ICD-9 and ICD-10 Codes Used

Type of Cancer	ICD-9	ICD-10
Total	Sum	Sum
Lip, Oral Cavity and Pharynx	Sum of subgroups	Sum of subgroups
Lip	140	C00
Base of Tongue	141.0	C01
Other & Unspecified Parts of Tongue	141.1-141.9	C02
Parotid Gland	142.0	C07
Other & Unspecified Major Salivary glands	142.1-142.9	C08
Floor of Mouth	144	C04
Gum	143	C03
Palate	145.2-145.5	C05
Other & Unspecified Parts of Mouth	145.0, 145.1, 145.6-145.9	C06
Nasopharynx	147	C11
Tonsil	146.0-146.2	C09
Oropharynx	146.3-146.9	C10
Pyriform Sinus	148.1	C12
Hypopharynx	148.0, 148.2-148.9	C13
Other & Unspecified Oral (Buccal) Cavity & Pharynx	149	C14
Digestive System	Sum of Subgroups	Sum of Subgroups
Esophagus	150	C15
Stomach	151	C16
Small Intestine	152	C17
Colorectal	Sum of Colon, Rectum, Rectosigmoid Ju	Inction, Anus, Anal Canal and Anorectum
Colon (excluding Rectum)	Sum of Subgroups	Sum of Subgroups
Cecum	153.4	C18.0
Appendix	153.5	C18.1
Ascending Colon	153.6	C18.2
Hepatic Flexure	153.0	C18.3
Transverse Colon	153.1	C18.4
Splenic Flexure	153.7	C18.5
Descending Colon	153.2	C18.6
Sigmoid Colon	153.3	C18.7
Large Intestine, NOS	153.8-153.9, 159.0	C18.8-C18.9, C26.0
Rectum	154.1	C20
Rectosigmoid Junction	154.0	C19
Anus, Anal Canal and Anorectum	154.2-154.8	C21
Liver	155.0, 155.2	C22.0, C22.2-C22.4, C22.7, C22.9
Intrahepatic Bile Ducts	155.1	C22.1
Gallbladder	156.0	C23
Other & Unspecified Biliary Tract	156.1-156.9	C24
Pancreas	157	C25
Retroperitoneum	158.0	C48.0
Peritoneum, Omentum and Mesentery	158.8-158.9	C48.1, C48.2
Other Digestive Organs	159.8, 159.9	C26.8-C26.9, C48.8
Respiratory System	Sum of Subgroups	Sum of Subgroups
Nasal Cavity and Middle Ear	160.0, 160.1	C30
Accessory Sinuses	160.2-160.9	C31
Larynx	161	C32
Lung and Bronchus	162.2-162.9	C34
Pleura	163	C38.4
Trachea	162.0	C33
Mediastinum and Other Respiratory Organs	164.2-164.9, 165	C38.1, C38.3, C38.8, C39
	-	
Bones, Joints and Articular Cartilage	Sum of Subgroups	Sum of Subgroups
Bones, Joints & Articular Cartilage of Limbs	170.4, 170.5, 170.7, 170.8	C40
Bones, Joints & Articular Cartilage of Other & Unspec Sites	170.0-170.3, 170.6, 170.9	C41
Soft Tissue (Including Heart)	Sum of Subgroups	Sum of Subgroups
Heart Derinherel Nerves & Autonomia Nerveus System	164.1	C38.0
Peripheral Nerves & Autonomic Nervous System		C47
Connective, Subcutaneous & Other Soft Tissues	171	C49

Table 297. ICD-9 and ICD-10 Codes Used (Continued)

Type of Cancer	ICD-9	173 $C44$ 175 $C50$ Sum of Subgroups $C53$ 180 $C53$ Sum of Corpus Uteri and Uterus, NOS $C54$ 179 $C55$ 33.0 $C56$ 44.0 $C51$ 181 $C58$ 44.0 $C51$ 181 $C58$ 44.9 $C57$ Sum of Subgroups $C67$ Sum of Subgroups $C66$ 9.0 $C68$ 190 $C68$ 191 $C71$ 22.3 $C70$ 23.4 $C37$, $C75$ 24.0 $C71$ 24.0 $C71$ 25.2 $C82$ -C85, $C96.3$ 38.6 $C90.0$, $C91.0$ 04.0 $C91.0$ 04.1 $C91.0$ 05.1 $C92.0$, $C92.4$ - $C92.5$, $C94.0$, $C94.2$	ICD-10	
Skin (Excluding Basal And Squamous)	Sum of Subgroups	Sum of Subaroups		
Melanomas Of The Skin	172	0 1		
Other Non-Epithelial Skin	173			
Breast	174-175	C50		
Female Genital System	Sum of Subgroups	Sum of Subgroups		
Cervix Uteri	180	C53		
Corpus Uteri & Uterus, NOS	Sum of Corpus Uteri and Uterus, NOS	Sum of Corpus Uteri and Uterus, NOS		
Corpus Uteri	182	C54		
Uterus, NOS	179			
Ovary	183.0			
Vagina	184.0			
Vulva	184.1-184.4			
Placenta	-			
Other Female Genital Organs	183.2-183.9, 184.8, 184.9			
Male Genital System	Sum of Subgroups	0 1		
Prostate				
Testis Penis	187.1-187.4			
Other Male Genital Organs	187.5-187.9			
Urinary System	Sum of Subgroups			
Urinary Bladder		5 1		
Kidney and Renal Pelvis	Sum of Kidney and Renal Pelvis			
Kidney	189.0	-		
Renal Pelvis	189.1			
Ureter	189.2			
Other Urinary Organs	189.3-189.9			
Eye and Orbit	190			
Brain and Other Central Nervous System	Sum of Subgroups	Sum of Subgroups		
Brain	191	C71		
Meninges	192.1, 192.3	C70		
Spinal Cord, Cranial Nerves, & Other Parts of CNS	192.0, 192.2, 192.8, 192.9	C72		
Endocrine System	Sum of Subgroups	Sum of Subgroups		
Thyroid Gland	193			
Adrenal Gland	194.0			
Other Endocrine (Including Thymus)	164.0, 194.1-194.9			
Hodgkin's Lymphoma				
Non-Hodgkin's Lymphoma	200, 202.8, 202.9, 202.0-202.2			
Multiple Myeloma	203.0, 238.6	C90.0, C90.2		
Leukemia	Sum of subgroups			
	Sum of subgroups	C01 0		
Acute Lymphocytic				
Chronic Lymphocytic Other Lymphocytic	202.4, 204.2, 204.8-204.9			
Myeloid and Monocytic	Sum of subgroups	691.2-691.4, 691.7, 691.9		
Acute Myeloid Leukemia	205.0, 207.0, 207.2	C02 0 C02 4-C02 5 C04 0 C04 2		
Acute Monocytic Leukemia	203.0, 207.0, 207.2			
Chronic Myeloid Leukemia	205.1			
Other Myeloid/Monocytic Leukemia	205.2-205.3, 205.8-205.9, 206.1-206.2,			
	206.8-206.9			
Other	Sum of subgroups			
Other Acute	208.0	C94.4, C94.5, C95.0		
Aleukemic, Subleukemic and NOS	203.1, 207.1, 207.8, 208.1-208.2, 208.8 208.9			
Mesothelioma	N/A	C45		
Kaposi's Sarcoma	176	C46		
Other, III-Defined and Unspecified Sites	All Others	All Others		

APPENDIX B – FORMULAS

AGE-ADJUSTED RATE:

$$\frac{E_t}{S_t} \times 100,000$$

$$E_t = \text{Total Expected Number of Events} = \sum_{i=1}^k E_i$$

$$S_t = \text{Total Standard Population} = \sum_{i=1}^k S_i$$

$$CR = \text{Crude Rate} = \frac{N_t}{P_t} \times 100,000$$

$$P_t = \text{Total State Population} = \sum_{i=1}^k P_i$$

$$N_t = \text{Total Number of Events} = \sum_{i=1}^k N_i$$

$$E_i = \text{Age-Specific Expected Number of Events} = \frac{N_i}{P_i} \times S_i$$

$$S_i = \text{Standard Age-Specific Population}$$

$$k = \text{Number of Age Groups}$$

AGE-ADJUSTED RATE CONFIDENCE INTERVALS:

$$w_{i} = \frac{stdmil_{i}}{\left(pop_{i} \times \sum_{j=x}^{y} stdmil_{j}\right)}$$

$$w_{m} = \max(w_{i})$$

$$v = \sum_{i=x}^{y} (w_{i}^{2} \times count_{i})$$

$$CI_{low} = \left(\frac{v}{2 \times rate}\right) \times \left(ChiInv\left(\frac{p}{2}, \frac{(2 \times rate^{2})}{v}\right)\right) \times 100,000$$

$$CI_{upper} = \left(\frac{v + w_{m}^{2}}{2(rate + w_{m})}\right) \times \left(ChiInv\left(1 - \frac{p}{2}, \frac{2(rate + w_{m})^{2}}{(v + w_{m}^{2})}\right)\right) \times 100,000$$

AGE-ADJUSTED RATE STANDARD ERROR:

$$SE_{AArate} = \left[\sum_{i=x}^{y} \left(\frac{stdmil_{i}}{\sum_{j=x}^{y} stdmil_{j}}\right)^{2} \times \left(\frac{count_{i}}{population_{i}^{2}}\right)\right]^{\frac{1}{2}} \times 100,000$$

CAUSE SPECIFIC SURVIVAL RATE:

$$\begin{split} L_{x} &= L_{x-1} - D_{x-1} - U_{x-1} - W_{x-1} \\ L_{x}^{*} &= L_{x} - \frac{1}{2} \left(U_{x} + W_{x} \right) \\ P_{x} &= 1 - \frac{D_{x}}{L_{x}^{*}} \\ CP_{x} &= P_{1}, P_{2}, \dots, P_{x} \end{split}$$

- L_1 = Total number of cases included in table
- L_x = Number of cases alive at beginning of interval x
- L_x^* = Adjusted number of cases alive at during interval x
- D_x = Number of cases dying from Cancer during interval x
- U_x = Number of cases untraced (lost to follow up) during interval x, where the definition for "lost to follow up" is: alive with follow up date prior to some prescribed date
- W_x = Number of cases withdrawn alive during interval *x*, where the definition of "withdrawn alive" is: alive with follow up date later than some specified date (This is the same as in previous definition.)
- P_x = Cause specific survival rate for interval x
- CP_x = Cumulative cause specific survival rate

CRUDE RATE:

$$CR = \frac{Number of Events}{Population} \times 100,000$$

CRUDE RATE CONFIDENCE INTERVALS:

$$CI_{lower} = \left(\frac{100,000}{Population}\right) \times \left(Events - \left(1.96 \times \sqrt{Events}\right)\right)$$

$$CI_{upper} = \left(\frac{100,000}{Population}\right) \times \left(Events + \left(1.96 \times \sqrt{Events}\right)\right)$$

MEDIAN SURVIVAL RATE:

$$MedianSurvival = (Interval - 1) + \left(\frac{(CP_{x-1} - .5)}{(CP_{x-1} - CP_x)}\right)$$

ELSE IF: CP_x for first interval is less than .5, then median survival:

$$MedianSurvival = \frac{.5}{(1 - CP_x)}$$

ELSE IF: CP_x for interval is equal to .5, then median survival:

MedianSurvival = Interval

 CP_x = Cumulative cause specific survival rate for interval x

PERCENTAGE (BRFSS) CONFIDENCE INTERVALS:

 $CI_{lower} = Weighted \% - 1.96 \times \sqrt{\frac{Weighted \% \times (1 - Weighted \%)}{Total \operatorname{Re} sponses}}$

$$CI_{upper} = Weighted\% + 1.96 \times \sqrt{\frac{Weighted\% \times (1 - Weighted\%)}{Total \text{Re sponses}}}$$

REFERENCES

- Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use, Nov 2006 Sub (2000-2004) -Linked To County Attributes - Total U.S., 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
- Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying) - Linked To County Attributes - Total U.S., 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
- 3). "ICD-9 to ICD-10" text document, ICD Conversion Programs, Surveillance, Epidemiology and End Results (SEER), National Cancer Institute, October 2002. <u>http://seer.cancer.gov/tools/</u>, 2002.
- 4). National Cancer Institute, Surveillance, Epidemiology and End Results (SEER), February 2003.
 <u>http://seer.cancer.gov/</u>, 2003.
- 5). National Cancer Institute, "What you need to know about..." publications. <u>http://cancer.gov/cancer_information/list.aspx?viewid=920AFA90-5547-4739-8D2D-89968F77A87D</u>., 2003.
- 6). Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds). SEER Summary Staging Manual - 2000: Codes and Coding Instructions, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001. http://seer.cancer.gov/tools/ssm/. 2003.

466

FEEDBACK AND SUGGESTIONS

In a continuing effort to provide an annual Cancer Report that is useful to the communities of Nevada, feedback and suggestions on the information contained in this report is welcome.

Please return the completed survey by mail, fax or email to:

Center for Health Data & Research, Bureau of Health Planning & Statistics 4150 Technology Way, Suite #104 Carson City, Nevada 89706 Fax: 775/ 684-4156

1. How did you first find the report?

	Hard Copy	Electronic Copy	State Website	
2.	Please rate the overall val	ue of the report:		

Extremely				No
Valuable				Value
5	4	3	2	1

3. Please rate the general information included in this report:

Type of Information	Extremely Helpful 5	4	Somewhat Helpful 3	2	Not Helpful 1	Not Applicable 0
General Sections						
Overview						
Cancer Incidence						
Inpatient Discharge						
Mortality						
Survival Rate						
(PLEASE CONTINUE SURVEY ON NEXT PAGE)						

4. Please rate the information on specific types of cancer included in this report:

Type of Information	Extremely Helpful 5	4	Somewhat Helpful 3	2	Not Helpful 1	Not Applicable 0		
Type of Cancer								
All Cancers								
Lung and Bronchus								
Breast								
Prostate								
Colorectal								
Urinary Bladder								
Non-Hodgkin's Lymphoma								
Kidney & Renal Pelvis								
Leukemia								
Lip, Oral Cavity & Pharynx								
Pancreas								
All Other Cancers								
Other Comments:	o the mailing	list fo	or future editic	ons of t	his report, pl	ease fill out the		
lowing information and retu	Irn it to the ad	ldress	listed at the to	op of th				
			nail Notificati	-				
Name:	Ti filiation:	tle:			_ Phone:			
City: Email Address:			State:					